Term,Overlap,P-value,Adjusted P-value,Old P-value,Old Adjusted P-value,Odds Ratio,Combined Score,Genes
"positive regulation of transcription, DNA-templated (GO:0045893)",94/1183,5.884401487523454E-28,2.005404026947993E-24,0,0,4.541148339128137,284.73035311861406,RET;CALCOCO1;MAML2;PTPRN;SIX1;FHL5;BRCA1;FGF1;BRCA2;PKD2;FGF2;ETS2;HOXA10;RPS6KA3;FGF7;MECOM;CHEK1;TNFSF11;CAPN3;TEAD1;MEF2C;PARP1;HGF;LMO2;IL18;PAX3;MITF;FOS;PROX1;SOX10;PAX2;RUNX2;DCN;ACTA2;NR5A2;MYCN;TAL1;IRF7;RARB;HOXB2;PPARG;PRKD1;ERG;PPARA;ZFPM2;MET;ATF3;SKAP1;PRKN;YAP1;BLM;HLF;EPAS1;GATA4;GATA3;ASCL1;FOXO1;ERBB2;E2F1;E2F2;TNNI2;FADD;OTX1;NKX2-5;ZNF423;E2F5;PPARGC1A;RXRG;NFE2;STAT5B;EGR1;ARNT2;TCF7L2;JUN;EGR2;STAT1;HMGA1;HMGA2;INHBA;KLF4;HNRNPAB;ESR1;FLI1;AGT;KLF1;COL1A1;CXCL10;NR4A1;BMP2;IL6;WT1;BCL3;CAMK1;BMPR1B
positive regulation of transcription by RNA polymerase II (GO:0045944),77/908,1.4791732647343844E-24,2.5205112431073912E-21,0,0,4.714552922094909,258.6901538228698,CALCOCO1;MAML2;PTPRN;SIX1;FHL5;BRCA1;FGF1;PKD2;FGF2;HOXA10;RPS6KA3;TNFSF11;TEAD1;MEF2C;PARP1;HGF;LMO2;IL18;PAX3;MITF;FOS;PROX1;PAX2;RUNX2;DCN;NR5A2;MYCN;TAL1;IRF7;RARB;HOXB2;PPARG;PRKD1;ERG;PPARA;ZFPM2;MET;ATF3;SKAP1;PRKN;YAP1;HLF;EPAS1;GATA4;GATA3;ASCL1;FOXO1;MUC1;TERT;E2F1;E2F2;FADD;OTX1;NKX2-5;E2F5;PPARGC1A;RXRG;NGFR;STAT5B;EGR1;ARNT2;TCF7L2;JUN;EGR2;STAT1;HMGA1;HMGA2;INHBA;KLF4;ESR1;CXCL10;NR4A1;BMP2;IL6;WT1;CAMK1;BMPR1B
positive regulation of nucleic acid-templated transcription (GO:1903508),56/511,3.261765122738603E-23,3.705365179431053E-20,0,0,6.043108562388768,312.8951720147918,RET;CALCOCO1;SIX1;BRCA1;BRCA2;FGF2;ETS2;FGF7;MECOM;CAPN3;TEAD1;MEF2C;PAX3;MITF;FOS;SOX10;PAX2;RUNX2;ACTA2;NR5A2;MYCN;TAL1;IRF7;PPARG;PPARA;SKAP1;YAP1;BLM;GATA4;GATA3;FOXO1;E2F1;TNNI2;NKX2-5;ZNF423;PPARGC1A;NFE2;EGR1;ARNT2;JUN;EGR2;STAT1;HMGA1;HMGA2;INHBA;KLF4;HNRNPAB;ESR1;FLI1;AGT;KLF1;COL1A1;BMP2;IL6;WT1;BCL3
cellular response to cytokine stimulus (GO:0071345),49/482,5.177204105176603E-19,4.410977897610466E-16,0,0,5.4644481769193085,230.07977958894287,F13A1;CIB1;BRCA1;FGF2;ZFP36;CCND1;LEPR;TNFSF11;SIRPA;CTSG;TIMP1;CD36;ANXA1;DUSP1;HGF;IL18;LIFR;FOS;SIGIRR;KIT;PRTN3;CCL14;OPRD1;CCL13;CXCR4;GATA3;PTGS2;IL2RG;FOXO1;SOCS3;MUC1;S1PR1;NDN;CCL2;CCL19;CCL16;STAT5A;STAT5B;EGR1;CCL21;STAT1;CXCL10;IL6;COL1A2;CXCL12;SAA1;SDC1;VIM;TDGF1
positive regulation of cell population proliferation (GO:0008284),46/474,4.1043861726584934E-17,2.7975496152840293E-14,0,0,5.15214437964069,194.40014695868535,CCL14;YAP1;FLT4;PDGFA;IRS2;CIB1;LAMC1;FGF1;FGF2;AQP1;FGF7;CCND2;TERT;GRK5;MDK;SIX2;CXCR2;ERBB2;E2F1;KDR;TIMP1;NKX2-5;TCF7L2;MEF2C;CR1;STAT1;IL18;HMGA2;CDC7;LIFR;PROX1;MAPK15;PAX2;AGT;CDC25B;TGFBR2;BMP2;IL6;PRC1;PRTN3;CALR;ZFPM2;FGFR4;TDGF1;FGFR3;EZH2
cytokine-mediated signaling pathway (GO:0019221),52/621,1.7451041998050986E-16,9.91219185489296E-14,0,0,4.4150131698395025,160.19675384095558,F13A1;IRS2;FGF2;LMNB1;CCND1;CFL1;LEPR;TNFSF11;CTSG;TIMP1;CD36;TNFRSF4;ANXA1;CISH;HGF;IL18;LIFR;FOS;KIT;IRF7;LTA;PRTN3;CCL14;YAP1;OPRD1;CCL13;PELI2;GATA3;PTGS2;IL2RG;FOXO1;SOCS3;MUC1;CXCR2;S1PR1;NDN;CCL2;CCL19;CCL16;STAT5A;STAT5B;EGR1;CCL21;STAT1;MX1;CXCL10;IL6;COL1A2;CXCL12;SAA1;SDC1;VIM
regulation of cell population proliferation (GO:0042127),57/764,9.631504170310017E-16,4.689166601773791E-13,0,0,3.916417562227504,135.4153150235067,ALK;FLT4;SIX1;IRS2;CIB1;FGF1;PKD2;FGF2;ADRA1A;FGF7;CCND2;SIX3;KDR;TIMP1;TNS2;KLF11;CR1;LIFR;PROX1;SSTR2;CDC25B;TGFBR2;KIT;PRTN3;SGK1;CCL14;YAP1;PDGFA;GATA3;GRK5;CXCR2;ERBB2;NKX2-5;STAT5A;STAT5B;TCF7L2;JUN;CDKN2C;STAT1;CDKN2A;HMGA1;CDC7;INHBA;KLF4;MAPK15;AGT;CXCL10;BMP2;IL6;WT1;PRC1;CALR;FGFR4;TDGF1;FGFR3;EZH2;CDKN3
regulation of transcription by RNA polymerase II (GO:0006357),107/2206,3.006994742115281E-15,1.2809797601411098E-12,0,0,2.6326878677082073,88.0313831573368,MAML2;FGF1;FGF2;ETS2;HOXA10;RPS6KA3;ZFP36;CCND1;RUVBL1;TNFSF11;ZNF205;PITX1;SOX5;MEF2C;HGF;LMO2;RFX2;MITF;SOX10;RUNX2;SAP30;MYCN;HOXB2;PRKD1;ERG;EZR;ZFPM2;ATF3;SKAP1;EPAS1;GATA4;GATA3;FOXO1;FADD;OTX1;NKX2-5;PPARGC1A;STAT5A;NFE2;STAT5B;EGR1;JUN;EGR2;CBX4;CAV1;CBX2;HMGA1;HMGA2;INHBA;ESR1;FLI1;CXCL10;NR4A1;BMP2;IL6;MRGBP;CALR;BMPR1B;EZH2;CALCOCO1;PTPRN;SIX1;FHL5;BRCA1;PKD2;MECOM;SIX2;SIX3;TEAD1;KLF11;PARP1;IL18;PAX3;FOS;PROX1;PAX2;DCN;NR5A2;TAL1;ELF5;KIT;IRF7;RARB;PPARG;PPARA;MET;PRKN;YAP1;HLF;SATB1;ASCL1;HOXD10;MUC1;ERBB2;E2F1;E2F2;E2F5;RXRG;ARNT2;TCF7L2;STAT1;CDKN2A;KLF4;KLF1;PER2;WT1;CAMK1
regulation of apoptotic process (GO:0042981),55/742,4.260185595001018E-15,1.6131902786403856E-12,0,0,3.8731758295077072,128.1613108928923,ALK;FLT4;ITSN1;CIB1;AQP1;RPS6KA3;CCND2;CFL1;KDR;CTLA4;CAPN3;VAV3;KLF11;MEF2C;ANXA1;HGF;PLAUR;PAX2;VAV2;MELK;BIN1;SGK1;CRYAB;ARHGEF6;PRKN;MAGED1;ASCL1;FOXO1;GRK5;E2F1;PMAIP1;BAK1;FADD;NKX2-5;ECT2;BARD1;NGFR;JUN;CBX4;STAT1;SIAH2;HMGA2;AGT;GADD45G;CXCL10;BMP2;IL6;PROC;WT1;BCL3;SPRY2;CALR;TEK;TDGF1;MAD2L1
negative regulation of apoptotic process (GO:0043066),43/485,1.1698546629153596E-14,3.9868646912155456E-12,0,0,4.625396771797123,148.37954515124488,PRKN;YAP1;FLT4;SIX1;GATA4;CIB1;ASCL1;FOXO1;AQP1;RPS6KA3;CCND2;GRK5;MDK;CFL1;KDR;CCL2;CAPN3;CTSG;NKX2-5;PPARGC1A;BARD1;NGFR;MEF2C;ANXA1;CBX4;SIAH2;HGF;CAV1;PLAUR;HMGA2;PRKCA;KLF4;MAPK8IP2;PAX2;IL6;PROC;WT1;BCL3;SPRY2;TEK;CRYAB;TDGF1;MAD2L1
positive regulation of cellular process (GO:0048522),49/625,1.8043281287950535E-14,5.196287727439652E-12,0,0,4.077103500280583,129.02402963070864,FLT4;IRS2;CIB1;FGF1;FGF2;RPS6KA3;ZFP36;FGF7;CCND2;CCND1;MDK;CHEK1;KDR;SIRPA;TIMP1;CD36;CR1;PRKCA;LIFR;PROX1;CDC25B;TGFBR2;MMP14;TAL1;PRTN3;CCL14;LRP1;PDGFA;IL2RG;EXOSC4;GRK5;CXCR2;ERBB2;NKX2-5;EGR2;CAV1;HMGA2;CDC7;MAPK15;IL6;CXCL12;PRC1;SAA1;CALR;BMPR1B;FGFR4;TDGF1;FGFR3;EZH2
positive regulation of MAPK cascade (GO:0043410),32/274,1.829678777267483E-14,5.196287727439652E-12,0,0,6.183499089508334,195.5967578282433,RET;CCL14;NRP1;CCL13;FLT4;PELI2;PDGFA;GATA4;CIB1;ADRB2;FGF1;FGF2;ADRA1A;ERBB2;KDR;TNFSF11;CCL2;CD36;CCL19;CCL16;CCL21;CAV2;PLA2G2A;PRKCA;BMP2;IL6;KIT;SPRY2;TEK;FGFR4;FGFR3;EZH2
cellular response to growth factor stimulus (GO:0071363),24/158,1.1291122037574695E-13,2.960011069542658E-11,0,0,8.262204417343213,246.31428021946897,STAT5B;NRP1;MEF2C;ANXA1;HGF;FLT4;CIB1;KLF4;RUNX2;TGFBR2;VIL1;NR4A1;ZFP36;BMP2;CLEC3B;MAPKAPK2;ERBB2;KDR;CCL2;SPRY2;PRKD1;BMPR1B;TDGF1;SOX5
"regulation of transcription, DNA-templated (GO:0006355)",101/2244,2.388853964174653E-12,5.815153078505155E-10,0,0,2.3855549164939394,63.837944276712946,FGF2;ETS2;HOXA10;RPS6KA3;FGF7;RUVBL1;CAPN3;ZNF205;PITX1;TNFRSF4;SOX5;MEF2C;RFX2;MITF;SOX10;RUNX2;SAP30;MYCN;HOXB2;ERG;ZFPM2;ATF3;SKAP1;BLM;MAGED1;EPAS1;GATA4;GATA3;FOXO1;OTX1;NKX2-5;ZNF423;PPARGC1A;STAT5A;NFE2;STAT5B;EGR1;CDT1;JUN;EGR2;CBX4;HMGA1;HMGA2;INHBA;ESR1;FLI1;COL1A1;NR4A1;BMP2;IL6;MRGBP;BCL3;CALR;EZH2;RET;CALCOCO1;SIX1;BRCA1;BRCA2;MECOM;SIX2;SIX3;TEAD1;KLF11;PAX3;RHOH;FOS;PROX1;PAX2;ACTA2;NR5A2;TAL1;ELF5;KIT;IRF7;PPARG;PPARA;CRYAB;YAP1;HLF;SATB1;ASCL1;HOXD10;ERBB2;E2F1;E2F2;TNNI2;E2F5;RXRG;RUNX1T1;ARNT2;TCF7L2;STAT1;CDKN2A;KLF4;HNRNPAB;AGT;KLF1;PER2;CENPF;WT1
positive regulation of intracellular signal transduction (GO:1902533),42/546,2.81761416723688E-12,6.401619387962192E-10,0,0,3.9394127377998345,104.76919636356659,RET;PRKN;FLT4;PELI2;PDGFA;IRS2;GATA3;ADRB2;FGF1;FGF2;ADRA1A;FGF7;ERBB2;KDR;TNFSF11;PMAIP1;CCL19;FADD;ECT2;IKBKE;LURAP1;TCF7L2;CCL21;VWF;CAV2;TRAT1;HGF;CAV1;IL18;ESR1;AGT;DCN;BMP2;IL6;KIT;SPRY2;S100A4;PRKD1;TEK;FGFR4;MET;FGFR3
positive regulation of epithelial cell proliferation (GO:0050679),20/123,3.5444212612607056E-12,7.549617286485303E-10,0,0,8.88726442033124,234.3184696074223,STAT5A;YAP1;NRP1;TCF7L2;FLT4;PTPRN;PRKCA;LAMC1;PROX1;FGF1;FGF2;PAX2;NR4A1;FGF7;BMP2;MDK;ERBB2;KDR;PRKD1;TEK
positive regulation of cell differentiation (GO:0045597),28/258,4.993586328877014E-12,1.001067188753698E-9,0,0,5.641747471587947,146.8144427530572,YAP1;FBN2;ASCL1;RPS6KA3;ZFP36;MDK;KDR;CD36;APOB;NKX2-5;ECT2;SOX5;MEF2C;HGF;PLA2G2A;IL18;RUNX2;PAX2;AGT;TGFBR2;COL1A1;BMP2;IL6;PPARG;PRKD1;CAMK1;BMPR1B;EZH2
positive regulation of ERK1 and ERK2 cascade (GO:0070374),23/172,5.681422712879835E-12,1.0756827003052489E-9,0,0,7.098476414644232,183.80666655817555,CCL14;NRP1;CCL13;CCL21;FLT4;PLA2G2A;PDGFA;CIB1;PRKCA;GATA4;FGF2;ADRA1A;BMP2;KDR;TNFSF11;CCL2;SPRY2;CD36;CCL19;TEK;FGFR4;FGFR3;CCL16
protein phosphorylation (GO:0006468),39/496,9.07939959478752E-12,1.6285575694229405E-9,0,0,4.014304038977698,102.06373257536225,RET;ALK;FLT4;AURKA;RPS6KA3;GRK3;GRK5;CHEK1;ERBB2;KDR;CCL2;NEK2;CTSG;PAK3;IKBKE;PAK5;PAK4;PLK4;PRKCA;CDC7;BMX;MAPK15;CIT;CDC25B;TGFBR2;CCNA2;BMP2;MELK;MAPKAPK2;KIT;PRKD1;ERG;CAMK1;TEK;SGK1;BMPR1B;FGFR4;TDGF1;FGFR3
regulation of endothelial cell migration (GO:0010594),17/89,1.033013611745998E-11,1.7602551944151807E-9,0,0,10.748020508826583,271.8814501807955,NRP1;ANXA3;FLT4;PRKCA;PROX1;GATA3;FGF1;FGF2;DCN;AGT;SH3BP1;RHOJ;KDR;PRKD1;CALR;TEK;TDGF1
regulation of angiogenesis (GO:0045765),24/203,2.8150168485910563E-11,4.5683701999992E-9,0,0,6.170782520999483,149.90970632704227,ANXA3;STAT1;HMGA2;PRKCA;GATA4;BRCA1;FGF1;KLF4;FGF2;DCN;AQP1;CDH5;CXCL10;EFNA3;IL6;RHOJ;ADAM12;ERBB2;KDR;SPRY2;PPARG;PRKD1;TEK;PAK4
regulation of protein kinase B signaling (GO:0051896),24/207,4.2624997467912E-11,6.60299960775655E-9,0,0,6.03465597134068,144.0990168308163,RET;TCF7L2;CCL21;TRAT1;HGF;IL18;PDGFA;GATA4;CIB1;IRS2;GATA3;FGF1;FGF2;ESR1;FGF7;KIT;ERBB2;SPRY2;CCL19;TEK;PPARA;FGFR4;FGFR3;MET
positive regulation of endothelial cell migration (GO:0010595),16/86,6.406831714061023E-11,9.493253252834768E-9,0,0,10.381618381618381,243.66770365152632,STAT5A;NRP1;ANXA3;FLT4;PRKCA;PROX1;GATA3;FGF1;FGF2;AGT;KDR;PRKD1;CALR;TEK;MET;TDGF1
"negative regulation of transcription, DNA-templated (GO:0045892)",55/948,7.707549739597075E-11,1.0547746186283729E-8,0,0,2.9471674275705633,68.62843533268888,BRCA1;ETS2;ZFP36;MECOM;CCND1;SIX3;CAPN3;ZNF205;TNFRSF4;KLF11;MEF2C;PARP1;MITF;PROX1;SOX10;PAX2;RUNX2;SAP30;IRF7;RARB;PPARG;PPARA;EZR;ZFPM2;CRYAB;ATF3;PRKN;YAP1;SATB1;GATA3;ASCL1;FOXO1;MUC1;E2F1;NKX2-5;ZNF423;RUNX1T1;TCF7L2;JUN;CBX4;STAT1;CDKN2A;CAV1;CBX2;HMGA1;HMGA2;KLF4;ESR1;PER2;CENPF;BMP2;WT1;BCL3;CALR;EZH2
positive regulation of protein kinase B signaling (GO:0051897),21/161,7.737489866698746E-11,1.0547746186283729E-8,0,0,6.868514150943396,159.91521016092332,RET;TCF7L2;CCL21;TRAT1;HGF;IL18;PDGFA;IRS2;GATA3;FGF1;FGF2;ESR1;FGF7;KIT;ERBB2;SPRY2;CCL19;TEK;FGFR4;FGFR3;MET
positive regulation of pri-miRNA transcription by RNA polymerase II (GO:1902895),11/34,1.0556907986597427E-10,1.3837670160893857E-8,0,0,21.523943097575636,494.4406078156847,EGR1;NGFR;JUN;TERT;WT1;PPARG;GATA3;FOS;KLF4;FGF2;TEAD1
negative regulation of programmed cell death (GO:0043069),32/381,1.354840308879432E-10,1.6860337456223792E-8,0,0,4.263943331691377,96.88603389297279,FLT4;CIB1;ASCL1;FOXO1;AQP1;RPS6KA3;CCND2;MECOM;GRK5;CFL1;KDR;CAPN3;NKX2-5;BARD1;NGFR;ANXA1;CBX4;SIAH2;HGF;PLAUR;HMGA2;PAX2;IL6;PROC;WT1;BCL3;SPRY2;TEK;TDGF1;CRYAB;MET;MAD2L1
regulation of ERK1 and ERK2 cascade (GO:0070372),25/238,1.431187251435583E-10,1.6860337456223792E-8,0,0,5.405209031969595,122.5217464886373,CCL14;NRP1;CCL13;FLT4;PDGFA;GATA4;CIB1;FGF2;ADRA1A;ERBB2;KDR;SIRPA;CCL2;CD36;CCL19;CCL16;CCL21;PLA2G2A;PRKCA;BMP2;SPRY2;TEK;EZR;FGFR4;FGFR3
transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169),33/404,1.434711814056602E-10,1.6860337456223792E-8,0,0,4.141731871352681,93.871884547563,CYFIP2;RET;ALK;NRP1;SHC3;FLT4;ITSN1;PDGFA;IRS2;ADRB2;FGF1;FGF2;FOXO1;FGF7;STMN1;ERBB2;KDR;POLR2H;PAK3;VAV3;NGFR;CAV2;HGF;VAV2;COL1A1;EFNA3;MAPKAPK2;KIT;PRKD1;TEK;FGFR4;MET;FGFR3
positive regulation of cell motility (GO:2000147),24/221,1.6862580884829546E-10,1.9155891885166362E-8,0,0,5.601745903517127,126.05798708494531,RET;CCL21;HGF;CAV1;FAM107A;PDGFA;PRKCA;CIB1;SEMA3F;FGF1;MYLK;COL1A1;VIL1;CDH5;MMP14;BMP2;CXCL12;MDK;KIT;KDR;PECAM1;SPRY2;CCL19;TDGF1
regulation of pri-miRNA transcription by RNA polymerase II (GO:1902893),12/45,1.879230550991451E-10,2.0659411992835046E-8,0,0,16.394709216880116,367.1593246723172,EGR1;NGFR;JUN;TERT;WT1;PPARG;GATA3;FOS;KLF4;PPARA;FGF2;TEAD1
positive regulation of multicellular organismal process (GO:0051240),30/345,2.2506333894976304E-10,2.3969245598149762E-8,0,0,4.415375788869765,98.08598028922174,LRP1;EPAS1;CXCR4;SIX1;ADRB1;ADRB2;FGF2;ADRA1A;TERT;MDK;CFL1;LEPR;CD36;PPARGC1A;LURAP1;SOX5;CAV1;IL18;INHBA;PAX2;AGT;GADD45G;TGFBR2;COL1A1;PER2;BMP2;IL6;SAA1;BMPR1B;EZH2
positive regulation of gene expression (GO:0010628),36/482,2.485371696050653E-10,2.5667111333759472E-8,0,0,3.771223699935312,83.40222886917199,PRKN;YAP1;CALCOCO1;BRCA1;FGF1;PLD1;FGF2;RIMS2;CDH5;FGF7;ERBB2;E2F1;HABP4;POLR2H;CD36;PPARGC1A;LURAP1;EGR1;MEF2C;HMGA2;MITF;INHBA;KLF4;AGT;ACTA2;BMP2;IL6;MYCN;ACTC1;WT1;BCL3;SAA1;SPRY2;VIM;EZR;FGFR4
positive regulation of epithelial cell migration (GO:0010634),16/94,2.584464339970478E-10,2.5905454325351144E-8,0,0,9.313011774550237,205.59714602040023,NRP1;ANXA3;FLT4;PRKCA;PROX1;GATA3;FGF1;FGF2;AGT;VIL1;FGF7;KDR;PRKD1;CALR;TEK;TDGF1
positive regulation of protein phosphorylation (GO:0001934),31/371,3.01725964196078E-10,2.9379488170863825E-8,0,0,4.231777493606138,92.76691842493693,OPRD1;NRP1;FLT4;PELI2;PDGFA;CIB1;FGF1;FGF2;C3;VTN;FGF7;CCND2;CCND1;ERBB2;KDR;LEPR;CCL19;CCL21;HGF;CAV1;PLAUR;INHBA;AGT;BMP2;IL6;PECAM1;SPRY2;PRKD1;CAMK1;TEK;TDGF1
regulation of MAPK cascade (GO:0043408),20/166,9.190917475769982E-10,8.700735210395584E-8,0,0,6.255922643029814,130.17095597295724,RET;CAV2;DUSP1;CAV1;FLT4;PELI2;PDGFA;ADRB2;FGF2;ADRA1A;BMP2;IL6;KIT;ERBB2;KDR;TEK;PAK3;FGFR3;PAK5;PAK4
mitotic cell cycle phase transition (GO:0044772),22/209,1.7774820436441512E-9,1.637205082361964E-7,0,0,5.386733416770964,108.53227148241265,PLK4;CDKN2C;CDKN2A;CDC7;INHBA;TUBG1;PKMYT1;CDC25B;AURKA;EPS8;CCNA2;CCNB2;CCND2;MELK;DBF4;CCND1;CCNE2;PRKAR2B;E2F1;RCC1;NEK2;CDKN3
apoptotic process (GO:0006915),23/231,2.2521239462598486E-9,2.019799581277254E-7,0,0,5.069506471017134,100.94093104660531,CYFIP2;NGFR;PARP1;MX1;PAX3;CXCR4;GZMB;CIB1;ADRA1A;FOXO1;CIT;TGFBR2;MELK;CHEK1;LTA;PAEP;CAPN3;PMAIP1;FADD;BAK1;PAK5;ARHGEF6;PAK4
positive regulation of phosphorylation (GO:0042327),24/253,2.6631053329528917E-9,2.3271443524880655E-7,0,0,4.811003122115155,94.98735343300773,RET;ALK;NRP1;HGF;FLT4;PELI2;PLAUR;CIB1;FGF1;FGF2;C3;FGF7;BMP2;CCND2;CCND1;KIT;ERBB2;KDR;LEPR;PECAM1;TEK;FGFR4;FGFR3;MET
regulation of cell migration (GO:0030334),31/408,3.0402905011651395E-9,2.590327506992699E-7,0,0,3.8091082663796305,74.70161357343159,RET;FAM107A;PDGFA;CIB1;SEMA3F;FGF1;FGF2;MYLK;CDH5;FGF7;PARD6B;MDK;KDR;NGFR;ANXA1;HGF;CAV1;PRKCA;MITF;MAPK15;COL1A1;VIL1;MMP14;BMP2;CXCL12;KIT;PECAM1;SPRY2;AMOTL2;SGK1;TDGF1
extracellular matrix organization (GO:0030198),26/300,3.94193249997337E-9,3.276611209733963E-7,0,0,4.3665487866487815,84.49968258256644,COL17A1;FBN2;LAMA1;PDGFA;LAMC1;FGF2;VTN;ACAN;KDR;CTSG;TIMP1;A2M;DST;VWF;CMA1;BGN;DCN;COL1A1;MMP14;COL3A1;VCAN;COL1A2;COL2A1;ADAM12;PECAM1;COL8A1
cellular component assembly (GO:0022607),24/261,4.945443986813717E-9,3.922354313201191E-7,0,0,4.64668210108542,88.86686162256042,YAP1;FAM107A;FANCA;PDGFA;RHOH;PARVA;MITF;LAMC1;EPS8;VIL1;PARD6B;CHAF1A;SH3BP1;RHOJ;REPS2;RAC3;CAPN3;ELOB;FLNC;EZR;PPARGC1A;NEFH;TEAD1;SKAP2
gland development (GO:0048732),13/71,4.948979913956901E-9,3.922354313201191E-7,0,0,10.115780651340996,193.45504253936667,ANXA1;CAV1;SIX1;PROX1;PKD2;MDK;WT1;SIX3;FADD;EZR;NKX2-5;MET;TDGF1
supramolecular fiber organization (GO:0097435),28/351,6.234693457591372E-9,4.736460181507366E-7,0,0,3.9980102605222325,75.53495327581427,PRKN;COL17A1;UBE2L6;CIB1;RND1;SPTA1;SH3BP1;STMN1;RAC3;CAPN3;CD36;DST;TPM3;SIAH2;H4-16;RHOH;SNCAIP;GFAP;COL1A1;COL3A1;COL1A2;COL2A1;ACTC1;SAA1;COL8A1;EVL;VIM;ALDOA
positive regulation of angiogenesis (GO:0045766),16/116,6.254128760793177E-9,4.736460181507366E-7,0,0,7.255944055944056,137.06495728377897,ANXA3;HMGA2;PRKCA;GATA4;BRCA1;FGF1;KLF4;FGF2;AQP1;CDH5;MDK;ADAM12;KDR;PRKD1;TEK;PAK4
positive regulation of cell migration (GO:0030335),24/269,8.95935163773735E-9,6.637710952480193E-7,0,0,4.493092248775995,83.25955133136178,RET;NRP1;HGF;CAV1;FAM107A;PDGFA;PRKCA;CIB1;SEMA3F;FGF1;MYLK;COL1A1;VIL1;CDH5;VTN;MMP14;BMP2;CXCL12;MDK;KIT;KDR;PECAM1;SPRY2;TDGF1
lymphocyte migration (GO:0072676),10/40,1.2541597201864584E-8,9.030809032371577E-7,0,0,14.96168582375479,272.2161277613352,CCL14;RET;CCL13;CCL21;S1PR1;SAA1;CCL2;GATA3;CCL19;CCL16
positive regulation of protein serine/threonine kinase activity (GO:0071902),15/106,1.3076243367128138E-8,9.030809032371577E-7,0,0,7.461282903143368,135.44070463361453,PDGFA;HMGA2;CIB1;ADRB2;PROX1;FGF1;PKD2;FGF2;CCND2;CCND1;KIT;ERBB2;TNFSF11;CAMK1;EZH2
regulation of cell cycle process (GO:0010564),15/106,1.3076243367128138E-8,9.030809032371577E-7,0,0,7.461282903143368,135.44070463361453,PLK4;CAV2;HMGA2;MKI67;PKMYT1;AURKA;DBF4;RACGAP1;PRC1;CHEK1;SIX3;RCC1;NEK2;ECT2;BUB1
regulation of cell cycle (GO:0051726),25/296,1.324942639725877E-8,9.030809032371577E-7,0,0,4.235635213494992,76.83150686081247,GATA3;BRCA1;PKD2;CCNB2;MECOM;CCND1;GRK5;CHEK1;BARD1;TCF7L2;JUN;CDKN2C;DUSP1;CDKN2A;HMGA2;PROX1;INHBA;GADD45G;PER2;NR4A1;CENPF;BMP2;BIN1;CALR;CDKN3
regulation of intracellular signal transduction (GO:1902531),31/437,1.528112411412693E-8,1.0098094119844748E-6,0,0,3.53168058827729,63.55841058827072,BLM;ITSN1;GATA4;BRCA1;AKAP5;FGF1;AURKA;AKAP12;RACGAP1;PRKAR2B;CHEK1;TNFSF11;RAC3;CAPN3;A2M;PAK3;ECT2;PAK5;PAK4;BARD1;VAV3;RFC4;VWF;RHOH;VAV2;BCL3;RHOJ;TEK;EZR;SGK1;ARHGEF6
regulation of endothelial cell proliferation (GO:0001936),14/92,1.540789008896499E-8,1.0098094119844748E-6,0,0,8.11107144981855,145.90508504804623,STAT5A;NRP1;CAV2;STAT1;FLT4;CAV1;PRKCA;PROX1;FGF2;NR4A1;BMP2;KDR;PRKD1;TEK
extracellular structure organization (GO:0043062),21/216,1.722280681720907E-8,1.0972959365706765E-6,0,0,4.917271407837446,87.90621513263353,COL17A1;FBN2;VWF;LAMA1;BGN;PDGFA;LAMC1;FGF2;DCN;COL1A1;VTN;ACAN;MMP14;COL3A1;VCAN;COL1A2;COL2A1;ADAM12;KDR;PECAM1;COL8A1
negative regulation of nucleic acid-templated transcription (GO:1903507),32/464,1.73867313893241E-8,1.0972959365706765E-6,0,0,3.429826921352345,61.28263311225991,GATA3;BRCA1;ASCL1;FOXO1;MECOM;SIX3;E2F1;CAPN3;NKX2-5;ZNF423;TNFRSF4;RUNX1T1;TCF7L2;JUN;CBX4;CDKN2A;HMGA1;HMGA2;PROX1;KLF4;PAX2;RUNX2;PER2;CENPF;BMP2;WT1;BCL3;PPARG;CALR;ZFPM2;CRYAB;EZH2
external encapsulating structure organization (GO:0045229),21/217,1.8682153704684277E-8,1.1576141786466185E-6,0,0,4.891930592991914,87.05531514590827,COL17A1;FBN2;VWF;LAMA1;BGN;PDGFA;LAMC1;FGF2;DCN;COL1A1;VTN;ACAN;MMP14;COL3A1;VCAN;COL1A2;COL2A1;ADAM12;KDR;PECAM1;COL8A1
positive regulation of cellular biosynthetic process (GO:0031328),19/180,2.196349494831544E-8,1.3366355497117683E-6,0,0,5.372612486513282,94.74002580638044,CDT1;EGR1;CCL21;HGF;IRS2;PLD1;PKD2;PTGS2;KLF4;FGF2;IL6;BCL3;ERBB2;ZNF205;CD36;CCL19;VIM;FGFR4;PPARGC1A
regulation of protein phosphorylation (GO:0001932),23/266,3.2909984582529965E-8,1.9676706571449494E-6,0,0,4.331480506309363,74.62919895314423,PRKN;HGF;FLT4;PELI2;PLAUR;PDGFA;CIB1;FGF1;FGF2;C3;CDH5;FGF7;BMP2;CCND2;CCND1;ERBB2;KDR;LEPR;PECAM1;SIRPA;TEK;ECT2;ATF3
branching morphogenesis of an epithelial tube (GO:0048754),10/44,3.390341597769933E-8,1.9921179595172296E-6,0,0,13.198782961460447,227.01576805089732,NRP1;BMP2;WT1;KDR;SIX1;PKD2;FGF2;MET;PAX2;TGFBR2
positive regulation of macromolecule metabolic process (GO:0010604),28/384,4.328298640086326E-8,2.5001426721041014E-6,0,0,3.6211839517150324,61.39900695521978,PRKN;YAP1;CALCOCO1;BRCA1;FGF1;FGF2;RIMS2;CDH5;FGF7;E2F1;CD36;PPARGC1A;EGR1;MEF2C;HMGA2;MITF;INHBA;KLF4;SELE;ACTA2;BMP2;IL6;MYCN;ACTC1;WT1;SPRY2;EZR;FGFR4
positive regulation of cellular protein metabolic process (GO:0032270),14/102,5.9390960278267985E-8,3.3181047971858572E-6,0,0,7.185667580679182,119.56321250387177,CYFIP2;INHBA;PLD1;KLF4;AGT;IL6;BCL3;ERBB2;CAPN3;FADD;BAK1;VIM;EZR;FGFR4
positive regulation of vasculature development (GO:1904018),14/102,5.9390960278267985E-8,3.3181047971858572E-6,0,0,7.185667580679182,119.56321250387177,ANXA3;HMGA2;PRKCA;GATA4;BRCA1;FGF1;FGF2;AQP1;CDH5;ADAM12;KDR;PRKD1;TEK;PAK4
positive regulation of protein modification process (GO:0031401),20/214,7.300675476518057E-8,4.013016455479603E-6,0,0,4.696422073984233,77.17496015006802,HGF;FLT4;PELI2;PLAUR;CIB1;FGF1;FGF2;C3;CDH5;FGF7;BMP2;CCND2;CCND1;ERBB2;KDR;LEPR;PECAM1;CAMK1;TEK;RAMP1
negative regulation of transcription by RNA polymerase II (GO:0000122),39/684,8.396306562004007E-8,4.542002025922168E-6,0,0,2.816244701569481,45.884761840175855,PRKN;YAP1;SATB1;GATA3;ASCL1;ETS2;ZFP36;CCND1;E2F1;ZNF205;NKX2-5;KLF11;TCF7L2;MEF2C;JUN;PARP1;CBX4;STAT1;CAV1;CBX2;HMGA2;MITF;PROX1;KLF4;SOX10;ESR1;SAP30;PER2;BMP2;WT1;IRF7;RARB;PPARG;CALR;PPARA;EZR;ZFPM2;ATF3;EZH2
MAPK cascade (GO:0000165),24/303,8.779566472661604E-8,4.6261982913554545E-6,0,0,3.9385998518632035,63.995369671840706,RET;MEF2C;SHC3;HGF;IL18;PDGFA;IRS2;FGF1;IL2RG;FGF2;SPTB;SPTA1;FGF7;ZFP36;DLG2;KIT;MAPKAPK2;ERBB2;KDR;CCL2;TEK;FGFR4;FGFR3;MET
negative regulation of epithelial cell apoptotic process (GO:1904036),9/37,8.823441576822317E-8,4.6261982913554545E-6,0,0,14.395724115334207,233.8336156359125,YAP1;CDH5;TCF7L2;MDK;KDR;GATA3;TEK;PPARA;PAK4
branching involved in ureteric bud morphogenesis (GO:0001658),7/19,1.0297300682298081E-7,5.237791153025651E-6,0,0,26.027587519025875,418.7526228185259,BMP2;WT1;SIX1;FGF1;PKD2;FGF2;PAX2
ureteric bud morphogenesis (GO:0060675),7/19,1.0297300682298081E-7,5.237791153025651E-6,0,0,26.027587519025875,418.7526228185259,BMP2;WT1;SIX1;GATA3;PKD2;FGF2;PAX2
positive regulation of endothelial cell proliferation (GO:0001938),12/77,1.2616067146243685E-7,6.279911454815399E-6,0,0,8.30982412506662,132.00745264518503,STAT5A;NRP1;NR4A1;BMP2;MDK;FLT4;KDR;PRKCA;PROX1;PRKD1;TEK;FGF2
cell cycle G1/S phase transition (GO:0044843),11/63,1.271460945957343E-7,6.279911454815399E-6,0,0,9.506070542360865,150.9367137155929,CCNA2;DBF4;CDKN2C;CCND1;CCNE2;CDKN2A;E2F1;RCC1;CDC7;INHBA;CDKN3
cellular protein modification process (GO:0006464),50/1025,1.6384027114651052E-7,7.976680629532969E-6,0,0,2.4122038299253488,37.689174417394476,RET;RAB3A;F13A1;UBE2L6;LAMC1;C4A;CHEK1;ELOB;NEK2;CTSG;TIMP1;IKBKE;ANXA1;CISH;PARP1;DUSP1;PRKCA;CDC25B;TGFBR2;VCAN;MELK;MAPKAPK2;PRKD1;ERG;SGK1;SERPINC1;EPAS1;AURKA;C3;SOCS3;GRK3;GRK5;ERBB2;CCL2;APOB;PAK3;PAK5;PAK4;PLK4;GAD1;KLHL3;BMX;PPP1CA;COL3A1;PTPRB;BMP2;IL6;PROC;CAMK1;BMPR1B
regulation of protein serine/threonine kinase activity (GO:0071900),14/111,1.7504316354125974E-7,8.402071849980467E-6,0,0,6.51594230631234,101.37655021015004,BLM;CDKN2C;HMGA2;CIB1;ADRB2;PKMYT1;CCNA2;CCNB2;CCND2;CCND1;CCNE2;CAMK1;EZH2;CDKN3
positive regulation of macromolecule biosynthetic process (GO:0010557),15/129,1.8918166849646525E-7,8.954598975499355E-6,0,0,5.948898408812729,92.09226729737998,CDT1;CCL21;HGF;IRS2;PLD1;KLF4;FGF2;IL6;BCL3;ERBB2;KDR;CCL2;CCL19;VIM;FGFR4
embryonic organ development (GO:0048568),11/66,2.0886662724456505E-7,9.750924186979148E-6,0,0,8.986175115207374,138.22148099026148,COL2A1;TAL1;KIT;KDR;RARB;PDGFA;GATA3;NKX2-5;PCSK5;TEAD1;TGFBR2
negative regulation of cellular macromolecule biosynthetic process (GO:2000113),33/547,2.4280818958386006E-7,1.1182301487862096E-5,0,0,2.967176343923539,45.19304523537965,GATA3;BRCA1;ASCL1;FOXO1;MECOM;SIX3;E2F1;CAPN3;NKX2-5;ZNF423;TNFRSF4;RUNX1T1;TCF7L2;JUN;CBX4;CDKN2A;HMGA1;GZMB;HMGA2;PROX1;KLF4;PAX2;RUNX2;PER2;CENPF;BMP2;WT1;BCL3;PPARG;CALR;ZFPM2;CRYAB;EZH2
regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0000079),12/82,2.5725265382679483E-7,1.1689560589889556E-5,0,0,7.714285714285714,117.05045512741447,CCNA2;CCNB2;BLM;CCND2;CDKN2C;CCND1;CCNE2;CDKN2A;PROX1;PKD2;PKMYT1;CDKN3
kidney mesenchyme development (GO:0072074),5/8,2.8256168470065637E-7,1.2670660808682065E-5,0,0,74.06060606060606,1116.7872039871104,WT1;SIX2;SIX1;PKD2;PAX2
monocyte chemotaxis (GO:0002548),9/42,2.8655759749401795E-7,1.2682964834540431E-5,0,0,12.211426188490409,183.96911990578252,CCL14;CCL13;IL6;ANXA1;CCL21;CCL2;TNFSF11;CCL19;CCL16
regulation of gene expression (GO:0010468),51/1079,3.2037039038785394E-7,1.3997721672330849E-5,0,0,2.3328453060498924,34.88487423804459,CALCOCO1;SIX1;BRCA1;FGF1;BRCA2;FGF2;RIMS2;CDH5;FGF7;KDR;SIRPA;ZNF205;CD36;MEF2C;RHOH;MITF;PROX1;SAP30;ACTA2;NR5A2;MYCN;EZR;PRKN;YAP1;OPRD1;MAGED1;GATA4;GATA3;ASCL1;AURKA;TERT;E2F1;ZNF423;PPARGC1A;EGR1;ARNT2;HMGA1;HMGA2;INHBA;KLF4;HNRNPAB;ESR1;KLF1;BMP2;IL6;ACTC1;WT1;SPRY2;CALR;FGFR4;EZH2
phosphorylation (GO:0016310),27/400,3.565748542169235E-7,1.5382368394573107E-5,0,0,3.3217927832009955,49.31773282910341,RET;ALK;AURKA;GRK3;GRK5;CHEK1;ERBB2;CCL2;NEK2;CTSG;PAK3;IKBKE;PAK5;PAK4;PLK4;PRKCA;BMX;CDC25B;TGFBR2;BMP2;MELK;MAPKAPK2;PRKD1;ERG;CAMK1;SGK1;BMPR1B
G1/S transition of mitotic cell cycle (GO:0000082),12/85,3.846563820388968E-7,1.6386361874857007E-5,0,0,7.396121357841121,109.2474829784919,KLF11;CDT1;DBF4;CDKN2C;CCND1;CCNE2;CDKN2A;E2F1;RCC1;CDC7;INHBA;CDKN3
positive regulation of osteoblast differentiation (GO:0045669),9/44,4.379932994744899E-7,1.8428162526037798E-5,0,0,11.512450851900393,168.55450928136398,FBN2;YAP1;MEF2C;BMP2;IL6;HGF;PRKD1;BMPR1B;RUNX2
renal system development (GO:0072001),10/57,4.557203967166593E-7,1.894018429280945E-5,0,0,9.541697236488139,139.32200807656795,CENPF;STAT1;WT1;SIX2;SIX1;PROX1;GATA3;PCSK5;PAX2;AGT
cytoskeleton organization (GO:0007010),14/120,4.64673464358254E-7,1.9079604416059392E-5,0,0,5.959943965328547,86.9074911014193,CCL13;DST;RHOH;RND1;BIN1;MDK;DPYSL2;CFL1;RAC3;CCL2;PAK5;NECTIN2;SH3D19;PAK4
axonogenesis (GO:0007409),20/240,4.710427651512816E-7,1.9110877900423423E-5,0,0,4.1358288770053475,60.252065933460315,RET;NRP1;RAB3A;SHC3;LAMA1;CXCR4;PRKCA;IRS2;SEMA3F;SPTB;PAX2;SPTA1;EFNA3;PARD6B;CXCL12;FEZ1;EVL;EZR;PAK3;NEFH
positive regulation of chemotaxis (GO:0050921),9/45,5.368097949741012E-7,2.152291507378514E-5,0,0,11.192087155963304,161.58712379904173,NRP1;IL6;CCL21;MDK;KDR;CCL19;PRKD1;FGF2;MET
protein autophosphorylation (GO:0046777),16/159,5.488604100105335E-7,2.1750189271115094E-5,0,0,5.062871860074657,72.9834328256281,ALK;FLT4;BMX;MAPK15;AURKA;MELK;GRK5;MAPKAPK2;KIT;ERBB2;KDR;NEK2;PRKD1;TEK;FGFR4;FGFR3
regulated exocytosis (GO:0045055),17/180,6.016368292312556E-7,2.356756682781746E-5,0,0,4.725417120577949,67.68504065213497,RAB3A;VWF;PROS1;HGF;F13A1;PDGFA;SYT9;SYT7;RIMS2;CLEC3B;HABP4;PECAM1;SERPING1;CD36;TIMP1;A2M;ALDOA
cellular response to vascular endothelial growth factor stimulus (GO:0035924),8/34,6.162799310319568E-7,2.3866840965419418E-5,0,0,13.750396057032212,196.6246759113123,NRP1;NR4A1;ANXA1;FLT4;MAPKAPK2;KDR;SPRY2;PRKD1
positive regulation of binding (GO:0051099),12/90,7.243511241536842E-7,2.7736950911412986E-5,0,0,6.9202344999111745,97.83820327866292,PRKN;VTN;CDT1;TCF7L2;BMP2;LRP1;TERT;CAV1;STMN1;PLAUR;PPARG;MET
regulation of DNA binding (GO:0051101),9/47,7.935627744531068E-7,3.0049577059290976E-5,0,0,10.601943505552873,148.922671710184,PRKN;CDT1;JUN;BCL3;E2F1;HABP4;PLAUR;HMGA2;PPARG
regulation of inflammatory response (GO:0050727),18/206,8.873145515908462E-7,3.32304174925451E-5,0,0,4.3425930539638244,60.51432209217978,ANXA1;CMA1;PLA2G2A;IL18;GATA3;PTGS2;KLF4;SELE;AGT;CDH5;IL6;PROC;MDK;SAA1;SIRPA;PPARG;TEK;PPARA
positive regulation of blood vessel endothelial cell migration (GO:0043536),9/48,9.576470388853007E-7,3.547457726653375E-5,0,0,10.329569513055752,143.15529916153076,STAT5A;ANXA1;RHOJ;KDR;CIB1;PRKCA;PRKD1;PTGS2;FGF2
regulation of epithelial cell proliferation (GO:0050678),12/93,1.0373639862254853E-6,3.781755444592114E-5,0,0,6.6629030878453515,91.80699356958335,YAP1;TCF7L2;NR4A1;FGF7;ZFP36;MAGED1;ERBB2;LAMC1;PRKD1;FGF1;FGF2;PAX2
neutrophil migration (GO:1990266),11/77,1.043089823332332E-6,3.781755444592114E-5,0,0,7.484254992319508,103.08306341056304,CCL14;CCL13;CXCL10;CCL21;CXCR2;PECAM1;SAA1;CCL2;PRTN3;CCL19;CCL16
regulation of kinase activity (GO:0043549),12/94,1.1655680957358183E-6,4.1813221792291246E-5,0,0,6.581310201092773,89.9158472201224,ALK;RET;FLT4;KIT;ERBB2;KDR;IRS2;TEK;ECT2;FGFR4;MET;FGFR3
cellular response to DNA damage stimulus (GO:0006974),24/350,1.214876215207032E-6,4.3128105639849635E-5,0,0,3.362546085131807,45.80079760304704,BARD1;H2AX;VAV3;YAP1;FEN1;BLM;RFC4;PARP1;FANCA;CIB1;BRCA1;MAPK15;FOXO1;RAD51;CCND1;POLE2;CHEK1;MAPKAPK2;BCL3;IRF7;E2F1;CTLA4;BAK1;IKBKE
cellular response to organic cyclic compound (GO:0071407),15/150,1.3424371612380659E-6,4.7141397058277826E-5,0,0,5.018087855297158,67.84968541695797,EGR1;MEF2C;BLM;IL18;BRCA1;PKD2;SSTR2;ESR1;AQP1;ADCY5;GNG2;RAD51;WT1;CCL2;EZR
regulation of neuron differentiation (GO:0045664),11/79,1.3555918168166746E-6,4.7141397058277826E-5,0,0,7.263384386012469,98.13756523088462,ALK;MEF2C;BMP2;BIN1;SIX3;SIX1;DTX1;CALR;ASCL1;ECT2;NKX2-5
response to lipid (GO:0033993),13/114,1.5512647440488906E-6,5.340111361331938E-5,0,0,5.796250458379172,77.53319645741647,STAT5B;ANXA1;ASCL1;ESR1;SELE;FOXO1;RPS6KA3;MAPKAPK2;PPARG;CD36;FGFR4;PPARA;RXRG
positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050),6/18,1.7354944256868886E-6,5.914565002740916E-5,0,0,22.25854214123007,295.2421600775461,ANXA1;RHOJ;KDR;CIB1;PTGS2;FGF2
positive regulation of programmed cell death (GO:0043068),21/286,1.9251141058436146E-6,6.495830567044593E-5,0,0,3.6052865788536845,47.44746529322616,BARD1;VAV3;NGFR;KLF11;JUN;ITSN1;HMGA2;FOXO1;GADD45G;VAV2;BMP2;IL6;MELK;BIN1;E2F1;CTLA4;PMAIP1;FADD;BAK1;ECT2;ARHGEF6
positive regulation of phosphatidylinositol 3-kinase activity (GO:0043552),7/28,2.0345238590004125E-6,6.797703246542555E-5,0,0,14.866057838660579,194.82338579406945,CCL21;KIT;CCL19;PRKD1;TEK;FGF2;FGFR3
metanephric mesenchyme development (GO:0072075),5/11,2.2055308109550043E-6,7.297523304596752E-5,0,0,37.02462121212121,482.2287468753678,STAT1;WT1;SIX1;PKD2;PAX2
positive regulation of developmental process (GO:0051094),16/177,2.2993748922508483E-6,7.534874646914318E-5,0,0,4.4926667535363185,58.32772305135678,ALK;PRKN;DCN;PAX2;AURKA;CDC20;VIL1;RPS6KA3;BMP2;MDK;WT1;CFL1;KDR;CAMK1;BMPR1B;SOX5
protein-containing complex assembly (GO:0065003),20/267,2.491317972020615E-6,8.086106332044052E-5,0,0,3.678590140509645,47.46374015568969,YAP1;TLE4;TCF7L2;BLM;FANCA;MITF;LAMC1;VIL1;PARD6B;CXCL12;TERT;RUVBL1;REPS2;CAPN3;ELOB;DMD;FADD;PPARGC1A;TEAD1;SKAP2
positive regulation of cell cycle process (GO:0090068),12/101,2.5286786042086673E-6,8.129940267116168E-5,0,0,6.061499338298259,78.1194741085415,PLK4;GPSM2;FEN1;DBF4;RACGAP1;CDC7;ECT2;NDC80;CDC25B;CIT;AURKA;MAD2L1
regulation of cyclin-dependent protein kinase activity (GO:1904029),9/54,2.698398652963474E-6,8.594525803083664E-5,0,0,8.94954128440367,114.75864382673028,CCNA2;CCNB2;BLM;CCND2;CDKN2C;CCND1;CCNE2;PKMYT1;CDKN3
positive regulation of cell-substrate adhesion (GO:0010811),10/70,3.235036634907817E-6,1.011468335024389E-4,0,0,7.469348659003831,94.42354927444029,NRP1;CCL21;MDK;RAC3;CIB1;CD36;CALR;UTRN;FBLN2;SKAP1
wound healing (GO:0042060),10/70,3.235036634907817E-6,1.011468335024389E-4,0,0,7.469348659003831,94.42354927444029,COL3A1;RAB3A;DST;ERBB2;PDGFA;GATA4;FGF1;FGF2;PPL;SYT7
positive regulation of lipid kinase activity (GO:0090218),7/30,3.366073680365974E-6,1.0428708275170216E-4,0,0,13.571967440937065,171.03072490901792,CCL21;KIT;CCL19;PRKD1;TEK;FGF2;FGFR3
regulation of G1/S transition of mitotic cell cycle (GO:2000045),10/71,3.6915063124268366E-6,1.1146565403436085E-4,0,0,7.346523459581684,91.90115866935729,CCND2;ANXA1;CDKN2C;CCND1;CDKN2A;FAM107A;E2F1;CCL2;PKD2;KLF4
blood vessel morphogenesis (GO:0048514),9/56,3.6958975662801573E-6,1.1146565403436085E-4,0,0,8.567831348819052,107.1688945009389,NRP1;LAMA1;WT1;FLT4;CAV1;KDR;PROX1;NKX2-5;TGFBR2
chemokine-mediated signaling pathway (GO:0070098),9/56,3.6958975662801573E-6,1.1146565403436085E-4,0,0,8.567831348819052,107.1688945009389,CCL14;CCL13;CXCL10;CXCL12;CCL21;CCL2;CIB1;CCL19;CCL16
cellular response to oxygen-containing compound (GO:1901701),22/323,3.768574972071499E-6,1.1266055705982166E-4,0,0,3.3268773120331754,41.54875068477283,RET;EGR1;MEF2C;JUN;FOS;PKD2;SSTR2;ESR1;PAX2;FOXO1;AQP1;CXCL10;ZFP36;IL6;GNG2;WT1;SIRPA;CCL2;CTSG;PRKD1;VIM;EZR
positive regulation of signal transduction (GO:0009967),19/252,4.033757964387539E-6,1.1953954037071943E-4,0,0,3.6986237885107496,45.93991117649091,YAP1;NRP1;MAML2;VWF;CAV2;PRKCA;GATA3;SLC2A4;FGF1;PKD2;C3;RIMS2;VTN;BMP2;IL6;TERT;TNFSF11;BAK1;TEK
regulation of macrophage derived foam cell differentiation (GO:0010743),7/31,4.265045860085784E-6,1.2512187187456144E-4,0,0,13.00580289193303,160.8175022106077,PLA2G2A;IL18;PPARG;CD36;APOB;PPARA;AGT
inflammatory response (GO:0006954),18/230,4.295557221045683E-6,1.2512187187456144E-4,0,0,3.846206530864743,47.53114828084011,CCL14;CCL13;ANXA1;CCL21;IL18;CXCR4;FOS;SELE;CXCL10;BMP2;IL6;KIT;CXCR2;MAPKAPK2;CCL2;CCL19;TNFRSF4;CCL16
platelet degranulation (GO:0002576),13/125,4.393474480746966E-6,1.268895002575056E-4,0,0,5.224020337301587,64.44032922339977,VWF;PROS1;HGF;F13A1;PDGFA;CLEC3B;HABP4;PECAM1;SERPING1;CD36;TIMP1;A2M;ALDOA
granulocyte chemotaxis (GO:0071621),10/73,4.774441644424195E-6,1.3617591055477518E-4,0,0,7.112570698777596,87.1448771571957,CCL14;CCL13;CXCL10;ANXA1;CCL21;CXCR2;SAA1;CCL2;CCL19;CCL16
circulatory system development (GO:0072359),13/126,4.8014317876721966E-6,1.3617591055477518E-4,0,0,5.177523762700754,63.40704384955149,MEF2C;FLT4;PKD2;PCSK5;TGFBR2;CDH5;BMP2;COL3A1;WT1;TEK;ZFPM2;TDGF1;PDLIM4
lymphocyte chemotaxis (GO:0048247),8/44,4.95062479243729E-6,1.3617591055477518E-4,0,0,9.925756420035595,121.25300835360585,CCL14;CCL13;CXCL10;CCL21;SAA1;CCL2;CCL19;CCL16
positive regulation of cell-matrix adhesion (GO:0001954),8/44,4.95062479243729E-6,1.3617591055477518E-4,0,0,9.925756420035595,121.25300835360585,NRP1;CCL21;KDR;CIB1;CD36;TEK;UTRN;SKAP1
chordate embryonic development (GO:0043009),9/58,4.994715029151085E-6,1.3617591055477518E-4,0,0,8.217281407976035,100.30942402662093,COL1A1;ARNT2;BMP2;BRCA1;PROX1;GATA3;PKD2;NKX2-5;PCSK5
fat cell differentiation (GO:0045444),9/58,4.994715029151085E-6,1.3617591055477518E-4,0,0,8.217281407976035,100.30942402662093,PER2;TCF7L2;NR4A1;EGR2;HMGA2;PPARG;KLF4;PPARGC1A;FOXO1
positive regulation of mitochondrion organization (GO:0010822),9/58,4.994715029151085E-6,1.3617591055477518E-4,0,0,8.217281407976035,100.30942402662093,PRKN;KDR;PLAUR;PMAIP1;ZNF205;BAK1;PPARGC1A;DCN;AURKA
chondrocyte differentiation (GO:0002062),7/32,5.355323667294457E-6,1.4370821305621662E-4,0,0,12.484931506849316,151.53485005143733,MEF2C;BMP2;HMGA2;BMPR1B;FGFR3;RUNX2;SOX5
regulation of cell migration involved in sprouting angiogenesis (GO:0090049),7/32,5.355323667294457E-6,1.4370821305621662E-4,0,0,12.484931506849316,151.53485005143733,ANXA1;RHOJ;KDR;CIB1;PTGS2;KLF4;FGF2
regulation of actin cytoskeleton organization (GO:0032956),11/91,5.588659829419609E-6,1.487980679582971E-4,0,0,6.170074884792626,74.62564305485502,EPS8;LRP1;SH3BP1;MDK;FAM107A;RAC3;RHOH;PDGFA;EZR;PAK3;RND1
negative regulation of inflammatory response (GO:0050728),17/212,5.7218108235729144E-6,1.51162258036717E-4,0,0,3.943445962137551,47.60222437207195,ADRB1;GATA3;ADRB2;KLF4;ADCY5;CDH5;IL6;PROC;GNG2;PRKAR2B;MDK;SAA1;SIRPA;PPARG;TEK;PPARA;RAMP1
positive regulation of transferase activity (GO:0051347),14/148,5.8039448302798426E-6,1.5215264601225925E-4,0,0,4.707795131073173,56.761757506491804,ALK;RET;RFC4;FLT4;KLF4;MAPK15;KIT;ERBB2;KDR;NEK2;TEK;FGFR4;FGFR3;MET
negative regulation of cell differentiation (GO:0045596),16/191,6.168738971385711E-6,1.6048139247696566E-4,0,0,4.13026973026973,49.546782270815015,YAP1;CAV1;DTX1;GATA3;ASCL1;FOXO1;IL6;SIX3;E2F1;SOSTDC1;SPRY2;PPARG;CALR;ZFPM2;PPARA;RUNX1T1
response to tumor necrosis factor (GO:0034612),12/110,6.230827086242194E-6,1.608673933761663E-4,0,0,5.502285902813782,65.95040694892461,CCL14;CCL13;ZFP36;CCL21;CCL2;CIB1;GATA3;BRCA1;CCL19;SELE;TDGF1;CCL16
positive regulation of hydrolase activity (GO:0051345),14/149,6.277982194551092E-6,1.608673933761663E-4,0,0,4.672681962705164,55.971543027962774,CCL14;CCL13;CCL21;CAV2;ADRB1;BMP2;SH3BP1;ERBB2;CCL2;PRTN3;CCL19;ECT2;CCL16;EZH2
cell projection assembly (GO:0030031),6/22,6.467437033610027E-6,1.6448526425778337E-4,0,0,16.690489749430522,199.43016657856674,RHOJ;PDGFA;RHOH;RAC3;PARVA;NEFH
cellular response to chemokine (GO:1990869),9/60,6.666618227598621E-6,1.6829507347893407E-4,0,0,7.894225580140313,94.0865210946465,CCL14;CCL13;CXCL10;CXCL12;CCL21;DUSP1;CCL2;CCL19;CCL16
positive regulation of apoptotic process (GO:0043065),21/310,6.799262717681606E-6,1.7038152457249202E-4,0,0,3.301772540314683,39.28678895826963,BARD1;VAV3;NGFR;KLF11;JUN;ITSN1;HMGA2;FOXO1;GADD45G;VAV2;BMP2;IL6;MELK;BIN1;E2F1;CTLA4;PMAIP1;FADD;BAK1;ECT2;ARHGEF6
protein-containing complex subunit organization (GO:0043933),12/112,7.5174402712400545E-6,1.8700318572544602E-4,0,0,5.391685912240185,63.61264630821605,VIL1;YAP1;PARD6B;FANCA;REPS2;CAPN3;MITF;ELOB;LAMC1;PPARGC1A;TEAD1;SKAP2
hemopoiesis (GO:0030097),11/94,7.680373429249021E-6,1.8967183077449757E-4,0,0,5.946144023096997,70.02680097866063,MELK;MECOM;TAL1;FLT4;KIT;KDR;INHBA;TEK;NKX2-5;RUNX2;TGFBR2
positive regulation of phosphatidylinositol 3-kinase signaling (GO:0014068),10/77,7.787820720920793E-6,1.909416763805616E-4,0,0,6.686567164179104,78.65375181795636,HGF;KIT;KDR;IL18;PDGFA;IRS2;TEK;FGF2;DCN;AGT
blood vessel endothelial cell migration (GO:0043534),6/23,8.586381299057636E-6,2.0901705333706015E-4,0,0,15.707892268524722,183.23779686402096,NRP1;CDH5;NR4A1;KDR;FGF2;TDGF1
positive regulation of kinase activity (GO:0033674),12/114,9.031381983146975E-6,2.1829042410329713E-4,0,0,5.285423176198886,61.389160372866876,ALK;RET;CCL21;FLT4;KIT;ERBB2;KDR;CCL19;TEK;FGFR4;FGFR3;MET
positive regulation of protein kinase activity (GO:0045860),14/154,9.202273722681785E-6,2.2085456934436282E-4,0,0,4.504640371229699,52.23607984605467,EGR1;CCL21;HMGA2;CIB1;ADRB2;AGT;TGFBR2;CCL19;CAMK1;ECT2;PAK3;PAK5;EZH2;PAK4
cellular response to reactive oxygen species (GO:0034614),9/63,1.006247357036294E-5,2.390338252974846E-4,0,0,7.454510703363915,85.77679998550185,JUN;IL6;ANXA1;SIRPA;FOS;PKD2;ECT2;PAX2;AQP1
regulation of phosphatidylinositol 3-kinase activity (GO:0043551),7/35,1.0100020787217659E-5,2.390338252974846E-4,0,0,11.145547945205479,128.20693793072965,CCL21;KIT;CCL19;PRKD1;TEK;FGF2;FGFR3
positive regulation of cold-induced thermogenesis (GO:0120162),11/97,1.0423553536281957E-5,2.4331144144965007E-4,0,0,5.73783624477548,65.82125883994082,PER2;EPAS1;CAV1;LEPR;IL18;CXCR4;ADRB1;ADRB2;CD36;PPARGC1A;GADD45G
regulation of MAP kinase activity (GO:0043405),11/97,1.0423553536281957E-5,2.4331144144965007E-4,0,0,5.73783624477548,65.82125883994082,DUSP1;KIT;ERBB2;CBLC;TNFSF11;PDGFA;SPRY2;FGF1;FGF2;AGT;EZH2
positive regulation of DNA-binding transcription factor activity (GO:0051091),18/246,1.0894800669849568E-5,2.5194488559415317E-4,0,0,3.573339085418464,40.8333493204993,OPRD1;ALK;ANXA3;CAV1;IL18;CIB1;ESR1;AGT;IL6;KIT;TNFSF11;CAPN3;PPARG;PRKD1;CD36;RHEBL1;PPARGC1A;IKBKE
positive regulation of cell adhesion (GO:0045785),10/80,1.1015195995753763E-5,2.5194488559415317E-4,0,0,6.399014778325123,73.05265509779782,RET;CXCL12;CCL21;MDK;ERBB2;SAA1;RAC3;CIB1;PRKCA;FBLN2
regulation of fat cell differentiation (GO:0045598),10/80,1.1015195995753763E-5,2.5194488559415317E-4,0,0,6.399014778325123,73.05265509779782,YAP1;ZFP36;BMP2;IL6;E2F1;PPARG;GATA3;ZFPM2;FOXO1;RUNX1T1
negative regulation of cellular process (GO:0048523),30/566,1.1505524371382083E-5,2.614055137178009E-4,0,0,2.5650512497752205,29.171515403770147,PRKN;BLM;CIB1;GATA3;PKD2;FGF2;ADRA1A;RND1;MDK;SIRPA;TNS2;KLF11;CDKN2C;CR1;DUSP1;CDKN2A;HMGA1;PROX1;INHBA;KLF4;SSTR2;NR4A1;BMP2;IL6;WT1;TXNIP;PRTN3;PRKD1;CRYAB;CDKN3
negative regulation of fat cell differentiation (GO:0045599),7/36,1.2299533160053726E-5,2.7692209020197195E-4,0,0,10.76066761139978,121.6595619189266,YAP1;IL6;E2F1;GATA3;ZFPM2;FOXO1;RUNX1T1
skeletal system development (GO:0001501),14/158,1.2350985243749922E-5,2.7692209020197195E-4,0,0,4.378609177623098,49.48605451789588,PCSK5;ETS2;COL1A1;RPS6KA3;ACAN;BMP2;MMP14;VCAN;COL1A2;COL2A1;BMPR1B;PITX1;FGFR3;SOX5
axon guidance (GO:0007411),16/203,1.3337287878789744E-5,2.9708154961382644E-4,0,0,3.8628323548109647,43.36008785615363,RET;NRP1;SHC3;LAMA1;RHOH;CXCR4;PRKCA;IRS2;SEMA3F;SPTB;SPTA1;EFNA3;CXCL12;FEZ1;EVL;EZR
positive regulation of vascular endothelial growth factor production (GO:0010575),6/25,1.4505832028040602E-5,3.210121789062492E-4,0,0,14.052991248051793,156.5638102912704,C3;IL6;FLT4;GATA4;BRCA1;PTGS2
positive regulation of cell cycle (GO:0045787),9/66,1.4836844874085205E-5,3.250936075124742E-4,0,0,7.061081603090295,78.50790817639493,CCND2;CCND1;TAL1;CHEK1;PRKCA;PROX1;CALR;PKD2;CDC25B
negative regulation of endothelial cell proliferation (GO:0001937),7/37,1.4881045414303396E-5,3.250936075124742E-4,0,0,10.40144596651446,115.61646418517509,NGFR;MEF2C;CAV2;STAT1;CAV1;CCL2;PPARG
transcription initiation from RNA polymerase II promoter (GO:0006367),13/140,1.5233461774756128E-5,3.2968653025884485E-4,0,0,4.603455818022747,51.061606128163106,YAP1;MAML2;ESR1;NR4A1;NR5A2;RARB;E2F2;PPARG;POLR2H;PPARA;PPARGC1A;TEAD1;RXRG
regulation of osteoblast differentiation (GO:0045667),10/83,1.5335176949301753E-5,3.2968653025884485E-4,0,0,6.135096835144072,68.00976454674188,FBN2;YAP1;MEF2C;BMP2;IL6;HGF;PPARG;PRKD1;BMPR1B;RUNX2
epithelial cell differentiation (GO:0030855),11/101,1.5381501851865122E-5,3.2968653025884485E-4,0,0,5.481694828469022,60.75003299417765,VIL1;ANXA1;WT1;SIX3;KDR;SIX1;PPARG;GATA3;PROX1;ASCL1;PAX2
positive regulation of apoptotic cell clearance (GO:2000427),4/8,1.5767438552362905E-5,3.337604384251725E-4,0,0,44.333333333333336,490.2186527348688,C3;C4B;C4A;CCL2
regulation of apoptotic cell clearance (GO:2000425),4/8,1.5767438552362905E-5,3.337604384251725E-4,0,0,44.333333333333336,490.2186527348688,C3;C4B;C4A;CCL2
Ras protein signal transduction (GO:0007265),13/142,1.7744928827978765E-5,3.7330072497377553E-4,0,0,4.531617858168246,49.573229260698945,NGFR;GPSM2;JUN;SHC3;CDKN2A;RHOH;PLD1;FGF2;EPS8;CCNA2;COL1A2;CFL1;PRKD1
cartilage development (GO:0051216),8/52,1.7991906421037316E-5,3.735984462291187E-4,0,0,8.11774495527356,88.6911412902145,MEF2C;BMP2;COL2A1;HMGA2;FGF2;FGFR3;RUNX2;SOX5
sprouting angiogenesis (GO:0002040),8/52,1.7991906421037316E-5,3.735984462291187E-4,0,0,8.11774495527356,88.6911412902145,NRP1;NR4A1;FLT4;KDR;PARVA;TEK;FGF2;TDGF1
epithelium development (GO:0060429),12/122,1.8087952942430923E-5,3.735984462291187E-4,0,0,4.899013226957799,53.498519857906345,VIL1;BMP2;STAT1;WT1;KDR;SIX1;PPARG;PROX1;NKX2-5;PKD2;SOX10;PAX2
cellular response to organic substance (GO:0071310),12/123,1.9646831201087988E-5,4.033518116464329E-4,0,0,4.854628300355783,52.61249294167428,SIGIRR;STAT5B;CLEC3B;ERBB2;IL18;CXCR4;CCL2;CIB1;BMPR1B;KLF4;RAMP1;TGFBR2
response to interleukin-1 (GO:0070555),10/86,2.103899577619861E-5,4.2934669224721473E-4,0,0,5.892014519056262,63.45188740740407,CCL14;CCL13;ANXA1;CCL21;SIRPA;CCL2;PRKCA;CCL19;SELE;CCL16
cell chemotaxis (GO:0060326),9/69,2.1418224350333867E-5,4.344839796782013E-4,0,0,6.706995412844036,72.1087077953845,NRP1;NR4A1;CXCL12;CCL21;HGF;KIT;CXCR2;CXCR4;PARVA
regulation of GTPase activity (GO:0043087),15/189,2.278569397702665E-5,4.5948902410477405E-4,0,0,3.885525260625501,41.53384698079633,VAV3;CCL14;CCL13;CCL21;CAV2;ADRB1;VAV2;SH3BP1;ERBB2;CCL2;PRTN3;CCL19;ECT2;CCL16;EZH2
regulation of vascular endothelial growth factor production (GO:0010574),6/27,2.334803115000153E-5,4.6805935387767776E-4,0,0,12.713309469573707,135.58741875007615,C3;IL6;FLT4;GATA4;BRCA1;PTGS2
regulation of proteolysis (GO:0030162),8/54,2.3927917619342297E-5,4.74775930797444E-4,0,0,7.764003581733161,82.61260588293175,CYFIP2;DNAJC1;CAV1;PLAUR;CAPN3;BAK1;FADD;FGFR4
kidney development (GO:0001822),9/70,2.4101008224166023E-5,4.74775930797444E-4,0,0,6.596706271619793,70.14447236990898,CENPF;WT1;SIX2;SIX1;PROX1;GATA3;PCSK5;PAX2;AGT
neutrophil chemotaxis (GO:0030593),9/70,2.4101008224166023E-5,4.74775930797444E-4,0,0,6.596706271619793,70.14447236990898,CCL14;CCL13;CXCL10;CCL21;CXCR2;SAA1;CCL2;CCL19;CCL16
negative regulation of blood coagulation (GO:0030195),7/40,2.5440410916192668E-5,4.982811517378425E-4,0,0,9.454407084544071,100.01979555952,VTN;PROC;F12;PLAUR;PDGFA;SERPING1;A2M
muscle tissue morphogenesis (GO:0060415),5/17,2.644916693930062E-5,5.150786338807801E-4,0,0,18.50662878787879,195.06515839232503,BMP2;ACTC1;PROX1;NKX2-5;MYLK
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043154),8/55,2.7462309778988698E-5,5.287658289649348E-4,0,0,7.598422513267442,79.80392209239415,RPS6KA3;NGFR;HGF;SIAH2;PLAUR;KLF4;PAX2;AQP1
regulation of blood vessel endothelial cell migration (GO:0043535),8/55,2.7462309778988698E-5,5.287658289649348E-4,0,0,7.598422513267442,79.80392209239415,STAT5A;MEF2C;SH3BP1;KDR;PRKCA;PPARG;PRKD1;FGF2
cellular response to interleukin-9 (GO:0071355),4/9,2.7882225571303903E-5,5.308526522178977E-4,0,0,35.46485260770975,371.9383917501472,STAT5A;STAT5B;STAT1;IL2RG
interleukin-9-mediated signaling pathway (GO:0038113),4/9,2.7882225571303903E-5,5.308526522178977E-4,0,0,35.46485260770975,371.9383917501472,STAT5A;STAT5B;STAT1;IL2RG
cellular response to tumor necrosis factor (GO:0071356),15/194,3.09375896544872E-5,5.85751697458291E-4,0,0,3.776016629855788,39.208414504800245,CCL14;CCL13;CCL21;STAT1;CIB1;GATA3;BRCA1;ZFP36;LTA;TNFSF11;CCL2;CCL19;TDGF1;TNFRSF4;CCL16
muscle contraction (GO:0006936),12/129,3.169589697773828E-5,5.967934635366412E-4,0,0,4.604251791318766,47.69693294530393,ACTA2;ACTC1;TPM3;TNNI2;SCN4A;DMD;VIM;UTRN;ALDOA;ADRA1A;CRYAB;MYLK
regulation of actin filament-based process (GO:0032970),9/73,3.392326980020657E-5,6.352225465884835E-4,0,0,6.286518061926605,64.69713078832866,LRP1;SH3BP1;FAM107A;RAC3;RHOH;PDGFA;EZR;PAK3;RND1
positive regulation of epithelial to mesenchymal transition (GO:0010718),7/42,3.542923057247294E-5,6.404519729759274E-4,0,0,8.91324200913242,91.34266662659049,COL1A1;TCF7L2;BMP2;IL6;MDK;TGFBR2;EZH2
regulation of mitotic nuclear division (GO:0007088),8/57,3.58511869553752E-5,6.404519729759274E-4,0,0,7.287535609209359,74.59619016957318,DUSP1;CAV2;CHEK1;RCC1;NEK2;MKI67;PKMYT1;AURKA
cell migration involved in sprouting angiogenesis (GO:0002042),5/18,3.595451150579843E-5,6.404519729759274E-4,0,0,17.082167832167833,174.80619625259487,NRP1;NR4A1;KDR;FGF2;TDGF1
cellular response to glucocorticoid stimulus (GO:0071385),5/18,3.595451150579843E-5,6.404519729759274E-4,0,0,17.082167832167833,174.80619625259487,ZFP36;ANXA1;FAM107A;SSTR2;AQP1
dendritic cell migration (GO:0036336),5/18,3.595451150579843E-5,6.404519729759274E-4,0,0,17.082167832167833,174.80619625259487,EPS8;CCL21;CXCR2;CXCR4;CCL19
positive regulation of cell adhesion mediated by integrin (GO:0033630),5/18,3.595451150579843E-5,6.404519729759274E-4,0,0,17.082167832167833,174.80619625259487,RET;CCL21;RAC3;CIB1;SKAP1
positive regulation of glial cell differentiation (GO:0045687),5/18,3.595451150579843E-5,6.404519729759274E-4,0,0,17.082167832167833,174.80619625259487,EGR2;BMP2;BIN1;MDK;CXCR4
positive regulation of macrophage derived foam cell differentiation (GO:0010744),5/18,3.595451150579843E-5,6.404519729759274E-4,0,0,17.082167832167833,174.80619625259487,PLA2G2A;IL18;CD36;APOB;AGT
regulation of vascular endothelial cell proliferation (GO:1905562),5/18,3.595451150579843E-5,6.404519729759274E-4,0,0,17.082167832167833,174.80619625259487,MEF2C;MDK;CCL2;PPARG;FGF2
positive regulation of extrinsic apoptotic signaling pathway (GO:2001238),6/29,3.608180129441844E-5,6.404519729759274E-4,0,0,11.606615826483115,118.73245255777076,RET;CAV1;PMAIP1;FADD;INHBA;AGT
cellular response to fibroblast growth factor stimulus (GO:0044344),10/92,3.805561767146099E-5,6.719872799188551E-4,0,0,5.459209419680404,55.55543636518993,NR4A1;FGF7;ZFP36;CCL2;POLR2H;FGF1;FGFR4;FGF2;FGFR3;TDGF1
positive regulation of T cell activation (GO:0050870),9/75,4.2200356616029136E-5,7.413340997290067E-4,0,0,6.095391993327773,61.39938267813923,IL6;ANXA1;MDK;SIRPA;TNFSF11;RHOH;CCL2;GATA3;CCL19
cell projection organization (GO:0030030),6/30,4.426079673370787E-5,7.707020086358156E-4,0,0,11.122437357630979,111.50700830441033,RHOJ;PDGFA;RAC3;RHOH;PARVA;NEFH
positive regulation of metabolic process (GO:0009893),11/113,4.432441129478282E-5,7.707020086358156E-4,0,0,4.833807716635041,48.45396764667752,PER2;EPAS1;CAV1;LEPR;IL18;CXCR4;ADRB1;ADRB2;CD36;PPARGC1A;GADD45G
negative regulation of cell population proliferation (GO:0008285),22/379,4.5195334900807224E-5,7.779375328219409E-4,0,0,2.7968558581825165,27.98119110323483,KLF11;CDKN2C;MAGED1;CDKN2A;HMGA1;CIB1;GATA3;PROX1;INHBA;PKD2;SSTR2;KLF4;ADRA1A;PER2;BMP2;IL6;WT1;E2F1;PPARG;BMPR1B;TNS2;CDKN3
lipoprotein transport (GO:0042953),4/10,4.565361108109982E-5,7.779375328219409E-4,0,0,29.552532123960695,295.3606501099457,LRP1;PPARG;CD36;APOB
mesenchymal to epithelial transition (GO:0060231),4/10,4.565361108109982E-5,7.779375328219409E-4,0,0,29.552532123960695,295.3606501099457,WT1;SIX2;GATA3;PAX2
regulation of epithelial cell apoptotic process (GO:1904035),4/10,4.565361108109982E-5,7.779375328219409E-4,0,0,29.552532123960695,295.3606501099457,YAP1;ZFP36;MDK;TEK
positive regulation of peptidyl-tyrosine phosphorylation (GO:0050731),12/134,4.620035970073705E-5,7.808019746110678E-4,0,0,4.414417143073487,44.06702054833033,SOCS3;VTN;NRP1;FGF7;IL6;HGF;KIT;IL18;PECAM1;FGFR3;TDGF1;AGT
regulation of secretion by cell (GO:1903530),8/59,4.627992924631329E-5,7.808019746110678E-4,0,0,7.001031991744066,69.87591539665772,RIMS2;MEF2C;DNAJC1;RAB3A;ANXA1;SAA1;SNCAIP;SYN1
cellular response to interleukin-7 (GO:0098761),5/19,4.790659149109702E-5,8.003218813806797E-4,0,0,15.8612012987013,157.75959164021398,STAT5A;STAT5B;CISH;IRS2;IL2RG
interleukin-7-mediated signaling pathway (GO:0038111),5/19,4.790659149109702E-5,8.003218813806797E-4,0,0,15.8612012987013,157.75959164021398,STAT5A;STAT5B;CISH;IRS2;IL2RG
Notch signaling pathway (GO:0007219),8/60,5.2374324187954026E-5,8.706912040612065E-4,0,0,6.866044710438303,67.67924868982128,BMP2;MAML2;MDK;STAT1;DTX1;SORBS2;ASCL1;ZNF423
positive regulation of leukocyte cell-cell adhesion (GO:1903039),6/31,5.3859849054889534E-5,8.910406096071045E-4,0,0,10.676993166287016,104.94550337179261,IL6;MDK;CCL2;SIRPA;TNFSF11;SKAP1
positive regulation of DNA biosynthetic process (GO:2000573),8/61,5.9122442474270745E-5,9.733781833445154E-4,0,0,6.7361512888044555,65.5824951193837,CCT3;RFC4;HGF;NEK2;KLF4;FGFR4;FGF2;MAPK15
negative regulation of cytokine production (GO:0001818),14/182,5.978771170212308E-5,9.79598660965555E-4,0,0,3.7484532095901004,36.45262194140685,ANXA1;CR1;UBE2L6;INHBA;KLF4;SIGIRR;ZFP36;IL6;BCL3;SIRPA;HOMER3;EZR;PPARA;IKBKE
regulation of nuclear division (GO:0051783),5/20,6.271254557499507E-5,0.0010177350253313486,0,0,14.803030303030303,143.24816990109616,CAV2;RCC1;NEK2;MKI67;PKMYT1
regulation of tissue remodeling (GO:0034103),5/20,6.271254557499507E-5,0.0010177350253313486,0,0,14.803030303030303,143.24816990109616,MDK;FLT4;IL18;LEPR;SYT7
liver development (GO:0001889),6/32,6.50532824677157E-5,0.0010457622011791278,0,0,10.265813912738741,98.9655658338606,IL6;ANXA1;PROX1;PKD2;MET;AURKA
regulation of NMDA receptor activity (GO:2000310),6/32,6.50532824677157E-5,0.0010457622011791278,0,0,10.265813912738741,98.9655658338606,GRIA2;MEF2C;DLG2;CCL2;MAPK8IP2;GRIA4
negative regulation of response to external stimulus (GO:0032102),11/118,6.605684711619939E-5,0.0010569095538591903,0,0,4.60674447650631,44.33989193865748,SIGIRR;CDH5;PROC;SAA1;SIRPA;PPARG;GATA3;TEK;PPARA;KLF4;FGF2
lipoprotein localization (GO:0044872),4/11,7.048132081850519E-5,0.0011135218987524532,0,0,25.32944606413994,242.15362892344896,LRP1;PPARG;CD36;APOB
positive regulation of lipid localization (GO:1905954),4/11,7.048132081850519E-5,0.0011135218987524532,0,0,25.32944606413994,242.15362892344896,C3;LRP1;APOB;IKBKE
response to interferon-gamma (GO:0034341),9/80,7.065301451715113E-5,0.0011135218987524532,0,0,5.664685359865616,54.141531966356645,CCL14;CCL13;CCL21;STAT1;SIRPA;CCL2;CCL19;TDGF1;CCL16
enzyme linked receptor protein signaling pathway (GO:0007167),12/140,7.090206925741853E-5,0.0011135218987524532,0,0,4.206192263279446,40.18684813451815,ALK;RET;SHC3;FLT4;KIT;ERBB2;KDR;LIFR;TEK;FGFR4;FGFR3;MET
actin cytoskeleton reorganization (GO:0031532),8/63,7.479878219640958E-5,0.0011693314207585498,0,0,6.490534636987726,61.664680541312,NRP1;FGF7;ANXA1;KIT;S1PR1;PARVA;EZR;PDLIM4
heart development (GO:0007507),13/164,8.028875969666322E-5,0.0012494250824028688,0,0,3.866997792494481,36.46532872309215,MEF2C;GATA4;PKD2;PCSK5;TGFBR2;BMP2;COL3A1;WT1;TEK;ZFPM2;NKX2-5;TDGF1;PDLIM4
positive regulation of cytoskeleton organization (GO:0051495),9/82,8.585821650519764E-5,0.0013300218265896071,0,0,5.5089229609149175,51.579016988146584,PLK4;VIL1;GPSM2;NRP1;CCL21;BIN1;EVL;PROX1;TEK
receptor-mediated endocytosis (GO:0006898),12/143,8.704079488600753E-5,0.0013422399500973468,0,0,4.109232586428785,38.41776461854158,GRK3;LRP1;CAV2;CAV1;CXCR2;MX1;SAA1;ADRB2;CALR;CD36;APOB;RAMP1
receptor internalization (GO:0031623),7/49,9.866298040496088E-5,0.0015146100775680481,0,0,7.425038051750381,68.48707157848222,GRK3;LRP1;CAV1;CXCR2;MX1;CD36;RAMP1
"DNA-templated transcription, initiation (GO:0006352)",13/168,1.0259232431144448E-4,0.001561277379820155,0,0,3.7664277180406214,34.59368734048584,YAP1;MAML2;ESR1;NR4A1;NR5A2;RARB;E2F2;PPARG;POLR2H;PPARA;PPARGC1A;TEAD1;RXRG
regulation of lipid storage (GO:0010883),5/22,1.0267879976536279E-4,0.001561277379820155,0,0,13.060160427807487,119.94327123160554,C3;IL6;APOB;IKBKE;MEST
hemidesmosome assembly (GO:0031581),4/12,1.0386637001180773E-4,0.001561277379820155,0,0,22.162131519274375,203.28005457362545,COL17A1;DST;KRT5;LAMC1
negative regulation of leukocyte apoptotic process (GO:2000107),4/12,1.0386637001180773E-4,0.001561277379820155,0,0,22.162131519274375,203.28005457362545,CXCL12;CCL21;IRF7;CCL19
"negative regulation of blood coagulation, intrinsic pathway (GO:2000267)",3/5,1.0582601958288023E-4,0.001561277379820155,0,0,66.35633484162896,607.406920318733,F12;SERPING1;A2M
negative regulation of leukocyte adhesion to vascular endothelial cell (GO:1904995),3/5,1.0582601958288023E-4,0.001561277379820155,0,0,66.35633484162896,607.406920318733,CXCL12;CCL21;KLF4
negative regulation of vascular endothelial cell proliferation (GO:1905563),3/5,1.0582601958288023E-4,0.001561277379820155,0,0,66.35633484162896,607.406920318733,MEF2C;CCL2;PPARG
"regulation of blood coagulation, intrinsic pathway (GO:2000266)",3/5,1.0582601958288023E-4,0.001561277379820155,0,0,66.35633484162896,607.406920318733,F12;SERPING1;A2M
renal tubule development (GO:0061326),3/5,1.0582601958288023E-4,0.001561277379820155,0,0,66.35633484162896,607.406920318733,MEF2C;STAT1;PKD2
negative regulation of signal transduction (GO:0009968),17/267,1.0876982399894394E-4,0.0015977912077086247,0,0,3.0671495327102805,27.99165505496778,LRP1;SIAH2;GATA4;GATA3;MAPK8IP2;FGF2;AGT;DCN;SIGIRR;MMP14;BMP2;ERBB2;SOSTDC1;SPRY2;CALR;TNS2;EZH2
cellular response to hydrogen peroxide (GO:0070301),6/35,1.1013167698386168E-4,0.001603969039149575,0,0,9.202419291493205,83.86932039093192,IL6;ANXA1;SIRPA;ECT2;PAX2;AQP1
negative regulation of cell cycle G1/S phase transition (GO:1902807),6/35,1.1013167698386168E-4,0.001603969039149575,0,0,9.202419291493205,83.86932039093192,CDKN2C;CDKN2A;FAM107A;CCL2;PKD2;KLF4
regulation of cell growth (GO:0001558),15/217,1.1095402386992724E-4,0.0016090694185051577,0,0,3.342102233479162,30.43450187139008,CDKN2C;CISH;CDKN2A;FAM107A;CIB1;INHBA;AGT;RPS6KA3;MMP14;EXOSC4;WT1;ERBB2;SGK1;PAK5;PAK4
regulation of complement activation (GO:0030449),7/50,1.1255210827522226E-4,0.0016253287500082943,0,0,7.251991079961771,65.93578646362786,C4B;C3;C4A;VTN;CR1;PROS1;SERPING1
negative regulation of defense response (GO:0031348),9/85,1.1375662442763769E-4,0.00162968468859188,0,0,5.290650651859005,48.04677547423861,CDH5;PROC;SAA1;SIRPA;PPARG;GATA3;TEK;PPARA;KLF4
central nervous system development (GO:0007417),17/268,1.1381013963757847E-4,0.00162968468859188,0,0,3.054771567933872,27.74031627410966,PRKN;ARNT2;CNTNAP2;EGR2;CXCR4;PROX1;GRIN2C;PKD2;SOX10;GRIN2D;TGFBR2;C3;RPS6KA3;ACAN;VCAN;SIX3;PAFAH1B3
vascular endothelial growth factor receptor signaling pathway (GO:0048010),8/67,1.1657956500225636E-4,0.0016623563076472374,0,0,6.04925726253733,54.787739241822784,CYFIP2;VAV3;NRP1;FLT4;MAPKAPK2;KDR;PRKD1;VAV2
glucose homeostasis (GO:0042593),9/86,1.2459380672708188E-4,0.0017692320555245627,0,0,5.221672822590254,46.94519708584114,NGFR;TCF7L2;IL6;LEPR;PPARG;SLC2A4;FGFR4;PPARGC1A;FOXO1
regulation of phosphatidylinositol 3-kinase signaling (GO:0014066),10/106,1.27560653090851E-4,0.0018038452520067227,0,0,4.659722222222222,41.7833498464697,HGF;KIT;KDR;IL18;PDGFA;IRS2;TEK;FGF2;DCN;AGT
positive regulation of morphogenesis of an epithelium (GO:1905332),5/23,1.2881576940593472E-4,0.0018140667030389485,0,0,12.333964646464647,110.4768916804155,MDK;SIX1;FGF2;AGT;PAX2
endoderm formation (GO:0001706),6/36,1.2969823137348055E-4,0.0018189776646947396,0,0,8.895216400911162,79.61485626948338,VTN;MMP14;DUSP1;HMGA2;COL8A1;INHBA
negative regulation of angiogenesis (GO:0016525),9/87,1.36280896642754E-4,0.001901058946124223,0,0,5.154463655610445,45.878810858624725,CXCL10;EFNA3;STAT1;E2F2;SPRY2;PPARG;TEK;KLF4;DCN
brain development (GO:0007420),12/150,1.3743306892625306E-4,0.001901058946124223,0,0,3.899387488703685,34.67481009093889,CNTNAP2;ARNT2;EGR2;CENPF;SIX3;CXCR4;PROX1;GRIN2C;PAFAH1B3;PAX2;GRIN2D;TGFBR2
response to cytokine (GO:0034097),12/150,1.3743306892625306E-4,0.001901058946124223,0,0,3.899387488703685,34.67481009093889,SIGIRR;COL3A1;ANXA1;STAT1;MAPKAPK2;MX1;CXCR4;LIFR;PRKCA;TIMP1;SELE;IKBKE
microtubule cytoskeleton organization involved in mitosis (GO:1902850),11/128,1.377821477971488E-4,0.001901058946124223,0,0,4.2108393398715975,37.43367435118921,CDC20;GPSM2;DSN1;CENPF;STMN1;RCC1;TUBG1;BUB1;NDC80;AURKA;MAD2L1
regulation of cellular macromolecule biosynthetic process (GO:2000112),24/468,1.4289799871534072E-4,0.0019636950791204885,0,0,2.4537459074276176,21.72394366084421,ARNT2;MEF2C;MAGED1;HMGA1;PDGFA;RHOH;HMGA2;SIX1;GATA4;MITF;BRCA2;ESR1;SAP30;KLF1;CCNA2;BMP2;NR5A2;WT1;E2F1;ZNF205;CALR;ZNF423;PPARGC1A;EZH2
peptidyl-tyrosine phosphorylation (GO:0018108),8/69,1.4377780529172243E-4,0.0019678504435108033,0,0,5.8503207412687095,51.75920026837376,FLT4;KIT;ERBB2;KDR;TEK;BMX;FGFR4;FGFR3
cardiac right ventricle morphogenesis (GO:0003215),4/13,1.4739777958223916E-4,0.0020013212462799647,0,0,19.698664651045604,173.78901920154723,GATA4;GATA3;NKX2-5;ZFPM2
embryonic hemopoiesis (GO:0035162),4/13,1.4739777958223916E-4,0.0020013212462799647,0,0,19.698664651045604,173.78901920154723,TAL1;KIT;KDR;TGFBR2
DNA replication (GO:0006260),10/108,1.4908188103691537E-4,0.0020161549625944747,0,0,4.564156697161623,40.21485250852511,BARD1;BLM;FEN1;RFC4;DBF4;POLE2;CHEK1;MCM4;CDC7;BRCA1
negative regulation of G1/S transition of mitotic cell cycle (GO:2000134),6/37,1.519210510007808E-4,0.0020383737866561456,0,0,8.607833051656991,75.68135569271658,CDKN2C;CDKN2A;FAM107A;CCL2;PKD2;KLF4
negative regulation of stress-activated MAPK cascade (GO:0032873),6/37,1.519210510007808E-4,0.0020383737866561456,0,0,8.607833051656991,75.68135569271658,PRKN;MECOM;DUSP1;SIRPA;EZR;FOXO1
actin filament organization (GO:0007015),12/152,1.5576648027204162E-4,0.002081773195165168,0,0,3.8432860442098318,33.69467521026368,EPS8;SPTA1;VIL1;ACTC1;SH3BP1;TPM3;RAC3;RHOH;EVL;PROX1;ALDOA;RND1
endocrine system development (GO:0035270),5/24,1.5975843922071787E-4,0.0021267842221258065,0,0,11.68421052631579,102.14158819638371,MDK;WT1;SIX3;SIX1;NKX2-5
negative regulation of cysteine-type endopeptidase activity (GO:2000117),7/53,1.6401727580791053E-4,0.0021581887102446297,0,0,6.777992852888624,59.07385966426651,RPS6KA3;NGFR;HGF;SIAH2;KLF4;PAX2;AQP1
positive regulation of phagocytosis (GO:0050766),7/53,1.6401727580791053E-4,0.0021581887102446297,0,0,6.777992852888624,59.07385966426651,C4B;C3;C4A;SIRPA;CCL2;CALR;IL2RG
regulation of immune effector process (GO:0002697),7/53,1.6401727580791053E-4,0.0021581887102446297,0,0,6.777992852888624,59.07385966426651,C4B;C3;C4A;VTN;CR1;PROS1;SERPING1
DNA metabolic process (GO:0006259),17/277,1.6921520452853618E-4,0.0022102384810440295,0,0,2.9476545650611072,25.59843224526505,BARD1;CDT1;TCF7L2;FEN1;BLM;RFC4;PARP1;FANCA;CDC7;BRCA1;DBF4;RAD51;TERT;POLE2;CHEK1;MCM4;KPNA2
cellular response to metal ion (GO:0071248),11/131,1.692700245165762E-4,0.0022102384810440295,0,0,4.104934715821813,35.64731604159212,PRKN;MEF2C;JUN;DLG2;CAPN3;FOS;ECT2;SYT9;PKD2;SYT7;AQP1
myeloid leukocyte differentiation (GO:0002573),8/71,1.7600190199345287E-4,0.0022855695345881683,0,0,5.664015110239366,48.96549987139421,PARP1;KIT;E2F1;TNFSF11;PPARG;PRTN3;CCL19;TGFBR2
negative regulation of G0 to G1 transition (GO:0070317),6/38,1.770511611300694E-4,0.0022855695345881683,0,0,8.338411161731207,72.03613290108822,RAD51;CHEK1;E2F1;CDC7;BRCA1;EZH2
ventricular septum development (GO:0003281),6/38,1.770511611300694E-4,0.0022855695345881683,0,0,8.338411161731207,72.03613290108822,GATA4;GATA3;PROX1;NKX2-5;ZFPM2;TGFBR2
regulation of humoral immune response (GO:0002920),7/54,1.8488176373825061E-4,0.0023776492483772007,0,0,6.633440202079083,57.01968583422676,C4B;C3;C4A;VTN;CR1;PROS1;SERPING1
nervous system development (GO:0007399),23/447,1.8651481399350643E-4,0.0023896334063528944,0,0,2.459162344630242,21.116826783900184,PRKN;YAP1;ARNT2;MEF2C;EGR2;CXCR4;PROX1;INHBA;ASCL1;PKD2;SOX10;FGF2;RPS6KA3;ACAN;VCAN;MDK;DPYSL2;FEZ1;EVL;ECT2;TEAD1;PAFAH1B3;MET
positive regulation of transport (GO:0051050),9/91,1.92597090640506E-4,0.002458317920984436,0,0,4.902019467442381,41.93633616822241,ANXA1;LRP1;SIRPA;ZNF205;BAK1;CCL19;CALR;SGK1;IL2RG
outflow tract septum morphogenesis (GO:0003148),5/25,1.9607182978225796E-4,0.0024840624382822868,0,0,11.099431818181818,94.75617672508949,NRP1;PARVA;NKX2-5;ZFPM2;TGFBR2
receptor signaling pathway via STAT (GO:0097696),5/25,1.9607182978225796E-4,0.0024840624382822868,0,0,11.099431818181818,94.75617672508949,STAT5A;STAT5B;STAT1;CCL2;PKD2
positive regulation of cytokine production (GO:0001819),19/335,1.9874093177191447E-4,0.002508552205476609,0,0,2.7154350151542164,23.145033247605603,EGR1;ANXA1;FLT4;IL18;GATA4;GATA3;BRCA1;PTGS2;AGT;C3;IL6;MDK;SAA1;IRF7;PAEP;FADD;CCL19;POLR2H;LURAP1
organelle organization (GO:0006996),22/420,1.99666239851024E-4,0.0025109319018903685,0,0,2.503379783076137,21.325950375700884,PRKN;CCL13;DST;PARP1;CAV2;CAV1;PKD2;MAPK15;SYNE1;TERT;BIN1;MDK;DPYSL2;CFL1;CCL2;PRKD1;PPARGC1A;CEP55;NECTIN2;PAK5;SH3D19;PAK4
regulation of cellular component biogenesis (GO:0044087),6/39,2.0535250244227258E-4,0.002542589674244315,0,0,8.085317871194864,68.65067574160803,CCL19;CD36;SNCAIP;EZR;AGT;GFAP
regulation of T cell differentiation (GO:0045580),6/39,2.0535250244227258E-4,0.002542589674244315,0,0,8.085317871194864,68.65067574160803,CR1;MDK;FANCA;CTLA4;RHOH;GATA3
mesenchymal cell differentiation involved in kidney development (GO:0072161),3/6,2.081521476273955E-4,0.002542589674244315,0,0,44.23529411764706,374.9932607380858,STAT1;SIX2;PAX2
mesodermal cell fate commitment (GO:0001710),3/6,2.081521476273955E-4,0.002542589674244315,0,0,44.23529411764706,374.9932607380858,SIX2;KLF4;PAX2
negative regulation of cardiac muscle cell apoptotic process (GO:0010667),3/6,2.081521476273955E-4,0.002542589674244315,0,0,44.23529411764706,374.9932607380858,MDK;GATA4;NKX2-5
positive regulation of animal organ morphogenesis (GO:0110110),3/6,2.081521476273955E-4,0.002542589674244315,0,0,44.23529411764706,374.9932607380858,BMP2;SIX1;GATA3
positive regulation of gap junction assembly (GO:1903598),3/6,2.081521476273955E-4,0.002542589674244315,0,0,44.23529411764706,374.9932607380858,CNTNAP2;CAV1;AGT
regulation of macrophage apoptotic process (GO:2000109),3/6,2.081521476273955E-4,0.002542589674244315,0,0,44.23529411764706,374.9932607380858,MEF2C;CDKN2A;IRF7
regulation of peptidyl-tyrosine phosphorylation (GO:0050730),9/92,2.0935467960197837E-4,0.002548145528869794,0,0,4.842710290704101,41.02492682509759,NRP1;VTN;FGF7;IL6;HGF;PECAM1;PDGFA;TDGF1;AGT
mitotic spindle organization (GO:0007052),12/157,2.109849431413076E-4,0.0025588494171728694,0,0,3.709803296965836,31.398750407967267,CDC20;GPSM2;DSN1;CENPF;PRC1;STMN1;RCC1;TUBG1;BUB1;NDC80;AURKA;MAD2L1
activation of protein kinase activity (GO:0032147),10/114,2.3284900771847747E-4,0.0028063764528947124,0,0,4.2995137046861185,35.96594958620547,PRKAR2B;IL18;ADRB2;FGF1;ECT2;PAK3;PAK5;TGFBR2;ADCY5;PAK4
peptidyl-tyrosine modification (GO:0018212),7/56,2.330412371388508E-4,0.0028063764528947124,0,0,6.362035225048924,53.21394029194386,FLT4;KIT;ERBB2;KDR;TEK;FGFR4;FGFR3
regulation of nitric oxide biosynthetic process (GO:0045428),6/40,2.3710187647329228E-4,0.0028452225176795074,0,0,7.8471124212783065,65.50000942841947,CAV1;SIRPA;CD36;PKD2;PTGS2;KLF4
positive regulation of lymphocyte proliferation (GO:0050671),8/75,2.583349902956903E-4,0.0030891426207989917,0,0,5.324772020902353,43.98929097921938,VAV3;MEF2C;IL6;ANXA1;IL18;IRS2;CCL19;TNFRSF4
positive regulation of endothelial cell chemotaxis (GO:2001028),4/15,2.716217428093332E-4,0.0031923808535689944,0,0,16.115440115440116,132.3254921200219,KDR;PRKD1;FGF2;MET
regulation of branching involved in ureteric bud morphogenesis (GO:0090189),4/15,2.716217428093332E-4,0.0031923808535689944,0,0,16.115440115440116,132.3254921200219,SIX2;SIX1;AGT;PAX2
regulation of endothelial cell chemotaxis (GO:2001026),4/15,2.716217428093332E-4,0.0031923808535689944,0,0,16.115440115440116,132.3254921200219,PRKD1;FGF1;FGF2;MET
regulation of G0 to G1 transition (GO:0070316),6/41,2.7258885809523987E-4,0.0031923808535689944,0,0,7.62251871135698,62.562172290537674,RAD51;CHEK1;E2F1;CDC7;BRCA1;EZH2
response to growth factor (GO:0070848),6/41,2.7258885809523987E-4,0.0031923808535689944,0,0,7.62251871135698,62.562172290537674,STAT5B;ERBB2;CIB1;KLF4;BMPR1B;TGFBR2
T cell differentiation (GO:0030217),6/41,2.7258885809523987E-4,0.0031923808535689944,0,0,7.62251871135698,62.562172290537674,ANXA1;KIT;LEPR;RHOH;GATA3;FADD
regulation of nucleic acid-templated transcription (GO:1903506),22/430,2.7696037412559187E-4,0.0032324690240411545,0,0,2.440747693876605,19.993716958491383,ARNT2;MEF2C;MAGED1;HMGA1;RHOH;HMGA2;SIX1;GATA4;MITF;BRCA2;ESR1;SAP30;KLF1;BMP2;NR5A2;WT1;E2F1;ZNF205;CALR;ZNF423;PPARGC1A;EZH2
regulation of cell division (GO:0051302),8/76,2.8320503340454185E-4,0.003282866509668975,0,0,5.246197334769148,42.857966707670236,PLK4;BLM;TAL1;PRC1;TXNIP;CIB1;FGF1;AURKA
regulation of epithelial to mesenchymal transition (GO:0010717),8/76,2.8320503340454185E-4,0.003282866509668975,0,0,5.246197334769148,42.857966707670236,COL1A1;BMP2;IL6;MDK;SPRY2;GATA3;TGFBR2;EZH2
regulation of cellular component organization (GO:0051128),11/139,2.8449398344318054E-4,0.0032866287985571503,0,0,3.846792194700461,31.40828295818183,CISH;FAM107A;CD36;MKI67;SGK1;SNCAIP;PAK5;AGT;GFAP;AURKA;PAK4
negative regulation of endothelial cell apoptotic process (GO:2000352),5/27,2.872142096126361E-4,0.0032957105264641877,0,0,10.089359504132231,82.28157443399944,CDH5;KDR;GATA3;TEK;PAK4
response to glucocorticoid (GO:0051384),5/27,2.872142096126361E-4,0.0032957105264641877,0,0,10.089359504132231,82.28157443399944,ZFP36;IL6;ANXA1;FAM107A;SSTR2
positive regulation of protein binding (GO:0032092),7/58,2.9082496558768426E-4,0.0033148210124509295,0,0,6.111916912883875,49.76804959070951,PRKN;VTN;TCF7L2;BMP2;LRP1;TERT;CAV1
receptor metabolic process (GO:0043112),7/58,2.9082496558768426E-4,0.0033148210124509295,0,0,6.111916912883875,49.76804959070951,GRK3;LRP1;CAV1;CXCR2;MX1;CD36;RAMP1
regulation of protein binding (GO:0043393),10/118,3.0821226706763145E-4,0.003501291353888293,0,0,4.139421030225628,33.4660675814219,PRKN;VTN;TCF7L2;BMP2;TERT;LRP1;CAV1;CAMK1;AURKA;PPP1CA
calcium ion transmembrane import into cytosol (GO:0097553),6/42,3.1211567623627793E-4,0.0035253212139672013,0,0,7.410402429764616,59.81778127946687,CCL21;CCL19;PKD2;GRIN2C;FGF2;GRIN2D
double-strand break repair via homologous recombination (GO:0000724),9/97,3.123964221297226E-4,0.0035253212139672013,0,0,4.566383444537114,36.856365721208654,BLM;FEN1;RAD51;PARP1;MCM4;CDC7;BRCA1;BRCA2;RAD54B
double-strand break repair (GO:0006302),12/164,3.157295974280383E-4,0.003551176462160906,0,0,3.5376808070985777,28.515916286327695,BARD1;H2AX;BLM;FEN1;RAD51;PARP1;H4-16;CIB1;BRCA1;KPNA2;BRCA2;RAD54B
transcription by RNA polymerase II (GO:0006366),18/320,3.208794623761942E-4,0.0035967591749049904,0,0,2.6874234223056286,21.61882994461985,YAP1;MAML2;PARP1;DTX1;ESR1;NR4A1;NR5A2;RARB;E2F2;ELOB;PPARG;SNRPE;POLR2H;PPARA;PPARGC1A;TEAD1;RXRG;SOX5
regulation of small GTPase mediated signal transduction (GO:0051056),11/141,3.2189305996068726E-4,0.0035967591749049904,0,0,3.7872208436724564,30.4541455650592,VAV3;RACGAP1;SH3BP1;ITSN1;RHOJ;RAC3;RHOH;A2M;ECT2;VAV2;ARHGEF6
positive regulation of GTPase activity (GO:0043547),14/214,3.2850884414565955E-4,0.003658686734798718,0,0,3.1435034802784223,25.21387417333395,CCL14;CCL13;CCL21;ARHGEF15;CAV2;ADRB1;SH3BP1;ERBB2;CCL2;PRTN3;CCL19;ECT2;CCL16;EZH2
negative regulation of blood vessel morphogenesis (GO:2000181),8/78,3.3882240890238956E-4,0.0037566522944287,0,0,5.095782935599869,40.715481232656536,CXCL10;EFNA3;STAT1;SPRY2;PPARG;TEK;KLF4;DCN
cellular response to epidermal growth factor stimulus (GO:0071364),5/28,3.4331309351797915E-4,0.0037566522944287,0,0,9.650197628458498,76.97834993539689,VIL1;STAT5B;ZFP36;ERBB2;TDGF1
cellular response to interleukin-6 (GO:0071354),5/28,3.4331309351797915E-4,0.0037566522944287,0,0,9.650197628458498,76.97834993539689,YAP1;SOCS3;IL6;STAT1;TDGF1
response to ketone (GO:1901654),5/28,3.4331309351797915E-4,0.0037566522944287,0,0,9.650197628458498,76.97834993539689,CATSPER1;YAP1;CCL21;CAV1;CCL19
cellular response to corticosteroid stimulus (GO:0071384),4/16,3.5582397121351067E-4,0.0037566522944287,0,0,14.771730914588057,117.30341439096091,ZFP36;ANXA1;FAM107A;SSTR2
dendritic cell chemotaxis (GO:0002407),4/16,3.5582397121351067E-4,0.0037566522944287,0,0,14.771730914588057,117.30341439096091,CCL21;CXCR2;CXCR4;CCL19
DNA unwinding involved in DNA replication (GO:0006268),4/16,3.5582397121351067E-4,0.0037566522944287,0,0,14.771730914588057,117.30341439096091,BLM;RAD51;HMGA1;MCM4
mesenchyme development (GO:0060485),4/16,3.5582397121351067E-4,0.0037566522944287,0,0,14.771730914588057,117.30341439096091,BMP2;HMGA2;GATA4;PKD2
positive regulation of small molecule metabolic process (GO:0062013),4/16,3.5582397121351067E-4,0.0037566522944287,0,0,14.771730914588057,117.30341439096091,PMAIP1;IRS2;PPARG;PPARA
regulation of ATP biosynthetic process (GO:2001169),4/16,3.5582397121351067E-4,0.0037566522944287,0,0,14.771730914588057,117.30341439096091,PARP1;ANTKMT;PPARA;PPARGC1A
sympathetic nervous system development (GO:0048485),4/16,3.5582397121351067E-4,0.0037566522944287,0,0,14.771730914588057,117.30341439096091,NRP1;GATA3;SEMA3F;ASCL1
positive regulation of neuron differentiation (GO:0045666),6/43,3.559970638274059E-4,0.0037566522944287,0,0,7.209751893123191,57.249669904959944,MEF2C;BMP2;PROX1;ASCL1;ECT2;NKX2-5
epithelial cell differentiation involved in kidney development (GO:0035850),3/7,3.582488250262111E-4,0.0037566522944287,0,0,33.17477375565611,263.21803584201285,MEF2C;SIX2;PAX2
excitatory chemical synaptic transmission (GO:0098976),3/7,3.582488250262111E-4,0.0037566522944287,0,0,33.17477375565611,263.21803584201285,GRIN2C;PDLIM4;GRIN2D
hemostasis (GO:0007599),3/7,3.582488250262111E-4,0.0037566522944287,0,0,33.17477375565611,263.21803584201285,NFE2;VWF;FLI1
negative regulation of dendritic cell apoptotic process (GO:2000669),3/7,3.582488250262111E-4,0.0037566522944287,0,0,33.17477375565611,263.21803584201285,CXCL12;CCL21;CCL19
positive regulation of epithelial tube formation (GO:1905278),3/7,3.582488250262111E-4,0.0037566522944287,0,0,33.17477375565611,263.21803584201285,SIX1;GATA3;FGF2
regulation of bone remodeling (GO:0046850),3/7,3.582488250262111E-4,0.0037566522944287,0,0,33.17477375565611,263.21803584201285,MDK;LEPR;SYT7
regulation of morphogenesis of an epithelium (GO:1905330),3/7,3.582488250262111E-4,0.0037566522944287,0,0,33.17477375565611,263.21803584201285,CXCL10;SIX2;FGF1
response to organic cyclic compound (GO:0014070),7/60,3.5958619043548147E-4,0.003759109622712027,0,0,5.880675454467132,46.63702988293195,STAT5B;ANXA1;IL18;CCL2;PMAIP1;FGFR4;ESR1
cellular response to interferon-gamma (GO:0071346),10/121,3.772502015789277E-4,0.003931708522877632,0,0,4.026923475199338,31.74263474137505,CCL14;CCL13;CCL21;STAT1;IRF7;SIRPA;CCL2;CCL19;TDGF1;CCL16
DNA repair (GO:0006281),17/298,3.974572650777627E-4,0.004128293535523255,0,0,2.7243988425848937,21.333195736535764,BARD1;H2AX;FEN1;BLM;RFC4;PARP1;H4-16;FANCA;HMGA2;CIB1;BRCA1;BRCA2;RAD51;FANCD2;POLE2;CHEK1;KPNA2
"regulation of DNA-templated transcription, initiation (GO:2000142)",7/61,3.985353794563236E-4,0.004128293535523255,0,0,5.77147809910367,45.17748154519935,TCF7L2;JUN;IL6;CCND1;CDKN2A;MITF;RUNX2
skin development (GO:0043588),8/80,4.030329170945199E-4,0.004152833571270545,0,0,4.953724891939995,38.720752569367725,COL1A1;COL3A1;ANXA1;COL1A2;STMN1;TXNIP;PDGFA;MET
positive regulation of cell division (GO:0051781),6/44,4.0456007795241226E-4,0.004152833571270545,0,0,7.019661911041841,54.84258497463853,RACGAP1;TAL1;FGF1;ECT2;CDC25B;CIT
regulation of endothelial cell apoptotic process (GO:2000351),6/44,4.0456007795241226E-4,0.004152833571270545,0,0,7.019661911041841,54.84258497463853,CDH5;KDR;CCL2;GATA3;TEK;PAK4
cellular response to lipid (GO:0071396),14/219,4.1483926857207324E-4,0.004235076186347255,0,0,3.0660404051836343,23.877155793944095,RET;MEF2C;SSTR2;ESR1;PAX2;AQP1;ADCY5;CXCL10;ZFP36;IL6;SIRPA;CCL2;CTSG;VIM
peptidyl-serine modification (GO:0018209),12/169,4.1505734924882136E-4,0.004235076186347255,0,0,3.424133213692061,26.664046711562882,RPS6KA3;PARP1;MAPKAPK2;PRKCA;CDC7;PRKD1;CAMK1;SGK1;TDGF1;IKBKE;TGFBR2;AURKA
negative regulation of macromolecule metabolic process (GO:0010605),13/194,4.2291574809299835E-4,0.004302378714928175,0,0,3.2210712093308778,25.02236850990627,OPRD1;PRKN;YAP1;MEF2C;TRAT1;KLF4;FGF2;ESR1;AURKA;BMP2;MYCN;TERT;KDR
negative regulation of chemokine production (GO:0032682),4/17,4.57170702611382E-4,0.0046232574317495246,0,0,13.634746206174778,104.85738452061233,SIGIRR;IL6;SIRPA;KLF4
positive regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045737),4/17,4.57170702611382E-4,0.0046232574317495246,0,0,13.634746206174778,104.85738452061233,CCND2;CCND1;PROX1;PKD2
maintenance of blood-brain barrier (GO:0035633),5/30,4.799322042878951E-4,0.004824805168770344,0,0,8.877272727272727,67.83892600940655,CDH5;IL6;PECAM1;DMD;LAMC1
respiratory tube development (GO:0030323),5/30,4.799322042878951E-4,0.004824805168770344,0,0,8.877272727272727,67.83892600940655,FGF7;PROX1;FGF1;FGF2;PCSK5
amyloid fibril formation (GO:1990000),7/63,4.8653310712977704E-4,0.004848259734205498,0,0,5.564783105022831,42.449309683470716,PRKN;SIAH2;H4-16;SAA1;UBE2L6;CD36;SNCAIP
negative regulation of endopeptidase activity (GO:0010951),7/63,4.8653310712977704E-4,0.004848259734205498,0,0,5.564783105022831,42.449309683470716,VTN;CR1;BIN1;SERPINC1;SERPING1;TIMP1;AGT
positive regulation of DNA metabolic process (GO:0051054),7/63,4.8653310712977704E-4,0.004848259734205498,0,0,5.564783105022831,42.449309683470716,H2AX;RAD51;WT1;HGF;BRCA1;FGFR4;FGF2
regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122),14/224,5.198358747644398E-4,0.005165016504948136,0,0,2.9922660479505025,22.627508139528437,PRKN;CCL21;STAT1;PELI2;RHOH;ESR1;CAPN3;S100A4;PRKD1;FADD;CCL19;ECT2;IKBKE;LURAP1
negative regulation of cell cycle process (GO:0010948),7/64,5.359863538528074E-4,0.005310004342820836,0,0,5.466874949931907,41.17323214688296,RAD51;CHEK1;E2F1;NEK2;CDC7;BRCA1;EZH2
negative regulation of DNA binding (GO:0043392),5/31,5.618696258727449E-4,0.005458020398232623,0,0,8.535402097902098,63.88100392063264,PER2;JUN;E2F1;HABP4;HMGA2
receptor signaling pathway via JAK-STAT (GO:0007259),5/31,5.618696258727449E-4,0.005458020398232623,0,0,8.535402097902098,63.88100392063264,STAT5A;STAT5B;STAT1;CCL2;PKD2
regulation of cellular component size (GO:0032535),5/31,5.618696258727449E-4,0.005458020398232623,0,0,8.535402097902098,63.88100392063264,EPS8;VAV3;EZR;PPP1CA;VAV2
cellular response to hepatocyte growth factor stimulus (GO:0035729),3/8,5.637391960615855E-4,0.005458020398232623,0,0,26.53846153846154,198.53207668861904,NRP1;HGF;TDGF1
kidney epithelium development (GO:0072073),3/8,5.637391960615855E-4,0.005458020398232623,0,0,26.53846153846154,198.53207668861904,WT1;FGF1;PAX2
negative regulation of striated muscle cell apoptotic process (GO:0010664),3/8,5.637391960615855E-4,0.005458020398232623,0,0,26.53846153846154,198.53207668861904,MDK;GATA4;NKX2-5
positive regulation of myeloid cell apoptotic process (GO:0033034),3/8,5.637391960615855E-4,0.005458020398232623,0,0,26.53846153846154,198.53207668861904,MEF2C;ANXA1;CDKN2A
response to hepatocyte growth factor (GO:0035728),3/8,5.637391960615855E-4,0.005458020398232623,0,0,26.53846153846154,198.53207668861904,NRP1;HGF;TDGF1
interleukin-6-mediated signaling pathway (GO:0070102),4/18,5.775189024675884E-4,0.00552860792025152,0,0,12.660187884677681,94.40410142122148,YAP1;SOCS3;IL6;STAT1
positive regulation of cartilage development (GO:0061036),4/18,5.775189024675884E-4,0.00552860792025152,0,0,12.660187884677681,94.40410142122148,BMP2;MDK;BMPR1B;SOX5
regulation of cartilage development (GO:0061035),4/18,5.775189024675884E-4,0.00552860792025152,0,0,12.660187884677681,94.40410142122148,BMP2;MDK;BMPR1B;SOX5
regulation of production of miRNAs involved in gene silencing by miRNA (GO:1903798),4/18,5.775189024675884E-4,0.00552860792025152,0,0,12.660187884677681,94.40410142122148,IL6;MYCN;TERT;ESR1
regulation of wound healing (GO:0061041),6/47,5.817897500569356E-4,0.00555389206777041,0,0,6.505028057114284,48.45856530889638,VIL1;VTN;ANXA1;CAV1;FGF2;MYLK
cellular response to peptide hormone stimulus (GO:0071375),9/106,6.024180254779012E-4,0.005718776130442026,0,0,4.140783126832498,30.702080630970386,NR4A1;PARP1;PRKAR2B;CAV1;IRS2;PPARG;SLC2A4;FOXO1;ADCY5
small GTPase mediated signal transduction (GO:0007264),9/106,6.024180254779012E-4,0.005718776130442026,0,0,4.140783126832498,30.702080630970386,CCNA2;JUN;SHC3;CDKN2A;SIAH2;PRKD1;PLD1;RHEBL1;FGF2
cardiac muscle tissue morphogenesis (GO:0055008),5/32,6.538731189182371E-4,0.006172852047848621,0,0,8.218855218855218,60.265555037021485,BMP2;ACTC1;S1PR1;PROX1;NKX2-5
endodermal cell differentiation (GO:0035987),5/32,6.538731189182371E-4,0.006172852047848621,0,0,8.218855218855218,60.265555037021485,VTN;MMP14;HMGA2;COL8A1;INHBA
negative regulation of phosphorylation (GO:0042326),8/86,6.571761687161854E-4,0.00618689608559326,0,0,4.571260928240333,33.496181570125124,PRKN;CDKN2C;CDKN2A;SIRPA;CIB1;IRS2;INHBA;PPARA
G2/M transition of mitotic cell cycle (GO:0000086),10/130,6.657409042337767E-4,0.0062502617124757884,0,0,3.7231800766283527,27.233610204664494,PLK4;CCNA2;CCNB2;MELK;PRKAR2B;NEK2;PKMYT1;TUBG1;CDC25B;AURKA
cell cycle G2/M phase transition (GO:0044839),10/131,7.06771699622653E-4,0.006617247121741763,0,0,3.6922200056996295,26.78632825144761,PLK4;CCNA2;CCNB2;MELK;PRKAR2B;NEK2;PKMYT1;TUBG1;CDC25B;AURKA
positive regulation of NF-kappaB transcription factor activity (GO:0051092),11/155,7.17712308831032E-4,0.006620267044814585,0,0,3.4165546594982077,24.73394845437124,ALK;IL6;CAV1;IL18;CAPN3;TNFSF11;CIB1;PRKD1;CD36;RHEBL1;AGT
cardiac atrium morphogenesis (GO:0003209),4/19,7.187496498184849E-4,0.006620267044814585,0,0,11.81557067271353,85.52107043557338,BMP2;GATA4;PROX1;NKX2-5
excitatory postsynaptic potential (GO:0060079),4/19,7.187496498184849E-4,0.006620267044814585,0,0,11.81557067271353,85.52107043557338,MEF2C;GRIN2C;MAPK8IP2;GRIN2D
positive regulation of mitochondrial fission (GO:0090141),4/19,7.187496498184849E-4,0.006620267044814585,0,0,11.81557067271353,85.52107043557338,PRKN;KDR;DCN;AURKA
striated muscle cell differentiation (GO:0051146),4/19,7.187496498184849E-4,0.006620267044814585,0,0,11.81557067271353,85.52107043557338,MEF2C;BMP2;SDC1;NKX2-5
ureteric bud development (GO:0001657),4/19,7.187496498184849E-4,0.006620267044814585,0,0,11.81557067271353,85.52107043557338,BMP2;WT1;SIX1;PKD2
response to hydrogen peroxide (GO:0042542),6/49,7.298807463063743E-4,0.006704672731569066,0,0,6.201832918366266,44.793540760100505,IL6;ANXA1;SIRPA;ECT2;PAX2;AQP1
regulation of sprouting angiogenesis (GO:1903670),5/33,7.567031205766226E-4,0.0068987408782724075,0,0,7.9249188311688314,56.95274269270914,RHOJ;E2F2;FGF1;KLF4;FGF2
vasculogenesis (GO:0001570),5/33,7.567031205766226E-4,0.0068987408782724075,0,0,7.9249188311688314,56.95274269270914,WT1;CAV1;KDR;NKX2-5;TGFBR2
peptidyl-serine phosphorylation (GO:0018105),11/156,7.570801315944486E-4,0.0068987408782724075,0,0,3.392817416176704,24.380926605200298,RPS6KA3;MAPKAPK2;PRKCA;CDC7;PRKD1;CAMK1;SGK1;TDGF1;IKBKE;TGFBR2;AURKA
negative regulation of binding (GO:0051100),8/88,7.660310356743477E-4,0.0069616900522084715,0,0,4.456521739130435,31.972369866568553,JUN;CAV1;HABP4;E2F1;HMGA2;CAMK1;AURKA;PPP1CA
regulation of cell adhesion (GO:0030155),10/133,7.950985325939439E-4,0.00716850740497397,0,0,3.6318101112045604,25.920390417787353,RET;CXCL12;MDK;DUSP1;ERBB2;IL18;SAA1;CXCR4;PRKCA;RND1
regulation of cell motility (GO:2000145),10/133,7.950985325939439E-4,0.00716850740497397,0,0,3.6318101112045604,25.920390417787353,FGF7;PARD6B;CCL21;ERBB2;AMOTL2;GATA3;CCL19;FGF1;SGK1;FGF2
transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0007178),10/133,7.950985325939439E-4,0.00716850740497397,0,0,3.6318101112045604,25.920390417787353,CDH5;JUN;BMP2;COL3A1;COL1A2;INHBA;FOS;BMPR1B;RUNX2;TGFBR2
regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043281),8/89,8.256477417173417E-4,0.007342822749011249,0,0,4.401276944373817,31.24617175340856,RPS6KA3;NGFR;HGF;SIAH2;PMAIP1;KLF4;PAX2;AQP1
intestinal epithelial cell differentiation (GO:0060575),3/9,8.316694780276826E-4,0.007342822749011249,0,0,22.11425339366516,156.83595376649893,YAP1;PYY;GATA4
negative regulation of protein activation cascade (GO:2000258),3/9,8.316694780276826E-4,0.007342822749011249,0,0,22.11425339366516,156.83595376649893,F12;SERPING1;A2M
protein K6-linked ubiquitination (GO:0085020),3/9,8.316694780276826E-4,0.007342822749011249,0,0,22.11425339366516,156.83595376649893,BARD1;PRKN;BRCA1
regulation of gap junction assembly (GO:1903596),3/9,8.316694780276826E-4,0.007342822749011249,0,0,22.11425339366516,156.83595376649893,CNTNAP2;CAV1;AGT
regulation of lipid transport (GO:0032368),3/9,8.316694780276826E-4,0.007342822749011249,0,0,22.11425339366516,156.83595376649893,PRKN;LRP1;PPARA
regulation of tumor necrosis factor superfamily cytokine production (GO:1903555),3/9,8.316694780276826E-4,0.007342822749011249,0,0,22.11425339366516,156.83595376649893,ZFP36;MAPKAPK2;SIRPA
sympathetic ganglion development (GO:0061549),3/9,8.316694780276826E-4,0.007342822749011249,0,0,22.11425339366516,156.83595376649893,NRP1;SEMA3F;ASCL1
positive regulation of MAP kinase activity (GO:0043406),7/69,8.464762927555176E-4,0.0074542408416299845,0,0,5.024709088230962,35.54694448949824,KIT;ERBB2;TNFSF11;PDGFA;FGF1;FGF2;EZH2
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (GO:1901030),5/34,8.711381147835613E-4,0.007631976080160351,0,0,7.651253918495298,53.908516424529566,E2F1;PMAIP1;GZMB;ZNF205;BAK1
regulation of cell adhesion mediated by integrin (GO:0033628),5/34,8.711381147835613E-4,0.007631976080160351,0,0,7.651253918495298,53.908516424529566,RET;MUC1;CCL21;RAC3;CIB1
positive regulation of cyclin-dependent protein kinase activity (GO:1904031),4/20,8.827598060781337E-4,0.0076550774023264115,0,0,11.076530612244898,77.8952298328024,CCND2;CCND1;PROX1;PKD2
positive regulation of lymphocyte differentiation (GO:0045621),4/20,8.827598060781337E-4,0.0076550774023264115,0,0,11.076530612244898,77.8952298328024,MMP14;MDK;RHOH;GATA3
regulation of protein kinase A signaling (GO:0010738),4/20,8.827598060781337E-4,0.0076550774023264115,0,0,11.076530612244898,77.8952298328024,AKAP12;PRKAR2B;ADRB2;AKAP5
regulation of smooth muscle cell migration (GO:0014910),4/20,8.827598060781337E-4,0.0076550774023264115,0,0,11.076530612244898,77.8952298328024,NRP1;VTN;LRP1;PDGFA
response to lipopolysaccharide (GO:0032496),11/159,8.8608922310515E-4,0.007664446884117643,0,0,3.323530327562586,23.360074046685714,RPS6KA3;CXCL10;ZFP36;MEF2C;IL6;MAPKAPK2;SIRPA;CCL2;CTSG;VIM;SELE
regulation of cytoskeleton organization (GO:0051493),9/112,8.969955220487208E-4,0.007734529971406304,0,0,3.89837000089071,27.352755960391445,LRP1;SH3BP1;FAM107A;PDGFA;RAC3;RHOH;EZR;PAK3;RND1
blood circulation (GO:0008015),6/51,9.055391603847169E-4,0.007734529971406304,0,0,5.925588458618071,41.52048002117009,CXCL10;ACTC1;CXCL12;STAT1;SERPING1;HOXB2
DNA duplex unwinding (GO:0032508),6/51,9.055391603847169E-4,0.007734529971406304,0,0,5.925588458618071,41.52048002117009,BLM;ANXA1;RAD51;PARP1;HMGA1;MCM4
mesenchymal cell differentiation (GO:0048762),6/51,9.055391603847169E-4,0.007734529971406304,0,0,5.925588458618071,41.52048002117009,MEF2C;BMP2;HGF;HMGA2;S100A4;HNRNPAB
negative regulation of transport (GO:0051051),6/51,9.055391603847169E-4,0.007734529971406304,0,0,5.925588458618071,41.52048002117009,PRKN;TRAT1;SIRPA;PRTN3;PRKD1;CRYAB
carbohydrate homeostasis (GO:0033500),7/70,9.228383969106374E-4,0.00786258314167863,0,0,4.944698122780315,34.55382947864111,NGFR;TCF7L2;IL6;LEPR;PPARG;SLC2A4;FGFR4
negative regulation of gene expression (GO:0010629),17/322,9.467289296012387E-4,0.008046015441598558,0,0,2.5068944384862877,17.454246879763147,OPRD1;PRKN;YAP1;MEF2C;H4-16;GZMB;KLF4;FGF2;ESR1;AURKA;ZFP36;BMP2;MYCN;TERT;KDR;CALR;EZH2
regulation of regulated secretory pathway (GO:1903305),5/35,9.979731023361835E-4,0.008418545378123053,0,0,7.395833333333333,51.10361256087398,RIMS2;RAB3A;SYT9;SYN1;SYT7
respiratory system development (GO:0060541),5/35,9.979731023361835E-4,0.008418545378123053,0,0,7.395833333333333,51.10361256087398,FGF7;WT1;PROX1;FGF1;FGF2
response to estrogen (GO:0043627),5/35,9.979731023361835E-4,0.008418545378123053,0,0,7.395833333333333,51.10361256087398,KRT19;CAV1;BRCA1;GATA3;ESR1
cellular response to transforming growth factor beta stimulus (GO:0071560),9/114,0.0010178460911439476,0.00856498636695944,0,0,3.823722149410223,26.34570011548479,CDH5;MEF2C;JUN;CLEC3B;COL3A1;COL1A2;FOS;SOX5;TGFBR2
T cell activation (GO:0042110),8/92,0.0010271647246706639,0.00862211177753109,0,0,4.243434673640623,29.198874407288052,CCL21;MDK;KIT;LEPR;RHOH;GATA3;CCL19;TNFRSF4
negative regulation of multicellular organismal process (GO:0051241),13/214,0.0010572845467100936,0.008820087281169318,0,0,2.8975723235673483,19.854314514083086,MEF2C;GATA3;BRCA2;BMP2;PROC;MDK;PAEP;SOSTDC1;SPRY2;EVL;CALR;TIMP1;ZNF423
autonomic nervous system development (GO:0048483),4/21,0.0010714542647899349,0.008820087281169318,0,0,10.424436441243165,71.28999407380229,NRP1;GATA3;ASCL1;SOX10
chondroitin sulfate biosynthetic process (GO:0030206),4/21,0.0010714542647899349,0.008820087281169318,0,0,10.424436441243165,71.28999407380229,VCAN;CHPF;BGN;DCN
mitotic spindle assembly checkpoint signaling (GO:0007094),4/21,0.0010714542647899349,0.008820087281169318,0,0,10.424436441243165,71.28999407380229,CDC20;CENPF;BUB1;MAD2L1
mitotic spindle checkpoint signaling (GO:0071174),4/21,0.0010714542647899349,0.008820087281169318,0,0,10.424436441243165,71.28999407380229,CDC20;CENPF;BUB1;MAD2L1
negative regulation of reproductive process (GO:2000242),4/21,0.0010714542647899349,0.008820087281169318,0,0,10.424436441243165,71.28999407380229,DUSP1;PAEP;CALR;TIMP1
purinergic nucleotide receptor signaling pathway (GO:0035590),4/21,0.0010714542647899349,0.008820087281169318,0,0,10.424436441243165,71.28999407380229,C3;IL18;TXNIP;CTSG
spindle assembly checkpoint signaling (GO:0071173),4/21,0.0010714542647899349,0.008820087281169318,0,0,10.424436441243165,71.28999407380229,CDC20;CENPF;BUB1;MAD2L1
response to ionizing radiation (GO:0010212),7/72,0.001091788749214297,0.00896582182487307,0,0,4.79206181945908,32.681563894559375,H2AX;BLM;ANXA1;RAD51;FANCD2;BRCA1;ECT2
positive regulation of B cell activation (GO:0050871),6/53,0.0011120524923759671,0.009110276187541577,0,0,5.6728541656569575,38.58418921769802,VAV3;MEF2C;MMP14;IL6;IRS2;TNFRSF4
positive regulation of substrate adhesion-dependent cell spreading (GO:1900026),5/36,0.0011380180575644376,0.009300636787001448,0,0,7.156891495601173,48.51275336655149,NRP1;MDK;RAC3;CIB1;CALR
regulation of protein-containing complex assembly (GO:0043254),9/116,0.0011515631012027773,0.009388820691146089,0,0,3.751864871816857,25.387500310999194,OPRD1;CDH5;CDT1;TAL1;CD36;BAK1;CRYAB;MAPK15;GFAP
cell differentiation involved in metanephros development (GO:0072202),3/10,0.0011685354694117092,0.009414583640082989,0,0,18.9541047188106,127.97819182161604,STAT1;SIX2;PAX2
positive regulation of mesenchymal cell proliferation (GO:0002053),3/10,0.0011685354694117092,0.009414583640082989,0,0,18.9541047188106,127.97819182161604,STAT1;PDGFA;TGFBR2
regulation of attachment of spindle microtubules to kinetochore (GO:0051988),3/10,0.0011685354694117092,0.009414583640082989,0,0,18.9541047188106,127.97819182161604,RACGAP1;NEK2;ECT2
regulation of leukocyte tethering or rolling (GO:1903236),3/10,0.0011685354694117092,0.009414583640082989,0,0,18.9541047188106,127.97819182161604,CXCL12;CCL21;SELE
retinoic acid receptor signaling pathway (GO:0048384),3/10,0.0011685354694117092,0.009414583640082989,0,0,18.9541047188106,127.97819182161604,RARB;PPARG;RXRG
negative regulation of MAPK cascade (GO:0043409),8/94,0.0011820673155814863,0.009479155073713065,0,0,4.144324410622106,27.93477895005098,DUSP1;CAV1;CBLC;SIRPA;SPRY2;EZR;FOXO1;AGT
positive regulation of synaptic transmission (GO:0050806),7/73,0.001184894384214133,0.009479155073713065,0,0,4.719212674692127,31.79853464214659,RIMS2;KCTD13;CCL2;AKAP5;GRIN2C;ADRA1A;GRIN2D
regulation of Rho protein signal transduction (GO:0035023),7/73,0.001184894384214133,0.009479155073713065,0,0,4.719212674692127,31.79853464214659,EPS8;NRP1;COL3A1;STMN1;KCTD13;MET;F2RL2
cellular response to osmotic stress (GO:0071470),4/22,0.0012867387501940815,0.010216854874984629,0,0,9.844797178130511,65.52346883637364,CAPN3;PKD2;AQP1;MYLK
negative regulation of interleukin-2 production (GO:0032703),4/22,0.0012867387501940815,0.010216854874984629,0,0,9.844797178130511,65.52346883637364,ZFP36;CR1;HOMER3;EZR
negative regulation of mitotic metaphase/anaphase transition (GO:0045841),4/22,0.0012867387501940815,0.010216854874984629,0,0,9.844797178130511,65.52346883637364,CDC20;CENPF;BUB1;MAD2L1
regulation of erythrocyte differentiation (GO:0045646),5/37,0.0012920963765018707,0.010216854874984629,0,0,6.9328835227272725,46.114000441919146,STAT5B;ZFP36;STAT1;TAL1;INHBA
skeletal muscle tissue development (GO:0007519),5/37,0.0012920963765018707,0.010216854874984629,0,0,6.9328835227272725,46.114000441919146,EGR2;MEF2C;CAV2;CAV1;SIX1
regulation of programmed cell death (GO:0043067),12/194,0.0013953595184164518,0.011007836200840898,0,0,2.949978428038474,19.394937546885636,PRKN;ALK;CXCL10;MECOM;MAGED1;STAT1;BCL3;PMAIP1;CALR;SGK1;PAX2;AGT
actin-myosin filament sliding (GO:0033275),5/38,0.0014610433241423685,0.011398297021636517,0,0,6.722451790633609,43.888228963593335,ACTC1;TPM3;TNNI2;DMD;VIM
DNA replication initiation (GO:0006270),5/38,0.0014610433241423685,0.011398297021636517,0,0,6.722451790633609,43.888228963593335,CDT1;DBF4;POLE2;MCM4;CDC7
muscle filament sliding (GO:0030049),5/38,0.0014610433241423685,0.011398297021636517,0,0,6.722451790633609,43.888228963593335,ACTC1;TPM3;TNNI2;DMD;VIM
response to cAMP (GO:0051591),5/38,0.0014610433241423685,0.011398297021636517,0,0,6.722451790633609,43.888228963593335,STAT1;WT1;PKD2;EZR;AQP1
cellular response to lipopolysaccharide (GO:0071222),9/120,0.0014615774056499877,0.011398297021636517,0,0,3.6159186709645423,23.605581330784798,CXCL10;ZFP36;MEF2C;IL6;IL18;SIRPA;CCL2;CTSG;VIM
glycosaminoglycan catabolic process (GO:0006027),6/56,0.0014872401596949232,0.011571950831598855,0,0,5.3316628701594535,34.71356719097143,ACAN;VCAN;BGN;SDC1;FGF2;DCN
cell morphogenesis involved in neuron differentiation (GO:0048667),7/76,0.001501956586677702,0.011659836098855599,0,0,4.513334656872477,29.34112825984551,MEF2C;PARD6B;RAB3A;MAPK8IP2;PAK3;NEFH;PAX2
negative regulation of G protein-coupled receptor signaling pathway (GO:0045744),4/23,0.0015305131432173378,0.011827638984319018,0,0,9.326172574292874,60.45367018272906,GRK3;STMN1;GPRASP1;MET
negative regulation of reactive oxygen species metabolic process (GO:2000378),4/23,0.0015305131432173378,0.011827638984319018,0,0,9.326172574292874,60.45367018272906,PRKN;BRCA1;PPARA;PAX2
cellular response to interleukin-2 (GO:0071352),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,STAT5A;STAT5B;IL2RG
hepatocyte growth factor receptor signaling pathway (GO:0048012),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,NRP1;HGF;STMN1
interleukin-2-mediated signaling pathway (GO:0038110),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,STAT5A;STAT5B;IL2RG
mesonephros development (GO:0001823),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,GATA3;FGF1;PAX2
negative regulation of receptor signaling pathway via STAT (GO:1904893),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,SOCS3;CAV1;BCL3
positive regulation of DNA-dependent DNA replication (GO:2000105),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,CDT1;DBF4;CDC7
positive regulation of leukocyte apoptotic process (GO:2000108),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,MEF2C;ANXA1;CDKN2A
regulation of cardiac muscle cell apoptotic process (GO:0010665),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,MDK;GATA4;NKX2-5
regulation of dendritic cell apoptotic process (GO:2000668),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,CXCL12;CCL21;CCL19
regulation of histone H3-K9 acetylation (GO:2000615),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,CHEK1;BRCA1;CAMK1
regulation of mesenchymal cell proliferation (GO:0010464),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,STAT1;PDGFA;TGFBR2
response to prostaglandin E (GO:0034695),3/11,0.001580308066840836,0.0118889401584847,0,0,16.583993212669682,106.96900288738678,GNG2;CCL21;CCL19
cellular response to peptide (GO:1901653),6/57,0.0016315456516867736,0.012193656975764309,0,0,5.2268524721961676,33.54712807113475,NGFR;LRP1;CAV1;CD36;ADRB2;VIM
positive regulation of cell junction assembly (GO:1901890),6/57,0.0016315456516867736,0.012193656975764309,0,0,5.2268524721961676,33.54712807113475,CNTNAP2;NRP1;CAV1;KDR;TEK;AGT
positive regulation of proteolysis (GO:0045862),6/57,0.0016315456516867736,0.012193656975764309,0,0,5.2268524721961676,33.54712807113475,CYFIP2;CAPN3;BAK1;FADD;FGFR4;SH3D19
regulation of signal transduction (GO:0009966),12/198,0.0016588064084627186,0.012370267483678216,0,0,2.885942039782463,18.474810963274045,GRK3;GRK5;GNG7;DTX1;LIFR;PRKD1;GATA3;CD36;TIMP1;MAPK8IP2;TDGF1;ESR1
negative regulation of apoptotic signaling pathway (GO:2001234),7/78,0.0017475802940822179,0.013003828913170739,0,0,4.38574827963213,27.847410174315623,PRKN;TCF7L2;HGF;SIAH2;PLAUR;GATA4;MAPK8IP2
eye development (GO:0001654),6/58,0.0017862447476694719,0.013254955501314284,0,0,5.126073243385316,32.435944914407784,FBN2;LAMA1;WT1;SIX3;BMPR1B;PAX2
cardiac muscle cell differentiation (GO:0055007),4/24,0.0018046653029958415,0.013254955501314284,0,0,8.859410430839002,55.96826343785105,MEF2C;BMP2;WT1;NKX2-5
heterochromatin assembly (GO:0031507),4/24,0.0018046653029958415,0.013254955501314284,0,0,8.859410430839002,55.96826343785105,CDKN2A;H4-16;HMGA1;HMGA2
negative regulation of neuron differentiation (GO:0045665),4/24,0.0018046653029958415,0.013254955501314284,0,0,8.859410430839002,55.96826343785105,SIX3;DTX1;CALR;ASCL1
positive regulation of phospholipase activity (GO:0010518),4/24,0.0018046653029958415,0.013254955501314284,0,0,8.859410430839002,55.96826343785105,KIT;ESR1;FGF2;FGFR3
regulation of keratinocyte proliferation (GO:0010837),4/24,0.0018046653029958415,0.013254955501314284,0,0,8.859410430839002,55.96826343785105,FGF7;ZFP36;MDK;PRKD1
digestive tract development (GO:0048565),5/40,0.001846934213619109,0.013536240430137469,0,0,6.337662337662338,39.890692984749215,PYY;KIT;RARB;GATA4;PCSK5
positive regulation of protein localization to membrane (GO:1905477),8/101,0.0018763032582684066,0.01372197747677839,0,0,3.8310080952732464,24.052799633017287,PRKN;LRP1;ERBB2;E2F1;PMAIP1;GZMB;CIB1;AKAP5
recombinational repair (GO:0000725),7/79,0.0018815321012182892,0.01373075246456516,0,0,4.324613140537798,27.139840132538318,FEN1;BLM;RAD51;PARP1;BRCA1;BRCA2;RAD54B
cellular macromolecule biosynthetic process (GO:0034645),16/314,0.0019003562561042942,0.01383849171111845,0,0,2.410099967146947,15.100996881830989,BARD1;FEN1;BLM;RFC4;DTX1;CDC7;BRCA1;INHBA;DBF4;TERT;POLE2;CHEK1;BCL3;E2F1;MCM4;POLR2H
mitotic DNA damage checkpoint signaling (GO:0044773),6/59,0.0019518113764637954,0.014182885225988517,0,0,5.029097004340912,31.376523268055074,BLM;CCND1;FANCD2;CHEK1;HMGA2;BRCA1
generation of neurons (GO:0048699),12/202,0.0019618913790763483,0.014225799616791905,0,0,2.824601920505652,17.608134179477467,YAP1;PER2;NRP1;MEF2C;RACGAP1;SIX3;ERBB2;SIX1;ASCL1;MET;RUNX2;CIT
negative regulation of cell cycle (GO:0045786),7/80,0.002023306451069374,0.01453279066289467,0,0,4.265152936761118,26.45683856123941,NR4A1;BMP2;DUSP1;CDKN2A;GATA3;INHBA;MAD2L1
negative regulation of cellular response to growth factor stimulus (GO:0090288),7/80,0.002023306451069374,0.01453279066289467,0,0,4.265152936761118,26.45683856123941,BMP2;SOSTDC1;SPRY2;PPARG;BMPR1B;FGF2;AGT
cellular response to fluid shear stress (GO:0071498),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,MEF2C;KLF4;PKD2
dermatan sulfate biosynthetic process (GO:0030208),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,VCAN;BGN;DCN
ganglion development (GO:0061548),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,NRP1;SEMA3F;ASCL1
melanocyte differentiation (GO:0030318),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,MEF2C;KIT;MITF
negative regulation of complement activation (GO:0045916),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,CR1;SERPING1;A2M
negative regulation of gene silencing by miRNA (GO:0060965),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,TERT;PPARG;ESR1
negative regulation of production of miRNAs involved in gene silencing by miRNA (GO:1903799),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,IL6;TERT;ESR1
positive regulation of branching involved in ureteric bud morphogenesis (GO:0090190),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,SIX1;AGT;PAX2
positive regulation of cardiocyte differentiation (GO:1905209),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,MEF2C;GATA4;NKX2-5
positive regulation of cellular senescence (GO:2000774),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,CDKN2A;HMGA1;HMGA2
positive regulation of fatty acid oxidation (GO:0046321),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,IRS2;PPARA;PPARGC1A
regulation of astrocyte differentiation (GO:0048710),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,BMP2;IL6;BIN1
regulation of leukocyte cell-cell adhesion (GO:1903037),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,MDK;PPARA;SKAP1
replicative senescence (GO:0090399),3/12,0.002072457823405754,0.01453279066289467,0,0,14.740573152337857,91.08229664036905,TERT;CDKN2A;CHEK1
"chemical synaptic transmission, postsynaptic (GO:0099565)",4/25,0.0021110653632153615,0.01471270093627393,0,0,8.437101824856926,51.977293511173166,MEF2C;GRIN2C;MAPK8IP2;GRIN2D
negative regulation of sequestering of calcium ion (GO:0051283),4/25,0.0021110653632153615,0.01471270093627393,0,0,8.437101824856926,51.977293511173166,CCL21;CCL19;PKD2;FGF2
regulation of mitochondrial fission (GO:0090140),4/25,0.0021110653632153615,0.01471270093627393,0,0,8.437101824856926,51.977293511173166,PRKN;KDR;DCN;AURKA
regulation of insulin secretion (GO:0050796),8/104,0.0022577980971071826,0.015703216152941384,0,0,3.7107170099160944,22.610754021233255,PRKN;PER2;TCF7L2;IL6;IRS2;PRKCA;SYT7;ADCY5
nucleic acid-templated transcription (GO:0097659),5/42,0.00230255153663298,0.015949381375701618,0,0,5.994471744471745,36.40884727069847,TERT;BCL3;E2F1;DTX1;POLR2H
regulation of DNA recombination (GO:0000018),5/42,0.00230255153663298,0.015949381375701618,0,0,5.994471744471745,36.40884727069847,BLM;PPP4C;RAD51;CHEK1;KPNA2
positive regulation of cellular metabolic process (GO:0031325),8/105,0.002397649904382262,0.016540872214847673,0,0,3.6722734671730874,22.15580348900404,PPARG;GATA3;INHBA;PPARA;KLF4;SELE;AGT;TGFBR2
regulation of JNK cascade (GO:0046328),8/105,0.002397649904382262,0.016540872214847673,0,0,3.6722734671730874,22.15580348900404,PRKN;MECOM;CCL21;FLT4;SIRPA;CCL19;MAPK8IP2;GADD45G
DNA-dependent DNA replication (GO:0006261),9/129,0.0024062063580841315,0.016566366198688322,0,0,3.343176605504587,20.158365006546024,CDT1;BLM;RFC4;DBF4;RAD51;POLE2;HMGA1;MCM4;CDC7
metanephros development (GO:0001656),4/26,0.0024515604783613134,0.016810700423049007,0,0,8.053184910327767,48.40794033745568,WT1;SIX1;PKD2;PAX2
regulation of regulatory T cell differentiation (GO:0045589),4/26,0.0024515604783613134,0.016810700423049007,0,0,8.053184910327767,48.40794033745568,CR1;MDK;FANCA;CTLA4
chromosome organization (GO:0051276),8/106,0.0025441998594561786,0.017370467640760452,0,0,3.634614486526876,21.712965505379614,CDT1;TCF7L2;PARP1;SATB1;H4-16;HMGA2;NDC80;EZH2
development of primary male sexual characteristics (GO:0046546),5/43,0.002558678038633142,0.017370467640760452,0,0,5.836423444976076,34.83331911640588,WT1;KIT;GATA4;GATA3;INHBA
heart looping (GO:0001947),5/43,0.002558678038633142,0.017370467640760452,0,0,5.836423444976076,34.83331911640588,MEF2C;GATA4;PKD2;NKX2-5;TGFBR2
male gonad development (GO:0008584),5/43,0.002558678038633142,0.017370467640760452,0,0,5.836423444976076,34.83331911640588,WT1;KIT;GATA4;GATA3;INHBA
positive regulation of phospholipase C activity (GO:0010863),5/43,0.002558678038633142,0.017370467640760452,0,0,5.836423444976076,34.83331911640588,KIT;ADRA1A;FGF2;ESR1;SELE
regulation of cell differentiation (GO:0045595),10/156,0.0026340251076410214,0.017604536076577932,0,0,3.0560541646984727,18.15064568801728,ALK;RPS6KA3;BIN1;MDK;SIX1;GATA3;CAMK1;BMPR1B;KLF4;RUNX2
cellular response to interleukin-15 (GO:0071350),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,STAT5A;STAT5B;IL2RG
chondroitin sulfate catabolic process (GO:0030207),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,VCAN;BGN;DCN
dermatan sulfate metabolic process (GO:0030205),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,VCAN;BGN;DCN
endochondral bone morphogenesis (GO:0060350),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,MEF2C;BMPR1B;FGFR3
interleukin-15-mediated signaling pathway (GO:0035723),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,STAT5A;STAT5B;IL2RG
kinetochore organization (GO:0051383),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,CDT1;CENPF;NDC80
positive regulation of cell aging (GO:0090343),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,CDKN2A;HMGA1;HMGA2
regulation of homotypic cell-cell adhesion (GO:0034110),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,PLAUR;TNFSF11;PRKCA
regulation of mitotic cell cycle spindle assembly checkpoint (GO:0090266),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,DUSP1;NDC80;MAD2L1
response to nitric oxide (GO:0071731),3/13,0.002649978581949671,0.017604536076577932,0,0,13.265837104072398,78.70891407203946,CCL19;FOXO1;AQP1
regulation of cytokinesis (GO:0032465),7/84,0.002674746165793104,0.01773450376074494,0,0,4.042756330427563,23.94888743750242,PLK4;RACGAP1;PRC1;ECT2;CDC25B;CIT;AURKA
anterior/posterior pattern specification (GO:0009952),6/63,0.002732446261214083,0.018046854376390687,0,0,4.675218798705191,27.595750143714056,BMP2;WT1;SIX2;GATA4;PCSK5;TDGF1
negative regulation of peptidase activity (GO:0010466),6/63,0.002732446261214083,0.018046854376390687,0,0,4.675218798705191,27.595750143714056,VTN;LRP1;SERPINC1;SERPING1;TIMP1;AGT
camera-type eye development (GO:0043010),4/27,0.0028279699959403307,0.01833237544944059,0,0,7.702652075322883,45.200673181127826,FBN2;LAMA1;WT1;PAX2
cellular senescence (GO:0090398),4/27,0.0028279699959403307,0.01833237544944059,0,0,7.702652075322883,45.200673181127826,CDKN2A;HMGA1;HMGA2;CALR
chondroitin sulfate proteoglycan biosynthetic process (GO:0050650),4/27,0.0028279699959403307,0.01833237544944059,0,0,7.702652075322883,45.200673181127826,VCAN;CHPF;BGN;DCN
peptide hormone secretion (GO:0030072),4/27,0.0028279699959403307,0.01833237544944059,0,0,7.702652075322883,45.200673181127826,RIMS2;IL6;ANXA1;PTPRN
positive regulation of erythrocyte differentiation (GO:0045648),4/27,0.0028279699959403307,0.01833237544944059,0,0,7.702652075322883,45.200673181127826,STAT5B;STAT1;TAL1;INHBA
positive regulation of nitric oxide biosynthetic process (GO:0045429),4/27,0.0028279699959403307,0.01833237544944059,0,0,7.702652075322883,45.200673181127826,CD36;PKD2;PTGS2;KLF4
regulation of blood coagulation (GO:0030193),4/27,0.0028279699959403307,0.01833237544944059,0,0,7.702652075322883,45.200673181127826,VTN;PROC;CAV1;F12
release of sequestered calcium ion into cytosol (GO:0051209),4/27,0.0028279699959403307,0.01833237544944059,0,0,7.702652075322883,45.200673181127826,CCL21;CCL19;PKD2;FGF2
cardiac ventricle morphogenesis (GO:0003208),5/44,0.002834847964159387,0.01833237544944059,0,0,5.686480186480186,33.35556766139269,MEF2C;GATA4;GATA3;PROX1;TGFBR2
neurogenesis (GO:0022008),5/44,0.002834847964159387,0.01833237544944059,0,0,5.686480186480186,33.35556766139269,ANXA1;CXCR4;SIX1;ASCL1;CIT
positive regulation of receptor-mediated endocytosis (GO:0048260),5/44,0.002834847964159387,0.01833237544944059,0,0,5.686480186480186,33.35556766139269,C3;VTN;CCL21;CCL19;SELE
negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090101),8/108,0.00285826587696732,0.018448807024061792,0,0,3.5615560640732267,20.86195773001013,BMP2;CAV1;SOSTDC1;SPRY2;PPARG;BMPR1B;PPARA;TGFBR2
regulation of transcription initiation from RNA polymerase II promoter (GO:0060260),6/64,0.0029596669590912215,0.019067192810175583,0,0,4.594375932762548,26.751574106106272,TCF7L2;IL6;CCND1;CDKN2A;NKX2-5;RUNX2
regulation of receptor signaling pathway via JAK-STAT (GO:0046425),5/45,0.003131936971552978,0.020101019207255273,0,0,5.544034090909091,31.96747506916523,SOCS3;IL6;CAV1;BCL3;KIT
zymogen activation (GO:0031638),5/45,0.003131936971552978,0.020101019207255273,0,0,5.544034090909091,31.96747506916523,CYFIP2;MMP14;F12;BAK1;FADD
regulation of cell-matrix adhesion (GO:0001952),6/65,0.003200716205075849,0.02050383614078664,0,0,4.516273502953554,25.943194256562485,CCL21;CDKN2A;CIB1;CD36;UTRN;SKAP1
positive regulation of fibroblast proliferation (GO:0048146),4/28,0.0032420810318680745,0.020593322398318327,0,0,7.381330309901738,42.30638890264492,E2F1;PDGFA;AGT;AQP1
positive regulation of nitric oxide metabolic process (GO:1904407),4/28,0.0032420810318680745,0.020593322398318327,0,0,7.381330309901738,42.30638890264492,CD36;PKD2;PTGS2;KLF4
positive regulation of response to wounding (GO:1903036),4/28,0.0032420810318680745,0.020593322398318327,0,0,7.381330309901738,42.30638890264492,VTN;ANXA1;MDK;MYLK
ventricular septum morphogenesis (GO:0060412),4/28,0.0032420810318680745,0.020593322398318327,0,0,7.381330309901738,42.30638890264492,PROX1;NKX2-5;ZFPM2;TGFBR2
activation of cysteine-type endopeptidase activity (GO:0097202),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,CYFIP2;BAK1;FADD
branching involved in blood vessel morphogenesis (GO:0001569),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,NRP1;KDR;TGFBR2
low-density lipoprotein particle remodeling (GO:0034374),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,PLA2G2A;APOB;AGT
negative regulation of fibroblast growth factor receptor signaling pathway (GO:0040037),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,SPRY2;GATA3;FGF2
pancreas development (GO:0031016),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,TCF7L2;PROX1;MET
positive regulation of cardiac muscle cell proliferation (GO:0060045),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,MEF2C;ZFPM2;FGF2
positive regulation of glucose metabolic process (GO:0010907),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,PMAIP1;IRS2;PPARGC1A
positive regulation of glycoprotein biosynthetic process (GO:0010560),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,CCL21;CCL19;RAMP1
positive regulation of lymphocyte migration (GO:2000403),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,CXCL10;CXCL12;CCL21
positive regulation of T-helper cell differentiation (GO:0045624),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,ANXA1;IL18;CCL19
response to chemokine (GO:1990868),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,CXCL12;CCL21;DUSP1
smooth muscle contraction (GO:0006939),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,ACTA2;ADRA1A;MYLK
vascular endothelial growth factor signaling pathway (GO:0038084),3/14,0.003317410210292477,0.020593322398318327,0,0,12.059234882764294,68.84099681667077,NRP1;FLT4;KDR
regulation of Wnt signaling pathway (GO:0030111),8/111,0.0033851201606172093,0.020975435467969906,0,0,3.4572882184354934,19.666320322760395,PRKN;BMP2;TERT;LRP1;CTNND2;SOSTDC1;ESR1;PPP1CA
cellular calcium ion homeostasis (GO:0006874),9/136,0.003432774708095838,0.021184166852649098,0,0,3.15776926966698,17.918402972977123,CCL14;CDH5;CCL13;CXCL12;CAV2;CAV1;CALR;BAK1;CCL19
positive regulation of smooth muscle cell proliferation (GO:0048661),5/46,0.003450820623301008,0.021184166852649098,0,0,5.408536585365853,30.661768482745444,JUN;IL6;STAT1;IL18;FGF2
regulation of B cell proliferation (GO:0030888),5/46,0.003450820623301008,0.021184166852649098,0,0,5.408536585365853,30.661768482745444,VAV3;MEF2C;CTLA4;IRS2;TNFRSF4
cellular component disassembly (GO:0022411),6/66,0.0034561023386364136,0.021184166852649098,0,0,4.4407744874715265,25.168594841619672,MMP14;CMA1;CTSG;LAMC1;TIMP1;A2M
ERBB signaling pathway (GO:0038127),6/66,0.0034561023386364136,0.021184166852649098,0,0,4.4407744874715265,25.168594841619672,VIL1;SHC3;ERBB2;REPS2;PRKCA;TDGF1
extracellular matrix disassembly (GO:0022617),6/66,0.0034561023386364136,0.021184166852649098,0,0,4.4407744874715265,25.168594841619672,MMP14;CMA1;CTSG;LAMC1;TIMP1;A2M
beta-catenin-TCF complex assembly (GO:1904837),4/29,0.0036956444338000394,0.022532765816039607,0,0,7.085714285714285,39.68425378674449,TLE4;TCF7L2;TERT;RUVBL1
regulation of DNA biosynthetic process (GO:2000278),4/29,0.0036956444338000394,0.022532765816039607,0,0,7.085714285714285,39.68425378674449,HGF;PDGFA;FGFR4;FGF2
collagen fibril organization (GO:0030199),7/89,0.0037025671528703582,0.022532765816039607,0,0,3.795272302038089,21.24870062521467,COL17A1;COL1A1;COL3A1;COL2A1;COL1A2;DST;COL8A1
second-messenger-mediated signaling (GO:0019932),7/89,0.0037025671528703582,0.022532765816039607,0,0,3.795272302038089,21.24870062521467,RCAN1;CXCR2;TNFSF11;CXCR4;CD36;SELE;AGT
determination of heart left/right asymmetry (GO:0061371),5/47,0.003792373000628219,0.02295631827023263,0,0,5.279491341991342,29.43191475699431,MEF2C;GATA4;PKD2;NKX2-5;TGFBR2
embryonic heart tube morphogenesis (GO:0003143),5/47,0.003792373000628219,0.02295631827023263,0,0,5.279491341991342,29.43191475699431,MEF2C;GATA4;PKD2;NKX2-5;TGFBR2
epithelial to mesenchymal transition (GO:0001837),5/47,0.003792373000628219,0.02295631827023263,0,0,5.279491341991342,29.43191475699431,BMP2;HGF;HMGA2;S100A4;HNRNPAB
positive regulation of cellular component organization (GO:0051130),8/114,0.00398436025975613,0.024075708803632787,0,0,3.3589223263244246,18.55931726114507,CDC20;CDH5;CDT1;LRP1;TAL1;BAK1;CCL19;CAMK1
acute-phase response (GO:0006953),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,SIGIRR;IL6;SAA1
dermatan sulfate proteoglycan biosynthetic process (GO:0050651),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,VCAN;BGN;DCN
endoderm development (GO:0007492),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,DUSP1;GATA4;LAMC1
myoblast differentiation (GO:0045445),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,TCF7L2;EPAS1;SDC1
positive regulation of sprouting angiogenesis (GO:1903672),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,FGF1;KLF4;FGF2
regulation of extracellular matrix disassembly (GO:0010715),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,IL6;LRP1;FGFR4
regulation of extracellular matrix organization (GO:1903053),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,LRP1;FGFR4;AGT
regulation of macrophage differentiation (GO:0045649),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,PRKCA;INHBA;FADD
regulation of phospholipase C activity (GO:1900274),3/15,0.004078860474730785,0.024259609943948546,0,0,11.053733031674208,60.81694966351241,KIT;ESR1;FGF2
cellular response to alcohol (GO:0097306),5/48,0.004157465349412292,0.024514535927327753,0,0,5.156448202959831,28.272030386799408,BLM;GNG2;RAD51;BRCA1;ADCY5
cellular response to ionizing radiation (GO:0071479),5/48,0.004157465349412292,0.024514535927327753,0,0,5.156448202959831,28.272030386799408,YAP1;BLM;RAD51;ECT2;CRYAB
positive regulation of endocytosis (GO:0045807),5/48,0.004157465349412292,0.024514535927327753,0,0,5.156448202959831,28.272030386799408,C3;VTN;LRP1;CCL21;CCL19
regulation of interleukin-2 production (GO:0032663),5/48,0.004157465349412292,0.024514535927327753,0,0,5.156448202959831,28.272030386799408,ZFP36;ANXA1;CR1;HOMER3;EZR
neuron projection morphogenesis (GO:0048812),9/140,0.004157688311618381,0.024514535927327753,0,0,3.060718537712725,16.781295519405166,CNTNAP2;PARD6B;RAB3A;CTNND2;MAPK8IP2;SGK1;PAK3;NEFH;PAX2
chondroitin sulfate metabolic process (GO:0030204),4/30,0.004190371102842424,0.024559125054888113,0,0,6.812837955695098,37.300056036540525,VCAN;CHPF;BGN;DCN
positive regulation of B cell proliferation (GO:0030890),4/30,0.004190371102842424,0.024559125054888113,0,0,6.812837955695098,37.300056036540525,VAV3;MEF2C;IRS2;TNFRSF4
regulation of vasoconstriction (GO:0019229),4/30,0.004190371102842424,0.024559125054888113,0,0,6.812837955695098,37.300056036540525,PER2;CAV1;ADRA1A;AGT
cellular response to molecule of bacterial origin (GO:0071219),8/115,0.004201282249706505,0.024559125054888113,0,0,3.3273594388246113,18.208527008231677,CXCL10;ZFP36;MEF2C;IL6;SIRPA;CCL2;CTSG;VIM
positive regulation of protein metabolic process (GO:0051247),8/115,0.004201282249706505,0.024559125054888113,0,0,3.3273594388246113,18.208527008231677,BARD1;PRKN;IL18;PAEP;INHBA;KLF4;FOXO1;AGT
cellular response to calcium ion (GO:0071277),6/69,0.004313405262735818,0.025128350658809685,0,0,4.228658205879163,23.029389311420907,MEF2C;CAPN3;PKD2;ECT2;SYT9;SYT7
cellular response to decreased oxygen levels (GO:0036294),6/69,0.004313405262735818,0.025128350658809685,0,0,4.228658205879163,23.029389311420907,OPRD1;TERT;EPAS1;PMAIP1;PTGS2;AQP1
negative regulation of mitotic cell cycle phase transition (GO:1901991),7/92,0.004448860850213192,0.02582176424226791,0,0,3.660757453666398,19.82339406051026,CDKN2C;CDKN2A;FAM107A;CCL2;PKD2;KLF4;AURKA
positive regulation of cellular component biogenesis (GO:0044089),7/92,0.004448860850213192,0.02582176424226791,0,0,3.660757453666398,19.82339406051026,VIL1;CDH5;CDT1;TAL1;SDC1;PRKCA;BAK1
cellular response to mechanical stimulus (GO:0071260),5/49,0.004546964765204428,0.02582176424226791,0,0,5.038997933884297,27.17680414155041,CHEK1;HABP4;BAK1;FADD;AQP1
mitotic cytokinesis (GO:0000281),5/49,0.004546964765204428,0.02582176424226791,0,0,5.038997933884297,27.17680414155041,RACGAP1;STMN1;ECT2;CEP55;CIT
regulation of smooth muscle cell proliferation (GO:0048660),5/49,0.004546964765204428,0.02582176424226791,0,0,5.038997933884297,27.17680414155041,TCF7L2;IL6;STAT1;IL18;PPARG
caveola assembly (GO:0070836),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CAV2;CAV1
cellular response to salt stress (GO:0071472),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CAPN3;AQP1
chemokine (C-X-C motif) ligand 12 signaling pathway (GO:0038146),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CXCL12;CXCR4
establishment of protein localization to telomere (GO:0070200),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,TERT;BRCA2
establishment of T cell polarity (GO:0001768),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CCL21;CCL19
forebrain regionalization (GO:0021871),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,BMP2;SIX3
mature conventional dendritic cell differentiation (GO:0097029),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,PRTN3;CCL19
metanephric distal tubule development (GO:0072235),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,PKD2;PAX2
metanephric epithelium development (GO:0072207),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,WT1;PAX2
metanephric mesenchymal cell differentiation (GO:0072162),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,STAT1;PAX2
metanephric renal vesicle morphogenesis (GO:0072283),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,SIX2;PAX2
monocyte extravasation (GO:0035696),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,PECAM1;SIRPA
negative regulation of B cell differentiation (GO:0045578),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CR1;INHBA
negative regulation of metallopeptidase activity (GO:1905049),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,LRP1;TIMP1
negative regulation of regulatory T cell differentiation (GO:0045590),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,MDK;CTLA4
nephric duct development (GO:0072176),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,GATA3;PKD2
nephron tubule formation (GO:0072079),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,SIX1;PAX2
positive regulation of cardioblast differentiation (GO:0051891),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,GATA4;NKX2-5
positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway (GO:0038033),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,KDR;PRKD1
positive regulation of glycoprotein metabolic process (GO:1903020),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CCL21;CCL19
positive regulation of mitochondrial depolarization (GO:0051901),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,KDR;DCN
positive regulation of prostaglandin biosynthetic process (GO:0031394),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,ANXA1;PTGS2
positive regulation of protein localization to cell cortex (GO:1904778),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,GPSM2;EPB41L2
regulation of cardioblast differentiation (GO:0051890),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,GATA4;NKX2-5
regulation of endothelial tube morphogenesis (GO:1901509),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CXCL10;FGF1
regulation of guanyl-nucleotide exchange factor activity (GO:1905097),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,STMN1;MET
regulation of heart growth (GO:0060420),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,WT1;PROX1
regulation of type B pancreatic cell apoptotic process (GO:2000674),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,TCF7L2;IL6
response to prostaglandin (GO:0034694),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CCL21;CCL19
response to salt stress (GO:0009651),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,CAPN3;AQP1
ventricular cardiac muscle cell differentiation (GO:0055012),2/5,0.00472443301368285,0.02582176424226791,0,0,29.423626787057938,157.5637486639694,MEF2C;NKX2-5
cellular response to cAMP (GO:0071320),4/31,0.004727928664077223,0.02582176424226791,0,0,6.560174687158814,35.1249339723523,WT1;PKD2;EZR;AQP1
regulation of cellular senescence (GO:2000772),4/31,0.004727928664077223,0.02582176424226791,0,0,6.560174687158814,35.1249339723523,TERT;CDKN2A;HMGA1;HMGA2
regulation of developmental growth (GO:0048638),4/31,0.004727928664077223,0.02582176424226791,0,0,6.560174687158814,35.1249339723523,STAT5A;STAT5B;SIX1;FGFR3
negative regulation of DNA-binding transcription factor activity (GO:0043433),9/143,0.004775819079971474,0.02604158627926845,0,0,2.9917328495138986,15.98838813288573,SIGIRR;TCF7L2;CDKN2A;PROX1;NFKBIE;PKD2;KLF4;TNFRSF4;ESR1
adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189),8/118,0.004906913575511745,0.02654383730945221,0,0,3.23611400041606,17.20677454807247,CXCL10;GNG2;S1PR1;ADRB1;ADRB2;ADRA1A;RAMP1;ADCY5
positive regulation of protein-containing complex assembly (GO:0031334),8/118,0.004906913575511745,0.02654383730945221,0,0,3.23611400041606,17.20677454807247,CDH5;CDT1;PARP1;TAL1;CD36;BAK1;ESR1;SKAP1
eosinophil chemotaxis (GO:0048245),3/16,0.004938026072239642,0.02654383730945221,0,0,10.202923773059519,54.185581546753575,CCL13;CCL21;CCL2
eosinophil migration (GO:0072677),3/16,0.004938026072239642,0.02654383730945221,0,0,10.202923773059519,54.185581546753575,CCL13;CCL21;CCL2
negative regulation of receptor signaling pathway via JAK-STAT (GO:0046426),3/16,0.004938026072239642,0.02654383730945221,0,0,10.202923773059519,54.185581546753575,SOCS3;CAV1;BCL3
positive regulation of leukocyte adhesion to vascular endothelial cell (GO:1904996),3/16,0.004938026072239642,0.02654383730945221,0,0,10.202923773059519,54.185581546753575,IL6;MDK;SELE
regulation of cholesterol storage (GO:0010885),3/16,0.004938026072239642,0.02654383730945221,0,0,10.202923773059519,54.185581546753575,PPARG;APOB;PPARA
regulation of interleukin-1 production (GO:0032652),3/16,0.004938026072239642,0.02654383730945221,0,0,10.202923773059519,54.185581546753575,ANXA1;SAA1;SIRPA
regulation of neurotransmitter transport (GO:0051588),3/16,0.004938026072239642,0.02654383730945221,0,0,10.202923773059519,54.185581546753575,MEF2C;SNCAIP;SYN1
positive regulation of cell morphogenesis involved in differentiation (GO:0010770),5/50,0.004961732913529789,0.0266105287451394,0,0,4.9267676767676765,26.141430384384254,NRP1;MDK;RAC3;CIB1;CALR
negative regulation of neuron apoptotic process (GO:0043524),6/71,0.004966049378494325,0.0266105287451394,0,0,4.098125109514631,21.74108912041526,PRKN;MEF2C;MDK;SIX1;CCL2;PPARGC1A
negative regulation of cell migration (GO:0030336),9/144,0.004996993750675374,0.0267343087948221,0,0,2.9694189602446484,15.734709945309776,NGFR;COL3A1;LRP1;MITF;EVL;CALR;TIMP1;FGF2;MAPK15
negative regulation of cell death (GO:0060548),7/94,0.005006006205530875,0.026740547254622604,0,0,3.5762347136933816,18.943733148423654,PRKN;MECOM;GATA4;PRKD1;FGF2;PPARGC1A;PAX2
positive regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043123),10/171,0.00505829340312559,0.026977564816669814,0,0,2.7691868351538518,14.63993238553156,PRKN;CCL21;PELI2;S100A4;PRKD1;FADD;CCL19;ECT2;IKBKE;LURAP1
hematopoietic progenitor cell differentiation (GO:0002244),4/32,0.00530993846037253,0.028056680769303337,0,0,6.32555879494655,33.134384150595814,FLT4;KIT;KDR;INHBA
modulation by host of symbiont process (GO:0051851),4/32,0.00530993846037253,0.028056680769303337,0,0,6.32555879494655,33.134384150595814,JUN;HMGA2;AQP1;SAP30
negative regulation of microtubule polymerization or depolymerization (GO:0031111),4/32,0.00530993846037253,0.028056680769303337,0,0,6.32555879494655,33.134384150595814,CDH5;STMN1;CIB1;FKBP4
regulation of cellular biosynthetic process (GO:0031326),4/32,0.00530993846037253,0.028056680769303337,0,0,6.32555879494655,33.134384150595814,C3;SIRPA;MITF;FGFR4
skeletal muscle organ development (GO:0060538),4/32,0.00530993846037253,0.028056680769303337,0,0,6.32555879494655,33.134384150595814,MEF2C;WT1;CAV1;SIX1
cell morphogenesis involved in differentiation (GO:0000904),6/72,0.005318255803101513,0.028056680769303337,0,0,4.0358252226133775,21.134042258684048,NRP1;MEF2C;PARVA;LAMC1;PROX1;TEK
negative regulation of epithelial cell proliferation (GO:0050680),6/72,0.005318255803101513,0.028056680769303337,0,0,4.0358252226133775,21.134042258684048,MAGED1;CAV2;STAT1;CAV1;GATA3;BRCA2
gonad development (GO:0008406),5/51,0.005402624785053684,0.02832637733455839,0,0,4.819416996047431,25.161551405941452,WT1;KIT;GATA4;GATA3;INHBA
intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630),5/51,0.005402624785053684,0.02832637733455839,0,0,4.819416996047431,25.161551405941452,BCL3;E2F1;BRCA1;BAK1;IKBKE
positive regulation of fat cell differentiation (GO:0045600),5/51,0.005402624785053684,0.02832637733455839,0,0,4.819416996047431,25.161551405941452,ZFP36;BMP2;SIX1;PPARG;PTGS2
regulation of substrate adhesion-dependent cell spreading (GO:1900024),5/51,0.005402624785053684,0.02832637733455839,0,0,4.819416996047431,25.161551405941452,NRP1;MDK;RAC3;CIB1;CALR
positive regulation of cytosolic calcium ion concentration (GO:0007204),9/147,0.005708461111862058,0.029883925451959902,0,0,2.904417630634224,15.00365743960783,CAV1;CXCR2;SAA1;CXCR4;CD36;ESR1;ADRA1A;F2RL2;ADCY5
positive regulation of protein localization to cell periphery (GO:1904377),5/52,0.0058704874982786065,0.030294520331343597,0,0,4.716634429400387,24.233207381686725,GPSM2;LRP1;EPB41L2;CIB1;AKAP5
response to peptide hormone (GO:0043434),5/52,0.0058704874982786065,0.030294520331343597,0,0,4.716634429400387,24.233207381686725,STAT5A;STAT5B;ANXA1;STAT1;CAV1
adenylate cyclase-activating adrenergic receptor signaling pathway (GO:0071880),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,ADRB1;ADRB2;ADRA1A
aorta morphogenesis (GO:0035909),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,LRP1;PROX1;MYLK
embryo development ending in birth or egg hatching (GO:0009792),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,NR5A2;BRCA1;TDGF1
mesonephric tubule development (GO:0072164),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,WT1;SIX1;PKD2
positive regulation of cardiac muscle tissue growth (GO:0055023),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,MEF2C;ZFPM2;FGF2
positive regulation of muscle hypertrophy (GO:0014742),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,PARP1;PRKCA;AGT
positive regulation of smooth muscle cell migration (GO:0014911),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,NRP1;VTN;MDK
positive regulation of stem cell differentiation (GO:2000738),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,GATA4;NKX2-5;SOX5
regulation of stem cell proliferation (GO:0072091),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,YAP1;TERT;HMGA2
regulation of steroid biosynthetic process (GO:0050810),3/17,0.005898212860035294,0.030294520331343597,0,0,9.473658694246929,48.62929313940271,EGR1;BMP2;FGFR4
mitotic G2 DNA damage checkpoint signaling (GO:0007095),4/33,0.005937972854571421,0.030294520331343597,0,0,6.107123309093752,31.307480434691563,BLM;CHEK1;HMGA2;BRCA1
muscle cell development (GO:0055001),4/33,0.005937972854571421,0.030294520331343597,0,0,6.107123309093752,31.307480434691563,BIN1;SDC1;DMD;NKX2-5
regulation of histone acetylation (GO:0035065),4/33,0.005937972854571421,0.030294520331343597,0,0,6.107123309093752,31.307480434691563,CHEK1;BRCA1;CAMK1;PPARGC1A
regulation of neurotransmitter secretion (GO:0046928),4/33,0.005937972854571421,0.030294520331343597,0,0,6.107123309093752,31.307480434691563,RIMS2;MEF2C;SNCAIP;SYN1
calcium ion homeostasis (GO:0055074),7/97,0.005938010440533311,0.030294520331343597,0,0,3.456494165398275,17.719306515172992,CCL14;CDH5;CCL13;CXCL12;CAV1;CALR;CCL19
positive regulation of intracellular protein transport (GO:0090316),9/148,0.005962213385400417,0.0303271988320069,0,0,2.8833740347171806,14.769545724717025,TCF7L2;ERBB2;E2F1;PMAIP1;GZMB;CIB1;AKAP5;CAMK1;ECT2
regulation of cytosolic calcium ion concentration (GO:0051480),9/148,0.005962213385400417,0.0303271988320069,0,0,2.8833740347171806,14.769545724717025,CAV2;CAV1;CXCR2;SAA1;CXCR4;CD36;ESR1;ADRA1A;ADCY5
regulation of G2/M transition of mitotic cell cycle (GO:0010389),9/149,0.006224574336700256,0.03161452956702604,0,0,2.8626310615989516,14.540019445443157,PLK4;CENPF;CCND1;PRKAR2B;NEK2;CDC7;TUBG1;CDC25B;AURKA
regulation of peptidyl-serine phosphorylation (GO:0033135),7/98,0.00627573821456417,0.031803588602289164,0,0,3.4183350895679663,17.334596549762846,OPRD1;IL6;CAV1;SPRY2;DMD;PRKD1;CAMK1
regulation of anatomical structure morphogenesis (GO:0022603),8/123,0.00628046218583938,0.031803588602289164,0,0,3.0946174509999005,15.690675083493987,MEF2C;IL6;FLT4;CFL1;ERBB2;PAK3;FGF2;SH3D19
fibroblast growth factor receptor signaling pathway (GO:0008543),6/75,0.006484618366777294,0.03278869346287391,0,0,3.859760324848965,19.44671656193495,FGF7;POLR2H;FGF1;FGFR4;FGF2;FGFR3
regulation of cytokine production (GO:0001817),9/150,0.006495731721551335,0.03279622771414363,0,0,2.8421823150497754,14.314963801584385,IL6;ANXA1;MAPKAPK2;IRF7;SAA1;SIRPA;GATA3;LURAP1;AGT
B cell receptor signaling pathway (GO:0050853),4/34,0.006613552822076582,0.03295934331679308,0,0,5.903250188964475,29.62625374712648,VAV3;MEF2C;CTLA4;BMX
cell-substrate junction assembly (GO:0007044),4/34,0.006613552822076582,0.03295934331679308,0,0,5.903250188964475,29.62625374712648,COL17A1;DST;LAMC1;KRT5
epithelial tube morphogenesis (GO:0060562),4/34,0.006613552822076582,0.03295934331679308,0,0,5.903250188964475,29.62625374712648,MEF2C;GATA3;PKD2;MET
negative regulation of blood vessel endothelial cell migration (GO:0043537),4/34,0.006613552822076582,0.03295934331679308,0,0,5.903250188964475,29.62625374712648,MEF2C;PPARG;KLF4;FGF2
positive regulation of DNA binding (GO:0043388),4/34,0.006613552822076582,0.03295934331679308,0,0,5.903250188964475,29.62625374712648,PRKN;PLAUR;PPARG;GATA3
regulation of mitotic cell cycle (GO:0007346),10/178,0.0066665937591827325,0.03295934331679308,0,0,2.6528461959496443,13.29247379124413,CDC20;CAV2;TAL1;RCC1;NEK2;PRKCA;MKI67;PKMYT1;CDC25B;MAD2L1
positive regulation of leukocyte chemotaxis (GO:0002690),5/54,0.00689046762589742,0.03295934331679308,0,0,4.52365491651206,22.517018565746373,CXCL10;IL6;CXCL12;MDK;CALR
actomyosin structure organization (GO:0031032),6/76,0.006911704674492649,0.03295934331679308,0,0,3.8044256426944356,18.925263636633144,KRT19;ACTC1;EPB41L2;KCTD13;CAPN3;CIT
cellular response to hormone stimulus (GO:0032870),6/76,0.006911704674492649,0.03295934331679308,0,0,3.8044256426944356,18.925263636633144,STAT5B;MEF2C;WT1;CAV1;LMO2;RAMP1
regulation of BMP signaling pathway (GO:0030510),6/76,0.006911704674492649,0.03295934331679308,0,0,3.8044256426944356,18.925263636633144,CDH5;BMP2;SOSTDC1;PPARG;ZNF423;BMPR1B
DNA strand elongation (GO:0022616),3/18,0.006962355297133161,0.03295934331679308,0,0,8.841628959276019,43.91847054848402,RFC4;TERT;MCM4
negative regulation of interleukin-8 production (GO:0032717),3/18,0.006962355297133161,0.03295934331679308,0,0,8.841628959276019,43.91847054848402,ANXA1;BCL3;KLF4
negative regulation of Rho protein signal transduction (GO:0035024),3/18,0.006962355297133161,0.03295934331679308,0,0,8.841628959276019,43.91847054848402,STMN1;KCTD13;MET
positive chemotaxis (GO:0050918),3/18,0.006962355297133161,0.03295934331679308,0,0,8.841628959276019,43.91847054848402,NRP1;FGF7;MET
positive regulation of cardiac muscle hypertrophy (GO:0010613),3/18,0.006962355297133161,0.03295934331679308,0,0,8.841628959276019,43.91847054848402,PARP1;PRKCA;AGT
positive regulation of fatty acid metabolic process (GO:0045923),3/18,0.006962355297133161,0.03295934331679308,0,0,8.841628959276019,43.91847054848402,PPARG;PPARA;PPARGC1A
regulation of adaptive immune response (GO:0002819),3/18,0.006962355297133161,0.03295934331679308,0,0,8.841628959276019,43.91847054848402,IRF7;FADD;SKAP1
regulation of fatty acid metabolic process (GO:0019217),3/18,0.006962355297133161,0.03295934331679308,0,0,8.841628959276019,43.91847054848402,CAV1;PPARG;PPARA
epithelial tube formation (GO:0072175),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,GATA3;PAX2
establishment of lymphocyte polarity (GO:0001767),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CCL21;CCL19
foam cell differentiation (GO:0090077),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,STAT1;PPARG
glomerulus vasculature development (GO:0072012),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,PECAM1;TEK
hepatocyte differentiation (GO:0070365),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,ANXA1;PROX1
macrophage derived foam cell differentiation (GO:0010742),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,STAT1;PPARG
mesenchymal to epithelial transition involved in metanephros morphogenesis (GO:0003337),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,SIX2;PAX2
negative regulation of cellular extravasation (GO:0002692),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CXCL12;CCL21
negative regulation of fat cell proliferation (GO:0070345),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,PER2;E2F1
negative regulation of sequestering of triglyceride (GO:0010891),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,PPARG;PPARA
negative regulation of trophoblast cell migration (GO:1901164),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CALR;TIMP1
nephric duct morphogenesis (GO:0072178),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,GATA3;PAX2
neutrophil extravasation (GO:0072672),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,PECAM1;PRTN3
plasma membrane raft assembly (GO:0044854),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CAV2;CAV1
positive regulation of antigen processing and presentation (GO:0002579),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CCL21;CCL19
positive regulation of dendritic cell antigen processing and presentation (GO:0002606),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CCL21;CCL19
positive regulation of endothelial cell development (GO:1901552),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CDH5;PROC
positive regulation of establishment of endothelial barrier (GO:1903142),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CDH5;PROC
positive regulation of extrinsic apoptotic signaling pathway via death domain receptors (GO:1902043),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,PMAIP1;ATF3
positive regulation of fever generation (GO:0031622),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,TNFSF11;PTGS2
positive regulation of heart rate by epinephrine-norepinephrine (GO:0001996),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,ADRB1;ADRA1A
positive regulation of nuclear cell cycle DNA replication (GO:0010571),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,DBF4;CDC7
positive regulation of plasminogen activation (GO:0010756),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,CLEC3B;F12
regulation of glucagon secretion (GO:0070092),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,IL6;SYT7
regulation of type B pancreatic cell proliferation (GO:0061469),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,NR4A1;PTPRN
skeletal muscle thin filament assembly (GO:0030240),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,ACTC1;PROX1
taurine metabolic process (GO:0019530),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,STAT5A;STAT5B
ventricular cardiac muscle cell development (GO:0055015),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,PROX1;NKX2-5
vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane (GO:1990668),2/6,0.006982583883428581,0.03295934331679308,0,0,22.066591422121896,109.54597964097579,TAP1;CALR
cellular response to amyloid-beta (GO:1904646),4/35,0.007338145822784945,0.03425808351239876,0,0,5.712530173359666,28.075195417103373,NGFR;LRP1;ADRB2;CD36
lung development (GO:0030324),4/35,0.007338145822784945,0.03425808351239876,0,0,5.712530173359666,28.075195417103373,FGF7;PROX1;FGF1;FGF2
negative regulation of Ras protein signal transduction (GO:0046580),4/35,0.007338145822784945,0.03425808351239876,0,0,5.712530173359666,28.075195417103373,STMN1;KCTD13;SPRY2;MET
positive regulation of cell cycle G1/S phase transition (GO:1902808),4/35,0.007338145822784945,0.03425808351239876,0,0,5.712530173359666,28.075195417103373,CCND2;ANXA1;CCND1;EZH2
positive regulation of lymphocyte activation (GO:0051251),4/35,0.007338145822784945,0.03425808351239876,0,0,5.712530173359666,28.075195417103373,IL6;CCL2;SIRPA;TNFSF11
regulation of postsynaptic membrane potential (GO:0060078),4/35,0.007338145822784945,0.03425808351239876,0,0,5.712530173359666,28.075195417103373,MEF2C;GRIN2C;MAPK8IP2;GRIN2D
regulation of T cell receptor signaling pathway (GO:0050856),4/35,0.007338145822784945,0.03425808351239876,0,0,5.712530173359666,28.075195417103373,TRAT1;SH2D1A;EZR;NECTIN2
semaphorin-plexin signaling pathway (GO:0071526),4/35,0.007338145822784945,0.03425808351239876,0,0,5.712530173359666,28.075195417103373,NRP1;SH3BP1;SEMA3F;MET
mitotic sister chromatid segregation (GO:0000070),7/102,0.007771209708080348,0.03618071405073473,0,0,3.2737322758952176,15.901596153005835,DSN1;PRC1;H4-16;KIF22;TUBG1;NDC80;CEP55
regulation of cell death (GO:0010941),7/102,0.007771209708080348,0.03618071405073473,0,0,3.2737322758952176,15.901596153005835,PRKN;LRP1;SNCG;PRKD1;CD36;FGF2;CRYAB
negative regulation of protein serine/threonine kinase activity (GO:0071901),6/78,0.007826396841798245,0.03638794056868815,0,0,3.698367501898254,17.938018250011666,DUSP1;PRKAR2B;CDKN2A;CBLC;SPRY2;AGT
cellular response to interleukin-1 (GO:0071347),9/155,0.007990094496277382,0.03709842240233422,0,0,2.7441403795400277,13.25297055848393,CCL14;EGR1;CCL13;CCL21;PELI2;SIRPA;CCL2;CCL19;CCL16
Rho protein signal transduction (GO:0007266),5/56,0.008028249679555084,0.03717428655967897,0,0,4.3458110516934045,20.967620260715538,EPS8;NGFR;COL1A2;CFL1;RHOJ
telomere maintenance (GO:0000723),5/56,0.008028249679555084,0.03717428655967897,0,0,4.3458110516934045,20.967620260715538,BLM;RAD51;PARP1;TERT;H4-16
aortic valve development (GO:0003176),4/36,0.008113163925984178,0.0372545480570581,0,0,5.533730158730159,26.640856484578737,BMP2;GATA4;GATA3;NKX2-5
positive regulation of bone mineralization (GO:0030501),4/36,0.008113163925984178,0.0372545480570581,0,0,5.533730158730159,26.640856484578737,FBN2;MEF2C;BMP2;BMPR1B
regulation of ossification (GO:0030278),4/36,0.008113163925984178,0.0372545480570581,0,0,5.533730158730159,26.640856484578737,MEF2C;BMP2;MDK;S1PR1
atrioventricular valve morphogenesis (GO:0003181),3/19,0.008133035139216909,0.0372545480570581,0,0,8.288602941176471,39.8832745155279,BMP2;GATA4;TGFBR2
DNA double-strand break processing (GO:0000729),3/19,0.008133035139216909,0.0372545480570581,0,0,8.288602941176471,39.8832745155279,BARD1;BLM;BRCA1
positive regulation of focal adhesion assembly (GO:0051894),3/19,0.008133035139216909,0.0372545480570581,0,0,8.288602941176471,39.8832745155279,NRP1;KDR;TEK
positive regulation of neutrophil chemotaxis (GO:0090023),3/19,0.008133035139216909,0.0372545480570581,0,0,8.288602941176471,39.8832745155279,CCL21;MDK;CCL19
regulation of neuroinflammatory response (GO:0150077),3/19,0.008133035139216909,0.0372545480570581,0,0,8.288602941176471,39.8832745155279,IL6;IL18;PTGS2
cellular response to organonitrogen compound (GO:0071417),7/103,0.008182954906110927,0.03743289975842422,0,0,3.2394644216133943,15.567900514244558,EGR1;MEF2C;WT1;BRCA1;EZR;PKD2;AQP1
membrane organization (GO:0061024),12/242,0.008250910830490385,0.03769316904867458,0,0,2.328547042875791,11.171045354269848,RABIF;CR1;BIN1;ITSN1;MX1;REPS2;SYP;ADRB2;APOB;SYT9;CEP55;STX11
cellular metal ion homeostasis (GO:0006875),7/104,0.008610544408538368,0.03928344758272926,0,0,3.2059031210281033,15.243324714174182,CCL14;CDH5;CCL13;CXCL12;CAV1;CALR;CCL19
regulation of bone mineralization (GO:0030500),5/57,0.008643318846439856,0.03932767774187855,0,0,4.262019230769231,20.24871972626922,FBN2;MEF2C;BMP2;S1PR1;BMPR1B
regulation of reactive oxygen species metabolic process (GO:2000377),5/57,0.008643318846439856,0.03932767774187855,0,0,4.262019230769231,20.24871972626922,PRKN;BRCA1;PAX2;AGT;TGFBR2
regulation of response to external stimulus (GO:0032101),8/130,0.008670311664654252,0.03939789620418892,0,0,2.9160070525565516,13.844765663077009,ANXA1;CMA1;CAV1;NMT2;CXCR4;CD36;PTGS2;SELE
glutamate receptor signaling pathway (GO:0007215),4/37,0.008939962186225897,0.04024754442623231,0,0,5.3657665086236515,25.31152212111557,GRIA2;HOMER3;GRIN2C;GRIA4
positive regulation of calcium ion transport (GO:0051928),4/37,0.008939962186225897,0.04024754442623231,0,0,5.3657665086236515,25.31152212111557,CXCL12;CAV1;CCL2;MYLK
positive regulation of cytokinesis (GO:0032467),4/37,0.008939962186225897,0.04024754442623231,0,0,5.3657665086236515,25.31152212111557,RACGAP1;ECT2;CDC25B;CIT
positive regulation of myeloid cell differentiation (GO:0045639),4/37,0.008939962186225897,0.04024754442623231,0,0,5.3657665086236515,25.31152212111557,STAT5B;STAT1;TAL1;INHBA
regulation of p38MAPK cascade (GO:1900744),4/37,0.008939962186225897,0.04024754442623231,0,0,5.3657665086236515,25.31152212111557,BMP2;DUSP1;EZR;GADD45G
regulation of transport (GO:0051049),4/37,0.008939962186225897,0.04024754442623231,0,0,5.3657665086236515,25.31152212111557,PRKN;NRP1;TRAT1;LEPR
regulation of vascular associated smooth muscle cell proliferation (GO:1904705),4/37,0.008939962186225897,0.04024754442623231,0,0,5.3657665086236515,25.31152212111557,JUN;MEF2C;PPARG;FGF2
chemical synaptic transmission (GO:0007268),14/306,0.008964622401960541,0.040305320772930774,0,0,2.14285033213616,10.102402088093129,GRIA2;RAB3A;GAD1;AKAP5;GRIN2C;SYN1;GRIN2D;RPS6KA3;DLG2;PRKAR2B;SNCG;CAMK1;PDLIM4;GRIA4
muscle organ development (GO:0007517),5/58,0.009290214135866394,0.04123991910174215,0,0,4.181389365351629,19.563858120650565,CXCL10;MEF2C;CAPN3;DMD;UTRN
positive regulation of mitotic cell cycle phase transition (GO:1901992),5/58,0.009290214135866394,0.04123991910174215,0,0,4.181389365351629,19.563858120650565,CCND2;ANXA1;CCND1;CDC7;CDC25B
regulation of neurotransmitter receptor activity (GO:0099601),5/58,0.009290214135866394,0.04123991910174215,0,0,4.181389365351629,19.563858120650565,GRIA2;MEF2C;DLG2;MAPK8IP2;GRIA4
regulation of phagocytosis (GO:0050764),5/58,0.009290214135866394,0.04123991910174215,0,0,4.181389365351629,19.563858120650565,SIRPA;PRTN3;CALR;IL2RG;SYT7
phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200),6/81,0.009357313927307721,0.04123991910174215,0,0,3.549886104783599,16.583637289005996,OPRD1;CXCR2;ADRA1A;ESR1;AGT;F2RL2
adrenergic receptor signaling pathway (GO:0071875),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,ADRB1;ADRB2;ADRA1A
embryonic digestive tract development (GO:0048566),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,SIX2;RARB;PCSK5
fatty acid transport (GO:0015908),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,SLC27A6;PPARG;CD36
hepaticobiliary system development (GO:0061008),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,PROX1;PKD2;MET
insulin secretion (GO:0030073),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,RIMS2;ANXA1;PTPRN
maintenance of protein location in nucleus (GO:0051457),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,BARD1;BCL3;SYNE1
negative regulation of lipid storage (GO:0010888),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,IL6;PPARG;PPARA
positive regulation of G2/M transition of mitotic cell cycle (GO:0010971),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,CCND1;CDC7;CDC25B
regulation of protein modification by small protein conjugation or removal (GO:1903320),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,PRKN;EGR1;EPAS1
regulation of T cell migration (GO:2000404),3/20,0.009412499398464572,0.04123991910174215,0,0,7.800638807559222,36.395571143290276,CXCL10;CXCL12;CCL21
"complement activation, alternative pathway (GO:0006957)",2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,C3;CR1
establishment of centrosome localization (GO:0051660),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,EZR;MAD2L1
metanephric nephron tubule development (GO:0072234),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,PKD2;PAX2
negative regulation of p38MAPK cascade (GO:1903753),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,DUSP1;EZR
negative regulation of retinoic acid receptor signaling pathway (GO:0048387),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,CALR;EZH2
positive regulation of histone H4 acetylation (GO:0090240),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,MUC1;BRCA1
positive regulation of hormone metabolic process (GO:0032352),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,EGR1;GATA3
positive regulation of membrane depolarization (GO:1904181),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,KDR;DCN
positive regulation of mitotic cell cycle spindle assembly checkpoint (GO:0090267),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,NDC80;MAD2L1
positive regulation of spindle checkpoint (GO:0090232),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,NDC80;MAD2L1
positive regulation of unsaturated fatty acid biosynthetic process (GO:2001280),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,ANXA1;PTGS2
receptor-mediated endocytosis of virus by host cell (GO:0019065),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,CAV2;CAV1
regulation of endothelial cell chemotaxis to fibroblast growth factor (GO:2000544),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,FGF1;FGF2
regulation of fat cell proliferation (GO:0070344),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,PER2;E2F1
regulation of glial cell apoptotic process (GO:0034350),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,CCL2;PRKCA
regulation of lens fiber cell differentiation (GO:1902746),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,SPRY2;FGF2
regulation of metallopeptidase activity (GO:1905048),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,LRP1;TIMP1
regulation of prostaglandin biosynthetic process (GO:0031392),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,ANXA1;PTGS2
regulation of skeletal muscle contraction (GO:0014819),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,DMD;SCN4A
regulation of T-helper 1 cell differentiation (GO:0045625),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,ANXA1;CCL19
skin morphogenesis (GO:0043589),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,COL1A1;COL1A2
sphingosine-1-phosphate receptor signaling pathway (GO:0003376),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,S1PR1;EZR
white fat cell differentiation (GO:0050872),2/7,0.009632328522590008,0.04123991910174215,0,0,17.65237020316027,81.9534284822553,PER2;PPARG
negative regulation of endothelial cell migration (GO:0010596),4/38,0.009819837244998799,0.04188486274212254,0,0,5.207683073229291,24.07694534125496,MEF2C;PPARG;FGF2;DCN
regulation of cell communication (GO:0010646),4/38,0.009819837244998799,0.04188486274212254,0,0,5.207683073229291,24.07694534125496,GRK3;ANXA1;GRK5;TDGF1
response to estradiol (GO:0032355),4/38,0.009819837244998799,0.04188486274212254,0,0,5.207683073229291,24.07694534125496,STAT5B;ANXA1;SSTR2;ESR1
defense response to virus (GO:0051607),8/133,0.009880130416240442,0.04208935557318428,0,0,2.84558352402746,13.138712383319046,CXCL10;IL6;EXOSC4;STAT1;MX1;IRF7;PMAIP1;FADD
cell-cell junction organization (GO:0045216),6/82,0.009911981621482744,0.04217232629964193,0,0,3.5029972425368663,16.16286777089025,CDH5;PARD6B;CTNND2;PRTN3;NECTIN3;NECTIN2
positive regulation of tyrosine phosphorylation of STAT protein (GO:0042531),5/59,0.00996969741322719,0.04236499848413749,0,0,4.1037457912457915,18.910902059418298,SOCS3;IL6;KIT;IL18;FGFR3
response to calcium ion (GO:0051592),7/107,0.009991825024983093,0.04240615153815988,0,0,3.109246575342466,14.321152470484869,MEF2C;CAV1;CAPN3;ECT2;SYT9;PKD2;SYT7
negative regulation of Wnt signaling pathway (GO:0030178),10/191,0.010677547183087395,0.04500675461597182,0,0,2.460659173175843,11.170438245925586,TLE4;PRKN;TCF7L2;BMP2;LRP1;MDK;CAV1;SIAH2;SOSTDC1;NKX2-5
peptidyl-threonine phosphorylation (GO:0018107),5/60,0.010682514577741614,0.04500675461597182,0,0,4.028925619834711,18.28788574447995,CHEK1;PRKCA;PRKD1;CIT;TGFBR2
DNA integrity checkpoint signaling (GO:0031570),4/39,0.01075402615115288,0.04500675461597182,0,0,5.0586329770003235,22.928127850650988,H2AX;CDT1;CHEK1;E2F1
endothelial cell migration (GO:0043542),4/39,0.01075402615115288,0.04500675461597182,0,0,5.0586329770003235,22.928127850650988,NRP1;CDH5;NR4A1;STAT1
negative regulation of cellular metabolic process (GO:0031324),4/39,0.01075402615115288,0.04500675461597182,0,0,5.0586329770003235,22.928127850650988,PRKN;TRAT1;BRCA1;PAX2
odontogenesis (GO:0042476),4/39,0.01075402615115288,0.04500675461597182,0,0,5.0586329770003235,22.928127850650988,BMP2;COL1A2;INHBA;AQP1
regulation of receptor-mediated endocytosis (GO:0048259),4/39,0.01075402615115288,0.04500675461597182,0,0,5.0586329770003235,22.928127850650988,C3;VTN;CCL21;CCL19
response to peptide (GO:1901652),4/39,0.01075402615115288,0.04500675461597182,0,0,5.0586329770003235,22.928127850650988,STAT5A;STAT5B;ANXA1;STAT1
calcium ion transport into cytosol (GO:0060402),3/21,0.010802677604420465,0.04500675461597182,0,0,7.366892911010558,33.35700562839637,GRIN2C;ADRA1A;GRIN2D
cellular response to inorganic substance (GO:0071241),3/21,0.010802677604420465,0.04500675461597182,0,0,7.366892911010558,33.35700562839637,BLM;FOXO1;AQP1
positive regulation of lipid storage (GO:0010884),3/21,0.010802677604420465,0.04500675461597182,0,0,7.366892911010558,33.35700562839637,C3;APOB;IKBKE
regulation of cardiac muscle cell proliferation (GO:0060043),3/21,0.010802677604420465,0.04500675461597182,0,0,7.366892911010558,33.35700562839637,MEF2C;ZFPM2;FGF2
regulation of lipopolysaccharide-mediated signaling pathway (GO:0031664),3/21,0.010802677604420465,0.04500675461597182,0,0,7.366892911010558,33.35700562839637,SIGIRR;PRKCA;CD36
response to progesterone (GO:0032570),3/21,0.010802677604420465,0.04500675461597182,0,0,7.366892911010558,33.35700562839637,CATSPER1;YAP1;CAV1
sterol transport (GO:0015918),3/21,0.010802677604420465,0.04500675461597182,0,0,7.366892911010558,33.35700562839637,CAV1;CD36;APOB
post-translational protein modification (GO:0043687),15/345,0.010824276593004192,0.045041678423636496,0,0,2.0322410147991543,9.1978493365025,RAB3A;CISH;EPAS1;SERPINC1;KLHL3;LAMC1;C3;C4A;SOCS3;IL6;VCAN;PROC;ELOB;TIMP1;APOB
regulation of canonical Wnt signaling pathway (GO:0060828),12/253,0.011478013040119268,0.04770374200088593,0,0,2.2209998754228435,9.921921568160474,COL1A1;PRKN;TLE4;TCF7L2;BMP2;MDK;SIAH2;CTNND2;CAV1;RUVBL1;NKX2-5;PPP1CA
regulation of cell cycle G2/M phase transition (GO:1902749),6/85,0.011715900789196206,0.04839485848780099,0,0,3.3694530146189554,14.983311692612919,PLK4;CENPF;PRKAR2B;NEK2;TUBG1;AURKA
positive regulation of cation channel activity (GO:2001259),4/40,0.011743705390085511,0.04839485848780099,0,0,4.917863441672965,21.85713863482992,ANTKMT;CCL2;ADRB2;PKD2
positive regulation of ossification (GO:0045778),4/40,0.011743705390085511,0.04839485848780099,0,0,4.917863441672965,21.85713863482992,FBN2;MEF2C;BMP2;BMPR1B
positive regulation of wound healing (GO:0090303),4/40,0.011743705390085511,0.04839485848780099,0,0,4.917863441672965,21.85713863482992,VTN;ANXA1;F12;MYLK
stem cell differentiation (GO:0048863),4/40,0.011743705390085511,0.04839485848780099,0,0,4.917863441672965,21.85713863482992,MEF2C;KIT;HMGA2;PAX2
sulfur compound catabolic process (GO:0044273),4/40,0.011743705390085511,0.04839485848780099,0,0,4.917863441672965,21.85713863482992,ACAN;VCAN;BGN;DCN
synaptic vesicle exocytosis (GO:0016079),4/40,0.011743705390085511,0.04839485848780099,0,0,4.917863441672965,21.85713863482992,RIMS2;RAB3A;STX11;SYT7
cellular divalent inorganic cation homeostasis (GO:0072503),7/111,0.012076131077874813,0.049704655450962996,0,0,2.9890454864769933,13.201192361949937,CCL14;CDH5;CCL13;CXCL12;CAV1;CALR;CCL19
glucose metabolic process (GO:0006006),5/62,0.012211049506531488,0.05003356092206654,0,0,3.8871610845295055,17.12455401707129,PER2;IRS2;ENO2;ALDOA;PPARGC1A
positive regulation of interleukin-1 production (GO:0032732),5/62,0.012211049506531488,0.05003356092206654,0,0,3.8871610845295055,17.12455401707129,EGR1;IL6;SAA1;CD36;CCL19
response to retinoic acid (GO:0032526),5/62,0.012211049506531488,0.05003356092206654,0,0,3.8871610845295055,17.12455401707129,RET;ASCL1;RXRG;PAX2;AQP1
negative regulation of myeloid cell differentiation (GO:0045638),3/22,0.012305198377721569,0.05003356092206654,0,0,6.97880447725649,30.6909220550094,ZFP36;H4-16;CIB1
negative regulation of phosphate metabolic process (GO:0045936),3/22,0.012305198377721569,0.05003356092206654,0,0,6.97880447725649,30.6909220550094,CDKN2C;CDKN2A;INHBA
"positive regulation of DNA-templated transcription, initiation (GO:2000144)",3/22,0.012305198377721569,0.05003356092206654,0,0,6.97880447725649,30.6909220550094,JUN;MITF;NKX2-5
positive regulation of granulocyte chemotaxis (GO:0071624),3/22,0.012305198377721569,0.05003356092206654,0,0,6.97880447725649,30.6909220550094,CCL21;MDK;CCL19
positive regulation of neutrophil migration (GO:1902624),3/22,0.012305198377721569,0.05003356092206654,0,0,6.97880447725649,30.6909220550094,CCL21;MDK;CCL19
regulation of platelet activation (GO:0010543),3/22,0.012305198377721569,0.05003356092206654,0,0,6.97880447725649,30.6909220550094,PDGFA;PLA2G4A;PRKCA
regulation of neuron death (GO:1901214),6/86,0.01236543455084647,0.05003356092206654,0,0,3.3271640091116175,14.615733199334397,PRKN;EGR1;MEF2C;SNCG;FOS;PPARGC1A
axon extension involved in axon guidance (GO:0048846),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,NRP1;SEMA3F
cellular response to interleukin-21 (GO:0098757),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,STAT1;IL2RG
fusion of virus membrane with host plasma membrane (GO:0019064),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,CXCR4;NECTIN2
immunological synapse formation (GO:0001771),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,CCL21;CCL19
interleukin-21-mediated signaling pathway (GO:0038114),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,STAT1;IL2RG
membrane fusion involved in viral entry into host cell (GO:0039663),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,CXCR4;NECTIN2
mitotic spindle elongation (GO:0000022),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,RACGAP1;PRC1
mitotic spindle midzone assembly (GO:0051256),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,RACGAP1;PRC1
myoblast migration (GO:0051451),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,ANXA1;SIX1
negative regulation of glial cell apoptotic process (GO:0034351),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,CCL2;PRKCA
neuron projection extension involved in neuron projection guidance (GO:1902284),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,NRP1;SEMA3F
positive regulation of adaptive immune response (GO:0002821),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,FADD;SKAP1
positive regulation of astrocyte differentiation (GO:0048711),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,BMP2;BIN1
positive regulation of cell migration by vascular endothelial growth factor signaling pathway (GO:0038089),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,KDR;PRKD1
positive regulation of dendritic cell chemotaxis (GO:2000510),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,CCL21;CALR
positive regulation of homotypic cell-cell adhesion (GO:0034112),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,PLAUR;TNFSF11
positive regulation of oligodendrocyte differentiation (GO:0048714),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,MDK;CXCR4
regulation of actin filament length (GO:0030832),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,EPS8;CXCL12
regulation of phospholipase A2 activity (GO:0032429),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,ANXA1;LRP1
regulation of protein localization to cell cortex (GO:1904776),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,GPSM2;EPB41L2
regulation of T-helper 2 cell differentiation (GO:0045628),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,ANXA1;IL18
skeletal myofibril assembly (GO:0014866),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,ACTC1;PROX1
spleen development (GO:0048536),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,FADD;NKX2-5
thyroid gland development (GO:0030878),2/8,0.012655202322424107,0.05003356092206654,0,0,14.709556057185853,64.27615437207585,SIX1;NKX2-5
cortical cytoskeleton organization (GO:0030865),4/41,0.012789990094353847,0.050274839955660795,0,0,4.784703070417356,20.856962971735296,RAC3;RHOH;EZR;RND1
gluconeogenesis (GO:0006094),4/41,0.012789990094353847,0.050274839955660795,0,0,4.784703070417356,20.856962971735296,PER2;ENO2;ALDOA;PPARGC1A
positive regulation of biomineral tissue development (GO:0070169),4/41,0.012789990094353847,0.050274839955660795,0,0,4.784703070417356,20.856962971735296,FBN2;MEF2C;BMP2;BMPR1B
regulation of cell development (GO:0060284),4/41,0.012789990094353847,0.050274839955660795,0,0,4.784703070417356,20.856962971735296,YAP1;PER2;ASCL1;FOXO1
regulation of release of cytochrome c from mitochondria (GO:0090199),4/41,0.012789990094353847,0.050274839955660795,0,0,4.784703070417356,20.856962971735296,PRKN;HGF;PLAUR;PMAIP1
negative regulation of intracellular signal transduction (GO:1902532),10/198,0.01348415369720786,0.0529423914747516,0,0,2.36818292981169,10.19796425667576,SH3BP1;DUSP1;STAT1;CAV1;PLAUR;RHOH;CIB1;PPARA;ESR1;CIT
plasma membrane organization (GO:0007009),5/64,0.013881436979127727,0.05403661670009534,0,0,3.7550077041602465,16.060929468158104,RAB3A;CR1;BIN1;CXCR4;SYT7
protein secretion (GO:0009306),5/64,0.013881436979127727,0.05403661670009534,0,0,3.7550077041602465,16.060929468158104,RIMS2;RAB3A;ANXA1;PTPRN;PCSK5
regulation of extrinsic apoptotic signaling pathway (GO:2001236),5/64,0.013881436979127727,0.05403661670009534,0,0,3.7550077041602465,16.060929468158104,TCF7L2;CAV1;SIAH2;FADD;AGT
regulation of chemokine production (GO:0032642),4/42,0.013893933446179271,0.05403661670009534,0,0,4.658551139754147,19.921376106669914,SIGIRR;EGR1;IL6;IL18
positive regulation of cell cycle G2/M phase transition (GO:1902751),3/23,0.013921405358768693,0.05403661670009534,0,0,6.629524886877828,28.336761659556387,CCND1;CDC7;CDC25B
positive regulation of cholesterol efflux (GO:0010875),3/23,0.013921405358768693,0.05403661670009534,0,0,6.629524886877828,28.336761659556387,LRP1;CAV1;PPARG
positive regulation of histone acetylation (GO:0035066),3/23,0.013921405358768693,0.05403661670009534,0,0,6.629524886877828,28.336761659556387,MUC1;BRCA1;PPARGC1A
regulation of interferon-gamma-mediated signaling pathway (GO:0060334),3/23,0.013921405358768693,0.05403661670009534,0,0,6.629524886877828,28.336761659556387,SOCS3;STAT1;PPARG
regulation of neural precursor cell proliferation (GO:2000177),3/23,0.013921405358768693,0.05403661670009534,0,0,6.629524886877828,28.336761659556387,MDK;SIX3;PROX1
regulation of protein export from nucleus (GO:0046825),3/23,0.013921405358768693,0.05403661670009534,0,0,6.629524886877828,28.336761659556387,BARD1;TCF7L2;CAMK1
regulation of cation channel activity (GO:2001257),6/89,0.01446520742083461,0.05601980328432312,0,0,3.2064110656750007,13.582386135615515,GRIA2;MEF2C;DLG2;DMD;MAPK8IP2;GRIA4
transforming growth factor beta receptor signaling pathway (GO:0007179),6/89,0.01446520742083461,0.05601980328432312,0,0,3.2064110656750007,13.582386135615515,CDH5;JUN;COL3A1;COL1A2;FOS;TGFBR2
"G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger (GO:0007187)",5/65,0.014771498758364376,0.05714105308570464,0,0,3.6922348484848486,15.562975597164403,OPRD1;ANXA1;CCL2;SSTR2;AGT
cellular glucose homeostasis (GO:0001678),4/43,0.015056526235908863,0.05811171167834361,0,0,4.538868538868539,19.04483705433064,NGFR;PPARGC1A;FOXO1;PAX2
positive regulation of T cell differentiation (GO:0045582),4/43,0.015056526235908863,0.05811171167834361,0,0,4.538868538868539,19.04483705433064,CR1;MDK;RHOH;GATA3
cardiac muscle cell development (GO:0055013),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,ACTC1;SORBS2;NKX2-5
dendritic cell differentiation (GO:0097028),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,PRTN3;CCL19;TGFBR2
establishment of mitotic spindle orientation (GO:0000132),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,GPSM2;NDC80;MAD2L1
positive regulation of cell-substrate junction organization (GO:0150117),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,NRP1;KDR;TEK
protein kinase B signaling (GO:0043491),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,KDR;CCL2;PAX2
regulation of cardiac muscle hypertrophy (GO:0010611),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,PARP1;PRKCA;AGT
regulation of cell size (GO:0008361),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,VAV3;EZR;VAV2
regulation of ruffle assembly (GO:1900027),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,EPS8;CAV1;EVL
response to gamma radiation (GO:0010332),3/24,0.015652372491057668,0.05945778968821778,0,0,6.313510019392372,26.246099437090134,YAP1;FANCD2;CRYAB
positive regulation of T cell proliferation (GO:0042102),5/66,0.015698992008717036,0.05945778968821778,0,0,3.6315201192250375,15.085911158811296,IL6;ANXA1;IL18;CCL19;FADD
positive regulation of supramolecular fiber organization (GO:1902905),6/91,0.01599550315304124,0.05945778968821778,0,0,3.130644512930457,12.946616491416702,VIL1;CCL21;BIN1;EVL;PROX1;MET
actin-mediated cell contraction (GO:0070252),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,ACTC1;PARVA
cellular response to nitric oxide (GO:0071732),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,FOXO1;AQP1
cellular response to reactive nitrogen species (GO:1902170),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,FOXO1;AQP1
endochondral ossification (GO:0001958),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,MEF2C;FGFR3
endothelial cell chemotaxis (GO:0035767),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,NR4A1;NRP1
muscle cell fate commitment (GO:0042693),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,MEF2C;WT1
negative regulation of exocytosis (GO:0045920),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,PRKN;ANXA1
negative regulation of nitric oxide biosynthetic process (GO:0045019),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,CAV1;SIRPA
negative regulation of nitric oxide metabolic process (GO:1904406),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,CAV1;SIRPA
negative regulation of systemic arterial blood pressure (GO:0003085),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,ADRB1;ADRB2
positive regulation of ATP biosynthetic process (GO:2001171),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,PPARA;PPARGC1A
positive regulation of fatty acid beta-oxidation (GO:0032000),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,IRS2;PPARA
positive regulation of protein kinase C signaling (GO:0090037),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,FLT4;ADRA1A
positive regulation of smooth muscle cell apoptotic process (GO:0034393),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,CDKN2A;PPARG
regulation of animal organ morphogenesis (GO:2000027),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,WT1;SIX2
regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process (GO:1902959),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,EFNA3;BIN1
regulation of dendritic cell antigen processing and presentation (GO:0002604),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,CCL21;CCL19
regulation of DNA-templated transcription in response to stress (GO:0043620),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,RPS6KA3;MUC1
regulation of mammary gland epithelial cell proliferation (GO:0033599),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,GATA3;BRCA2
regulation of mitotic centrosome separation (GO:0046602),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,CHEK1;NEK2
regulation of nephron tubule epithelial cell differentiation (GO:0072182),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,GATA3;PAX2
regulation of nuclear cell cycle DNA replication (GO:0033262),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,DBF4;CDC7
regulation of vesicle fusion (GO:0031338),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,ANXA1;RAB3A
response to leptin (GO:0044321),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,CCND1;LEPR
skeletal muscle fiber development (GO:0048741),2/9,0.016033365235760603,0.05945778968821778,0,0,12.607545952918413,52.108038902630256,CAV2;SIX1
hexose biosynthetic process (GO:0019319),4/44,0.016278696593989138,0.06017114749708783,0,0,4.425170068027211,18.22239889936288,PER2;ENO2;ALDOA;PPARGC1A
neurotransmitter secretion (GO:0007269),4/44,0.016278696593989138,0.06017114749708783,0,0,4.425170068027211,18.22239889936288,RIMS2;RAB3A;GAD1;SYN1
response to amyloid-beta (GO:1904645),4/44,0.016278696593989138,0.06017114749708783,0,0,4.425170068027211,18.22239889936288,NGFR;LRP1;ADRB2;CD36
peptidyl-threonine modification (GO:0018210),5/67,0.01666453050129774,0.06153057415863781,0,0,3.5727639296187683,14.628584517560887,CHEK1;PRKCA;PRKD1;CIT;TGFBR2
positive regulation of T cell migration (GO:2000406),3/25,0.017498918696404287,0.06426327038507092,0,0,6.026223776223776,24.379788466052194,CXCL10;CXCL12;CCL21
regulation of AMPA receptor activity (GO:2000311),3/25,0.017498918696404287,0.06426327038507092,0,0,6.026223776223776,24.379788466052194,MEF2C;ADRB2;MAPK8IP2
regulation of calcium ion import (GO:0090279),3/25,0.017498918696404287,0.06426327038507092,0,0,6.026223776223776,24.379788466052194,CXCL12;CCL2;PKD2
regulation of dopamine secretion (GO:0014059),3/25,0.017498918696404287,0.06426327038507092,0,0,6.026223776223776,24.379788466052194,PRKN;SYT9;SYT7
regulation of neutrophil chemotaxis (GO:0090022),3/25,0.017498918696404287,0.06426327038507092,0,0,6.026223776223776,24.379788466052194,CCL21;MDK;CCL19
mitotic G2/M transition checkpoint (GO:0044818),4/45,0.017561309852185413,0.06442297521662851,0,0,4.317017864056192,17.449632710860026,BLM;CHEK1;HMGA2;BRCA1
positive regulation of peptidyl-serine phosphorylation (GO:0033138),6/93,0.01763417796188524,0.06453907027580096,0,0,3.058361479852329,12.349407763741644,OPRD1;IL6;CAV1;SPRY2;PRKD1;CAMK1
negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512),5/68,0.01766870673923776,0.06453907027580096,0,0,3.515873015873016,14.189923507435324,FBN2;CAV1;SPRY2;PPARA;TGFBR2
positive regulation of protein localization to nucleus (GO:1900182),5/68,0.01766870673923776,0.06453907027580096,0,0,3.515873015873016,14.189923507435324,CCT3;YAP1;NGFR;TERT;ECT2
regulation of tyrosine phosphorylation of STAT protein (GO:0042509),5/68,0.01766870673923776,0.06453907027580096,0,0,3.515873015873016,14.189923507435324,SOCS3;IL6;KIT;IL18;FGFR3
negative regulation of immune response (GO:0050777),9/178,0.018436156270615678,0.06727025756986962,0,0,2.3678681939091253,9.455943177856149,IL6;COL3A1;CR1;GNG2;PRKAR2B;ADRB1;ADRB2;RAMP1;ADCY5
erythrocyte differentiation (GO:0030218),4/46,0.018905168566322964,0.0686874354733781,0,0,4.214015765036173,16.722562725435857,TAL1;KIT;INHBA;KLF1
positive regulation of response to stimulus (GO:0048584),4/46,0.018905168566322964,0.0686874354733781,0,0,4.214015765036173,16.722562725435857,CDKN2A;HMGA1;HMGA2;GATA3
regulation of double-strand break repair via homologous recombination (GO:0010569),4/46,0.018905168566322964,0.0686874354733781,0,0,4.214015765036173,16.722562725435857,PPP4C;RAD51;PARP1;CHEK1
regulation of fibroblast proliferation (GO:0048145),4/46,0.018905168566322964,0.0686874354733781,0,0,4.214015765036173,16.722562725435857,E2F1;PDGFA;AGT;AQP1
regulation of immune response (GO:0050776),9/179,0.019045546144684698,0.06912377131106012,0,0,2.35381813275769,9.323290032920863,COL17A1;C3;COL1A1;COL3A1;COL1A2;COL2A1;SH2D1A;IRF7;NECTIN2
DNA modification (GO:0006304),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,EXOSC4;PARP1;H4-16
endothelial cell development (GO:0001885),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,PECAM1;EZR;MET
hippo signaling (GO:0035329),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,YAP1;AMOTL2;TEAD1
lamellipodium assembly (GO:0030032),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,KIT;S1PR1;ARHGEF6
negative regulation of signaling receptor activity (GO:2000272),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,CBLC;PPARG;PPARA
positive regulation of G1/S transition of mitotic cell cycle (GO:1900087),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,CCND2;ANXA1;CCND1
positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:1900740),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,E2F1;PMAIP1;GZMB
regulation of chondrocyte differentiation (GO:0032330),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,MDK;BMPR1B;SOX5
regulation of monocyte chemotaxis (GO:0090025),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,CXCL10;CXCL12;DUSP1
regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:1900739),3/26,0.019461621966348024,0.06988957603931936,0,0,5.763918945504623,22.70586848068912,E2F1;PMAIP1;GZMB
adrenal gland development (GO:0030325),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,MDK;WT1
DNA replication-dependent nucleosome assembly (GO:0006335),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,CHAF1A;H4-16
DNA replication-dependent nucleosome organization (GO:0034723),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,CHAF1A;H4-16
endothelium development (GO:0003158),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,KDR;PECAM1
negative regulation of cholesterol storage (GO:0010887),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,PPARG;PPARA
negative regulation of vascular endothelial growth factor signaling pathway (GO:1900747),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,SPRY2;DCN
neuron remodeling (GO:0016322),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,C3;RND1
positive regulation of cell activation (GO:0050867),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,CAPN3;PLA2G4A
regulation of bile acid biosynthetic process (GO:0070857),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,PROX1;FGFR4
regulation of glycoprotein biosynthetic process (GO:0010559),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,CCL21;CCL19
smooth muscle tissue development (GO:0048745),2/10,0.019749583259726165,0.07011102057202788,0,0,11.031038374717832,43.292665690784396,PROX1;MYLK
epidermal growth factor receptor signaling pathway (GO:0007173),4/47,0.020311012638606442,0.07187947151855738,0,0,4.115804461319412,16.037610924887655,VIL1;SHC3;REPS2;TDGF1
positive regulation of cell-cell adhesion (GO:0022409),4/47,0.020311012638606442,0.07187947151855738,0,0,4.115804461319412,16.037610924887655,MDK;PLAUR;TNFSF11;SKAP1
telomere organization (GO:0032200),4/47,0.020311012638606442,0.07187947151855738,0,0,4.115804461319412,16.037610924887655,BLM;TERT;PARP1;H4-16
positive regulation of cellular protein localization (GO:1903829),5/71,0.02091865814622108,0.0738764631733901,0,0,3.355544077134986,12.976270753483616,PRKN;YAP1;CDT1;NGFR;NDC80
regulation of endopeptidase activity (GO:0052548),5/71,0.02091865814622108,0.0738764631733901,0,0,3.355544077134986,12.976270753483616,VTN;SERPINC1;SERPING1;TIMP1;AGT
defense response to symbiont (GO:0140546),7/124,0.021006413403343558,0.07403294403163893,0,0,2.655153572961792,10.25666572112438,IL6;EXOSC4;STAT1;MX1;IRF7;PMAIP1;FADD
fatty acid metabolic process (GO:0006631),7/124,0.021006413403343558,0.07403294403163893,0,0,2.655153572961792,10.25666572112438,PER2;SLC27A6;PPARG;CD36;PPARA;PTGS2;PPARGC1A
glycosaminoglycan biosynthetic process (GO:0006024),6/97,0.02124966786459176,0.0748128802505462,0,0,2.923327242233848,11.25894350718164,ACAN;VCAN;CHPF;BGN;SDC1;DCN
acute inflammatory response (GO:0002526),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,SIGIRR;IL6;SAA1
calcium-ion regulated exocytosis (GO:0017156),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,RIMS2;SYT9;SYT7
negative regulation of actin filament bundle assembly (GO:0032232),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,PRKN;STMN1;MET
negative regulation of plasma membrane bounded cell projection assembly (GO:0120033),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,YAP1;CCL21;EVL
positive regulation of BMP signaling pathway (GO:0030513),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,CDH5;ZNF423;BMPR1B
positive regulation of gene silencing by miRNA (GO:2000637),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,ZFP36;IL6;MYCN
positive regulation of mitotic cell cycle (GO:0045931),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,TAL1;PRKCA;CDC25B
positive regulation of striated muscle cell differentiation (GO:0051155),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,MEF2C;MMP14;PROX1
regulation of vasculature development (GO:1901342),3/27,0.021540832869153908,0.07513936378513461,0,0,5.523472850678733,21.198011402444397,IL6;ERBB2;FGF2
base-excision repair (GO:0006284),4/48,0.02177951958910513,0.07573939057109212,0,0,4.022057307771593,15.391549455969782,FEN1;RFC4;PARP1;HMGA2
negative regulation of MAP kinase activity (GO:0043407),4/48,0.02177951958910513,0.07573939057109212,0,0,4.022057307771593,15.391549455969782,DUSP1;CBLC;SPRY2;AGT
substrate adhesion-dependent cell spreading (GO:0034446),4/48,0.02177951958910513,0.07573939057109212,0,0,4.022057307771593,15.391549455969782,NRP1;PARVA;LAMC1;TEK
cellular response to oxidative stress (GO:0034599),7/125,0.021842952579105904,0.07580527738247751,0,0,2.6325168330624567,10.066420427620034,JUN;PARP1;PRKD1;FOS;PKD2;PPARGC1A;FOXO1
regulation of protein secretion (GO:0050708),7/125,0.021842952579105904,0.07580527738247751,0,0,2.6325168330624567,10.066420427620034,PER2;IL6;DNAJC1;SAA1;PRKCA;EZR;SYT7
cell junction organization (GO:0034330),5/72,0.022082869139131853,0.07632699596973769,0,0,3.305291723202171,12.602922398805164,SH3BP1;CTNND2;SNCG;FLNC;PAK3
cytoskeleton-dependent cytokinesis (GO:0061640),5/72,0.022082869139131853,0.07632699596973769,0,0,3.305291723202171,12.602922398805164,RACGAP1;STMN1;ECT2;CEP55;CIT
extrinsic apoptotic signaling pathway (GO:0097191),5/72,0.022082869139131853,0.07632699596973769,0,0,3.305291723202171,12.602922398805164,CIB1;BAK1;FADD;INHBA;FGFR3
negative regulation of supramolecular fiber organization (GO:1902904),5/72,0.022082869139131853,0.07632699596973769,0,0,3.305291723202171,12.602922398805164,PRKN;CDH5;STMN1;CIB1;CRYAB
negative regulation of neuron death (GO:1901215),6/98,0.02222622991605212,0.07666699549990448,0,0,2.8914033871446962,11.006075409975864,PRKN;MEF2C;MDK;SIX1;CCL2;PPARGC1A
regulation of neuron apoptotic process (GO:0043523),6/98,0.02222622991605212,0.07666699549990448,0,0,2.8914033871446962,11.006075409975864,PRKN;MEF2C;MDK;SIX1;CCL2;PPARGC1A
response to UV (GO:0009411),6/99,0.02323259622246029,0.07908957371545824,0,0,2.860166066573591,10.760513849208436,FEN1;CCND1;PARP1;BCL3;BAK1;AQP1
regulation of actin filament polymerization (GO:0030833),5/73,0.023288346062656753,0.07908957371545824,0,0,3.2565173796791442,12.243861249232046,VIL1;CCL21;BIN1;EVL;PAK3
response to molecule of bacterial origin (GO:0002237),5/73,0.023288346062656753,0.07908957371545824,0,0,3.2565173796791442,12.243861249232046,C4B;RPS6KA3;IL6;MAPKAPK2;SELE
regulation of cellular localization (GO:0060341),4/49,0.023311304909507703,0.07908957371545824,0,0,3.932476694381456,14.781459648597416,PRKN;PARD6B;PARP1;ADCY5
histone mRNA metabolic process (GO:0008334),3/28,0.023736687519296976,0.07908957371545824,0,0,5.302262443438914,19.834350382945026,EXOSC4;LSM1;SNRPE
leukocyte cell-cell adhesion (GO:0007159),3/28,0.023736687519296976,0.07908957371545824,0,0,5.302262443438914,19.834350382945026,PECAM1;EZR;SELE
positive regulation of cell communication (GO:0010647),3/28,0.023736687519296976,0.07908957371545824,0,0,5.302262443438914,19.834350382945026,RIMS2;KCTD13;GATA3
protein depolymerization (GO:0051261),3/28,0.023736687519296976,0.07908957371545824,0,0,5.302262443438914,19.834350382945026,VIL1;CFL1;STMN1
regulation of calcineurin-NFAT signaling cascade (GO:0070884),3/28,0.023736687519296976,0.07908957371545824,0,0,5.302262443438914,19.834350382945026,RCAN1;CIB1;HOMER3
regulation of extrinsic apoptotic signaling pathway in absence of ligand (GO:2001239),3/28,0.023736687519296976,0.07908957371545824,0,0,5.302262443438914,19.834350382945026,RET;TERT;INHBA
regulation of immunoglobulin production (GO:0002637),3/28,0.023736687519296976,0.07908957371545824,0,0,5.302262443438914,19.834350382945026,IL6;CR1;TNFRSF4
actin filament depolymerization (GO:0030042),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,VIL1;CFL1
atrial septum morphogenesis (GO:0060413),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,GATA4;NKX2-5
cellular response to increased oxygen levels (GO:0036295),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,CAV1;FOXO1
columnar/cuboidal epithelial cell differentiation (GO:0002065),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,PYY;GATA4
desensitization of G protein-coupled receptor signaling pathway (GO:0002029),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,GRK3;ADRB2
establishment of epithelial cell apical/basal polarity (GO:0045198),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,SH3BP1;EZR
inositol phosphate biosynthetic process (GO:0032958),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,ITPKA;FGF2
myotube cell development (GO:0014904),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,CAV2;SIX1
negative regulation of potassium ion transmembrane transport (GO:1901380),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,BIN1;CAV1
negative regulation of response to cytokine stimulus (GO:0060761),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,SIGIRR;KLF4
negative regulation of steroid biosynthetic process (GO:0010894),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,BMP2;PROX1
positive regulation by host of viral process (GO:0044794),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,CAV2;CFL1
positive regulation of bone resorption (GO:0045780),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,TNFSF11;PRKCA
positive regulation of chondrocyte differentiation (GO:0032332),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,BMPR1B;SOX5
positive regulation of cytoplasmic transport (GO:1903651),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,PRKN;EZR
positive regulation of interleukin-13 production (GO:0032736),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,IL18;GATA3
positive regulation of keratinocyte proliferation (GO:0010838),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,FGF7;MDK
positive regulation of macrophage differentiation (GO:0045651),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,PRKCA;FADD
positive regulation of nitric-oxide synthase biosynthetic process (GO:0051770),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,KDR;CCL2
positive regulation of production of miRNAs involved in gene silencing by miRNA (GO:1903800),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,IL6;MYCN
regulation of cardiac muscle cell differentiation (GO:2000725),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,BMP2;MEF2C
regulation of coagulation (GO:0050818),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,PROC;CAV1
regulation of mitochondrial depolarization (GO:0051900),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,KDR;DCN
regulation of phospholipase activity (GO:0010517),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,LRP1;FGFR3
regulation of synapse maturation (GO:0090128),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,CDC20;ARHGEF15
T cell homeostasis (GO:0043029),2/11,0.023787210404443867,0.07908957371545824,0,0,9.804865813895159,36.65654212990673,PMAIP1;FADD
positive regulation of translation (GO:0045727),6/100,0.0242691123236199,0.08061319181179008,0,0,2.829593369844424,10.521986788029642,IL6;BCL3;ERBB2;HABP4;VIM;PLD1
negative regulation of protein binding (GO:0032091),5/74,0.02453554518898985,0.0812605811507069,0,0,3.2091567852437417,11.898373637769293,CAV1;ADRB2;CAMK1;AURKA;PPP1CA
regulation of cytokine-mediated signaling pathway (GO:0001959),5/74,0.02453554518898985,0.0812605811507069,0,0,3.2091567852437417,11.898373637769293,SIGIRR;SOCS3;STAT1;LIFR;FADD
regulation of stress fiber assembly (GO:0051492),5/74,0.02453554518898985,0.0812605811507069,0,0,3.2091567852437417,11.898373637769293,NRP1;ARHGEF15;STMN1;EVL;MET
actin polymerization or depolymerization (GO:0008154),4/50,0.02490692255966141,0.08241047775080203,0,0,3.846790890269151,14.204696584790739,VIL1;CFL1;FAM107A;EVL
regulation of mitotic cell cycle phase transition (GO:1901990),9/188,0.025202459349580715,0.08330745049793509,0,0,2.234431858951361,8.22452738918309,CDC20;PLK4;CENPF;PRKAR2B;E2F1;NEK2;TUBG1;AURKA;MAD2L1
cellular response to chemical stress (GO:0062197),6/101,0.02533611270649102,0.08366809312376104,0,0,2.799664308835871,10.290234818488516,PARP1;CAV1;PRKD1;PKD2;PPARGC1A;FOXO1
establishment of mitotic spindle localization (GO:0040001),3/29,0.026049120012432102,0.08560790839186944,0,0,5.098068221371388,18.596586902913145,GPSM2;NDC80;MAD2L1
glial cell differentiation (GO:0010001),3/29,0.026049120012432102,0.08560790839186944,0,0,5.098068221371388,18.596586902913145,EGR2;SOX10;PAX2
lamellipodium organization (GO:0097581),3/29,0.026049120012432102,0.08560790839186944,0,0,5.098068221371388,18.596586902913145,KIT;S1PR1;ARHGEF6
negative regulation of wound healing (GO:0061045),3/29,0.026049120012432102,0.08560790839186944,0,0,5.098068221371388,18.596586902913145,VTN;PROC;FGF2
regulation of actin polymerization or depolymerization (GO:0008064),3/29,0.026049120012432102,0.08560790839186944,0,0,5.098068221371388,18.596586902913145,CXCL12;SH3BP1;PAK3
calcium-mediated signaling (GO:0019722),6/102,0.026433920611047757,0.08670529493979862,0,0,2.7703587699316627,10.06501045440476,RCAN1;CXCR2;KDR;TNFSF11;CXCR4;SELE
positive regulation of cell growth (GO:0030307),6/102,0.026433920611047757,0.08670529493979862,0,0,2.7703587699316627,10.06501045440476,RIMS2;RPS6KA3;MMP14;EXOSC4;ERBB2;CIB1
mitotic metaphase plate congression (GO:0007080),4/51,0.02656686549904464,0.08697394584125277,0,0,3.764751290587157,13.658858383213602,CDT1;KIF22;CEP55;NDC80
positive regulation of actin filament bundle assembly (GO:0032233),4/51,0.02656686549904464,0.08697394584125277,0,0,3.764751290587157,13.658858383213602,VIL1;NRP1;ARHGEF15;EVL
positive regulation of growth (GO:0045927),5/76,0.02715681601895694,0.08881998943628144,0,0,3.118437900128041,11.24548377584807,RPS6KA3;MMP14;EXOSC4;ERBB2;CIB1
cellular response to hypoxia (GO:0071456),7/131,0.02735045122841254,0.0893675338316682,0,0,2.504363676535572,9.01326059883591,OPRD1;TERT;EPAS1;PMAIP1;ELOB;PTGS2;AQP1
angiotensin maturation (GO:0002003),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,CMA1;CTSG
attachment of mitotic spindle microtubules to kinetochore (GO:0051315),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,CDT1;NDC80
calcium ion-regulated exocytosis of neurotransmitter (GO:0048791),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,RIMS2;SYT7
cardiocyte differentiation (GO:0035051),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,BMP2;NKX2-5
double-strand break repair via break-induced replication (GO:0000727),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,MCM4;CDC7
glomerular visceral epithelial cell differentiation (GO:0072112),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,NPHS1;WT1
macrophage chemotaxis (GO:0048246),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,SAA1;CCL2
megakaryocyte differentiation (GO:0030219),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,TAL1;KIT
mitotic nuclear membrane disassembly (GO:0007077),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,CCNB2;PRKCA
modulation by host of viral process (GO:0044788),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,CAV2;CFL1
negative regulation of calcineurin-mediated signaling (GO:0106057),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,RCAN1;HOMER3
negative regulation of calcineurin-NFAT signaling cascade (GO:0070885),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,RCAN1;HOMER3
negative regulation of cell division (GO:0051782),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,BLM;TXNIP
negative regulation of cellular response to vascular endothelial growth factor stimulus (GO:1902548),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,SPRY2;DCN
negative regulation of hemostasis (GO:1900047),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,VTN;PROC
negative regulation of microtubule polymerization (GO:0031115),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,CDH5;STMN1
positive regulation of neuroinflammatory response (GO:0150078),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,IL6;IL18
regulation of actin filament depolymerization (GO:0030834),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,VIL1;SH3BP1
regulation of angiotensin levels in blood (GO:0002002),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,CMA1;CTSG
regulation of DNA-dependent DNA replication (GO:0090329),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,CDT1;BLM
regulation of oxidative stress-induced cell death (GO:1903201),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,PRKN;GATA4
regulation of plasminogen activation (GO:0010755),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,CLEC3B;F12
regulation of sister chromatid cohesion (GO:0007063),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,FEN1;BUB1
regulation of ventricular cardiac muscle cell action potential (GO:0098911),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,BIN1;CAV1
urogenital system development (GO:0001655),2/12,0.02813017115577252,0.08976369222740893,0,0,8.82392776523702,31.509474591675207,ANXA1;PAX2
myeloid cell differentiation (GO:0030099),4/52,0.028291566380210294,0.08994184535798198,0,0,3.686130007558579,13.141759468571319,TAL1;KIT;INHBA;KLF1
negative regulation of BMP signaling pathway (GO:0030514),4/52,0.028291566380210294,0.08994184535798198,0,0,3.686130007558579,13.141759468571319,BMP2;SOSTDC1;PPARG;BMPR1B
negative regulation of cellular biosynthetic process (GO:0031327),4/52,0.028291566380210294,0.08994184535798198,0,0,3.686130007558579,13.141759468571319,CAV1;SIRPA;BRCA1;PROX1
signal transduction in response to DNA damage (GO:0042770),4/52,0.028291566380210294,0.08994184535798198,0,0,3.686130007558579,13.141759468571319,H2AX;CHEK1;BCL3;E2F1
artery morphogenesis (GO:0048844),3/30,0.028477874342844964,0.09011383078961527,0,0,4.908999497234792,17.469302238438775,NRP1;LRP1;PKD2
establishment of spindle orientation (GO:0051294),3/30,0.028477874342844964,0.09011383078961527,0,0,4.908999497234792,17.469302238438775,GPSM2;NDC80;MAD2L1
regulation of catecholamine secretion (GO:0050433),3/30,0.028477874342844964,0.09011383078961527,0,0,4.908999497234792,17.469302238438775,PRKN;SYT9;SYT7
response to alcohol (GO:0097305),3/30,0.028477874342844964,0.09011383078961527,0,0,4.908999497234792,17.469302238438775,CCL21;CCL19;TGFBR2
TRIF-dependent toll-like receptor signaling pathway (GO:0035666),3/30,0.028477874342844964,0.09011383078961527,0,0,4.908999497234792,17.469302238438775,IRF7;FADD;IKBKE
cellular response to UV (GO:0034644),5/77,0.028531680541971506,0.09020034071153886,0,0,3.0749684343434343,10.936863878326847,PARP1;CHEK1;TIMP1;BAK1;AQP1
bicellular tight junction assembly (GO:0070830),4/53,0.03008139827027302,0.09492352343063931,0,0,3.6107177564903514,12.65140725816986,CDH5;PARD6B;PECAM1;ECT2
cardiac muscle tissue development (GO:0048738),4/53,0.03008139827027302,0.09492352343063931,0,0,3.6107177564903514,12.65140725816986,BMP2;ACTC1;GATA4;NKX2-5
embryonic skeletal system morphogenesis (GO:0048704),3/31,0.03102251581844073,0.09744215106842949,0,0,4.733435681965093,16.439421029122542,COL2A1;SIX1;TGFBR2
MyD88-independent toll-like receptor signaling pathway (GO:0002756),3/31,0.03102251581844073,0.09744215106842949,0,0,4.733435681965093,16.439421029122542,IRF7;FADD;IKBKE
peptide cross-linking (GO:0018149),3/31,0.03102251581844073,0.09744215106842949,0,0,4.733435681965093,16.439421029122542,COL3A1;ANXA1;F13A1
positive regulation of mononuclear cell migration (GO:0071677),3/31,0.03102251581844073,0.09744215106842949,0,0,4.733435681965093,16.439421029122542,CXCL10;CXCL12;CALR
renal water homeostasis (GO:0003091),3/31,0.03102251581844073,0.09744215106842949,0,0,4.733435681965093,16.439421029122542,PRKAR2B;ADCY5;AQP1
axon development (GO:0061564),5/79,0.031411667751339446,0.09857363139646853,0,0,2.991554054054054,10.352499775206939,PARD6B;RAB3A;PAK3;NEFH;PAX2
adenylate cyclase-modulating G protein-coupled receptor signaling pathway (GO:0007188),8/165,0.0316251135514095,0.09897005232617408,0,0,2.2618606888309114,7.8120229095701905,AKAP12;CXCL10;GRK5;S1PR1;ADRB2;AKAP5;RAMP1;ADCY5
negative regulation of canonical Wnt signaling pathway (GO:0090090),8/165,0.0316251135514095,0.09897005232617408,0,0,2.2618606888309114,7.8120229095701905,TLE4;PRKN;TCF7L2;BMP2;MDK;CAV1;SIAH2;NKX2-5
regulation of neuron projection development (GO:0010975),8/165,0.0316251135514095,0.09897005232617408,0,0,2.2618606888309114,7.8120229095701905,RET;MDK;CFL1;CIB1;PRKD1;CAMK1;FKBP4;PAK3
regulation of focal adhesion assembly (GO:0051893),4/54,0.03193667545501649,0.09976186063308541,0,0,3.5383219954648526,12.18598176197359,NRP1;FAM107A;KDR;TEK
regulation of megakaryocyte differentiation (GO:0045652),4/54,0.03193667545501649,0.09976186063308541,0,0,3.5383219954648526,12.18598176197359,NFE2;MEF2C;H4-16;CIB1
negative regulation of inflammatory response to antigenic stimulus (GO:0002862),7/136,0.032606600546172926,0.1005910912035499,0,0,2.4066758698807122,8.23863040528762,IL6;GNG2;PRKAR2B;ADRB1;ADRB2;RAMP1;ADCY5
cytoplasmic sequestering of protein (GO:0051220),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,PKD2;NFKBIE
entry into host (GO:0044409),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,CXCR4;MET
establishment of protein localization to chromosome (GO:0070199),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,TERT;BRCA2
negative regulation by host of viral transcription (GO:0043922),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,JUN;HMGA2
negative regulation of cellular senescence (GO:2000773),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,TERT;HMGA2
negative regulation of hydrogen peroxide-induced cell death (GO:1903206),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,HGF;MET
negative regulation of macrophage derived foam cell differentiation (GO:0010745),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,PPARG;PPARA
negative regulation of potassium ion transport (GO:0043267),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,BIN1;CAV1
pathway-restricted SMAD protein phosphorylation (GO:0060389),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,BMP2;TGFBR2
plasma membrane repair (GO:0001778),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,RAB3A;SYT7
positive regulation of calcium ion import (GO:0090280),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,CXCL12;CCL2
positive regulation of cellular carbohydrate metabolic process (GO:0010676),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,PMAIP1;IRS2
positive regulation of purine nucleotide biosynthetic process (GO:1900373),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,PPARA;PPARGC1A
positive regulation of reactive oxygen species biosynthetic process (GO:1903428),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,ZNF205;CD36
positive regulation of vascular endothelial cell proliferation (GO:1905564),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,MDK;FGF2
regulation of leukocyte adhesion to vascular endothelial cell (GO:1904994),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,IL6;MDK
regulation of short-term neuronal synaptic plasticity (GO:0048172),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,RAB3A;SYP
semaphorin-plexin signaling pathway involved in neuron projection guidance (GO:1902285),2/13,0.032762943437775936,0.1005910912035499,0,0,8.021342089062179,27.420614421538456,NRP1;SEMA3F
negative regulation of extrinsic apoptotic signaling pathway (GO:2001237),5/80,0.03291743709957725,0.10097446051787513,0,0,2.9515151515151516,10.07574299049365,TCF7L2;TERT;SIAH2;BRCA1;FADD
aortic valve morphogenesis (GO:0003180),3/32,0.033682442049471774,0.10258245085308293,0,0,4.569979716024341,15.495789354200202,GATA4;GATA3;NKX2-5
DNA damage checkpoint signaling (GO:0000077),3/32,0.033682442049471774,0.10258245085308293,0,0,4.569979716024341,15.495789354200202,H2AX;CHEK1;E2F1
establishment or maintenance of epithelial cell apical/basal polarity (GO:0045197),3/32,0.033682442049471774,0.10258245085308293,0,0,4.569979716024341,15.495789354200202,DLG2;SH3BP1;EZR
long-chain fatty acid transport (GO:0015909),3/32,0.033682442049471774,0.10258245085308293,0,0,4.569979716024341,15.495789354200202,SLC27A6;PPARG;CD36
regulation of cell morphogenesis (GO:0022604),3/32,0.033682442049471774,0.10258245085308293,0,0,4.569979716024341,15.495789354200202,VIL1;CFL1;SH3D19
regulation of chemotaxis (GO:0050920),3/32,0.033682442049471774,0.10258245085308293,0,0,4.569979716024341,15.495789354200202,CCL21;CXCR4;CCL19
regulation of intracellular estrogen receptor signaling pathway (GO:0033146),3/32,0.033682442049471774,0.10258245085308293,0,0,4.569979716024341,15.495789354200202,YAP1;BRCA1;ESR1
regulation of transcription involved in G1/S transition of mitotic cell cycle (GO:0000083),3/32,0.033682442049471774,0.10258245085308293,0,0,4.569979716024341,15.495789354200202,CDT1;KLF11;E2F1
regulation of inflammatory response to antigenic stimulus (GO:0002861),7/137,0.03373326245841109,0.10264549862345088,0,0,2.388040042149631,8.093714651153379,IL6;GNG2;PRKAR2B;ADRB1;ADRB2;RAMP1;ADCY5
negative regulation of protein modification by small protein conjugation or removal (GO:1903321),4/55,0.03385765433336809,0.10284036182541752,0,0,3.4687652838913343,11.743817682296495,PER2;CAV1;CAPN3;SPRY2
positive regulation of response to DNA damage stimulus (GO:2001022),4/55,0.03385765433336809,0.10284036182541752,0,0,3.4687652838913343,11.743817682296495,H2AX;PMAIP1;HMGA2;BRCA1
positive regulation of cellular amide metabolic process (GO:0034250),5/81,0.034467447151216975,0.10450628104212406,0,0,2.9125299043062203,9.808643346959512,IL6;ERBB2;BCL3;VIM;PLD1
regulation of interleukin-8 production (GO:0032677),5/81,0.034467447151216975,0.10450628104212406,0,0,2.9125299043062203,9.808643346959512,IL6;ANXA1;BCL3;FADD;KLF4
regulation of autophagy (GO:0010506),10/231,0.034561695018316484,0.10469889477548673,0,0,2.011130181515577,6.767471745365963,PRKN;HGF;LEPR;PRKD1;MET;MAPK15;FOXO1;DCN;DEPP1;GFAP
modulation of chemical synaptic transmission (GO:0050804),6/109,0.03500588536133077,0.10585630639877132,0,0,2.5811531061326494,8.65264230983532,RIMS2;MEF2C;KCTD13;MAPK8IP2;SNCAIP;SYN1
regulation of protein ubiquitination (GO:0031396),6/109,0.03500588536133077,0.10585630639877132,0,0,2.5811531061326494,8.65264230983532,PRKN;PER2;CAV1;FAM107A;SPRY2;BRCA1
"nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay (GO:0000288)",4/56,0.035844534351165656,0.10800899475576707,0,0,3.401883830455259,11.323388670682505,ZFP36;EXOSC4;LSM1;LSM4
positive regulation of interleukin-1 beta production (GO:0032731),4/56,0.035844534351165656,0.10800899475576707,0,0,3.401883830455259,11.323388670682505,EGR1;IL6;CD36;CCL19
sensory organ development (GO:0007423),4/56,0.035844534351165656,0.10800899475576707,0,0,3.401883830455259,11.323388670682505,SIX3;GATA3;ASCL1;BMPR1B
tight junction assembly (GO:0120192),4/56,0.035844534351165656,0.10800899475576707,0,0,3.401883830455259,11.323388670682505,CDH5;PARD6B;PECAM1;ECT2
ephrin receptor signaling pathway (GO:0048013),5/82,0.03606195985545549,0.10838173128005912,0,0,2.874557260920897,9.55076454141842,VAV3;EFNA3;ITSN1;PAK3;VAV2
regulation of G protein-coupled receptor signaling pathway (GO:0008277),5/82,0.03606195985545549,0.10838173128005912,0,0,2.874557260920897,9.55076454141842,C3;GRK5;GNG7;NMT2;SYP
positive regulation of response to external stimulus (GO:0032103),7/139,0.03606363945762531,0.10838173128005912,0,0,2.3516154697661547,7.813172175456843,CCL21;MDK;PLA2G2A;IL18;PRKCA;CCL19;AGT
actin filament bundle assembly (GO:0051017),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,EPS8;FAM107A;EZR
actin filament bundle organization (GO:0061572),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,EPS8;FAM107A;EZR
apoptotic cell clearance (GO:0043277),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,ANXA1;LRP1;RHOH
exonucleolytic catabolism of deadenylated mRNA (GO:0043928),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,EXOSC4;LSM1;LSM4
negative regulation of JNK cascade (GO:0046329),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,PRKN;MECOM;SIRPA
positive regulation of cholesterol transport (GO:0032376),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,LRP1;CAV1;PPARG
positive regulation of organelle organization (GO:0010638),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,ANXA1;ADRB2;PPARGC1A
positive regulation of telomere maintenance via telomerase (GO:0032212),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,CCT3;NEK2;MAPK15
regulation of cholesterol efflux (GO:0010874),3/33,0.03645689337680078,0.10861008661407053,0,0,4.417420814479638,14.628839966561598,LRP1;CAV1;PPARG
antiviral innate immune response (GO:0140374),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,CXCL10;MX1
aorta development (GO:0035904),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,LRP1;PKD2
atrial septum development (GO:0003283),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,GATA4;NKX2-5
atrioventricular valve development (GO:0003171),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,BMP2;TGFBR2
bone morphogenesis (GO:0060349),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,BMPR1B;FGFR3
cellular response to low-density lipoprotein particle stimulus (GO:0071404),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,PPARG;CD36
cGMP-mediated signaling (GO:0019934),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,CD36;AQP1
cytoplasmic sequestering of transcription factor (GO:0042994),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,PKD2;NFKBIE
endothelial cell differentiation (GO:0045446),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,KDR;PROX1
growth hormone receptor signaling pathway via JAK-STAT (GO:0060397),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,STAT5A;STAT5B
heterochromatin organization (GO:0070828),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,MECOM;HMGA2
negative regulation of coagulation (GO:0050819),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,VTN;PROC
negative regulation of pri-miRNA transcription by RNA polymerase II (GO:1902894),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,PPARG;PPARA
negative regulation of smooth muscle cell migration (GO:0014912),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,MEF2C;LRP1
negative regulation of T cell differentiation (GO:0045581),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,MDK;CTLA4
nuclear membrane disassembly (GO:0051081),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,CCNB2;PRKCA
ovarian follicle development (GO:0001541),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,KIT;INHBA
peptidyl-serine dephosphorylation (GO:0070262),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,DUSP1;PPP1CA
polarized epithelial cell differentiation (GO:0030859),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,SH3BP1;EZR
positive regulation of brown fat cell differentiation (GO:0090336),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,SIX1;PTGS2
positive regulation of granulocyte macrophage colony-stimulating factor production (GO:0032725),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,IL18;PAEP
positive regulation of T cell receptor signaling pathway (GO:0050862),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,TRAT1;NECTIN2
positive regulation of type 2 immune response (GO:0002830),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,IL6;IL18
regulation of cAMP-dependent protein kinase activity (GO:2000479),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,PRKAR2B;ADRB2
regulation of cell projection organization (GO:0031344),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,SPRY2;CCL19
regulation of fatty acid beta-oxidation (GO:0031998),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,IRS2;PPARA
regulation of integrin-mediated signaling pathway (GO:2001044),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,PRKD1;TIMP1
regulation of nitric-oxide synthase biosynthetic process (GO:0051769),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,KDR;CCL2
regulation of protein kinase C signaling (GO:0090036),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,FLT4;ADRA1A
regulation of response to interferon-gamma (GO:0060330),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,SOCS3;STAT1
regulation of retinoic acid receptor signaling pathway (GO:0048385),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,CALR;EZH2
regulation of trophoblast cell migration (GO:1901163),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,CALR;TIMP1
renal absorption (GO:0070293),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,KLHL3;SGK1
response to UV-A (GO:0070141),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,CCND1;TIMP1
response to X-ray (GO:0010165),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,BLM;ANXA1
sequestering of extracellular ligand from receptor (GO:0035581),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,FBN2;BMP2
striated muscle cell development (GO:0055002),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,CAPN3;SDC1
thymus development (GO:0048538),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,SIX1;FADD
vasodilation (GO:0042311),2/14,0.037670542035364234,0.10861008661407053,0,0,7.352520692249812,24.108010021777286,ADRB1;ADRB2
regulation of interleukin-1 beta production (GO:0032651),5/83,0.03770121257759549,0.10861008661407053,0,0,2.837558275058275,9.301694851921681,EGR1;IL6;SIRPA;CD36;CCL19
positive regulation of cellular catabolic process (GO:0031331),7/141,0.038497986369863325,0.11081177157812011,0,0,2.3162781980508416,7.544464006672853,IRS2;PRKD1;EZR;PPARA;FOXO1;DCN;SH3D19
positive regulation of calcium ion transport into cytosol (GO:0010524),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,CXCL10;CAV1;CAPN3
positive regulation of release of sequestered calcium ion into cytosol (GO:0051281),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,CXCL10;CAPN3;PKD2
positive regulation of telomerase activity (GO:0051973),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,NEK2;KLF4;MAPK15
regulation of glucose metabolic process (GO:0010906),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,PRKN;PMAIP1;IRS2
response to steroid hormone (GO:0048545),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,CATSPER1;YAP1;CAV1
sister chromatid segregation (GO:0000819),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,DSN1;TUBG1;NDC80
striated muscle tissue development (GO:0014706),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,MEF2C;CAV1;SIX1
synaptic vesicle recycling (GO:0036465),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,RAB3A;SNCG;SYT7
ventricular cardiac muscle tissue morphogenesis (GO:0055010),3/34,0.03934496297250898,0.11239533429196194,0,0,4.274704422712013,13.830324477840147,PROX1;NKX2-5;ZFPM2
response to insulin (GO:0032868),5/84,0.03938541814752419,0.11241667089343588,0,0,2.8014959723820483,9.06104547376628,PARP1;IRS2;PPARG;SLC2A4;FOXO1
protein-DNA complex assembly (GO:0065004),7/143,0.04103767917603333,0.11703465324846994,0,0,2.281980257856567,7.286966843795015,H2AX;CDT1;CHAF1A;RAD51;PARP1;H4-16;MCM4
positive regulation of protein catabolic process (GO:0045732),5/85,0.04111476493962899,0.11715645394168528,0,0,2.766335227272727,8.82844898666015,PRKN;BARD1;EZR;FOXO1;SH3D19
positive regulation of apoptotic signaling pathway (GO:2001235),4/59,0.04220174286463607,0.11937335769748643,0,0,3.215831787260359,10.179052285190052,CAV1;PMAIP1;FADD;AGT
response to reactive oxygen species (GO:0000302),4/59,0.04220174286463607,0.11937335769748643,0,0,3.215831787260359,10.179052285190052,JUN;PTPRN;FOS;PKD2
"base-excision repair, gap-filling (GO:0006287)",3/35,0.04234560642307747,0.11937335769748643,0,0,4.1409078054298645,13.093097497353838,FEN1;RFC4;PARP1
cellular response to virus (GO:0098586),3/35,0.04234560642307747,0.11937335769748643,0,0,4.1409078054298645,13.093097497353838,CXCL10;IL6;CCL19
embryonic skeletal system development (GO:0048706),3/35,0.04234560642307747,0.11937335769748643,0,0,4.1409078054298645,13.093097497353838,COL1A1;SIX1;PCSK5
muscle cell differentiation (GO:0042692),3/35,0.04234560642307747,0.11937335769748643,0,0,4.1409078054298645,13.093097497353838,MEF2C;DMD;SYNE1
negative regulation of organelle assembly (GO:1902116),3/35,0.04234560642307747,0.11937335769748643,0,0,4.1409078054298645,13.093097497353838,YAP1;FEZ1;BRCA1
"nuclear-transcribed mRNA catabolic process, exonucleolytic (GO:0000291)",3/35,0.04234560642307747,0.11937335769748643,0,0,4.1409078054298645,13.093097497353838,EXOSC4;LSM1;LSM4
peptidyl-tyrosine dephosphorylation (GO:0035335),3/35,0.04234560642307747,0.11937335769748643,0,0,4.1409078054298645,13.093097497353838,PTPRB;DUSP1;TNS2
cardiac myofibril assembly (GO:0055003),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,ACTC1;PROX1
catecholamine metabolic process (GO:0006584),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,PRKN;SNCAIP
embryonic cranial skeleton morphogenesis (GO:0048701),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,SIX1;TGFBR2
establishment of apical/basal cell polarity (GO:0035089),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,SH3BP1;EZR
histone mRNA catabolic process (GO:0071044),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,EXOSC4;LSM1
interleukin-27-mediated signaling pathway (GO:0070106),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,STAT1;MX1
macrophage migration (GO:1905517),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,SAA1;CCL2
mitotic recombination (GO:0006312),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,RAD51;RAD54B
peptidyl-tyrosine autophosphorylation (GO:0038083),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,KDR;BMX
positive regulation of acute inflammatory response (GO:0002675),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,IL6;PTGS2
positive regulation of chromatin organization (GO:1905269),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,TAL1;H4-16
positive regulation of protein export from nucleus (GO:0046827),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,TCF7L2;CAMK1
positive regulation of telomerase RNA localization to Cajal body (GO:1904874),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,CCT3;RUVBL1
prostanoid biosynthetic process (GO:0046457),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,PLA2G4A;PTGS2
"protein localization to chromosome, telomeric region (GO:0070198)",2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,TERT;BRCA2
regulation of sequestering of triglyceride (GO:0010889),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,PPARG;PPARA
regulation of T cell chemotaxis (GO:0010819),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,CXCL10;CCL21
steroid hormone mediated signaling pathway (GO:0043401),2/15,0.04283850248357568,0.11937335769748643,0,0,6.786594894947039,21.37993198870518,CALCOCO1;ESR1
regulation of interferon-gamma production (GO:0032649),5/86,0.042889416914591943,0.11941759219356972,0,0,2.7320426487093155,8.603557945664631,CR1;IL18;SIRPA;FADD;INHBA
apical junction assembly (GO:0043297),4/60,0.044453119019752844,0.12367039152597363,0,0,3.1582442500809846,9.832625463379948,CDH5;PARD6B;PECAM1;ECT2
regulation of transcription from RNA polymerase II promoter in response to stress (GO:0043618),5/87,0.04470951377221246,0.12428223730481246,0,0,2.698586474501109,8.386043574672236,MUC1;EPAS1;CHEK1;ELOB;ATF3
activation of adenylate cyclase activity (GO:0007190),3/36,0.04545765095439701,0.12554268594212725,0,0,4.0152200740436035,12.410941393978344,ADRB1;ADRB2;ADCY5
cyclic-nucleotide-mediated signaling (GO:0019935),3/36,0.04545765095439701,0.12554268594212725,0,0,4.0152200740436035,12.410941393978344,RIMS2;CD36;AQP1
dendrite morphogenesis (GO:0048813),3/36,0.04545765095439701,0.12554268594212725,0,0,4.0152200740436035,12.410941393978344,CTNND2;PAK3;MAPK8IP2
membrane fusion (GO:0061025),3/36,0.04545765095439701,0.12554268594212725,0,0,4.0152200740436035,12.410941393978344,RABIF;MX1;STX11
positive regulation of cytokine-mediated signaling pathway (GO:0001961),3/36,0.04545765095439701,0.12554268594212725,0,0,4.0152200740436035,12.410941393978344,PRKN;CXCR4;FADD
positive regulation of myeloid leukocyte differentiation (GO:0002763),3/36,0.04545765095439701,0.12554268594212725,0,0,4.0152200740436035,12.410941393978344,TNFSF11;PRKCA;FADD
positive regulation of telomere maintenance via telomere lengthening (GO:1904358),3/36,0.04545765095439701,0.12554268594212725,0,0,4.0152200740436035,12.410941393978344,CCT3;NEK2;MAPK15
regulation of microtubule-based process (GO:0032886),3/36,0.04545765095439701,0.12554268594212725,0,0,4.0152200740436035,12.410941393978344,ERBB2;FAM107A;AURKA
regulation of translation (GO:0006417),8/178,0.046077687613290154,0.12715203189157315,0,0,2.0874949522142954,6.424112171537083,RPS6KA3;IL6;BCL3;ERBB2;GZMB;CALR;VIM;PLD1
positive regulation of neuron projection development (GO:0010976),5/88,0.04657517106544642,0.1284208600251144,0,0,2.665936473165389,8.175594563507838,ALK;RET;MDK;PRKD1;CAMK1
negative regulation of response to stimulus (GO:0048585),4/61,0.046770576048442945,0.12875131112527752,0,0,3.102677328241238,9.501952391553484,COL3A1;TERT;HMGA2;KLF4
pattern recognition receptor signaling pathway (GO:0002221),4/61,0.046770576048442945,0.12875131112527752,0,0,3.102677328241238,9.501952391553484,RPS6KA3;MAPKAPK2;CD36;APOB
anterograde trans-synaptic signaling (GO:0098916),10/244,0.047132265701972605,0.12964226110760502,0,0,1.8981235877787601,5.798383125619591,RPS6KA3;GRIA2;DLG2;PRKAR2B;GAD1;SNCG;AKAP5;CAMK1;SYN1;GRIA4
plasma membrane bounded cell projection assembly (GO:0120031),11/278,0.04755940837678706,0.13071166431297604,0,0,1.8309601477415902,5.576693828160009,PLK4;NRP1;CCL21;KIT;RFX2;S1PR1;PARVA;EZR;SSX2IP;MYLK;ARHGEF6
dendritic spine morphogenesis (GO:0060997),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,CTNND2;PAK3
negative regulation of epithelial cell differentiation (GO:0030857),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,CAV1;SPRY2
negative regulation of release of cytochrome c from mitochondria (GO:0090201),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,PRKN;HGF
neural tube development (GO:0021915),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,PROX1;PKD2
platelet-derived growth factor receptor signaling pathway (GO:0048008),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,NRP1;PDGFA
polyol biosynthetic process (GO:0046173),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,ITPKA;FGF2
positive regulation of alpha-beta T cell proliferation (GO:0046641),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,IL18;TGFBR2
positive regulation of vasoconstriction (GO:0045907),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,CAV1;ADRA1A
regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis (GO:1903587),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,NGFR;FGF2
regulation of fatty acid oxidation (GO:0046320),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,PPARA;PPARGC1A
regulation of granulocyte macrophage colony-stimulating factor production (GO:0032645),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,IL18;PAEP
regulation of interleukin-13 production (GO:0032656),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,IL18;GATA3
retrograde axonal transport (GO:0008090),2/16,0.048252865378906745,0.1312416322516474,0,0,6.301515640116092,19.101784781260555,DLG2;DST
positive regulation of inflammatory response (GO:0050729),5/89,0.04848648036089539,0.1316672799518141,0,0,2.6340638528138527,7.971915953898367,IL6;MDK;PLA2G2A;IL18;AGT
centromere complex assembly (GO:0034508),3/37,0.048679804207536904,0.1316672799518141,0,0,3.89692573862124,11.778423100866828,CENPF;RUVBL1;H4-16
neural crest cell migration (GO:0001755),3/37,0.048679804207536904,0.1316672799518141,0,0,3.89692573862124,11.778423100866828,NRP1;SEMA3F;SOX10
"phagocytosis, engulfment (GO:0006911)",3/37,0.048679804207536904,0.1316672799518141,0,0,3.89692573862124,11.778423100866828,SH3BP1;RHOH;CD36
positive regulation of signaling receptor activity (GO:2000273),3/37,0.048679804207536904,0.1316672799518141,0,0,3.89692573862124,11.778423100866828,NRP1;CCL2;ADRB2
regulation of actin cytoskeleton reorganization (GO:2000249),3/37,0.048679804207536904,0.1316672799518141,0,0,3.89692573862124,11.778423100866828,NRP1;MDK;TEK
regulation of intracellular steroid hormone receptor signaling pathway (GO:0033143),3/37,0.048679804207536904,0.1316672799518141,0,0,3.89692573862124,11.778423100866828,H4-16;CALR;ESR1
double-strand break repair via nonhomologous end joining (GO:0006303),4/62,0.04915399434866662,0.13263405600970377,0,0,3.049026507154586,9.186098423328474,H2AX;BARD1;H4-16;BRCA1
positive regulation of cysteine-type endopeptidase activity (GO:2001056),4/62,0.04915399434866662,0.13263405600970377,0,0,3.049026507154586,9.186098423328474,CYFIP2;PMAIP1;BAK1;FADD
regulation of neurogenesis (GO:0050767),4/62,0.04915399434866662,0.13263405600970377,0,0,3.049026507154586,9.186098423328474,YAP1;PER2;IL6;ASCL1
positive regulation of autophagy (GO:0010508),5/90,0.050443509418645754,0.13600591779963983,0,0,2.6029411764705883,7.774728108438903,PRKN;KDR;PRKD1;DCN;FOXO1
positive regulation of viral process (GO:0048524),4/63,0.05160320529522582,0.13902270643962814,0,0,2.9971943579691764,8.884198066778264,NR5A2;POLR2H;KPNA2;PPARA
negative regulation of innate immune response (GO:0045824),3/38,0.05201066271762746,0.1397889105218252,0,0,3.7853910795087264,11.190776363771825,CR1;SERPING1;A2M
positive regulation of signaling (GO:0023056),3/38,0.05201066271762746,0.1397889105218252,0,0,3.7853910795087264,11.190776363771825,RIMS2;KCTD13;GATA3
synaptic vesicle endocytosis (GO:0048488),3/38,0.05201066271762746,0.1397889105218252,0,0,3.7853910795087264,11.190776363771825,ITSN1;MX1;SNCG
sensory perception of sound (GO:0007605),5/91,0.05244630240014002,0.14073779415722612,0,0,2.5725422832980973,7.583765755006519,COL1A1;CLIC5;COL2A1;KIT;PAX3
toll-like receptor signaling pathway (GO:0002224),5/91,0.05244630240014002,0.14073779415722612,0,0,2.5725422832980973,7.583765755006519,RPS6KA3;MAPKAPK2;CD36;FADD;APOB
activation of protein kinase A activity (GO:0034199),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,PRKAR2B;ADCY5
cellular response to gamma radiation (GO:0071480),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,YAP1;CRYAB
gliogenesis (GO:0042063),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,ANXA1;PAX2
negative regulation of ATP metabolic process (GO:1903579),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,PARP1;PPARA
negative regulation of cell aging (GO:0090344),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,TERT;HMGA2
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator (GO:1902254),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,PRKN;MUC1
negative regulation of phagocytosis (GO:0050765),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,SIRPA;PRTN3
negative regulation of vascular associated smooth muscle cell proliferation (GO:1904706),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,MEF2C;PPARG
pharyngeal system development (GO:0060037),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,GATA3;NKX2-5
positive regulation of heart rate (GO:0010460),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,ADRB1;ADRA1A
positive regulation of positive chemotaxis (GO:0050927),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,CXCL12;KDR
positive regulation of stem cell proliferation (GO:2000648),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,TERT;HMGA2
positive regulation of telomere capping (GO:1904355),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,NEK2;MAPK15
positive regulation of transcription of Notch receptor target (GO:0007221),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,MAML2;STAT1
regulation of establishment of endothelial barrier (GO:1903140),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,CDH5;PROC
regulation of leukocyte migration (GO:0002685),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,ANXA1;RHOH
synaptic vesicle membrane organization (GO:0048499),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,SYP;STX11
vasculature development (GO:0001944),2/17,0.053900161171481685,0.14261781775808197,0,0,5.881113619262604,17.176508708665256,CDH5;FLT4
protein catabolic process (GO:0030163),4/64,0.0541179924872407,0.14308310193678536,0,0,2.947089947089947,8.595448854736894,PRKN;SIAH2;CAPN3;PMAIP1
positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090100),5/92,0.054494880069585055,0.14385635265464436,0,0,2.5428422152560084,7.398777101952805,CDH5;BMP2;INHBA;ZNF423;BMPR1B
regulation of lipid metabolic process (GO:0019216),5/92,0.054494880069585055,0.14385635265464436,0,0,2.5428422152560084,7.398777101952805,CAV1;IRS2;PPARG;PPARA;FGFR4
antigen receptor-mediated signaling pathway (GO:0050851),8/185,0.05540516504135911,0.14558492865698727,0,0,2.004214663408706,5.798358284335634,VAV3;MEF2C;TRAT1;CTLA4;GATA3;BMX;PAK3;SKAP1
cellular response to ketone (GO:1901655),3/39,0.05544871989341828,0.14558492865698727,0,0,3.680052790346908,10.643804361883586,GNG2;ADCY5;AQP1
DNA recombination (GO:0006310),3/39,0.05544871989341828,0.14558492865698727,0,0,3.680052790346908,10.643804361883586,BLM;RAD51;RAD54B
membrane protein proteolysis (GO:0033619),3/39,0.05544871989341828,0.14558492865698727,0,0,3.680052790346908,10.643804361883586,RET;NGFR;PRTN3
regulation of exit from mitosis (GO:0007096),3/39,0.05544871989341828,0.14558492865698727,0,0,3.680052790346908,10.643804361883586,CDC20;NEK2;MAD2L1
regulation of intracellular transport (GO:0032386),3/39,0.05544871989341828,0.14558492865698727,0,0,3.680052790346908,10.643804361883586,ANTKMT;NEFH;CRYAB
replication fork processing (GO:0031297),3/39,0.05544871989341828,0.14558492865698727,0,0,3.680052790346908,10.643804361883586,BLM;RAD51;BRCA2
cellular response to type I interferon (GO:0071357),4/65,0.05669809305248637,0.1485219839530158,0,0,2.8986283037805287,8.319105844716084,EGR1;STAT1;MX1;IRF7
mitotic G1 DNA damage checkpoint signaling (GO:0031571),4/65,0.05669809305248637,0.1485219839530158,0,0,2.8986283037805287,8.319105844716084,MUC1;CCND1;E2F1;AURKA
type I interferon signaling pathway (GO:0060337),4/65,0.05669809305248637,0.1485219839530158,0,0,2.8986283037805287,8.319105844716084,EGR1;STAT1;MX1;IRF7
proteolysis (GO:0006508),11/287,0.05719105488280443,0.1496982450388614,0,0,1.7704284378548054,5.065829177495451,RET;ACAN;MMP14;PROC;F12;HGF;CAPN3;GZMB;CTSG;PRTN3;PCSK5
nucleosome organization (GO:0034728),5/94,0.05872935703996701,0.1523465096445093,0,0,2.485444330949949,7.045776256018659,H2AX;NFE2;CHAF1A;H4-16;HMGA1
regulation of tumor necrosis factor production (GO:0032680),6/124,0.058881325463694636,0.1523465096445093,0,0,2.2513030384927224,6.376210916867312,ZFP36;IL6;MAPKAPK2;SIRPA;FADD;CCL19
negative regulation of ERBB signaling pathway (GO:1901185),3/40,0.05899237377779329,0.1523465096445093,0,0,3.580408462761404,10.13379871452814,ERBB2;CBLC;SPRY2
negative regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043124),3/40,0.05899237377779329,0.1523465096445093,0,0,3.580408462761404,10.13379871452814,STAT1;RHOH;ESR1
positive regulation of catalytic activity (GO:0043085),3/40,0.05899237377779329,0.1523465096445093,0,0,3.580408462761404,10.13379871452814,CAV1;CIB1;FGFR4
regulation of microtubule polymerization (GO:0031113),3/40,0.05899237377779329,0.1523465096445093,0,0,3.580408462761404,10.13379871452814,CDH5;STMN1;MET
regulation of sodium ion transmembrane transporter activity (GO:2000649),3/40,0.05899237377779329,0.1523465096445093,0,0,3.580408462761404,10.13379871452814,DMD;FXYD6;UTRN
cell-cell junction assembly (GO:0007043),4/66,0.059343198935820726,0.1523465096445093,0,0,2.851729939287543,8.054476678637966,CDH5;PARD6B;CTNND2;PRKCA
positive regulation of cell death (GO:0010942),4/66,0.059343198935820726,0.1523465096445093,0,0,2.851729939287543,8.054476678637966,EGR1;LRP1;CD36;FOS
3'-UTR-mediated mRNA stabilization (GO:0070935),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,ZFP36;MAPKAPK2
cellular response to alkaloid (GO:0071312),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,BLM;RAD51
chromatin disassembly (GO:0031498),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,NFE2;HMGA1
DNA strand elongation involved in DNA replication (GO:0006271),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,RFC4;MCM4
intermediate filament organization (GO:0045109),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,VIM;GFAP
mitochondrial fission (GO:0000266),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,PRKN;MX1
negative regulation of biosynthetic process (GO:0009890),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,IL6;PPARA
negative regulation of cation transmembrane transport (GO:1904063),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,BIN1;CAV1
neuron maturation (GO:0042551),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,C3;RND1
nitric oxide mediated signal transduction (GO:0007263),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,CD36;AGT
nucleosome disassembly (GO:0006337),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,NFE2;HMGA1
phosphatidylglycerol acyl-chain remodeling (GO:0036148),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,PLA2G2A;PLA2G4A
phosphatidylinositol acyl-chain remodeling (GO:0036149),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,PLA2G2A;PLA2G4A
positive regulation of CREB transcription factor activity (GO:0032793),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,OPRD1;PRKD1
positive regulation of extracellular matrix organization (GO:1903055),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,BMP2;IL6
positive regulation of nervous system process (GO:0031646),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,RIMS2;EGR2
positive regulation of response to endoplasmic reticulum stress (GO:1905898),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,PMAIP1;BAK1
regulation of B cell differentiation (GO:0045577),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,MMP14;INHBA
regulation of brown fat cell differentiation (GO:0090335),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,SIX1;PTGS2
regulation of chromosome segregation (GO:0051983),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,MKI67;BUB1
regulation of establishment or maintenance of cell polarity (GO:0032878),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,CDH5;TEK
regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (GO:1901028),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,ZNF205;BAK1
regulation of multicellular organism growth (GO:0040014),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,STAT5A;STAT5B
regulation of protein sumoylation (GO:0033233),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,EGR1;CAPN3
regulation of telomerase RNA localization to Cajal body (GO:1904872),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,CCT3;RUVBL1
T cell migration (GO:0072678),2/18,0.059767395362297214,0.1523465096445093,0,0,5.513261851015802,15.532485017732286,CXCL10;S1PR1
regulation of signal transduction by p53 class mediator (GO:1901796),7/156,0.060188487293833706,0.15330520530447328,0,0,2.0814869296068155,5.849548986609044,BARD1;BLM;RFC4;CHEK1;BRCA1;SGK1;AURKA
regulation of phosphorylation (GO:0042325),6/125,0.06074880791492398,0.15461683149668476,0,0,2.232269673245152,6.252604810558516,BARD1;CDH5;NRP1;CDKN2C;CDKN2A;INHBA
regulation of epidermal growth factor receptor signaling pathway (GO:0042058),4/67,0.0620529582186152,0.15758307124369644,0,0,2.806320411762589,7.800917135029502,PLAUR;CBLC;SPRY2;AGT
regulation of gene silencing by miRNA (GO:0060964),4/67,0.0620529582186152,0.15758307124369644,0,0,2.806320411762589,7.800917135029502,ZFP36;H4-16;PPARG;POLR2H
regulation of viral genome replication (GO:0045069),4/67,0.0620529582186152,0.15758307124369644,0,0,2.806320411762589,7.800917135029502,NR5A2;MX1;PROX1;PPARA
epithelial cell migration (GO:0010631),3/41,0.06263993438298283,0.15848321928523051,0,0,3.486008573469874,9.657471781575046,NRP1;STAT1;KIT
heart contraction (GO:0060047),3/41,0.06263993438298283,0.15848321928523051,0,0,3.486008573469874,9.657471781575046,ACTC1;TNNI2;DMD
negative regulation of cell-cell adhesion (GO:0022408),3/41,0.06263993438298283,0.15848321928523051,0,0,3.486008573469874,9.657471781575046,BMP2;KLF4;PPARA
regulation of mitochondrial membrane potential (GO:0051881),3/41,0.06263993438298283,0.15848321928523051,0,0,3.486008573469874,9.657471781575046,OPRD1;PMAIP1;BAK1
visual system development (GO:0150063),3/41,0.06263993438298283,0.15848321928523051,0,0,3.486008573469874,9.657471781575046,C3;SIX3;BMPR1B
regulation of vesicle-mediated transport (GO:0060627),5/96,0.06314664817282967,0.15964671882270287,0,0,2.4305694305694305,6.713951021951221,RIMS2;NRP1;RAB3A;PLD1;SYT7
canonical Wnt signaling pathway (GO:0060070),4/68,0.06482697647192098,0.16271910961084896,0,0,2.762329931972789,7.5578271177774665,TCF7L2;CAV1;GATA3;PPP1CA
actin filament capping (GO:0051693),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,EPS8;VIL1
activin receptor signaling pathway (GO:0032924),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,INHBA;TDGF1
barbed-end actin filament capping (GO:0051016),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,EPS8;VIL1
cellular response to glucagon stimulus (GO:0071377),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,PRKAR2B;ADCY5
dopamine metabolic process (GO:0042417),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,PRKN;SNCAIP
endocardial cushion morphogenesis (GO:0003203),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,BMP2;TGFBR2
establishment of skin barrier (GO:0061436),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,STMN1;MET
heart trabecula morphogenesis (GO:0061384),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,S1PR1;TEK
long-term memory (GO:0007616),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,SLC2A4;SGK1
negative regulation of cytokine production involved in inflammatory response (GO:1900016),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,SIRPA;PPARA
negative regulation of immune system process (GO:0002683),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,COL3A1;FADD
negative regulation of RNA metabolic process (GO:0051253),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,TERT;ESR1
negative regulation of striated muscle cell differentiation (GO:0051154),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,BMP2;NKX2-5
negative regulation of T cell receptor signaling pathway (GO:0050860),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,SH2D1A;EZR
positive regulation of actin cytoskeleton reorganization (GO:2000251),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,NRP1;TEK
positive regulation of G protein-coupled receptor signaling pathway (GO:0045745),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,C3;PRKCA
positive regulation of monocyte chemotaxis (GO:0090026),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,CXCL10;CXCL12
prostaglandin biosynthetic process (GO:0001516),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,PLA2G4A;PTGS2
Rac protein signal transduction (GO:0016601),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,EPS8;RHOH
regulation of centriole replication (GO:0046599),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,PLK4;BRCA1
regulation of collagen biosynthetic process (GO:0032965),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,IL6;VIM
regulation of epithelial cell differentiation (GO:0030856),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,CAV1;GATA3
regulation of exosomal secretion (GO:1903541),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,PRKN;SDC1
regulation of leukocyte chemotaxis (GO:0002688),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,IL6;MDK
regulation of mitochondrial membrane permeability (GO:0046902),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,PMAIP1;BAK1
regulation of oligodendrocyte differentiation (GO:0048713),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,MDK;CXCR4
regulation of synaptic vesicle exocytosis (GO:2000300),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,RIMS2;SYN1
regulation of vascular endothelial growth factor signaling pathway (GO:1900746),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,SPRY2;DCN
regulation of water loss via skin (GO:0033561),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,STMN1;MET
response to fatty acid (GO:0070542),2/19,0.0658420340825589,0.16271910961084896,0,0,5.18868676138627,14.11580587979327,CD36;FOXO1
phosphatidylinositol phosphate biosynthetic process (GO:0046854),3/42,0.0663896306771826,0.16336163274212154,0,0,3.396449704142012,9.211899793715412,SOCS3;CISH;ITPKA
regulation of double-strand break repair (GO:2000779),3/42,0.0663896306771826,0.16336163274212154,0,0,3.396449704142012,9.211899793715412,PPP4C;RAD51;CHEK1
regulation of extrinsic apoptotic signaling pathway via death domain receptors (GO:1902041),3/42,0.0663896306771826,0.16336163274212154,0,0,3.396449704142012,9.211899793715412,PMAIP1;BRCA1;FADD
regulation of nervous system development (GO:0051960),3/42,0.0663896306771826,0.16336163274212154,0,0,3.396449704142012,9.211899793715412,YAP1;PER2;ASCL1
skeletal system morphogenesis (GO:0048705),3/42,0.0663896306771826,0.16336163274212154,0,0,3.396449704142012,9.211899793715412,FBN2;SIX1;FGFR3
translesion synthesis (GO:0019985),3/42,0.0663896306771826,0.16336163274212154,0,0,3.396449704142012,9.211899793715412,RFC4;POLE2;UBE2L6
negative regulation of cellular catabolic process (GO:0031330),4/69,0.06766481804867386,0.16625933663293474,0,0,2.719693005407291,7.324647036577443,HGF;LEPR;TIMP1;MET
positive regulation of protein polymerization (GO:0032273),4/69,0.06766481804867386,0.16625933663293474,0,0,2.719693005407291,7.324647036577443,CCL21;BIN1;EVL;MET
positive regulation of defense response (GO:0031349),5/98,0.06774610411427977,0.16633913747944196,0,0,2.3780547409579667,6.401695598213416,MEF2C;MDK;PLA2G2A;IL18;AGT
cellular response to insulin stimulus (GO:0032869),6/129,0.06856718881168122,0.1682339665012308,0,0,2.1592310683926885,5.786612205233195,PARP1;CAV2;IRS2;PPARG;SLC2A4;FOXO1
positive regulation of stress-activated MAPK cascade (GO:0032874),5/99,0.070113845698954,0.17135047668949843,0,0,2.3526353965183753,6.25244615063519,BMP2;CCL21;FLT4;CCL19;GADD45G
cellular response to retinoic acid (GO:0071300),3/43,0.07023961735188654,0.17135047668949843,0,0,3.311368778280543,8.794474853083797,RET;PAX2;AQP1
myofibril assembly (GO:0030239),3/43,0.07023961735188654,0.17135047668949843,0,0,3.311368778280543,8.794474853083797,KRT19;ACTC1;CAPN3
negative regulation of type I interferon production (GO:0032480),3/43,0.07023961735188654,0.17135047668949843,0,0,3.311368778280543,8.794474853083797,SIRPA;UBE2L6;IKBKE
positive regulation of peptide hormone secretion (GO:0090277),3/43,0.07023961735188654,0.17135047668949843,0,0,3.311368778280543,8.794474853083797,TCF7L2;TNFSF11;IRS2
regulation of cytokine production involved in inflammatory response (GO:1900015),3/43,0.07023961735188654,0.17135047668949843,0,0,3.311368778280543,8.794474853083797,IL6;SIRPA;PPARA
signal release from synapse (GO:0099643),3/43,0.07023961735188654,0.17135047668949843,0,0,3.311368778280543,8.794474853083797,RAB3A;GAD1;SYN1
spermatid development (GO:0007286),3/43,0.07023961735188654,0.17135047668949843,0,0,3.311368778280543,8.794474853083797,RFX2;CIB1;NECTIN2
negative regulation of viral process (GO:0048525),4/70,0.07056600746941248,0.1720235718567652,0,0,2.6783481069195356,7.100854529120374,ZFP36;STAT1;MX1;PROX1
cardiac ventricle development (GO:0003231),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,GATA4;GATA3
establishment of epithelial cell polarity (GO:0090162),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,SH3BP1;EZR
granulocyte differentiation (GO:0030851),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,TAL1;E2F1
growth hormone receptor signaling pathway (GO:0060396),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,STAT5A;STAT5B
lipopolysaccharide-mediated signaling pathway (GO:0031663),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,IL18;CCL2
mesoderm development (GO:0007498),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,BMX;MEST
modulation by symbiont of entry into host (GO:0052372),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,CAV1;NECTIN2
positive regulation of activated T cell proliferation (GO:0042104),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,IL18;FADD
positive regulation of heart contraction (GO:0045823),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,NKX2-5;ADRA1A
positive regulation of interferon-alpha production (GO:0032727),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,STAT1;IRF7
positive regulation of nitrogen compound metabolic process (GO:0051173),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,GATA3;KLF4
positive regulation of peptidyl-lysine acetylation (GO:2000758),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,BRCA1;PPARGC1A
positive regulation of protein processing (GO:0010954),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,CLEC3B;F12
protein-DNA complex disassembly (GO:0032986),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,NFE2;HMGA1
regulation of acute inflammatory response (GO:0002673),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,IL6;F12
regulation of fibroblast growth factor receptor signaling pathway (GO:0040036),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,SPRY2;FGF2
regulation of smooth muscle contraction (GO:0006940),2/20,0.07211199013417019,0.17368032676837597,0,0,4.900175570604464,12.8851829232882,CAV1;ADRB2
cholesterol homeostasis (GO:0042632),4/71,0.07353003075826778,0.17659643750822876,0,0,2.6382373845060414,6.885961493968781,CAV1;IL18;APOB;FGFR4
nucleic acid metabolic process (GO:0090304),4/71,0.07353003075826778,0.17659643750822876,0,0,2.6382373845060414,6.885961493968781,FEN1;LSM1;POLR2H;KPNA2
phosphatidylinositol-mediated signaling (GO:0048015),4/71,0.07353003075826778,0.17659643750822876,0,0,2.6382373845060414,6.885961493968781,ERBB2;IRS2;GATA3;EZR
regulation of hematopoietic stem cell differentiation (GO:1902036),4/71,0.07353003075826778,0.17659643750822876,0,0,2.6382373845060414,6.885961493968781,YAP1;TAL1;LMO2;GATA3
embryonic organ morphogenesis (GO:0048562),3/44,0.0741879811616658,0.1775510110947732,0,0,3.2304381414854872,8.402864253541548,FBN2;SIX2;SIX1
intracellular steroid hormone receptor signaling pathway (GO:0030518),3/44,0.0741879811616658,0.1775510110947732,0,0,3.2304381414854872,8.402864253541548,YAP1;CALCOCO1;ESR1
mRNA stabilization (GO:0048255),3/44,0.0741879811616658,0.1775510110947732,0,0,3.2304381414854872,8.402864253541548,ZFP36;MAPKAPK2;E2F1
positive regulation of biosynthetic process (GO:0009891),3/44,0.0741879811616658,0.1775510110947732,0,0,3.2304381414854872,8.402864253541548,CD36;VIM;PPARA
positive regulation of stress fiber assembly (GO:0051496),3/44,0.0741879811616658,0.1775510110947732,0,0,3.2304381414854872,8.402864253541548,NRP1;ARHGEF15;EVL
protein deubiquitination (GO:0016579),10/267,0.07624210084224976,0.1823390032774647,0,0,1.7261952681246926,4.442952956702905,CDC20;BARD1;PRKN;CCNA2;SIAH2;RUVBL1;GATA3;BRCA1;ADRB2;ESR1
sterol homeostasis (GO:0055092),4/72,0.07655633678039796,0.18296212885525684,0,0,2.5993063892223556,6.679511398462674,CAV1;IL18;APOB;FGFR4
cell junction assembly (GO:0034329),5/102,0.0774871872960824,0.18452901227219293,0,0,2.279522024367385,5.830202822946767,CDH5;PARD6B;SH3BP1;CTNND2;FLNC
intrinsic apoptotic signaling pathway (GO:0097193),5/102,0.0774871872960824,0.18452901227219293,0,0,2.279522024367385,5.830202822946767,E2F1;PMAIP1;BRCA1;BAK1;IKBKE
regulation of protein catabolic process (GO:0042176),5/102,0.0774871872960824,0.18452901227219293,0,0,2.279522024367385,5.830202822946767,BARD1;PRKN;FOXO1;GFAP;MAD2L1
cellular response to radiation (GO:0071478),3/45,0.07823274705954297,0.18452901227219293,0,0,3.153361344537815,8.034975850966791,BLM;RAD51;ECT2
positive regulation of RNA metabolic process (GO:0051254),3/45,0.07823274705954297,0.18452901227219293,0,0,3.153361344537815,8.034975850966791,IL6;MYCN;HABP4
anterior/posterior axis specification (GO:0009948),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,SIX2;TDGF1
beta-catenin destruction complex disassembly (GO:1904886),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,CAV1;PPP1CA
cellular response to estradiol stimulus (GO:0071392),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,SSTR2;ESR1
endocardial cushion development (GO:0003197),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,BMP2;GATA4
epithelial cell development (GO:0002064),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,ACTA2;SIX3
error-prone translesion synthesis (GO:0042276),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,RFC4;POLE2
long-term synaptic potentiation (GO:0060291),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,GRIN2C;GRIN2D
myotube differentiation (GO:0014902),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,MEF2C;ADAM12
negative regulation of peptidyl-serine phosphorylation (GO:0033137),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,CAV1;DMD
negative regulation of response to wounding (GO:1903035),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,MDK;FGF2
negative regulation of small GTPase mediated signal transduction (GO:0051058),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,SH3BP1;SPRY2
neuron apoptotic process (GO:0051402),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,NGFR;CIT
positive regulation of antigen receptor-mediated signaling pathway (GO:0050857),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,TRAT1;NECTIN2
positive regulation of phosphatase activity (GO:0010922),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,MEF2C;BMP2
positive regulation of T cell cytokine production (GO:0002726),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,IL6;IL18
positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus (GO:1901522),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,BMP2;RUNX2
positive regulation of vascular associated smooth muscle cell proliferation (GO:1904707),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,JUN;FGF2
regulation of dendritic spine development (GO:0060998),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,MEF2C;CAMK1
regulation of ubiquitin protein ligase activity (GO:1904666),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,CDC20;MAD2L1
response to glucagon (GO:0033762),2/21,0.07856560939171126,0.18452901227219293,0,0,4.642033978852322,11.808504515417276,PRKAR2B;ADCY5
chromatin assembly (GO:0031497),4/73,0.07964433859604382,0.18667668908893903,0,0,2.561503828584574,6.481076832106004,H2AX;CHAF1A;H4-16;HMGA2
negative regulation of cell adhesion (GO:0007162),4/73,0.07964433859604382,0.18667668908893903,0,0,2.561503828584574,6.481076832106004,MUC1;MDK;DUSP1;RND1
positive regulation of JNK cascade (GO:0046330),4/73,0.07964433859604382,0.18667668908893903,0,0,2.561503828584574,6.481076832106004,CCL21;FLT4;CCL19;GADD45G
neutrophil mediated immunity (GO:0002446),16/488,0.08029888094782252,0.18808150259118842,0,0,1.5078819485599146,3.8028776620969063,RAB3A;CR1;ANXA3;PLAUR;PLD1;C3;PTPRB;DSN1;IL6;CXCR2;PECAM1;SIRPA;CTSG;PRTN3;CD36;ALDOA
modification-dependent protein catabolic process (GO:0019941),8/201,0.08097722707788371,0.189540102940541,0,0,1.8365445038593329,4.616314961034623,CDC20;PRKN;SIAH2;CBLC;UBE2L6;KLHL3;MAD2L1;AURKA
positive regulation of nucleocytoplasmic transport (GO:0046824),3/46,0.08237188402569912,0.1920132563335038,0,0,3.0798695148900346,7.688928472279375,TCF7L2;CAMK1;ECT2
positive regulation of organelle assembly (GO:1902117),3/46,0.08237188402569912,0.1920132563335038,0,0,3.0798695148900346,7.688928472279375,PLK4;GPSM2;SDC1
postreplication repair (GO:0006301),3/46,0.08237188402569912,0.1920132563335038,0,0,3.0798695148900346,7.688928472279375,RFC4;UBE2L6;BRCA1
regulation of DNA metabolic process (GO:0051052),3/46,0.08237188402569912,0.1920132563335038,0,0,3.0798695148900346,7.688928472279375,CDT1;PDGFA;KPNA2
"regulation of synaptic transmission, glutamatergic (GO:0051966)",3/46,0.08237188402569912,0.1920132563335038,0,0,3.0798695148900346,7.688928472279375,MEF2C;CCL2;MAPK8IP2
regulation of telomerase activity (GO:0051972),3/46,0.08237188402569912,0.1920132563335038,0,0,3.0798695148900346,7.688928472279375,NEK2;KLF4;MAPK15
"DNA damage response, signal transduction by p53 class mediator (GO:0030330)",4/74,0.08279341482035711,0.19260065372544508,0,0,2.5247813411078717,6.290257280329508,MUC1;BCL3;E2F1;AURKA
mitotic nuclear division (GO:0140014),4/74,0.08279341482035711,0.19260065372544508,0,0,2.5247813411078717,6.290257280329508,EPS8;DSN1;TUBG1;NDC80
regulation of peptide hormone secretion (GO:0090276),4/74,0.08279341482035711,0.19260065372544508,0,0,2.5247813411078717,6.290257280329508,PER2;IL6;PRKCA;SYT7
cellular protein metabolic process (GO:0044267),14/417,0.0841589518438429,0.1956437297979649,0,0,1.5436891527004541,3.820704725927165,PRKN;SERPINC1;SIAH2;UBE2L6;LAMC1;PCSK5;C3;C4A;IL6;VCAN;PROC;CTSG;TIMP1;APOB
female gonad development (GO:0008585),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,KIT;INHBA
limb morphogenesis (GO:0035108),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,BMPR1B;PCSK5
negative regulation of B cell activation (GO:0050869),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,CTLA4;INHBA
negative regulation of DNA recombination at telomere (GO:0048239),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,H4-16;POLR2H
negative regulation of lipid biosynthetic process (GO:0051055),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,BMP2;BRCA1
peptidyl-threonine dephosphorylation (GO:0035970),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,DUSP1;PPP1CA
phosphatidylserine acyl-chain remodeling (GO:0036150),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,PLA2G2A;PLA2G4A
positive regulation of lipid catabolic process (GO:0050996),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,IRS2;PPARA
positive regulation of neural precursor cell proliferation (GO:2000179),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,MDK;PROX1
regulation of chromosome organization (GO:0033044),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,CDT1;BUB1
regulation of DNA recombination at telomere (GO:0072695),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,H4-16;POLR2H
regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway (GO:1902235),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,PRKN;PMAIP1
regulation of membrane protein ectodomain proteolysis (GO:0051043),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,TIMP1;SH3D19
regulation of response to cytokine stimulus (GO:0060759),2/22,0.08519165754635596,0.196171060079717,0,0,4.409706546275395,10.860453555316337,LIFR;KLF4
integrin-mediated signaling pathway (GO:0007229),4/75,0.08600291094614183,0.19777187618384032,0,0,2.489093289898119,6.106677097263403,NRP1;COL3A1;DST;PRKD1
regulation of hematopoietic progenitor cell differentiation (GO:1901532),4/75,0.08600291094614183,0.19777187618384032,0,0,2.489093289898119,6.106677097263403,YAP1;TAL1;LMO2;GATA3
regulation of T cell activation (GO:0050863),3/47,0.08660331056088592,0.19901826189581875,0,0,3.009718222953517,7.363026536012402,CCL2;SIRPA;TNFSF11
neuron projection development (GO:0031175),7/171,0.08812989123422452,0.20238993889908163,0,0,1.8896452834391357,4.589841658792691,CNTNAP2;IL6;CTNND2;STMN1;SGK1;PAK3;NEFH
regulation of T cell proliferation (GO:0042129),4/76,0.08927214068334316,0.20487505417429866,0,0,2.4543965734441926,5.929983655599123,IL6;ANXA1;CR1;CCL19
protein modification by small protein removal (GO:0070646),10/276,0.09013747332835342,0.20672174233043636,0,0,1.667012358482413,4.01153070051949,CDC20;BARD1;PRKN;CCNA2;SIAH2;RUVBL1;GATA3;BRCA1;ADRB2;ESR1
cellular response to interleukin-12 (GO:0071349),3/48,0.09092490001731661,0.20782834289672367,0,0,2.942684766214178,7.055738201289494,CFL1;SIRPA;LMNB1
negative regulation of mitotic cell cycle (GO:0045930),3/48,0.09092490001731661,0.20782834289672367,0,0,2.942684766214178,7.055738201289494,CHEK1;BUB1;MAD2L1
nucleus organization (GO:0006997),3/48,0.09092490001731661,0.20782834289672367,0,0,2.942684766214178,7.055738201289494,BIN1;CEP55;SYNE1
phosphatidic acid biosynthetic process (GO:0006654),3/48,0.09092490001731661,0.20782834289672367,0,0,2.942684766214178,7.055738201289494,PLA2G2A;PLA2G4A;PLD1
positive regulation of DNA repair (GO:0045739),3/48,0.09092490001731661,0.20782834289672367,0,0,2.942684766214178,7.055738201289494,H2AX;PARP1;BRCA1
artery development (GO:0060840),2/23,0.09197930730994182,0.2092559942004551,0,0,4.199505535848651,10.020825034429558,NRP1;PKD2
ear morphogenesis (GO:0042471),2/23,0.09197930730994182,0.2092559942004551,0,0,4.199505535848651,10.020825034429558,SIX1;PAX2
mitotic cell cycle checkpoint signaling (GO:0007093),2/23,0.09197930730994182,0.2092559942004551,0,0,4.199505535848651,10.020825034429558,CHEK1;BUB1
positive regulation of epithelial cell apoptotic process (GO:1904037),2/23,0.09197930730994182,0.2092559942004551,0,0,4.199505535848651,10.020825034429558,IL6;CCL2
positive regulation of interleukin-17 production (GO:0032740),2/23,0.09197930730994182,0.2092559942004551,0,0,4.199505535848651,10.020825034429558,IL6;IL18
positive regulation of transcription initiation from RNA polymerase II promoter (GO:0060261),2/23,0.09197930730994182,0.2092559942004551,0,0,4.199505535848651,10.020825034429558,NKX2-5;ESR1
regulation of telomere capping (GO:1904353),2/23,0.09197930730994182,0.2092559942004551,0,0,4.199505535848651,10.020825034429558,NEK2;MAPK15
negative regulation of developmental process (GO:0051093),4/77,0.09260038725727056,0.21052843213660977,0,0,2.4206504519616066,5.75984565750978,PRKN;BMP2;ARHGEF15;FGFR3
neuron differentiation (GO:0030182),7/174,0.094471411947651,0.21463904794506306,0,0,1.8554124627457413,4.377767795823229,ALK;MEF2C;ERBB2;INHBA;ASCL1;MET;RUNX2
adherens junction organization (GO:0034332),3/49,0.09533448559658714,0.21559384665771,0,0,2.8785658075939407,6.765676496523421,CDH5;NECTIN3;NECTIN2
negative regulation of catabolic process (GO:0009895),3/49,0.09533448559658714,0.21559384665771,0,0,2.8785658075939407,6.765676496523421,ALK;PPARA;MAD2L1
negative regulation of cell projection organization (GO:0031345),3/49,0.09533448559658714,0.21559384665771,0,0,2.8785658075939407,6.765676496523421,SPRY2;CIB1;FKBP4
positive regulation of actin filament polymerization (GO:0030838),3/49,0.09533448559658714,0.21559384665771,0,0,2.8785658075939407,6.765676496523421,CCL21;BIN1;EVL
positive regulation of reactive oxygen species metabolic process (GO:2000379),3/49,0.09533448559658714,0.21559384665771,0,0,2.8785658075939407,6.765676496523421,CD36;AGT;TGFBR2
regulation of cellular protein metabolic process (GO:0032268),3/49,0.09533448559658714,0.21559384665771,0,0,2.8785658075939407,6.765676496523421,INHBA;KLF4;AGT
response to glucose (GO:0009749),3/49,0.09533448559658714,0.21559384665771,0,0,2.8785658075939407,6.765676496523421,TCF7L2;IRS2;PAX2
chromatin organization (GO:0006325),6/142,0.09779503752205068,0.21742989738843263,0,0,1.9515275358434945,4.537070156146586,MECOM;SATB1;RUVBL1;HMGA2;ESR1;EZH2
axon extension (GO:0048675),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,NRP1;SEMA3F
canonical glycolysis (GO:0061621),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,ENO2;ALDOA
cellular response to catecholamine stimulus (GO:0071870),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,PRKN;GNG2
dorsal/ventral pattern formation (GO:0009953),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,SIX3;BMPR1B
glucose catabolic process to pyruvate (GO:0061718),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,ENO2;ALDOA
inner ear morphogenesis (GO:0042472),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,SIX1;PAX2
leukotriene metabolic process (GO:0006691),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,MAPKAPK2;PLA2G4A
mammary gland development (GO:0030879),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,CAV1;TDGF1
negative regulation of ossification (GO:0030279),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,MEF2C;MDK
negative regulation of protein tyrosine kinase activity (GO:0061099),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,CAV1;CBLC
negative regulation of stress fiber assembly (GO:0051497),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,STMN1;MET
positive regulation of p38MAPK cascade (GO:1900745),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,BMP2;GADD45G
positive regulation of protein targeting to membrane (GO:0090314),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,ERBB2;CIB1
positive regulation of transcription from RNA polymerase II promoter in response to stress (GO:0036003),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,MUC1;ATF3
regulation of axon extension involved in axon guidance (GO:0048841),2/24,0.0989181259246389,0.21742989738843263,0,0,4.008413708187975,9.273315928238109,NRP1;SEMA3F
positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436),4/79,0.09943091952965903,0.21742989738843263,0,0,2.3558578987150414,5.4380082988845455,CDC20;PRKN;CAV1;ELOB
negative regulation of ERK1 and ERK2 cascade (GO:0070373),3/50,0.09982986516854211,0.21742989738843263,0,0,2.817175315297969,6.491582963739185,SIRPA;SPRY2;EZR
phosphatidic acid metabolic process (GO:0046473),3/50,0.09982986516854211,0.21742989738843263,0,0,2.817175315297969,6.491582963739185,PLA2G2A;PLA2G4A;PLD1
neuron development (GO:0048666),6/143,0.10028076246265615,0.21742989738843263,0,0,1.937183047071147,4.455097544667274,ALK;CNTNAP2;MEF2C;IL6;STMN1;ASCL1
negative regulation of cellular component organization (GO:0051129),4/80,0.10293163117688241,0.21742989738843263,0,0,2.3247404224847834,5.285739716378271,OPRD1;SPRY2;PRKD1;CRYAB
regulation of organelle organization (GO:0033043),4/80,0.10293163117688241,0.21742989738843263,0,0,2.3247404224847834,5.285739716378271,PRKN;CDT1;EZR;MAPK15
regulation of protein localization to plasma membrane (GO:1903076),4/80,0.10293163117688241,0.21742989738843263,0,0,2.3247404224847834,5.285739716378271,MMP14;LRP1;CIB1;AKAP5
cholesterol transport (GO:0030301),3/51,0.10440880573378661,0.21742989738843263,0,0,2.7583427601809953,6.232313444282442,CAV1;CD36;APOB
negative regulation of protein ubiquitination (GO:0031397),3/51,0.10440880573378661,0.21742989738843263,0,0,2.7583427601809953,6.232313444282442,PER2;CAV1;SPRY2
regulation of epithelial cell migration (GO:0010632),3/51,0.10440880573378661,0.21742989738843263,0,0,2.7583427601809953,6.232313444282442,VIL1;RHOJ;EVL
Fc receptor signaling pathway (GO:0038093),5/112,0.10491830425305301,0.21742989738843263,0,0,2.0654205607476634,4.656642021441175,VAV3;JUN;KIT;FOS;VAV2
cardiac conduction system development (GO:0003161),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,GATA4;NKX2-5
divalent inorganic cation homeostasis (GO:0072507),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,PRKN;CAV1
energy derivation by oxidation of organic compounds (GO:0015980),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,LEPR;PPARGC1A
glycolytic process through glucose-6-phosphate (GO:0061620),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,ENO2;ALDOA
in utero embryonic development (GO:0001701),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,ARNT2;BMP2
negative regulation of antigen receptor-mediated signaling pathway (GO:0050858),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,SH2D1A;EZR
negative regulation of endocytosis (GO:0045806),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,CAV1;PRKD1
peripheral nervous system development (GO:0007422),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,EGR2;SOX10
phosphatidylglycerol metabolic process (GO:0046471),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,PLA2G2A;PLA2G4A
positive regulation of ERBB signaling pathway (GO:1901186),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,PLAUR;AGT
positive regulation of lipid metabolic process (GO:0045834),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,PPARG;PPARA
positive regulation of release of cytochrome c from mitochondria (GO:0090200),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,PLAUR;PMAIP1
regulation of heterotypic cell-cell adhesion (GO:0034114),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,KLF4;SKAP1
regulation of interferon-alpha production (GO:0032647),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,STAT1;IRF7
regulation of myotube differentiation (GO:0010830),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,MMP14;NKX2-5
regulation of ryanodine-sensitive calcium-release channel activity (GO:0060314),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,DMD;PKD2
response to hexose (GO:0009746),2/25,0.105998062989128,0.21742989738843263,0,0,3.833938561193444,8.604640425519106,TCF7L2;IRS2
aggresome assembly (GO:0070842),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PRKN
alpha-beta T cell differentiation (GO:0046632),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ANXA1
atrial cardiac muscle tissue morphogenesis (GO:0055009),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PROX1
BMP signaling pathway involved in heart development (GO:0061312),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,BMP2
carbon dioxide transport (GO:0015670),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,AQP1
cardiac cell fate commitment (GO:0060911),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,WT1
caveolin-mediated endocytosis (GO:0072584),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CAV1
cellular response to antibiotic (GO:0071236),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MEF2C
cellular response to erythropoietin (GO:0036018),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,KIT
cellular response to heparin (GO:0071504),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,EGR1
cellular response to indole-3-methanol (GO:0071681),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,BRCA1
cerebellar granule cell differentiation (GO:0021707),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PROX1
cerebral cortex neuron differentiation (GO:0021895),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ASCL1
ciliary neurotrophic factor-mediated signaling pathway (GO:0070120),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,LIFR
constitutive secretory pathway (GO:0045054),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,RAB3A
de novo centriole assembly (GO:0097742),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PLK4
de novo centriole assembly involved in multi-ciliated epithelial cell differentiation (GO:0098535),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PLK4
diaphragm development (GO:0060539),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,WT1
double-strand break repair via synthesis-dependent strand annealing (GO:0045003),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,RAD51
embryonic skeletal joint morphogenesis (GO:0060272),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,COL2A1
G protein-coupled opioid receptor signaling pathway (GO:0038003),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,OPRD1
gamma-aminobutyric acid metabolic process (GO:0009448),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,GAD1
glial cell-derived neurotrophic factor receptor signaling pathway (GO:0035860),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,RET
glucose import in response to insulin stimulus (GO:0044381),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,SLC2A4
glutamate catabolic process (GO:0006538),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,GAD1
heart field specification (GO:0003128),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MEF2C
hemoglobin metabolic process (GO:0020027),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,INHBA
histone-threonine phosphorylation (GO:0035405),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PRKCA
immature B cell differentiation (GO:0002327),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,KIT
lipid transport across blood-brain barrier (GO:1990379),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CD36
lymph node development (GO:0048535),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,FADD
mesonephric duct development (GO:0072177),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PKD2
metanephric nephron tubule morphogenesis (GO:0072282),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PAX2
mitochondrial DNA repair (GO:0043504),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PARP1
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway (GO:2001268),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PLAUR
negative regulation of gene silencing by RNA (GO:0060967),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PPARG
negative regulation of gonadotropin secretion (GO:0032277),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,INHBA
negative regulation of immunoglobulin production (GO:0002638),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CR1
negative regulation of insulin-like growth factor receptor signaling pathway (GO:0043569),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,BMP2
negative regulation of macrophage differentiation (GO:0045650),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,INHBA
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway (GO:1903377),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PRKN
negative regulation of pinocytosis (GO:0048550),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CAV1
negative regulation of posttranscriptional gene silencing (GO:0060149),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PPARG
negative regulation of response to food (GO:0032096),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PPARA
negative regulation of smooth muscle contraction (GO:0045986),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ADRB2
negative regulation of synapse organization (GO:1905809),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ARHGEF15
p38MAPK cascade (GO:0038066),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ZFP36
PML body organization (GO:0030578),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,HABP4
positive regulation of action potential (GO:0045760),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ADRA1A
positive regulation of AMPA receptor activity (GO:2000969),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ADRB2
positive regulation of axon extension involved in axon guidance (GO:0048842),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,NRP1
positive regulation of cAMP-dependent protein kinase activity (GO:2000481),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ADRB2
positive regulation of cardiac muscle contraction (GO:0060452),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ADRA1A
"positive regulation of CD4-positive, alpha-beta T cell proliferation (GO:2000563)",1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,TGFBR2
positive regulation of cell fate commitment (GO:0010455),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,FGF2
positive regulation of DNA ligation (GO:0051106),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,RAD51
positive regulation of dopamine receptor signaling pathway (GO:0060161),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CAV2
positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation (GO:1905007),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,TGFBR2
positive regulation of glial cell proliferation (GO:0060252),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,IL6
positive regulation of heat generation (GO:0031652),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PTGS2
positive regulation of histone H3-K9 acetylation (GO:2000617),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,BRCA1
positive regulation of leukocyte mediated immunity (GO:0002705),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,KIT
positive regulation of leukocyte tethering or rolling (GO:1903238),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,SELE
positive regulation of low-density lipoprotein receptor activity (GO:1905599),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PPARG
positive regulation of natural killer cell proliferation (GO:0032819),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,IL18
positive regulation of neurotransmitter transport (GO:0051590),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PRKN
positive regulation of neutrophil extravasation (GO:2000391),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MDK
positive regulation of prostaglandin secretion (GO:0032308),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,TNFSF11
positive regulation of protein catabolic process in the vacuole (GO:1904352),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,LRP1
positive regulation of smooth muscle cell differentiation (GO:0051152),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,KIT
positive regulation of T-helper 1 cell cytokine production (GO:2000556),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,IL18
positive regulation of vascular associated smooth muscle cell apoptotic process (GO:1905461),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PPARG
postsynaptic endocytosis (GO:0140239),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MX1
postsynaptic neurotransmitter receptor internalization (GO:0098884),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MX1
protein localization to axon (GO:0099612),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CNTNAP2
protein localization to membrane raft (GO:1903044),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CAV1
reelin-mediated signaling pathway (GO:0038026),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,STAT5A
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0106070),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PRKCA
regulation of astrocyte activation (GO:0061888),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,IL6
regulation of circadian sleep/wake cycle (GO:0042749),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ADRB1
regulation of dendritic cell cytokine production (GO:0002730),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,KIT
regulation of fever generation (GO:0031620),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PTGS2
regulation of germinal center formation (GO:0002634),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MEF2C
regulation of glomerular mesangial cell proliferation (GO:0072124),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PDGFA
regulation of histone H4-K16 acetylation (GO:2000618),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,BRCA1
regulation of hormone metabolic process (GO:0032350),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,TCF7L2
regulation of hydrogen peroxide biosynthetic process (GO:0010728),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,ZNF205
regulation of inflammatory response to wounding (GO:0106014),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MDK
regulation of inward rectifier potassium channel activity (GO:1901979),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CAV1
regulation of kidney development (GO:0090183),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,SIX2
regulation of microvillus assembly (GO:0032534),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PLD1
regulation of morphogenesis of a branching structure (GO:0060688),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,SIX2
regulation of neutrophil activation (GO:1902563),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PLA2G2A
regulation of NK T cell proliferation (GO:0051140),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,IL18
regulation of phosphatidylinositol biosynthetic process (GO:0010511),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PDGFA
regulation of plasma membrane organization (GO:1903729),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,RAB3A
regulation of platelet-derived growth factor receptor-beta signaling pathway (GO:2000586),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,LRP1
regulation of retinal ganglion cell axon guidance (GO:0090259),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,NRP1
regulation of skeletal muscle tissue development (GO:0048641),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MEF2C
regulation of sterol transport (GO:0032371),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,LRP1
regulation of synapse structural plasticity (GO:0051823),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CAMK1
regulation of T-helper 1 cell cytokine production (GO:2000554),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,IL18
regulation of triglyceride metabolic process (GO:0090207),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,C3
response to indole-3-methanol (GO:0071680),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,BRCA1
Schwann cell differentiation (GO:0014037),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,EGR2
secondary heart field specification (GO:0003139),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MEF2C
short-term memory (GO:0007614),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,SLC2A4
T cell extravasation (GO:0072683),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,CCL2
thorax and anterior abdomen determination (GO:0007356),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,WT1
Toll signaling pathway (GO:0008063),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PELI2
tonic smooth muscle contraction (GO:0014820),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,MYLK
tricuspid valve development (GO:0003175),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,TGFBR2
tricuspid valve morphogenesis (GO:0003186),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,TGFBR2
trivalent inorganic anion homeostasis (GO:0072506),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,FGFR4
trophoblast giant cell differentiation (GO:0060707),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,PLK4
vascular endothelial growth factor receptor-2 signaling pathway (GO:0036324),1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,KDR
"zygotic determination of anterior/posterior axis, embryo (GO:0007354)",1/5,0.10641815400349343,0.21742989738843263,0,0,11.008445945945946,24.663092179990752,WT1
negative regulation of protein modification process (GO:0031400),4/81,0.10648821416691193,0.21744268057569555,0,0,2.294431192390376,5.138885644474954,PRKN;SIRPA;CIB1;DMD
sulfur compound biosynthetic process (GO:0044272),5/113,0.10789490632593483,0.2201348008682965,0,0,2.0461910774410774,4.556044173256674,ACAN;VCAN;CHPF;BGN;DCN
regulation of mRNA stability (GO:0043488),6/146,0.10793581345390946,0.2201348008682965,0,0,1.895379108363163,4.219528127301548,ZFP36;EXOSC4;MAPKAPK2;E2F1;PRKCA;VIM
ameboidal-type cell migration (GO:0001667),3/52,0.10906904786402317,0.2215180662220447,0,0,2.701911533844307,5.986825680039984,AMOTL2;SEMA3F;SOX10
positive regulation of protein localization to plasma membrane (GO:1903078),3/52,0.10906904786402317,0.2215180662220447,0,0,2.701911533844307,5.986825680039984,LRP1;CIB1;AKAP5
protein homotetramerization (GO:0051289),3/52,0.10906904786402317,0.2215180662220447,0,0,2.701911533844307,5.986825680039984,TK1;PKD2;ALDOA
regulation of exocytosis (GO:0017157),3/52,0.10906904786402317,0.2215180662220447,0,0,2.701911533844307,5.986825680039984,RIMS2;RAB3A;ANXA1
regulation of intrinsic apoptotic signaling pathway (GO:2001242),3/52,0.10906904786402317,0.2215180662220447,0,0,2.701911533844307,5.986825680039984,CAV1;PLAUR;PMAIP1
regulation of release of sequestered calcium ion into cytosol (GO:0051279),3/52,0.10906904786402317,0.2215180662220447,0,0,2.701911533844307,5.986825680039984,CXCL10;CAPN3;DMD
regulation of telomere maintenance via telomerase (GO:0032210),3/52,0.10906904786402317,0.2215180662220447,0,0,2.701911533844307,5.986825680039984,CCT3;NEK2;MAPK15
DNA geometric change (GO:0032392),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,BLM;ANXA1
glial cell development (GO:0021782),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,MDK;SOX10
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage (GO:1902230),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,MUC1;CXCL12
organelle fission (GO:0048285),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,PRKN;MX1
phosphatidylethanolamine acyl-chain remodeling (GO:0036152),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,PLA2G2A;PLA2G4A
positive regulation of filopodium assembly (GO:0051491),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,NRP1;CCL21
positive regulation of T cell mediated cytotoxicity (GO:0001916),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,FADD;NECTIN2
regulation of actin filament bundle assembly (GO:0032231),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,PRKN;VIL1
regulation of viral life cycle (GO:1903900),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,KPNA2;NECTIN2
TOR signaling (GO:0031929),2/26,0.11320943873729689,0.2285650279719833,0,0,3.674003009781791,8.00387336951582,GATA3;RHEBL1
epidermis development (GO:0008544),4/83,0.11376557302091976,0.2286902827628245,0,0,2.2361146990441747,4.860453177949981,COL17A1;FGF7;KRT15;KRT5
positive regulation of plasma membrane bounded cell projection assembly (GO:0120034),4/83,0.11376557302091976,0.2286902827628245,0,0,2.2361146990441747,4.860453177949981,EPS8;NRP1;CCL21;CCL19
regulation of defense response (GO:0031347),4/83,0.11376557302091976,0.2286902827628245,0,0,2.2361146990441747,4.860453177949981,ANXA1;CMA1;PTGS2;SELE
regulation of Notch signaling pathway (GO:0008593),4/83,0.11376557302091976,0.2286902827628245,0,0,2.2361146990441747,4.860453177949981,YAP1;MMP14;MAML2;DTX1
heart morphogenesis (GO:0003007),3/53,0.11380830973173425,0.2286902827628245,0,0,2.647737556561086,5.754168477595202,BMP2;ACTC1;NKX2-5
positive regulation of chemokine production (GO:0032722),3/53,0.11380830973173425,0.2286902827628245,0,0,2.647737556561086,5.754168477595202,EGR1;IL6;IL18
positive regulation of macroautophagy (GO:0016239),3/53,0.11380830973173425,0.2286902827628245,0,0,2.647737556561086,5.754168477595202,KDR;ADRB2;DCN
regulation of DNA replication (GO:0006275),3/53,0.11380830973173425,0.2286902827628245,0,0,2.647737556561086,5.754168477595202,CCNA2;CDT1;BLM
lymphocyte differentiation (GO:0030098),4/84,0.1174845826075049,0.23444903691432953,0,0,2.2080498866213154,4.728424379828122,KIT;LEPR;RHOH;GATA3
cytoplasmic microtubule organization (GO:0031122),3/54,0.11862429100056149,0.23444903691432953,0,0,2.595688048975246,5.53347220577743,DST;CIB1;EZR
negative regulation of viral genome replication (GO:0045071),3/54,0.11862429100056149,0.23444903691432953,0,0,2.595688048975246,5.53347220577743,MX1;HMGA2;PROX1
regulation of potassium ion transmembrane transport (GO:1901379),3/54,0.11862429100056149,0.23444903691432953,0,0,2.595688048975246,5.53347220577743,GNG2;BIN1;CAV1
striated muscle contraction (GO:0006941),3/54,0.11862429100056149,0.23444903691432953,0,0,2.595688048975246,5.53347220577743,TNNI2;DMD;ALDOA
neutrophil degranulation (GO:0043312),15/481,0.12001311552112479,0.23444903691432953,0,0,1.4289599760455136,3.0296155608100053,RAB3A;CR1;ANXA3;PLAUR;PLD1;C3;PTPRB;DSN1;CXCR2;PECAM1;SIRPA;CTSG;PRTN3;CD36;ALDOA
positive regulation of cell projection organization (GO:0031346),5/117,0.12020659124387982,0.23444903691432953,0,0,1.9727069805194806,4.179265398582397,RET;NGFR;MDK;PRKD1;CAMK1
cellular response to cadmium ion (GO:0071276),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,JUN;FOS
cellular response to unfolded protein (GO:0034620),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,PRKN;BAK1
dendritic spine organization (GO:0097061),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,CTNND2;PAK3
entrainment of circadian clock by photoperiod (GO:0043153),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,PER2;PPP1CA
negative regulation of protein polymerization (GO:0032272),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,CDH5;STMN1
positive regulation of calcium ion transmembrane transport (GO:1904427),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,CXCL10;CAPN3
positive regulation of cellular component movement (GO:0051272),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,CCL21;CCL19
positive regulation of muscle cell differentiation (GO:0051149),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,MEF2C;CAMK1
protein export from nucleus (GO:0006611),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,EGR2;CALR
regulation of toll-like receptor signaling pathway (GO:0034121),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,IRF7;CD36
regulation of transcription regulatory region DNA binding (GO:2000677),2/27,0.12054293253427602,0.23444903691432953,0,0,3.52686230248307,7.46195645795547,PER2;GATA3
regulation of cellular response to stress (GO:0080135),5/118,0.12338360420045534,0.23444903691432953,0,0,1.9551488334674176,4.091064947549961,PRKN;MAPKAPK2;FKBP4;CRYAB;ATF3
interstrand cross-link repair (GO:0036297),3/55,0.12351467656145033,0.23444903691432953,0,0,2.545640445527323,5.323940441425664,RAD51;FANCD2;FANCA
negative regulation of cytokine-mediated signaling pathway (GO:0001960),3/55,0.12351467656145033,0.23444903691432953,0,0,2.545640445527323,5.323940441425664,SIGIRR;IL6;PPARG
regulation of cardiac conduction (GO:1903779),3/55,0.12351467656145033,0.23444903691432953,0,0,2.545640445527323,5.323940441425664,FXYD6;NKX2-5;AGT
negative regulation of protein phosphorylation (GO:0001933),6/152,0.1241159873899182,0.23444903691432953,0,0,1.816925141198864,3.7910847463877837,PRKN;CAV1;SIRPA;SPRY2;CIB1;DMD
regulation of Ras protein signal transduction (GO:0046578),4/86,0.12507869207166986,0.23444903691432953,0,0,2.1539737846358054,4.477706988833952,EPS8;SH3BP1;SPRY2;IRS2
transport across blood-brain barrier (GO:0150104),4/86,0.12507869207166986,0.23444903691432953,0,0,2.1539737846358054,4.477706988833952,LRP1;LEPR;SLC2A4;CD36
neutrophil activation involved in immune response (GO:0002283),15/485,0.12600789884534144,0.23444903691432953,0,0,1.4165017318159328,2.934156822245878,RAB3A;CR1;ANXA3;PLAUR;PLD1;C3;PTPRB;DSN1;CXCR2;PECAM1;SIRPA;CTSG;PRTN3;CD36;ALDOA
activation of transmembrane receptor protein tyrosine kinase activity (GO:0007171),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,ADRB2
amylin receptor signaling pathway (GO:0097647),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,RAMP1
"anterior/posterior axis specification, embryo (GO:0008595)",1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,TDGF1
cardiac ventricle formation (GO:0003211),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MEF2C
cellular hyperosmotic response (GO:0071474),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,AQP1
cellular response to bacterial lipopeptide (GO:0071221),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CD36
cellular response to cold (GO:0070417),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,FOXO1
cellular response to granulocyte macrophage colony-stimulating factor stimulus (GO:0097011),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,ZFP36
cellular water homeostasis (GO:0009992),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,AQP1
centromeric sister chromatid cohesion (GO:0070601),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,BUB1
cholesterol import (GO:0070508),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CD36
chondrocyte development (GO:0002063),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,BMPR1B
chromatin organization involved in negative regulation of transcription (GO:0097549),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,HMGA2
contact inhibition (GO:0060242),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,YAP1
determination of liver left/right asymmetry (GO:0071910),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PKD2
ear development (GO:0043583),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,GATA3
embryonic camera-type eye morphogenesis (GO:0048596),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,SIX3
embryonic skeletal joint development (GO:0072498),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,COL2A1
free ubiquitin chain polymerization (GO:0010994),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
glandular epithelial cell differentiation (GO:0002067),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,BMP2
glomerular epithelial cell differentiation (GO:0072311),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,WT1
histone-serine phosphorylation (GO:0035404),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,HMGA2
imitative learning (GO:0098596),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CNTNAP2
inclusion body assembly (GO:0070841),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
ISG15-protein conjugation (GO:0032020),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,UBE2L6
leukocyte chemotaxis involved in inflammatory response (GO:0002232),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MDK
maintenance of DNA repeat elements (GO:0043570),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,TCF7L2
megakaryocyte development (GO:0035855),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,KIT
metanephric collecting duct development (GO:0072205),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PAX2
mitotic DNA replication initiation (GO:1902975),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MCM4
negative regulation of actin filament depolymerization (GO:0030835),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,VIL1
negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis (GO:1903588),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,NGFR
negative regulation of cardiac muscle cell differentiation (GO:2000726),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,BMP2
negative regulation of erythrocyte differentiation (GO:0045647),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,ZFP36
negative regulation of fibroblast migration (GO:0010764),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,FGF2
negative regulation of histone H3-K9 methylation (GO:0051573),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,BRCA1
negative regulation of lens fiber cell differentiation (GO:1902747),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,SPRY2
negative regulation of meiotic cell cycle (GO:0051447),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,DUSP1
negative regulation of monocyte chemotaxis (GO:0090027),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,DUSP1
negative regulation of myeloid cell apoptotic process (GO:0033033),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,IRF7
negative regulation of neuron migration (GO:2001223),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,COL3A1
negative regulation of serine-type peptidase activity (GO:1902572),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CR1
nephron tubule development (GO:0072080),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MEF2C
neuroblast proliferation (GO:0007405),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,RACGAP1
norepinephrine biosynthetic process (GO:0042421),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,GATA3
nuclear cell cycle DNA replication initiation (GO:1902315),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MCM4
peptide antigen assembly with MHC protein complex (GO:0002501),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CALR
peroxisome proliferator activated receptor signaling pathway (GO:0035357),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PPARG
positive regulation of autophagosome maturation (GO:1901098),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,ADRB2
positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization (GO:1904925),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
positive regulation of cell-cell adhesion mediated by integrin (GO:0033634),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,SKAP1
positive regulation of centriole replication (GO:0046601),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PLK4
positive regulation of cholesterol metabolic process (GO:0090205),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,FGF1
positive regulation of cholesterol storage (GO:0010886),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,APOB
positive regulation of deacetylase activity (GO:0090045),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKD1
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway (GO:1902237),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PMAIP1
positive regulation of epithelial cell differentiation involved in kidney development (GO:2000698),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PAX2
positive regulation of gluconeogenesis (GO:0045722),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PPARGC1A
positive regulation of gonad development (GO:1905941),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,WT1
positive regulation of hemoglobin biosynthetic process (GO:0046985),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,KLF4
positive regulation of male gonad development (GO:2000020),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,WT1
positive regulation of natural killer cell mediated cytotoxicity directed against tumor cell target (GO:0002860),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,NECTIN2
positive regulation of natural killer cell mediated immune response to tumor cell (GO:0002857),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,NECTIN2
positive regulation of osteoblast proliferation (GO:0033690),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,BMP2
positive regulation of protein glycosylation (GO:0060050),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,RAMP1
positive regulation of receptor binding (GO:1900122),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,NRP1
positive regulation of T-helper 2 cell differentiation (GO:0045630),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,IL18
positive regulation of tau-protein kinase activity (GO:1902949),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,EGR1
positive regulation of toll-like receptor 3 signaling pathway (GO:0034141),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CAV1
presynaptic active zone organization (GO:1990709),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,RAB3A
pronephros development (GO:0048793),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PAX2
protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:0001844),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PMAIP1
protein K27-linked ubiquitination (GO:0044314),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
protein K29-linked ubiquitination (GO:0035519),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
protein localization to ciliary transition zone (GO:1904491),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MAPK15
regulation of blood vessel remodeling (GO:0060312),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,FLT4
regulation of cardiac muscle hypertrophy in response to stress (GO:1903242),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,FOXO1
regulation of digestive system process (GO:0044058),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,SGK1
regulation of DNA-dependent DNA replication initiation (GO:0030174),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CDT1
regulation of extracellular exosome assembly (GO:1903551),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,SDC1
regulation of glucokinase activity (GO:0033131),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
regulation of hepatocyte proliferation (GO:2000345),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MDK
regulation of hormone biosynthetic process (GO:0046885),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,EGR1
regulation of immunoglobulin mediated immune response (GO:0002889),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,NECTIN2
regulation of interleukin-1-mediated signaling pathway (GO:2000659),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,IL6
regulation of keratinocyte apoptotic process (GO:1902172),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,ZFP36
regulation of long-chain fatty acid import across plasma membrane (GO:0010746),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,IRS2
regulation of macromolecule biosynthetic process (GO:0010556),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MITF
regulation of mitotic sister chromatid segregation (GO:0033047),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,DUSP1
regulation of mitotic spindle checkpoint (GO:1903504),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,DUSP1
regulation of neutrophil extravasation (GO:2000389),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MDK
regulation of peptidyl-cysteine S-nitrosylation (GO:2000169),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,DMD
regulation of protein depolymerization (GO:1901879),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,SH3BP1
regulation of protein targeting (GO:1903533),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
"regulation of retrograde transport, endosome to Golgi (GO:1905279)",1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
regulation of saliva secretion (GO:0046877),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,AQP1
regulation of sarcomere organization (GO:0060297),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PROX1
regulation of serine-type endopeptidase activity (GO:1900003),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CR1
renal filtration cell differentiation (GO:0061318),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,WT1
response to catecholamine (GO:0071869),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,GNG2
response to gonadotropin (GO:0034698),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,WT1
response to granulocyte macrophage colony-stimulating factor (GO:0097012),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,ZFP36
response to heparin (GO:0071503),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,EGR1
response to manganese ion (GO:0010042),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PRKN
response to peptidoglycan (GO:0032494),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,IL6
retinal ganglion cell axon guidance (GO:0031290),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,NRP1
signal complex assembly (GO:0007172),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,MAPK8IP2
spinal cord dorsal/ventral patterning (GO:0021513),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,ASCL1
sterol import (GO:0035376),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CD36
T-helper 17 cell lineage commitment (GO:0072540),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,IL6
T-tubule organization (GO:0033292),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,BIN1
tripartite regional subdivision (GO:0007351),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,TDGF1
venous blood vessel morphogenesis (GO:0048845),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,PROX1
vocal learning (GO:0042297),1/6,0.1263052910137057,0.23444903691432953,0,0,8.806306306306306,18.22071763529804,CNTNAP2
internal peptidyl-lysine acetylation (GO:0018393),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,MRGBP;RUVBL1
negative regulation of oxidative stress-induced cell death (GO:1903202),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,PRKN;GATA4
photoperiodism (GO:0009648),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,PER2;PPP1CA
regulation of microtubule polymerization or depolymerization (GO:0031110),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,STMN1;FKBP4
regulation of multicellular organismal development (GO:2000026),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,RACGAP1;GATA3
regulation of neuron migration (GO:2001222),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,COL3A1;MDK
regulation of protein transport (GO:0051223),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,DNAJC1;SAA1
regulation of reactive oxygen species biosynthetic process (GO:1903426),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,CD36;PPARA
regulation of small molecule metabolic process (GO:0062012),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,PRKN;PPARA
regulation of sodium ion transmembrane transport (GO:1902305),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,FXYD6;UTRN
response to interferon-beta (GO:0035456),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,STAT1;IKBKE
sarcomere organization (GO:0045214),2/28,0.1279895717760244,0.2360327167817593,0,0,3.3910401111304047,6.971322264518416,KRT19;CAPN3
"DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest (GO:0006977)",3/56,0.12847714001658603,0.23667572604136497,0,0,2.4974814308887563,5.124842608321952,MUC1;E2F1;AURKA
positive regulation of establishment of protein localization to mitochondrion (GO:1903749),3/56,0.12847714001658603,0.23667572604136497,0,0,2.4974814308887563,5.124842608321952,E2F1;PMAIP1;GZMB
metal ion transport (GO:0030001),4/88,0.13287461053952315,0.24451224228871216,0,0,2.1024727351257964,4.243524527433569,CATSPER1;CAV1;PKD2;RAMP1
sensory perception of mechanical stimulus (GO:0050954),4/88,0.13287461053952315,0.24451224228871216,0,0,2.1024727351257964,4.243524527433569,COL1A1;CLIC5;COL2A1;PAX3
protein homooligomerization (GO:0051260),5/121,0.13314485277597776,0.24487731152754033,0,0,1.9042907523510972,3.8396550067156645,BLM;TK1;ECT2;PKD2;ALDOA
icosanoid metabolic process (GO:0006690),3/57,0.13350934698141187,0.2451507836813856,0,0,2.451106083459025,4.935507474161364,MAPKAPK2;PLA2G4A;PTGS2
negative regulation of DNA recombination (GO:0045910),3/57,0.13350934698141187,0.2451507836813856,0,0,2.451106083459025,4.935507474161364,BLM;H4-16;POLR2H
"positive regulation of gene expression, epigenetic (GO:0045815)",3/57,0.13350934698141187,0.2451507836813856,0,0,2.451106083459025,4.935507474161364,CHEK1;HMGA1;POLR2H
actin filament polymerization (GO:0030041),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,VIL1;FAM107A
aggrephagy (GO:0035973),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,PRKN;VIM
determination of bilateral symmetry (GO:0009855),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,PKD2;TDGF1
establishment of endothelial barrier (GO:0061028),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,PECAM1;EZR
glycolytic process (GO:0006096),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,ENO2;ALDOA
limb development (GO:0060173),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,BMPR1B;PCSK5
negative regulation of epithelial to mesenchymal transition (GO:0010719),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,SPRY2;GATA3
negative regulation of interferon-gamma production (GO:0032689),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,CR1;INHBA
negative regulation of transferase activity (GO:0051348),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,ZFP36;IRS2
positive regulation of dephosphorylation (GO:0035306),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,CDH5;BMP2
positive regulation of leukocyte migration (GO:0002687),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,IL6;MDK
positive regulation of viral genome replication (GO:0045070),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,NR5A2;PPARA
regulation of neuronal synaptic plasticity (GO:0048168),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,RAB3A;SYP
regulation of protein targeting to membrane (GO:0090313),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,ERBB2;CIB1
response to cadmium ion (GO:0046686),2/29,0.13554072101355852,0.24529320359389964,0,0,3.2652788228408998,6.525604739255504,JUN;FOS
regulation of mRNA catabolic process (GO:0061013),5/122,0.13647365964318597,0.24529320359389964,0,0,1.887917637917638,3.7600214218849706,ZFP36;EXOSC4;MAPKAPK2;PRKCA;VIM
regulation of type I interferon production (GO:0032479),4/89,0.13684581824444797,0.24529320359389964,0,0,2.0776310524209682,4.132201233668855,IRF7;UBE2L6;POLR2H;IKBKE
negative regulation of neuron projection development (GO:0010977),3/58,0.13860895824657857,0.24529320359389964,0,0,2.406417112299465,4.755317391580695,NGFR;CIB1;FKBP4
nucleosome assembly (GO:0006334),3/58,0.13860895824657857,0.24529320359389964,0,0,2.406417112299465,4.755317391580695,H2AX;CHAF1A;H4-16
regulation of calcium ion transport (GO:0051924),3/58,0.13860895824657857,0.24529320359389964,0,0,2.406417112299465,4.755317391580695,HOMER3;PKD2;MYLK
CENP-A containing chromatin organization (GO:0061641),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,RUVBL1;H4-16
CENP-A containing nucleosome assembly (GO:0034080),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,RUVBL1;H4-16
negative regulation of cytoskeleton organization (GO:0051494),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,PRKN;FKBP4
"negative regulation of gene expression, epigenetic (GO:0045814)",2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,H4-16;EZH2
phosphatidylcholine acyl-chain remodeling (GO:0036151),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,PLA2G2A;PLA2G4A
plasma membrane invagination (GO:0099024),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,SH3BP1;CD36
positive regulation of endopeptidase activity (GO:0010950),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,EFNA3;CR1
regulation of long-term synaptic potentiation (GO:1900271),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,FAM107A;AKAP5
regulation of protein localization to membrane (GO:1905475),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,PRKN;MMP14
regulation of striated muscle contraction (GO:0006942),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,DMD;NKX2-5
synaptic vesicle cycle (GO:0099504),2/30,0.14318807157655317,0.24529320359389964,0,0,3.1485004837149306,6.11941397561654,RAB3A;SYT7
negative regulation of autophagy (GO:0010507),3/59,0.1437736327560125,0.24529320359389964,0,0,2.3633241758241756,4.58370318762061,HGF;LEPR;MET
protein polymerization (GO:0051258),3/59,0.1437736327560125,0.24529320359389964,0,0,2.3633241758241756,4.58370318762061,PRKN;VIL1;FAM107A
selective autophagy (GO:0061912),3/59,0.1437736327560125,0.24529320359389964,0,0,2.3633241758241756,4.58370318762061,PRKN;KLHL3;VIM
regulation of stem cell differentiation (GO:2000736),4/91,0.14492973922078287,0.24529320359389964,0,0,2.029660906508197,3.9203026473379814,YAP1;TAL1;LMO2;GATA3
adenylate cyclase-activating dopamine receptor signaling pathway (GO:0007191),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,GNG2
ammonium transport (GO:0015696),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AQP1
angiotensin-activated signaling pathway (GO:0038166),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CAV1
atrioventricular valve formation (GO:0003190),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,GATA4
axon ensheathment in central nervous system (GO:0032291),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,SOX10
bleb assembly (GO:0032060),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MYLK
calcitonin family receptor signaling pathway (GO:0097646),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,RAMP1
cardiolipin acyl-chain remodeling (GO:0035965),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PLA2G4A
catecholamine uptake (GO:0090493),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MAPK15
Cdc42 protein signal transduction (GO:0032488),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,RHOJ
cellular amino acid biosynthetic process (GO:0008652),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,GAD1
cellular hypotonic response (GO:0071476),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MYLK
cellular response to gonadotropin stimulus (GO:0071371),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,WT1
cellular response to interleukin-18 (GO:0071351),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,IL18
cellular response to laminar fluid shear stress (GO:0071499),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,KLF4
cellular response to monoamine stimulus (GO:0071868),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,GNG2
cellular response to prostaglandin E stimulus (GO:0071380),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,GNG2
chylomicron remnant clearance (GO:0034382),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,APOB
collagen-activated tyrosine kinase receptor signaling pathway (GO:0038063),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,COL1A1
deadenylation-dependent decapping of nuclear-transcribed mRNA (GO:0000290),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,LSM1
death-inducing signaling complex assembly (GO:0071550),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FADD
definitive hemopoiesis (GO:0060216),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,TEK
dendrite arborization (GO:0140059),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,NRP1
desmosome organization (GO:0002934),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PRKCA
detection of molecule of bacterial origin (GO:0032490),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,C4B
dopamine transport (GO:0015872),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MAPK15
endothelial cell morphogenesis (GO:0001886),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MET
flavin-containing compound metabolic process (GO:0042726),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FLAD1
G-quadruplex DNA unwinding (GO:0044806),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,BLM
gas homeostasis (GO:0033483),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CAV1
gland morphogenesis (GO:0022612),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,EZR
glial cell migration (GO:0008347),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CCL2
glomerular epithelial cell development (GO:0072310),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,NPHS1
glomerular visceral epithelial cell development (GO:0072015),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,NPHS1
glycerol transport (GO:0015793),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AQP1
heart trabecula formation (GO:0060347),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,TEK
hyperosmotic response (GO:0006972),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AQP1
hypotonic response (GO:0006971),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MYLK
insulin secretion involved in cellular response to glucose stimulus (GO:0035773),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PTPRN
interleukin-18-mediated signaling pathway (GO:0035655),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,IL18
intermediate filament bundle assembly (GO:0045110),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,NEFH
macropinocytosis (GO:0044351),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MAPKAPK2
maintenance of protein location in extracellular region (GO:0071694),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FBN2
maintenance of synapse structure (GO:0099558),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,RAB3A
mitochondrial DNA metabolic process (GO:0032042),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PARP1
modulation by symbiont of host apoptotic process (GO:0052150),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CTSG
monoacylglycerol biosynthetic process (GO:0006640),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PLA2G4A
negative regulation by host of viral genome replication (GO:0044828),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PRKN
negative regulation of cardiocyte differentiation (GO:1905208),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,BMP2
negative regulation of centriole replication (GO:0046600),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,BRCA1
negative regulation of double-strand break repair via nonhomologous end joining (GO:2001033),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,HMGA2
negative regulation of interferon-gamma-mediated signaling pathway (GO:0060336),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PPARG
negative regulation of intracellular transport (GO:0032387),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CRYAB
negative regulation of lymphocyte differentiation (GO:0045620),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,INHBA
negative regulation of membrane protein ectodomain proteolysis (GO:0051045),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,TIMP1
negative regulation of neurotransmitter secretion (GO:0046929),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PRKN
negative regulation of protein sumoylation (GO:0033234),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CAPN3
negative regulation of response to interferon-gamma (GO:0060331),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PPARG
negative regulation of ruffle assembly (GO:1900028),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,EVL
negative regulation of steroid metabolic process (GO:0045939),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,BMP2
negative regulation of stress-activated protein kinase signaling cascade (GO:0070303),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FOXO1
negative regulation of T cell apoptotic process (GO:0070233),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FADD
negative regulation of type 2 immune response (GO:0002829),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,ANXA1
nodal signaling pathway (GO:0038092),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,TDGF1
noradrenergic neuron differentiation (GO:0003357),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,ASCL1
norepinephrine metabolic process (GO:0042415),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,GATA3
nose development (GO:0043584),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PROX1
"nuclear-transcribed mRNA catabolic process, deadenylation-independent decay (GO:0031086)",1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,ZFP36
nucleobase catabolic process (GO:0046113),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,DPYSL2
peptide transport (GO:0015833),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,TAP1
pituitary gland development (GO:0021983),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,SIX3
polyadenylation-dependent snoRNA 3'-end processing (GO:0071051),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,EXOSC4
positive regulation of activation of Janus kinase activity (GO:0010536),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AGT
positive regulation of adenylate cyclase activity (GO:0045762),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AKAP5
positive regulation of amyloid-beta clearance (GO:1900223),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,LRP1
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic process (GO:1902961),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,EFNA3
positive regulation of blood circulation (GO:1903524),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,NKX2-5
positive regulation of cardiac epithelial to mesenchymal transition (GO:0062043),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,TGFBR2
positive regulation of cardiac muscle cell differentiation (GO:2000727),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MEF2C
positive regulation of ER-associated ubiquitin-dependent protein catabolic process (GO:1903071),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CAV1
positive regulation of gliogenesis (GO:0014015),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,IL6
positive regulation of interleukin-5 production (GO:0032754),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,GATA3
positive regulation of intracellular estrogen receptor signaling pathway (GO:0033148),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,YAP1
positive regulation of IRE1-mediated unfolded protein response (GO:1903896),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,BAK1
positive regulation of lamellipodium morphogenesis (GO:2000394),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,VIL1
positive regulation of lipopolysaccharide-mediated signaling pathway (GO:0031666),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PRKCA
positive regulation of mast cell activation (GO:0033005),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,NECTIN2
positive regulation of mitophagy in response to mitochondrial depolarization (GO:0098779),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PRKN
positive regulation of NK T cell activation (GO:0051135),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,IL18
positive regulation of RNA polymerase II transcription preinitiation complex assembly (GO:0045899),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,ESR1
positive regulation of striated muscle contraction (GO:0045989),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,ADRA1A
positive regulation of synaptic plasticity (GO:0031915),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CDC20
"positive regulation of synaptic transmission, GABAergic (GO:0032230)",1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,ADRA1A
positive regulation of type I interferon-mediated signaling pathway (GO:0060340),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FADD
positive regulation of vascular associated smooth muscle cell differentiation (GO:1905065),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,KIT
positive regulation of vesicle fusion (GO:0031340),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,ANXA1
protein localization to basolateral plasma membrane (GO:1903361),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CAV1
regulation by virus of viral protein levels in host cell (GO:0046719),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,STAT1
regulation of aldosterone biosynthetic process (GO:0032347),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,BMP2
regulation of bile acid metabolic process (GO:1904251),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FGFR4
regulation of chromatin assembly or disassembly (GO:0001672),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,TAL1
regulation of cortisol biosynthetic process (GO:2000064),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,BMP2
regulation of dopamine metabolic process (GO:0042053),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PRKN
regulation of entry of bacterium into host cell (GO:2000535),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CAV1
regulation of extracellular matrix assembly (GO:1901201),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AGT
regulation of hemoglobin biosynthetic process (GO:0046984),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,KLF4
regulation of histone deacetylase activity (GO:1901725),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PRKD1
regulation of I-kappaB phosphorylation (GO:1903719),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,SIRPA
regulation of ketone biosynthetic process (GO:0010566),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,EGR1
regulation of lysosomal protein catabolic process (GO:1905165),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,LRP1
regulation of male gonad development (GO:2000018),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,WT1
regulation of mesenchymal stem cell differentiation (GO:2000739),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,SOX5
regulation of muscle organ development (GO:0048634),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CENPF
regulation of NAD(P)H oxidase activity (GO:0033860),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AGT
regulation of natural killer cell chemotaxis (GO:2000501),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,CCL2
regulation of natural killer cell mediated cytotoxicity directed against tumor cell target (GO:0002858),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,NECTIN2
regulation of natural killer cell proliferation (GO:0032817),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,IL18
regulation of neurotrophin TRK receptor signaling pathway (GO:0051386),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AGT
regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway (GO:1903376),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PRKN
regulation of skeletal muscle satellite cell proliferation (GO:0014842),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FGF2
regulation of systemic arterial blood pressure by renin-angiotensin (GO:0003081),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,AGT
regulation of T cell tolerance induction (GO:0002664),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,TGFBR2
regulation of vascular associated smooth muscle cell apoptotic process (GO:1905459),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PPARG
regulation of vascular associated smooth muscle cell differentiation (GO:1905063),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,KIT
response to lead ion (GO:0010288),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PPP1CA
riboflavin metabolic process (GO:0006771),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FLAD1
smooth muscle cell migration (GO:0014909),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PARVA
"substrate-dependent cell migration, cell extension (GO:0006930)",1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,NRP1
synaptic vesicle budding from presynaptic endocytic zone membrane (GO:0016185),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,MX1
T-helper 17 cell differentiation (GO:0072539),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,IL6
tachykinin receptor signaling pathway (GO:0007217),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,GRK5
TRAIL-activated apoptotic signaling pathway (GO:0036462),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,FADD
ureter development (GO:0072189),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,PAX2
vascular wound healing (GO:0061042),1/7,0.14575080319179776,0.24529320359389964,0,0,7.338213213213213,14.132348866004438,KDR
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193),3/60,0.14900103034940734,0.2503922640191224,0,0,2.3217432722076685,4.420139619692783,AKAP12;AKAP5;ADCY5
cellular protein catabolic process (GO:0044257),3/60,0.14900103034940734,0.2503922640191224,0,0,2.3217432722076685,4.420139619692783,PRKN;SIAH2;GZMB
homophilic cell adhesion via plasma membrane adhesion molecules (GO:0007156),3/60,0.14900103034940734,0.2503922640191224,0,0,2.3217432722076685,4.420139619692783,PECAM1;NECTIN3;NECTIN2
negative regulation of growth (GO:0045926),5/126,0.15015006045378815,0.25207458424951235,0,0,1.8251314800901577,3.460668451562023,CDKN2C;CDKN2A;WT1;INHBA;FGFR3
phosphatidylinositol biosynthetic process (GO:0006661),5/126,0.15015006045378815,0.25207458424951235,0,0,1.8251314800901577,3.460668451562023,SOCS3;CISH;ITPKA;BMX;FGF2
activation of protein kinase B activity (GO:0032148),2/31,0.150923631180985,0.25262658893162915,0,0,3.0397758231493732,5.748159310333402,IL18;FGF1
negative regulation of peptidyl-tyrosine phosphorylation (GO:0050732),2/31,0.150923631180985,0.25262658893162915,0,0,3.0397758231493732,5.748159310333402,SOCS3;CAV1
positive regulation of locomotion (GO:0040017),2/31,0.150923631180985,0.25262658893162915,0,0,3.0397758231493732,5.748159310333402,CCL21;CCL19
positive regulation of Rho protein signal transduction (GO:0035025),2/31,0.150923631180985,0.25262658893162915,0,0,3.0397758231493732,5.748159310333402,COL3A1;F2RL2
prostaglandin metabolic process (GO:0006693),2/31,0.150923631180985,0.25262658893162915,0,0,3.0397758231493732,5.748159310333402,PLA2G4A;PTGS2
regulation of calcium ion-dependent exocytosis (GO:0017158),2/31,0.150923631180985,0.25262658893162915,0,0,3.0397758231493732,5.748159310333402,SYT9;SYT7
visual perception (GO:0007601),4/93,0.15319552642948006,0.2563035611544762,0,0,1.983846722209483,3.721776247040356,COL1A1;COL2A1;SIX3;PAX2
regulation of endocytosis (GO:0030100),3/61,0.15428881449989185,0.25800602542474554,0,0,2.2815961928537996,4.2641413233764816,LRP1;PRKD1;CCL19
plasma membrane bounded cell projection organization (GO:0120036),5/128,0.15719719363242848,0.26068585506996705,0,0,1.7952697708795269,3.321705525903267,CNTNAP2;IL6;CCL21;STMN1;PKD2
activation of phospholipase C activity (GO:0007202),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,ADRA1A;SELE
cellular response to glucose stimulus (GO:0071333),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,PTPRN;PAX2
cellular response to topologically incorrect protein (GO:0035967),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,PRKN;BAK1
chromatin remodeling at centromere (GO:0031055),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,RUVBL1;H4-16
ERBB2 signaling pathway (GO:0038128),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,ERBB2;PRKCA
membrane depolarization (GO:0051899),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,CAV1;SCN4A
mitochondrial membrane organization (GO:0007006),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,PMAIP1;BAK1
negative regulation of cell-matrix adhesion (GO:0001953),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,CDKN2A;FAM107A
negative regulation of intracellular steroid hormone receptor signaling pathway (GO:0033144),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,BRCA1;CALR
positive regulation of glucose transmembrane transport (GO:0010828),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,C3;IRS2
positive regulation of receptor signaling pathway via STAT (GO:1904894),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,IL6;KIT
positive regulation of telomere maintenance (GO:0032206),2/32,0.1587397142035675,0.26068585506996705,0,0,2.9382994732881866,5.407909139588904,NEK2;MAPK15
ciliary basal body-plasma membrane docking (GO:0097711),4/95,0.16163485357103513,0.26068585506996705,0,0,1.9400463482096135,3.5355704932313246,PLK4;PRKAR2B;NEK2;TUBG1
regulation of cell cycle phase transition (GO:1901987),4/95,0.16163485357103513,0.26068585506996705,0,0,1.9400463482096135,3.5355704932313246,CDC20;DBF4;SIX3;MAD2L1
sensory perception of light stimulus (GO:0050953),4/95,0.16163485357103513,0.26068585506996705,0,0,1.9400463482096135,3.5355704932313246,COL1A1;COL2A1;SIX3;PAX2
alpha-beta T cell activation (GO:0046631),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,ANXA1
anterograde axonal protein transport (GO:0099641),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,DLG2
antigen processing and presentation of endogenous peptide antigen via MHC class I (GO:0019885),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,TAP1
axo-dendritic protein transport (GO:0099640),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,DLG2
box C/D snoRNP assembly (GO:0000492),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,RUVBL1
brown fat cell differentiation (GO:0050873),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PPARGC1A
cell-cell adhesion mediated by cadherin (GO:0044331),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CDH5
cellular response to interferon-alpha (GO:0035457),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,GATA3
cellular response to potassium ion (GO:0035865),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,DLG2
chromatin silencing at telomere (GO:0006348),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,EZH2
collecting duct development (GO:0072044),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PAX2
commissural neuron axon guidance (GO:0071679),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,NRP1
coronary vasculature morphogenesis (GO:0060977),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,NRP1
DNA damage induced protein phosphorylation (GO:0006975),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CHEK1
dopamine uptake (GO:0090494),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,MAPK15
dynamin family protein polymerization involved in membrane fission (GO:0003373),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,MX1
dynamin family protein polymerization involved in mitochondrial fission (GO:0003374),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,MX1
entry of bacterium into host cell (GO:0035635),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,MET
forebrain neuron differentiation (GO:0021879),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,INHBA
fructose metabolic process (GO:0006000),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,ALDOA
integrin activation (GO:0033622),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CXCL12
lens fiber cell development (GO:0070307),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PROX1
lens fiber cell differentiation (GO:0070306),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,SIX3
lipid import into cell (GO:0140354),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CD36
lymphatic endothelial cell differentiation (GO:0060836),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PROX1
macromolecule modification (GO:0043412),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PARP1
mast cell activation involved in immune response (GO:0002279),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,KIT
mast cell degranulation (GO:0043303),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,KIT
meiotic sister chromatid cohesion (GO:0051177),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,BUB1
mitophagy (GO:0000423),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PRKN
multi-ciliated epithelial cell differentiation (GO:1903251),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PLK4
myeloid leukocyte mediated immunity (GO:0002444),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,IL6
negative regulation by symbiont of host apoptotic process (GO:0033668),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CTSG
negative regulation by symbiont of host programmed cell death (GO:0052041),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CTSG
negative regulation of appetite (GO:0032099),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PPARA
negative regulation of B cell apoptotic process (GO:0002903),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,IRS2
negative regulation of cAMP-dependent protein kinase activity (GO:2000480),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PRKAR2B
"negative regulation of complement activation, classical pathway (GO:0045959)",1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CR1
negative regulation of long-term synaptic potentiation (GO:1900272),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,FAM107A
negative regulation of mitochondrial fusion (GO:0010637),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PRKN
negative regulation of mitochondrial membrane potential (GO:0010917),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PMAIP1
negative regulation of mitotic nuclear division (GO:0045839),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CHEK1
negative regulation of phospholipase activity (GO:0010519),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,ANXA1
neuron fate specification (GO:0048665),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,ASCL1
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity (GO:1990264),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PTPRB
platelet activating factor metabolic process (GO:0046469),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PLA2G4A
positive regulation of aspartic-type peptidase activity (GO:1905247),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,EFNA3
positive regulation of dendritic cell cytokine production (GO:0002732),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,KIT
positive regulation of early endosome to late endosome transport (GO:2000643),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,EZR
positive regulation of endocytic recycling (GO:2001137),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,AKAP5
positive regulation of extracellular matrix disassembly (GO:0090091),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,IL6
positive regulation of intracellular steroid hormone receptor signaling pathway (GO:0033145),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,YAP1
positive regulation of membrane invagination (GO:1905155),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,C3
positive regulation of myotube differentiation (GO:0010831),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,MMP14
positive regulation of protein localization to early endosome (GO:1902966),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,EZR
positive regulation of protein localization to endosome (GO:1905668),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,EZR
positive regulation of T-helper 2 cell cytokine production (GO:2000553),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,IL6
pre-replicative complex assembly involved in nuclear cell cycle DNA replication (GO:0006267),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,MCM4
progesterone receptor signaling pathway (GO:0050847),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,YAP1
protein localization to presynapse (GO:1905383),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,DLG2
proximal/distal pattern formation (GO:0009954),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,SIX3
pyrimidine nucleobase catabolic process (GO:0006208),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,DPYSL2
regulation of activation of Janus kinase activity (GO:0010533),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,AGT
regulation of cardiac muscle cell action potential involved in regulation of contraction (GO:0098909),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CAV1
regulation of Cdc42 protein signal transduction (GO:0032489),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,NRP1
regulation of chaperone-mediated autophagy (GO:1904714),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,GFAP
regulation of chemokine (C-C motif) ligand 5 production (GO:0071649),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,SIRPA
regulation of dendritic cell chemotaxis (GO:2000508),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CALR
regulation of dopamine receptor signaling pathway (GO:0060159),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CAV2
regulation of epithelial to mesenchymal transition involved in endocardial cushion formation (GO:1905005),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,TGFBR2
regulation of establishment of protein localization to mitochondrion (GO:1903747),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PRKN
regulation of extracellular matrix constituent secretion (GO:0003330),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,BMP2
regulation of intrinsic apoptotic signaling pathway by p53 class mediator (GO:1902253),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PRKN
regulation of microvillus organization (GO:0032530),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PLD1
regulation of MyD88-independent toll-like receptor signaling pathway (GO:0034127),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,IRF7
regulation of myeloid leukocyte differentiation (GO:0002761),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,IRF7
regulation of nitric oxide metabolic process (GO:0080164),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,SIRPA
regulation of pattern recognition receptor signaling pathway (GO:0062207),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CD36
regulation of positive chemotaxis (GO:0050926),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,KDR
regulation of protein glycosylation (GO:0060049),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,RAMP1
regulation of protein localization to early endosome (GO:1902965),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,EZR
regulation of protein localization to nucleolus (GO:1904749),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,TERT
regulation of proton transport (GO:0010155),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,ANTKMT
regulation of response to wounding (GO:1903034),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,VIL1
regulation of RNA biosynthetic process (GO:2001141),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,MITF
regulation of striated muscle tissue development (GO:0016202),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CENPF
regulation of toll-like receptor 3 signaling pathway (GO:0034139),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CAV1
replication fork protection (GO:0048478),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,BLM
response to hydroperoxide (GO:0033194),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PRKD1
response to potassium ion (GO:0035864),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,DLG2
self proteolysis (GO:0097264),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,CAPN3
sequestering of BMP from receptor via BMP binding (GO:0038098),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,BMP2
skeletal muscle tissue regeneration (GO:0043403),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,ANXA1
synaptic vesicle budding (GO:0070142),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,MX1
T-helper cell lineage commitment (GO:0002295),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,IL6
telomeric D-loop disassembly (GO:0061820),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,BLM
U4 snRNA 3'-end processing (GO:0034475),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,EXOSC4
vascular associated smooth muscle contraction (GO:0014829),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,ACTA2
venous blood vessel development (GO:0060841),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,PROX1
water homeostasis (GO:0030104),1/8,0.16476447529950383,0.26068585506996705,0,0,6.289575289575289,11.341602721099976,AQP1
neuropeptide signaling pathway (GO:0007218),3/63,0.16503622903493514,0.2608735939476155,0,0,2.205316742081448,3.97307716114958,OPRD1;PYY;SSTR2
positive regulation of Ras protein signal transduction (GO:0046579),3/63,0.16503622903493514,0.2608735939476155,0,0,2.205316742081448,3.97307716114958,COL3A1;IRS2;F2RL2
antigen processing and presentation of peptide antigen via MHC class I (GO:0002474),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,TAP1;CALR
negative chemotaxis (GO:0050919),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,PDGFA;SEMA3F
negative regulation of smooth muscle cell proliferation (GO:0048662),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,MEF2C;PPARG
neuron projection extension (GO:1990138),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,NRP1;SEMA3F
positive regulation of ATP metabolic process (GO:1903580),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,PPARA;PPARGC1A
positive regulation of histone modification (GO:0031058),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,BRCA1;PPARGC1A
positive regulation of receptor signaling pathway via JAK-STAT (GO:0046427),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,IL6;KIT
regulation of interleukin-17 production (GO:0032660),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,IL6;IL18
signal transduction by p53 class mediator (GO:0072331),2/33,0.16662893190664416,0.2622962586317983,0,0,2.843369984708367,5.095278930811979,BCL3;PMAIP1
diterpenoid metabolic process (GO:0016101),3/64,0.17049122598031557,0.2680046578140754,0,0,2.1690527408945925,3.8372092646823575,LRP1;SDC1;APOB
negative regulation of intrinsic apoptotic signaling pathway (GO:2001243),3/64,0.17049122598031557,0.2680046578140754,0,0,2.1690527408945925,3.8372092646823575,PRKN;CXCL12;PLAUR
regulation of cellular ketone metabolic process (GO:0010565),3/64,0.17049122598031557,0.2680046578140754,0,0,2.1690527408945925,3.8372092646823575,CAV1;PPARA;FGFR4
cellular protein-containing complex assembly (GO:0034622),6/168,0.17251632146836396,0.27106298919510574,0,0,1.6361258753058296,2.8751041671896673,CENPF;NSG2;BIN1;DMD;ADRB2;MAPK8IP2
cardiac muscle contraction (GO:0060048),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,TNNI2;DMD
negative regulation of extrinsic apoptotic signaling pathway via death domain receptors (GO:1902042),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,BRCA1;FADD
negative regulation of mitochondrion organization (GO:0010823),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,PRKN;HGF
phosphatidylinositol 3-kinase signaling (GO:0014065),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,ERBB2;GATA3
phosphatidylserine metabolic process (GO:0006658),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,PLA2G2A;PLA2G4A
positive regulation of epidermal growth factor receptor signaling pathway (GO:0045742),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,PLAUR;AGT
positive regulation of interleukin-12 production (GO:0032735),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,MDK;CCL19
protein destabilization (GO:0031648),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,PRKN;CAPN3
regulation of activated T cell proliferation (GO:0046006),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,IL18;FADD
regulation of myoblast differentiation (GO:0045661),2/34,0.17458418312748852,0.2729536846918315,0,0,2.7543735891647856,4.807341065494308,MEF2C;SOSTDC1
RNA splicing (GO:0008380),4/98,0.1746006551139063,0.2729536846918315,0,0,1.8778404979012882,3.277308421554756,WT1;LSM1;PPARGC1A;LSM4
BMP signaling pathway (GO:0030509),3/65,0.17599734693029842,0.2747590280982396,0,0,2.1339585461976354,3.707297071523708,BMP2;BMPR1B;RUNX2
chemical homeostasis (GO:0048878),3/65,0.17599734693029842,0.2747590280982396,0,0,2.1339585461976354,3.707297071523708,IRS2;PPARG;KLHL3
regulation of cellular catabolic process (GO:0031329),3/65,0.17599734693029842,0.2747590280982396,0,0,2.1339585461976354,3.707297071523708,PRKN;MAPK15;DEPP1
cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742),6/170,0.17905486187771458,0.27747517328843485,0,0,1.6160064448024891,2.779632940594193,CDH5;PECAM1;SELE;NECTIN3;NECTIN2;TGFBR2
cellular response to nutrient levels (GO:0031669),3/66,0.18155230785190155,0.27747517328843485,0,0,2.0999784529196295,3.5830073215850944,FAM107A;PPARA;FOXO1
bicarbonate transport (GO:0015701),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,CA12;AQP1
blood vessel diameter maintenance (GO:0097746),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,PER2;AGT
negative regulation of epithelial cell migration (GO:0010633),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,EVL;DCN
negative regulation of neurogenesis (GO:0050768),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,NGFR;IL6
positive regulation of immunoglobulin production (GO:0002639),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,IL6;TNFRSF4
protein localization to cilium (GO:0061512),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,ZNF423;MAPK15
regulation of blood circulation (GO:1903522),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,PER2;AGT
regulation of lipid biosynthetic process (GO:0046890),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,C3;PPARA
regulation of muscle cell differentiation (GO:0051147),2/35,0.18259864521732516,0.27747517328843485,0,0,2.6707709145632395,4.541551742792535,MEF2C;CAMK1
adult heart development (GO:0007512),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,NKX2-5
astral microtubule organization (GO:0030953),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,EZR
ATF6-mediated unfolded protein response (GO:0036500),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CALR
bone cell development (GO:0098751),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,KIT
cellular response to forskolin (GO:1904322),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,ADCY5
cellular response to leptin stimulus (GO:0044320),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,LEPR
cellular response to muramyl dipeptide (GO:0071225),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,VIM
chylomicron remodeling (GO:0034371),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,APOB
collagen-activated signaling pathway (GO:0038065),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,COL1A1
detection of mechanical stimulus involved in sensory perception of sound (GO:0050910),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,KIT
embryonic digestive tract morphogenesis (GO:0048557),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,SIX2
epithelial cell apoptotic process (GO:1904019),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,SIX3
"fructose 1,6-bisphosphate metabolic process (GO:0030388)",1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,ALDOA
histone phosphorylation (GO:0016572),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CCNA2
intestinal cholesterol absorption (GO:0030299),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CD36
kinetochore assembly (GO:0051382),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CENPF
mast cell mediated immunity (GO:0002448),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,KIT
mesodermal cell differentiation (GO:0048333),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,HMGA2
negative regulation of bone resorption (GO:0045779),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,IL6
negative regulation of lipid localization (GO:1905953),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,IL6
negative regulation of membrane potential (GO:0045837),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,PMAIP1
negative regulation of mRNA 3'-end processing (GO:0031441),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,BARD1
negative regulation of production of molecular mediator of immune response (GO:0002701),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CR1
negative regulation of ubiquitin protein ligase activity (GO:1904667),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,MAD2L1
neuronal ion channel clustering (GO:0045161),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CNTNAP2
nuclear RNA surveillance (GO:0071027),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,EXOSC4
one-carbon compound transport (GO:0019755),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,AQP1
pericardium development (GO:0060039),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,BMP2
positive regulation of autophagy of mitochondrion (GO:1903599),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,PRKN
positive regulation of B cell differentiation (GO:0045579),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,MMP14
positive regulation of cholesterol esterification (GO:0010873),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,AGT
positive regulation of chromatin binding (GO:0035563),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CDT1
positive regulation of DNA-directed DNA polymerase activity (GO:1900264),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,RFC4
positive regulation of ligase activity (GO:0051351),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,ANTKMT
positive regulation of NLRP3 inflammasome complex assembly (GO:1900227),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CD36
"positive regulation of phagocytosis, engulfment (GO:0060100)",1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,C3
positive regulation of protein kinase A signaling (GO:0010739),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,ADRB2
positive regulation of protein polyubiquitination (GO:1902916),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,PRKN
positive regulation of synapse maturation (GO:0090129),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CDC20
positive regulation of tumor necrosis factor-mediated signaling pathway (GO:1903265),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,PRKN
regulation of actin filament organization (GO:0110053),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CXCL12
regulation of cell adhesion molecule production (GO:0060353),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CAV1
regulation of cellular response to oxidative stress (GO:1900407),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,PRKN
"regulation of complement activation, classical pathway (GO:0030450)",1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CR1
regulation of DNA-directed DNA polymerase activity (GO:1900262),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,RFC4
regulation of ER-associated ubiquitin-dependent protein catabolic process (GO:1903069),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CAV1
regulation of glial cell proliferation (GO:0060251),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,IL6
regulation of histone H4 acetylation (GO:0090239),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,MUC1
regulation of pinocytosis (GO:0048548),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CAV1
regulation of skeletal muscle cell differentiation (GO:2001014),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,MEF2C
regulation of smooth muscle cell apoptotic process (GO:0034391),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,CDKN2A
response to forskolin (GO:1904321),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,ADCY5
response to misfolded protein (GO:0051788),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,F12
response to type I interferon (GO:0034340),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,MX1
response to UV-C (GO:0010225),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,BCL3
synapse pruning (GO:0098883),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,C3
T-helper 1 type immune response (GO:0042088),1/9,0.18335587599585554,0.27747517328843485,0,0,5.503096846846847,9.3350481163971,IL18
cell-matrix adhesion (GO:0007160),4/100,0.18343649220036493,0.27747517328843485,0,0,1.8385298563869992,3.117938446720662,COL17A1;VTN;COL3A1;CCL21
regulation of transforming growth factor beta receptor signaling pathway (GO:0017015),4/100,0.18343649220036493,0.27747517328843485,0,0,1.8385298563869992,3.117938446720662,CAV1;SPRY2;PPARA;TGFBR2
positive regulation of catabolic process (GO:0009896),3/67,0.18715384124999648,0.2829726224401012,0,0,2.067060237556561,3.4640298167178143,PRKN;BARD1;FOXO1
intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332),2/36,0.19066576513586098,0.2875172245942541,0,0,2.5920860443500198,4.29569132105993,BCL3;PMAIP1
regulation of cardiac muscle contraction (GO:0055117),2/36,0.19066576513586098,0.2875172245942541,0,0,2.5920860443500198,4.29569132105993,NKX2-5;ADRA1A
regulation of cell cycle G1/S phase transition (GO:1902806),2/36,0.19066576513586098,0.2875172245942541,0,0,2.5920860443500198,4.29569132105993,E2F1;EZH2
regulation of embryonic development (GO:0045995),2/36,0.19066576513586098,0.2875172245942541,0,0,2.5920860443500198,4.29569132105993,RACGAP1;CFL1
telomere maintenance via telomere lengthening (GO:0010833),2/36,0.19066576513586098,0.2875172245942541,0,0,2.5920860443500198,4.29569132105993,RAD51;TERT
"Wnt signaling pathway, calcium modulating pathway (GO:0007223)",2/36,0.19066576513586098,0.2875172245942541,0,0,2.5920860443500198,4.29569132105993,TCF7L2;GNG2
regulation of myeloid cell differentiation (GO:0045637),3/68,0.19279969784791098,0.2906065326252458,0,0,2.0351548903585104,3.3500755147667944,NFE2;MEF2C;H4-16
phosphate-containing compound metabolic process (GO:0006796),7/212,0.19476522297111853,0.2920191782685875,0,0,1.508519879719345,2.4678788319246614,ALK;PTPRB;ITPKA;PLA2G2A;PLA2G4A;ALDOA;PPP1CA
mitochondrion organization (GO:0007005),6/175,0.19582435157215833,0.2920191782685875,0,0,1.5677912415252524,2.5563419207537326,PRKN;TERT;PARP1;CAV2;MX1;PPARGC1A
chromatin remodeling (GO:0006338),4/103,0.19695640301704362,0.2920191782685875,0,0,1.7825419730181635,2.8962258538269627,SATB1;RUVBL1;HMGA2;ESR1
lysosome localization (GO:0032418),2/37,0.1987792509644351,0.2920191782685875,0,0,2.5178974524346986,4.067815318759853,RAB3A;KIT
"nucleotide-excision repair, DNA incision, 5'-to lesion (GO:0006296)",2/37,0.1987792509644351,0.2920191782685875,0,0,2.5178974524346986,4.067815318759853,RFC4;PARP1
positive regulation of exocytosis (GO:0045921),2/37,0.1987792509644351,0.2920191782685875,0,0,2.5178974524346986,4.067815318759853,RAB3A;SDC1
regulation of microtubule cytoskeleton organization (GO:0070507),2/37,0.1987792509644351,0.2920191782685875,0,0,2.5178974524346986,4.067815318759853,STMN1;FAM107A
arachidonate transport (GO:1903963),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,ANXA1
arachidonic acid secretion (GO:0050482),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,ANXA1
B cell homeostasis (GO:0001782),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,MEF2C
cAMP biosynthetic process (GO:0006171),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,ADCY5
cellular response to dopamine (GO:1903351),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,PRKN
cellular response to hydroxyurea (GO:0072711),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,BLM
cellular response to interleukin-4 (GO:0071353),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,GATA3
cellular response to oxidised low-density lipoprotein particle stimulus (GO:0140052),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CD36
cellular response to prostaglandin stimulus (GO:0071379),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,GNG2
chloride ion homeostasis (GO:0055064),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CA12
chylomicron assembly (GO:0034378),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,APOB
cytoplasmic pattern recognition receptor signaling pathway in response to virus (GO:0039528),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,IRF7
defense response to tumor cell (GO:0002357),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,KLF4
"DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator (GO:0006978)",1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,MUC1
dosage compensation (GO:0007549),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,BRCA1
ether lipid biosynthetic process (GO:0008611),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,PLA2G4A
granulocyte activation (GO:0036230),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CXCR2
granulocyte migration (GO:0097530),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,ANXA1
ionotropic glutamate receptor signaling pathway (GO:0035235),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,GRIA2
leptin-mediated signaling pathway (GO:0033210),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,LEPR
long-chain fatty acid import into cell (GO:0044539),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CD36
lung epithelium development (GO:0060428),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,ASCL1
methylguanosine-cap decapping (GO:0110156),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,LSM1
mitotic DNA replication (GO:1902969),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,MCM4
monovalent inorganic anion homeostasis (GO:0055083),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CA12
muscle cell migration (GO:0014812),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,SIX1
myelin maintenance (GO:0043217),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CXCR4
myeloid dendritic cell differentiation (GO:0043011),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,TGFBR2
negative regulation of cell adhesion mediated by integrin (GO:0033629),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,MUC1
negative regulation of circadian rhythm (GO:0042754),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,PER2
negative regulation of glycolytic process (GO:0045820),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,PPARA
negative regulation of heterotypic cell-cell adhesion (GO:0034115),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,KLF4
negative regulation of humoral immune response mediated by circulating immunoglobulin (GO:0002924),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CR1
negative regulation of interferon-beta production (GO:0032688),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,SIRPA
negative regulation of lipopolysaccharide-mediated signaling pathway (GO:0031665),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,SIGIRR
negative regulation of lymphocyte apoptotic process (GO:0070229),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,IRS2
negative regulation of peptidyl-lysine acetylation (GO:2000757),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,BRCA1
negative regulation of protein autophosphorylation (GO:0031953),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CAV1
negative regulation of purine nucleotide metabolic process (GO:1900543),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,PPARA
negative regulation of transcription by competitive promoter binding (GO:0010944),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,MUC1
negative regulation of transcription from RNA polymerase II promoter in response to stress (GO:0097201),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,JUN
negative regulation of transmembrane transport (GO:0034763),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,IRS2
negative regulation of tyrosine phosphorylation of STAT protein (GO:0042532),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,SOCS3
nuclear mRNA surveillance (GO:0071028),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,EXOSC4
"nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5' (GO:0034427)",1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,EXOSC4
phagosome-lysosome fusion (GO:0090385),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,SYT7
phosphate ion homeostasis (GO:0055062),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,FGFR4
phosphatidylcholine catabolic process (GO:0034638),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,PLA2G4A
pinocytosis (GO:0006907),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,MAPKAPK2
positive regulation of behavior (GO:0048520),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,MEF2C
positive regulation of coagulation (GO:0050820),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,F12
positive regulation of establishment of protein localization to telomere (GO:1904851),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,CCT3
positive regulation of hemostasis (GO:1900048),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,F12
positive regulation of keratinocyte migration (GO:0051549),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,FGF7
positive regulation of lipase activity (GO:0060193),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,FGFR3
positive regulation of skeletal muscle tissue development (GO:0048643),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,MEF2C
positive regulation of tissue remodeling (GO:0034105),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,IL18
positive regulation of vascular endothelial growth factor receptor signaling pathway (GO:0030949),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,VTN
positive regulation of vasculogenesis (GO:2001214),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,KDR
production of siRNA involved in RNA interference (GO:0030422),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,TERT
protein localization to endosome (GO:0036010),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,NRP1
protein poly-ADP-ribosylation (GO:0070212),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,PARP1
regulation of axon guidance (GO:1902667),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,NRP1
regulation of cell activation (GO:0050865),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,IL6
regulation of cell-cell adhesion involved in gastrulation (GO:0070587),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,KLF4
regulation of cell-cell adhesion mediated by integrin (GO:0033632),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,SKAP1
regulation of DNA methylation (GO:0044030),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,WT1
regulation of endoplasmic reticulum unfolded protein response (GO:1900101),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,BAK1
regulation of hair cycle (GO:0042634),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,TERT
regulation of mast cell activation (GO:0033003),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,NECTIN2
regulation of neutrophil migration (GO:1902622),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,RHOH
"regulation of phagocytosis, engulfment (GO:0060099)",1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,C3
regulation of protein neddylation (GO:2000434),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,EPAS1
regulation of RNA polymerase II transcription preinitiation complex assembly (GO:0045898),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,ESR1
regulation of store-operated calcium entry (GO:2001256),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,HOMER3
regulation of tau-protein kinase activity (GO:1902947),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,EGR1
regulation of type B pancreatic cell development (GO:2000074),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,FOXO1
response to dopamine (GO:1903350),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,PRKN
response to interleukin-4 (GO:0070670),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,GATA3
response to laminar fluid shear stress (GO:0034616),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,KLF4
small nucleolar ribonucleoprotein complex assembly (GO:0000491),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,RUVBL1
telomeric loop disassembly (GO:0090657),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,BLM
toxin transport (GO:1901998),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,ANTXR2
UV protection (GO:0009650),1/10,0.2015343624670533,0.2920191782685875,0,0,4.891391391391392,7.835008126629427,FEN1
cellular response to light stimulus (GO:0071482),3/70,0.20421548385277843,0.295652663113963,0,0,1.9742013912338758,3.1361759561701654,PARP1;BAK1;AQP1
regulation of plasma membrane bounded cell projection assembly (GO:0120032),3/70,0.20421548385277843,0.295652663113963,0,0,1.9742013912338758,3.1361759561701654,CAV1;PLD1;MAPK15
nucleotide-excision repair (GO:0006289),4/105,0.20613431168134247,0.2983039211082867,0,0,1.7470645023686042,2.75901199927703,RFC4;PARP1;POLR2H;BRCA2
connective tissue development (GO:0061448),2/38,0.20693306352140078,0.29857234567355373,0,0,2.447830448959117,3.856213937754639,COL2A1;SOX5
histone exchange (GO:0043486),2/38,0.20693306352140078,0.29857234567355373,0,0,2.447830448959117,3.856213937754639,RUVBL1;H4-16
lymphocyte proliferation (GO:0046651),2/38,0.20693306352140078,0.29857234567355373,0,0,2.447830448959117,3.856213937754639,MEF2C;TNFRSF4
positive regulation of insulin secretion (GO:0032024),2/38,0.20693306352140078,0.29857234567355373,0,0,2.447830448959117,3.856213937754639,TCF7L2;IRS2
positive regulation of production of molecular mediator of immune response (GO:0002702),2/38,0.20693306352140078,0.29857234567355373,0,0,2.447830448959117,3.856213937754639,IL6;TNFRSF4
regulation of apoptotic signaling pathway (GO:2001233),2/38,0.20693306352140078,0.29857234567355373,0,0,2.447830448959117,3.856213937754639,GATA4;MAPK8IP2
spliceosomal snRNP assembly (GO:0000387),2/38,0.20693306352140078,0.29857234567355373,0,0,2.447830448959117,3.856213937754639,SNRPE;LSM4
protein stabilization (GO:0050821),6/179,0.20964741584735516,0.30220241324566405,0,0,1.5312257232017064,2.392277022993886,CCT3;PRKN;PARVA;CALR;PPARGC1A;CRYAB
cellular response to BMP stimulus (GO:0071773),3/71,0.2099810195321985,0.30220241324566405,0,0,1.945069204152249,3.035743683164393,BMP2;BMPR1B;RUNX2
Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096),3/71,0.2099810195321985,0.30220241324566405,0,0,1.945069204152249,3.035743683164393,CYFIP2;VAV3;VAV2
histone acetylation (GO:0016573),3/71,0.2099810195321985,0.30220241324566405,0,0,1.945069204152249,3.035743683164393,MRGBP;RUVBL1;BRCA2
protein tetramerization (GO:0051262),3/71,0.2099810195321985,0.30220241324566405,0,0,1.945069204152249,3.035743683164393,TK1;PKD2;ALDOA
response to metal ion (GO:0010038),3/71,0.2099810195321985,0.30220241324566405,0,0,1.945069204152249,3.035743683164393,CAV1;CAPN3;PPP1CA
protein localization to nucleus (GO:0034504),4/106,0.21076935723339468,0.30320893602845467,0,0,1.7298474945533768,2.693356698512264,COL1A1;BCL3;SIX1;CALR
DNA replication-independent nucleosome assembly (GO:0006336),2/39,0.21512140826891363,0.3053126480243889,0,0,2.3815508510768106,3.6593784394902977,RUVBL1;H4-16
negative regulation of lymphocyte proliferation (GO:0050672),2/39,0.21512140826891363,0.3053126480243889,0,0,2.3815508510768106,3.6593784394902977,CR1;CTLA4
"nucleotide-excision repair, DNA incision (GO:0033683)",2/39,0.21512140826891363,0.3053126480243889,0,0,2.3815508510768106,3.6593784394902977,RFC4;PARP1
organophosphate biosynthetic process (GO:0090407),2/39,0.21512140826891363,0.3053126480243889,0,0,2.3815508510768106,3.6593784394902977,ITPKA;FGF2
regulation of heart rate by cardiac conduction (GO:0086091),2/39,0.21512140826891363,0.3053126480243889,0,0,2.3815508510768106,3.6593784394902977,BIN1;CAV1
regulation of ion transmembrane transporter activity (GO:0032412),2/39,0.21512140826891363,0.3053126480243889,0,0,2.3815508510768106,3.6593784394902977,FXYD6;UTRN
regulation of nitric-oxide synthase activity (GO:0050999),2/39,0.21512140826891363,0.3053126480243889,0,0,2.3815508510768106,3.6593784394902977,TERT;CAV1
regulation of protein tyrosine kinase activity (GO:0061097),2/39,0.21512140826891363,0.3053126480243889,0,0,2.3815508510768106,3.6593784394902977,CAV1;AGT
Fc-gamma receptor signaling pathway (GO:0038094),3/72,0.21578209357507236,0.3053126480243889,0,0,1.9167814282903797,2.9393578812483545,CYFIP2;VAV3;VAV2
positive regulation of protein secretion (GO:0050714),3/72,0.21578209357507236,0.3053126480243889,0,0,1.9167814282903797,2.9393578812483545,TCF7L2;IRS2;EZR
positive regulation of secretion by cell (GO:1903532),3/72,0.21578209357507236,0.3053126480243889,0,0,1.9167814282903797,2.9393578812483545,BMP2;RAB3A;EZR
angiogenesis involved in wound healing (GO:0060055),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,KDR
cell proliferation in forebrain (GO:0021846),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,SIX3
cell-cell junction maintenance (GO:0045217),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,PRTN3
cellular response to UV-A (GO:0071492),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,TIMP1
central nervous system myelination (GO:0022010),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,SOX10
chromatin-mediated maintenance of transcription (GO:0048096),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CHEK1
complement receptor mediated signaling pathway (GO:0002430),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CR1
cyclooxygenase pathway (GO:0019371),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,PTGS2
"DNA damage response, signal transduction resulting in transcription (GO:0042772)",1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,MUC1
embryonic eye morphogenesis (GO:0048048),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,FBN2
enteric nervous system development (GO:0048484),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,SOX10
formation of extrachromosomal circular DNA (GO:0001325),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BLM
hematopoietic stem cell proliferation (GO:0071425),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,MECOM
induction of positive chemotaxis (GO:0050930),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CXCL12
interleukin-35-mediated signaling pathway (GO:0070757),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,STAT1
intestinal lipid absorption (GO:0098856),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CD36
miRNA mediated inhibition of translation (GO:0035278),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,ZFP36
monocyte differentiation (GO:0030224),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,PPARG
negative regulation of bone remodeling (GO:0046851),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,IL6
negative regulation of calcium ion transmembrane transport (GO:1903170),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BIN1
negative regulation of centrosome duplication (GO:0010826),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BRCA1
negative regulation of intracellular estrogen receptor signaling pathway (GO:0033147),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BRCA1
negative regulation of nuclear division (GO:0051784),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CHEK1
negative regulation of oxidative stress-induced neuron death (GO:1903204),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,PRKN
negative regulation of platelet-derived growth factor receptor signaling pathway (GO:0010642),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,LRP1
negative regulation of sprouting angiogenesis (GO:1903671),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,E2F2
negative regulation of T-helper cell differentiation (GO:0045623),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,ANXA1
"negative regulation of translation, ncRNA-mediated (GO:0040033)",1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,ZFP36
negative regulation of voltage-gated potassium channel activity (GO:1903817),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CAV1
nuclear DNA replication (GO:0033260),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,MCM4
PERK-mediated unfolded protein response (GO:0036499),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CCL2
positive regulation of alcohol biosynthetic process (GO:1902932),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,FGF1
positive regulation of cellular extravasation (GO:0002693),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,MDK
positive regulation of dendrite development (GO:1900006),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,ALK
positive regulation of histone exchange (GO:1900051),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,H4-16
positive regulation of integrin activation (GO:0033625),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,SKAP1
positive regulation of myelination (GO:0031643),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,EGR2
positive regulation of posttranscriptional gene silencing (GO:0060148),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,ZFP36
positive regulation of protein localization to Cajal body (GO:1904871),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CCT3
positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress (GO:1990440),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,ATF3
positive regulation of transforming growth factor beta production (GO:0071636),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,PTGS2
positive regulation of viral release from host cell (GO:1902188),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CAV2
pyrimidine nucleoside salvage (GO:0043097),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,TK1
pyrimidine-containing compound salvage (GO:0008655),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,TK1
rDNA heterochromatin assembly (GO:0000183),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,H4-16
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel (GO:1902514),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BIN1
"regulation of CD4-positive, alpha-beta T cell proliferation (GO:2000561)",1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,TGFBR2
regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway (GO:2001267),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,PLAUR
regulation of establishment of protein localization to telomere (GO:0070203),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CCT3
regulation of histone exchange (GO:1900049),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,H4-16
regulation of inclusion body assembly (GO:0090083),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,SNCAIP
regulation of lamellipodium morphogenesis (GO:2000392),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,VIL1
regulation of long-term neuronal synaptic plasticity (GO:0048169),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,SYP
regulation of microtubule-based movement (GO:0060632),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,NEFH
regulation of mitochondrial fusion (GO:0010635),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,PRKN
regulation of mRNA 3'-end processing (GO:0031440),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BARD1
regulation of protein localization to Cajal body (GO:1904869),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CCT3
regulation of T-helper 2 cell cytokine production (GO:2000551),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,IL6
response to corticosteroid (GO:0031960),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,IL6
response to hydroxyurea (GO:0072710),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BLM
response to sterol (GO:0036314),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,TGFBR2
signal peptide processing (GO:0006465),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,PCSK5
skeletal muscle cell differentiation (GO:0035914),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,EGR2
T cell chemotaxis (GO:0010818),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,CXCL10
t-circle formation (GO:0090656),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BLM
telomere maintenance via recombination (GO:0000722),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,RAD51
telomere maintenance via telomere trimming (GO:0090737),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,BLM
vasoconstriction (GO:0042310),1/11,0.2193090852006174,0.3053126480243889,0,0,4.402027027027027,6.6790776172014725,ACTA2
"antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent (GO:0002479)",3/73,0.22161656955202658,0.3078961553335942,0,0,1.8893018745959922,2.84681244817926,TAP1;CD36;CALR
defense response to Gram-negative bacterium (GO:0050829),3/73,0.22161656955202658,0.3078961553335942,0,0,1.8893018745959922,2.84681244817926,IL6;CTSG;AQP1
insulin receptor signaling pathway (GO:0008286),3/73,0.22161656955202658,0.3078961553335942,0,0,1.8893018745959922,2.84681244817926,CAV2;IRS2;FOXO1
neurotransmitter transport (GO:0006836),3/73,0.22161656955202658,0.3078961553335942,0,0,1.8893018745959922,2.84681244817926,RAB3A;GAD1;SYN1
regulation of hydrolase activity (GO:0051336),3/73,0.22161656955202658,0.3078961553335942,0,0,1.8893018745959922,2.84681244817926,VAV3;CAV1;VAV2
"transcription, DNA-templated (GO:0006351)",7/221,0.22316107645672986,0.3097836317486295,0,0,1.444405325822558,2.1664078697228772,PARP1;BCL3;E2F1;DTX1;ELOB;POLR2H;SOX5
negative regulation of protein kinase B signaling (GO:0051898),2/40,0.22333872746666159,0.3097836317486295,0,0,2.3187596530830463,3.4759730687902985,CIB1;PPARA
positive regulation of intrinsic apoptotic signaling pathway (GO:2001244),2/40,0.22333872746666159,0.3097836317486295,0,0,2.3187596530830463,3.4759730687902985,CAV1;PMAIP1
response to organonitrogen compound (GO:0010243),2/40,0.22333872746666159,0.3097836317486295,0,0,2.3187596530830463,3.4759730687902985,PRKN;IL6
Fc receptor mediated stimulatory signaling pathway (GO:0002431),3/74,0.22748233733115134,0.31527442278347445,0,0,1.862596392836658,2.7579142218886714,CYFIP2;VAV3;VAV2
proteolysis involved in cellular protein catabolic process (GO:0051603),3/74,0.22748233733115134,0.31527442278347445,0,0,1.862596392836658,2.7579142218886714,PRKN;PMAIP1;GZMB
response to endoplasmic reticulum stress (GO:0034976),4/110,0.22959118542777304,0.31806778859262214,0,0,1.6642279553330765,2.4488365564455115,PRKN;JUN;BAK1;ATF3
carbohydrate catabolic process (GO:0016052),2/41,0.2315796925858527,0.3187025229975903,0,0,2.2591885165248597,3.304811494432305,ENO2;ALDOA
hexose metabolic process (GO:0019318),2/41,0.2315796925858527,0.3187025229975903,0,0,2.2591885165248597,3.304811494432305,IRS2;ALDOA
keratinocyte differentiation (GO:0030216),2/41,0.2315796925858527,0.3187025229975903,0,0,2.2591885165248597,3.304811494432305,ANXA1;TXNIP
regulation of filopodium assembly (GO:0051489),2/41,0.2315796925858527,0.3187025229975903,0,0,2.2591885165248597,3.304811494432305,NRP1;CCL21
regulation of viral transcription (GO:0046782),2/41,0.2315796925858527,0.3187025229975903,0,0,2.2591885165248597,3.304811494432305,ZFP36;POLR2H
nucleic acid phosphodiester bond hydrolysis (GO:0090305),3/75,0.23337731400881864,0.3187025229975903,0,0,1.8366327300150829,2.67248201125167,FEN1;RFC4;PARP1
Fc-epsilon receptor signaling pathway (GO:0038095),4/111,0.23436158255460576,0.3187025229975903,0,0,1.648589653930108,2.3919224600492326,VAV3;JUN;FOS;VAV2
actin crosslink formation (GO:0051764),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,EPS8
ATP transport (GO:0015867),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CR1
brain morphogenesis (GO:0048854),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PAX2
catecholamine biosynthetic process (GO:0042423),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,GATA3
cell cycle checkpoint signaling (GO:0000075),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,BUB1
cell differentiation in hindbrain (GO:0021533),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PROX1
cellular response to thyroid hormone stimulus (GO:0097067),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,LMO2
chromatin assembly or disassembly (GO:0006333),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CHAF1A
cochlea morphogenesis (GO:0090103),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PAX2
depurination (GO:0045007),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,H4-16
digestive system development (GO:0055123),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,KIT
dosage compensation by inactivation of X chromosome (GO:0009048),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,BRCA1
epithelial cell-cell adhesion (GO:0090136),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,KIT
ethanol oxidation (GO:0006069),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,ALDH2
exit from mitosis (GO:0010458),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,EPS8
gas transport (GO:0015669),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,AQP1
inorganic ion transmembrane transport (GO:0098660),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PKD2
keratan sulfate catabolic process (GO:0042340),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,ACAN
mitochondrial genome maintenance (GO:0000002),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PARP1
mitotic G1/S transition checkpoint signaling (GO:0044819),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CCND1
negative regulation by host of viral process (GO:0044793),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PRKN
negative regulation of amyloid fibril formation (GO:1905907),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CRYAB
negative regulation of B cell proliferation (GO:0030889),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CTLA4
negative regulation of cardiac muscle hypertrophy (GO:0010614),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,FOXO1
negative regulation of cilium assembly (GO:1902018),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,YAP1
negative regulation of fatty acid biosynthetic process (GO:0045717),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,BRCA1
negative regulation of histone acetylation (GO:0035067),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,BRCA1
negative regulation of leukocyte chemotaxis (GO:0002689),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,DUSP1
negative regulation of oxidoreductase activity (GO:0051354),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PRKN
negative regulation of release of sequestered calcium ion into cytosol (GO:0051280),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PKD2
negative regulation of ryanodine-sensitive calcium-release channel activity (GO:0060315),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PKD2
nuclear body organization (GO:0030575),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,HABP4
nucleoside salvage (GO:0043174),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,TK1
P-body assembly (GO:0033962),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,LSM4
phagolysosome assembly (GO:0001845),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,SYT7
polyol transport (GO:0015791),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,AQP1
positive regulation of actin filament depolymerization (GO:0030836),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,VIL1
positive regulation of endoplasmic reticulum unfolded protein response (GO:1900103),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,BAK1
positive regulation of protein depolymerization (GO:1901881),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,VIL1
"positive regulation of protein localization to chromosome, telomeric region (GO:1904816)",1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CCT3
positive regulation of pseudopodium assembly (GO:0031274),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CCL21
positive regulation of sodium ion transmembrane transport (GO:1902307),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,DMD
positive regulation of T-helper 1 type immune response (GO:0002827),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,IL18
positive regulation of ubiquitin protein ligase activity (GO:1904668),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CDC20
protein auto-ADP-ribosylation (GO:0070213),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PARP1
protein localization to synapse (GO:0035418),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,NPHS1
pyrimidine nucleobase metabolic process (GO:0006206),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,DPYSL2
regulation of actin nucleation (GO:0051125),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,VIL1
regulation of B cell apoptotic process (GO:0002902),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,IRS2
regulation of cell communication by electrical coupling involved in cardiac conduction (GO:1901844),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CAV1
regulation of cholesterol esterification (GO:0010872),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,AGT
regulation of chromatin binding (GO:0035561),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CDT1
regulation of feeding behavior (GO:0060259),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,LEPR
regulation of histone H3-K9 methylation (GO:0051570),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,BRCA1
regulation of keratinocyte migration (GO:0051547),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,FGF7
regulation of pseudopodium assembly (GO:0031272),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CCL21
regulation of response to oxidative stress (GO:1902882),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,PRKN
regulation of vascular associated smooth muscle cell migration (GO:1904752),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,MEF2C
sensory perception of taste (GO:0050909),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,CD36
smooth muscle cell differentiation (GO:0051145),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,MEF2C
sno(s)RNA 3'-end processing (GO:0031126),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,EXOSC4
synaptic vesicle fusion to presynaptic active zone membrane (GO:0031629),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,STX11
toll-like receptor 3 signaling pathway (GO:0034138),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,FADD
very-low-density lipoprotein particle assembly (GO:0034379),1/12,0.23668899228488882,0.3187025229975903,0,0,4.0016380016380015,5.766393447767713,APOB
phosphatidylinositol metabolic process (GO:0046488),4/112,0.23915577831136678,0.32189687696885383,0,0,1.6332409507012682,2.3365800742502056,PLA2G2A;PLA2G4A;BMX;FGF2
RNA transport (GO:0050658),3/76,0.23929944492210847,0.32196309052291583,0,0,1.8113804004214964,2.590345709897188,ZFP36;DDX39A;TGFBR2
determination of left/right symmetry (GO:0007368),2/42,0.2398391968312523,0.3223075641959416,0,0,2.2025959367945824,3.1448369492379444,PKD2;TDGF1
heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules (GO:0007157),2/42,0.2398391968312523,0.3223075641959416,0,0,2.2025959367945824,3.1448369492379444,SELE;NECTIN3
negative regulation of protein catabolic process (GO:0042177),2/42,0.2398391968312523,0.3223075641959416,0,0,2.2025959367945824,3.1448369492379444,TIMP1;MAD2L1
positive regulation of protein modification by small protein conjugation or removal (GO:1903322),3/77,0.24524670438879914,0.32918502109374853,0,0,1.786810566222331,2.5113454876642503,CAV1;FAM107A;BRCA1
positive regulation of tumor necrosis factor production (GO:0032760),3/77,0.24524670438879914,0.32918502109374853,0,0,1.786810566222331,2.5113454876642503,IL6;CCL19;FADD
positive regulation of type I interferon production (GO:0032481),3/77,0.24524670438879914,0.32918502109374853,0,0,1.786810566222331,2.5113454876642503,STAT1;IRF7;POLR2H
DNA synthesis involved in DNA repair (GO:0000731),2/43,0.2481123479559558,0.3318814197115929,0,0,2.1487639707096844,2.99510541318927,RFC4;UBE2L6
DNA-dependent DNA replication maintenance of fidelity (GO:0045005),2/43,0.2481123479559558,0.3318814197115929,0,0,2.1487639707096844,2.99510541318927,BLM;RAD51
negative regulation of proteolysis (GO:0045861),2/43,0.2481123479559558,0.3318814197115929,0,0,2.1487639707096844,2.99510541318927,DNAJC1;TIMP1
positive regulation of leukocyte mediated cytotoxicity (GO:0001912),2/43,0.2481123479559558,0.3318814197115929,0,0,2.1487639707096844,2.99510541318927,FADD;NECTIN2
histone modification (GO:0016570),4/114,0.24881124498552995,0.3318814197115929,0,0,1.603380746237889,2.230399978905479,CCNA2;MRGBP;RUVBL1;EZH2
negative regulation of cell motility (GO:2000146),4/114,0.24881124498552995,0.3318814197115929,0,0,1.603380746237889,2.230399978905479,NGFR;MITF;GATA3;MAPK15
antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590),3/78,0.25121709667395525,0.3318814197115929,0,0,1.76289592760181,2.435331048402142,TAP1;CD36;CALR
calcium ion transport (GO:0006816),4/115,0.25367036873293974,0.3318814197115929,0,0,1.5888541602827317,2.1794624181121716,CATSPER1;CAV1;PKD2;RAMP1
cardiac cell development (GO:0055006),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,NKX2-5
chromatin organization involved in regulation of transcription (GO:0034401),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CHEK1
cranial nerve development (GO:0021545),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PAX2
DNA deamination (GO:0045006),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,EXOSC4
DNA replication-independent nucleosome organization (GO:0034724),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,H4-16
glucan biosynthetic process (GO:0009250),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PER2
glucose import (GO:0046323),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,SLC2A4
glycogen biosynthetic process (GO:0005978),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PER2
homeostasis of number of cells (GO:0048872),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PLA2G2A
icosanoid secretion (GO:0032309),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,ANXA1
lipid oxidation (GO:0034440),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PPARGC1A
mature B cell differentiation involved in immune response (GO:0002313),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,IL6
mitochondrial outer membrane permeabilization (GO:0097345),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PMAIP1
negative regulation of adenylate cyclase activity (GO:0007194),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,AKAP5
negative regulation of alcohol biosynthetic process (GO:1902931),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,BMP2
negative regulation of autophagosome assembly (GO:1902902),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,FEZ1
negative regulation of chromatin organization (GO:1905268),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,HMGA1
negative regulation of chromatin silencing (GO:0031936),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,HMGA1
negative regulation of DNA-dependent DNA replication (GO:2000104),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,BLM
negative regulation of epidermal growth factor-activated receptor activity (GO:0007175),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CBLC
negative regulation of gene silencing (GO:0060969),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,HMGA1
negative regulation of hippo signaling (GO:0035331),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CIT
negative regulation of histone methylation (GO:0031061),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,BRCA1
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:1902166),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,MUC1
negative regulation of locomotion (GO:0040013),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,GATA3
negative regulation of mononuclear cell migration (GO:0071676),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,DUSP1
negative regulation of myoblast differentiation (GO:0045662),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,SOSTDC1
negative regulation of myotube differentiation (GO:0010832),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,NKX2-5
negative regulation of nucleocytoplasmic transport (GO:0046823),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,BARD1
negative regulation of reactive oxygen species biosynthetic process (GO:1903427),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PPARA
positive regulation of calcineurin-mediated signaling (GO:0106058),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CIB1
positive regulation of calcineurin-NFAT signaling cascade (GO:0070886),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CIB1
positive regulation of calcium-mediated signaling (GO:0050850),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,TRAT1
"positive regulation of CD4-positive, alpha-beta T cell activation (GO:2000516)",1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,TGFBR2
positive regulation of ERAD pathway (GO:1904294),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CAV1
positive regulation of histone deacetylation (GO:0031065),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PRKD1
positive regulation of lipid transport (GO:0032370),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,LRP1
positive regulation of neuron migration (GO:2001224),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,MDK
positive regulation of nuclear-transcribed mRNA poly(A) tail shortening (GO:0060213),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,ZFP36
positive regulation of protein acetylation (GO:1901985),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CAMK1
positive regulation of ruffle assembly (GO:1900029),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,EPS8
positive regulation of sodium ion transport (GO:0010765),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,NKX2-5
positive regulation of steroid metabolic process (GO:0045940),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,AGT
positive regulation of transporter activity (GO:0032411),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,SGK1
protein heterotetramerization (GO:0051290),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PKD2
regulation of autophagosome maturation (GO:1901096),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,ADRB2
regulation of cell communication by electrical coupling (GO:0010649),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CAV1
regulation of chemokine (C-X-C motif) ligand 2 production (GO:2000341),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,KLF4
regulation of fibrinolysis (GO:0051917),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,F12
regulation of interleukin-5 production (GO:0032674),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,GATA3
regulation of membrane repolarization (GO:0060306),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CAV1
regulation of protein acetylation (GO:1901983),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,CAMK1
regulation of receptor signaling pathway via STAT (GO:1904892),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,IL6
response to interleukin-6 (GO:0070741),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,TDGF1
response to muramyl dipeptide (GO:0032495),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,VIM
response to thyroid hormone (GO:0097066),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,LMO2
spinal cord development (GO:0021510),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,PKD2
triglyceride-rich lipoprotein particle remodeling (GO:0034370),1/13,0.25368283402250574,0.3318814197115929,0,0,3.6679804804804803,5.031260535914632,APOB
positive regulation of Wnt signaling pathway (GO:0030177),5/153,0.25489842664402645,0.3333437597862019,0,0,1.4900952088452089,2.036796448725795,COL1A1;BMP2;TERT;CAV1;RUVBL1
mitotic spindle assembly (GO:0090307),2/44,0.2563944613724748,0.3349146509610556,0,0,2.09749543158121,2.8547713137472432,RACGAP1;PRC1
mRNA catabolic process (GO:0006402),2/44,0.2563944613724748,0.3349146509610556,0,0,2.09749543158121,2.8547713137472432,ZFP36;EXOSC4
negative regulation of epidermal growth factor receptor signaling pathway (GO:0042059),2/44,0.2563944613724748,0.3349146509610556,0,0,2.09749543158121,2.8547713137472432,CBLC;SPRY2
regulation of cellular response to heat (GO:1900034),3/79,0.25720865651483926,0.3357208354663241,0,0,1.7396106215765659,2.36216095260834,MAPKAPK2;FKBP4;CRYAB
regulation of ion transport (GO:0043269),3/79,0.25720865651483926,0.3357208354663241,0,0,1.7396106215765659,2.36216095260834,PRKN;SYT9;SYT7
tumor necrosis factor-mediated signaling pathway (GO:0033209),4/116,0.2585489978141428,0.3373411120025263,0,0,1.5745869776482022,2.1298966557448797,STAT1;LTA;TNFSF11;TNFRSF4
regulation of NIK/NF-kappaB signaling (GO:1901222),3/80,0.2632194498035177,0.34330343854970846,0,0,1.7169301286948346,2.29170199443035,BCL3;CCL19;EZR
action potential (GO:0001508),2/45,0.26468105323901947,0.3446820899650663,0,0,2.048611475668014,2.723075320784557,DMD;SCN4A
neural crest cell development (GO:0014032),2/45,0.26468105323901947,0.3446820899650663,0,0,2.048611475668014,2.723075320784557,SEMA3F;SOX10
positive regulation of Notch signaling pathway (GO:0045747),2/45,0.26468105323901947,0.3446820899650663,0,0,2.048611475668014,2.723075320784557,YAP1;MAML2
regulation of DNA repair (GO:0006282),2/45,0.26468105323901947,0.3446820899650663,0,0,2.048611475668014,2.723075320784557,H2AX;BRCA1
protein localization to membrane (GO:0072657),6/195,0.26797112642993515,0.34591797302864613,0,0,1.4004411179809813,1.8442073557685368,RAB3A;DLG2;CAV1;CAPN3;EZR;RAMP1
activation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0006919),3/81,0.2692475742783438,0.34591797302864613,0,0,1.694831186912635,2.2238286291226292,NGFR;PPARG;FADD
positive regulation of tumor necrosis factor superfamily cytokine production (GO:1903557),3/81,0.2692475742783438,0.34591797302864613,0,0,1.694831186912635,2.2238286291226292,IL6;CCL19;FADD
antigen processing and presentation of endogenous peptide antigen (GO:0002483),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,TAP1
cAMP metabolic process (GO:0046058),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,ADCY5
carbohydrate transport (GO:0008643),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,AQP1
cardiac left ventricle morphogenesis (GO:0003214),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,TGFBR2
cardiolipin metabolic process (GO:0032048),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,PLA2G4A
cell junction maintenance (GO:0034331),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,PRTN3
dicarboxylic acid catabolic process (GO:0043649),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,GAD1
genitalia development (GO:0048806),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,WT1
heart process (GO:0003015),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,ACTC1
immune response-regulating cell surface receptor signaling pathway (GO:0002768),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,KIT
intestinal absorption (GO:0050892),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,CD36
microvillus organization (GO:0032528),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,EZR
monoacylglycerol metabolic process (GO:0046462),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,PLA2G4A
myeloid dendritic cell activation (GO:0001773),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,TGFBR2
NAD biosynthesis via nicotinamide riboside salvage pathway (GO:0034356),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,PTGS2
negative regulation of cell activation (GO:0050866),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,PDGFA
negative regulation of cell migration involved in sprouting angiogenesis (GO:0090051),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,KLF4
negative regulation of cyclase activity (GO:0031280),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,AKAP5
negative regulation of viral transcription (GO:0032897),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,ZFP36
neuron fate commitment (GO:0048663),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,ASCL1
positive regulation of alpha-beta T cell differentiation (GO:0046638),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,TGFBR2
positive regulation of cyclase activity (GO:0031281),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,AKAP5
positive regulation of glycogen biosynthetic process (GO:0045725),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,IRS2
positive regulation of long-term synaptic potentiation (GO:1900273),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,AKAP5
positive regulation of macrophage chemotaxis (GO:0010759),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,MDK
positive regulation of protein-containing complex disassembly (GO:0043243),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,ADRB2
positive regulation of regulatory T cell differentiation (GO:0045591),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,CR1
positive regulation of sodium ion transmembrane transporter activity (GO:2000651),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,DMD
positive regulation of T cell chemotaxis (GO:0010820),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,CCL21
positive regulation of transmembrane transport (GO:0034764),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,C3
pyrimidine nucleoside biosynthetic process (GO:0046134),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,TK1
regulation of chromatin organization (GO:1902275),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,MKI67
regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:1902165),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,MUC1
regulation of IRE1-mediated unfolded protein response (GO:1903894),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,BAK1
regulation of lamellipodium organization (GO:1902743),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,VIL1
regulation of lipase activity (GO:0060191),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,PCSK5
regulation of vasculogenesis (GO:2001212),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,KDR
respiratory electron transport chain (GO:0022904),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,PPARGC1A
secondary palate development (GO:0062009),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,TGFBR2
substrate-dependent cell migration (GO:0006929),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,NRP1
sulfate transport (GO:0008272),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,RACGAP1
T cell differentiation in thymus (GO:0033077),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,FADD
T-helper cell differentiation (GO:0042093),1/14,0.2702991673049544,0.34591797302864613,0,0,3.3856548856548856,4.429201431331101,IL6
interleukin-12-mediated signaling pathway (GO:0035722),2/46,0.2729678339719828,0.34907106122946246,0,0,2.001949517750872,2.5993338864462903,CFL1;LMNB1
vesicle organization (GO:0016050),2/46,0.2729678339719828,0.34907106122946246,0,0,2.001949517750872,2.5993338864462903,CAV2;CAV1
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043280),4/119,0.27329137197955683,0.3493537118178281,0,0,1.5332741792369122,1.988988957346391,NGFR;PMAIP1;PPARG;FADD
positive regulation of protein ubiquitination (GO:0031398),3/82,0.2752911598449532,0.3516462791422791,0,0,1.6732917120109971,2.1584224486595267,CAV1;FAM107A;BRCA1
"regulation of gene expression, epigenetic (GO:0040029)",3/82,0.2752911598449532,0.3516462791422791,0,0,1.6732917120109971,2.1584224486595267,H4-16;POLR2H;EZH2
organonitrogen compound biosynthetic process (GO:1901566),5/158,0.2760521500673343,0.35235420502976605,0,0,1.441027926322044,1.854841404775253,PLA2G4A;DMD;PRKD1;INHBA;PCSK5
T cell receptor signaling pathway (GO:0050852),5/158,0.2760521500673343,0.35235420502976605,0,0,1.441027926322044,1.854841404775253,TRAT1;CTLA4;GATA3;PAK3;SKAP1
positive regulation of neuron death (GO:1901216),2/47,0.28125070177835076,0.35810414142958613,0,0,1.9573614246300477,2.4829302511431472,EGR1;FOS
positive regulation of pathway-restricted SMAD protein phosphorylation (GO:0010862),2/47,0.28125070177835076,0.35810414142958613,0,0,1.9573614246300477,2.4829302511431472,BMP2;INHBA
regulation of cellular metabolic process (GO:0031323),2/47,0.28125070177835076,0.35810414142958613,0,0,1.9573614246300477,2.4829302511431472,PRKN;PPARA
regulation of protein localization to nucleus (GO:1900180),2/47,0.28125070177835076,0.35810414142958613,0,0,1.9573614246300477,2.4829302511431472,YAP1;NGFR
endomembrane system organization (GO:0010256),6/199,0.2831633493938415,0.35810414142958613,0,0,1.3711331688835908,1.7300016925777069,CR1;CAV2;PRKD1;SYP;MAPK15;SYNE1
cellular response to arsenic-containing substance (GO:0071243),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,ATF3
cellular response to exogenous dsRNA (GO:0071360),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,CAV1
clathrin coat assembly (GO:0048268),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,NSG2
contractile actin filament bundle assembly (GO:0030038),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,KCTD13
detection of mechanical stimulus involved in sensory perception (GO:0050974),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,KIT
electron transport chain (GO:0022900),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PPARGC1A
engulfment of apoptotic cell (GO:0043652),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,RHOH
establishment of spindle localization (GO:0051293),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,CFL1
fibrinolysis (GO:0042730),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PLAUR
G protein-coupled glutamate receptor signaling pathway (GO:0007216),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,HOMER3
histone H3 deacetylation (GO:0070932),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PER2
icosanoid biosynthetic process (GO:0046456),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PLA2G4A
integrated stress response signaling (GO:0140467),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,CCL2
lipoxygenase pathway (GO:0019372),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PTGS2
macrophage differentiation (GO:0030225),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PARP1
microvillus assembly (GO:0030033),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,EZR
mitotic intra-S DNA damage checkpoint signaling (GO:0031573),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,FANCD2
modulation by host of viral genome replication (GO:0044827),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PRKN
myoblast fusion (GO:0007520),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,ADAM12
negative regulation of cellular component movement (GO:0051271),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,GATA3
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway (GO:1902236),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PRKN
negative regulation of mRNA processing (GO:0050686),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,BARD1
negative regulation of single stranded viral RNA replication via double stranded DNA intermediate (GO:0045869),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,HMGA2
negative regulation of ubiquitin-protein transferase activity (GO:0051444),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,MAD2L1
neurotrophin TRK receptor signaling pathway (GO:0048011),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,NGFR
placenta development (GO:0001890),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PPARG
positive regulation of chromosome organization (GO:2001252),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,FEN1
"positive regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043517)",1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PMAIP1
positive regulation of double-strand break repair via homologous recombination (GO:1905168),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,PARP1
positive regulation of exosomal secretion (GO:1903543),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,SDC1
positive regulation of glycogen metabolic process (GO:0070875),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,IRS2
positive regulation of heterotypic cell-cell adhesion (GO:0034116),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,SKAP1
positive regulation of histone H3-K4 methylation (GO:0051571),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,BRCA1
positive regulation of lyase activity (GO:0051349),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,AKAP5
positive regulation of membrane protein ectodomain proteolysis (GO:0051044),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,SH3D19
positive regulation of natural killer cell activation (GO:0032816),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,IL18
"positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay (GO:1900153)",1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,ZFP36
positive regulation of osteoclast differentiation (GO:0045672),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,TNFSF11
positive regulation of secretion (GO:0051047),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,AQP1
protein kinase A signaling (GO:0010737),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,EZR
protein localization to cell-cell junction (GO:0150105),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,CDH5
regulation of amyloid fibril formation (GO:1905906),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,CRYAB
regulation of integrin activation (GO:0033623),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,SKAP1
regulation of microglial cell activation (GO:1903978),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,IL6
"regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay (GO:1900151)",1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,ZFP36
regulation of nuclear-transcribed mRNA poly(A) tail shortening (GO:0060211),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,ZFP36
regulation of secretion (GO:0051046),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,SGK1
"regulation of synaptic transmission, GABAergic (GO:0032228)",1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,ADRA1A
regulation of triglyceride biosynthetic process (GO:0010866),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,C3
response to muscle stretch (GO:0035994),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,DMD
stress fiber assembly (GO:0043149),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,KCTD13
T cell proliferation (GO:0042098),1/15,0.28654635964744174,0.35810414142958613,0,0,3.143661518661519,3.929120885513255,TNFRSF4
anaphase-promoting complex-dependent catabolic process (GO:0031145),3/84,0.28741739807076055,0.3587979826465758,0,0,1.6318082788671024,2.0345708247111753,CDC20;AURKA;MAD2L1
nuclear export (GO:0051168),3/84,0.28741739807076055,0.3587979826465758,0,0,1.6318082788671024,2.0345708247111753,EGR2;DDX39A;CALR
vascular transport (GO:0010232),3/84,0.28741739807076055,0.3587979826465758,0,0,1.6318082788671024,2.0345708247111753,LRP1;LEPR;SLC2A4
potassium ion transport (GO:0006813),4/122,0.2881716515455139,0.3596078317345702,0,0,1.494062031592298,1.858910431978657,KCNK15;KCNQ5;PKD2;AQP1
histone H4 acetylation (GO:0043967),2/48,0.28952573656799624,0.3606373209882059,0,0,1.914711944253607,2.3733066811276458,RUVBL1;BRCA2
inositol phosphate metabolic process (GO:0043647),2/48,0.28952573656799624,0.3606373209882059,0,0,1.914711944253607,2.3733066811276458,ITPKA;FGF2
myelination (GO:0042552),2/48,0.28952573656799624,0.3606373209882059,0,0,1.914711944253607,2.3733066811276458,CXCR4;SOX10
regulation of mitochondrion organization (GO:0010821),2/48,0.28952573656799624,0.3606373209882059,0,0,1.914711944253607,2.3733066811276458,PRKN;PPARGC1A
regulation of protein metabolic process (GO:0051246),2/48,0.28952573656799624,0.3606373209882059,0,0,1.914711944253607,2.3733066811276458,PLAUR;KLF4
cellular defense response (GO:0006968),2/49,0.2977891937974547,0.3702537659473643,0,0,1.8738773353825464,2.2699577499506227,TRAT1;CXCR2
regulation of interferon-beta production (GO:0032648),2/49,0.2977891937974547,0.3702537659473643,0,0,1.8738773353825464,2.2699577499506227,IRF7;SIRPA
regulation of stress-activated MAPK cascade (GO:0032872),2/49,0.2977891937974547,0.3702537659473643,0,0,1.8738773353825464,2.2699577499506227,MAPK8IP2;FOXO1
response to unfolded protein (GO:0006986),2/49,0.2977891937974547,0.3702537659473643,0,0,1.8738773353825464,2.2699577499506227,PRKN;BAK1
RNA catabolic process (GO:0006401),2/49,0.2977891937974547,0.3702537659473643,0,0,1.8738773353825464,2.2699577499506227,FEN1;ZFP36
negative regulation of cellular amide metabolic process (GO:0034249),3/86,0.29958386508297846,0.3704853627195568,0,0,1.5923240473205038,1.9193251207394006,BIN1;GZMB;CALR
3'-UTR-mediated mRNA destabilization (GO:0061158),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,ZFP36
basement membrane organization (GO:0071711),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,CMA1
digestive tract morphogenesis (GO:0048546),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,SIX2
filopodium assembly (GO:0046847),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,EZR
glutamine family amino acid catabolic process (GO:0009065),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,GAD1
histone H2A acetylation (GO:0043968),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,RUVBL1
motor neuron axon guidance (GO:0008045),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,RHOH
negative regulation of anoikis (GO:2000811),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,CAV1
negative regulation of cell-substrate junction organization (GO:0150118),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,FAM107A
negative regulation of focal adhesion assembly (GO:0051895),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,FAM107A
negative regulation of histone modification (GO:0031057),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,BRCA1
negative regulation of immune effector process (GO:0002698),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,CR1
negative regulation of lyase activity (GO:0051350),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,AKAP5
negative regulation of platelet activation (GO:0010544),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,PDGFA
negative regulation of telomere maintenance (GO:0032205),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,PARP1
negative regulation of transcription regulatory region DNA binding (GO:2000678),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,PER2
neuron cell-cell adhesion (GO:0007158),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,RET
neutrophil activation (GO:0042119),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,CXCR2
nuclear transport (GO:0051169),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,HMGA1
odontogenesis of dentin-containing tooth (GO:0042475),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,BMP2
oligodendrocyte development (GO:0014003),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,SOX10
oogenesis (GO:0048477),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,MDK
positive regulation by host of viral transcription (GO:0043923),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,JUN
positive regulation of collagen biosynthetic process (GO:0032967),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,VIM
positive regulation of endothelial cell apoptotic process (GO:2000353),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,CCL2
positive regulation of immunoglobulin mediated immune response (GO:0002891),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,NECTIN2
positive regulation of myeloid leukocyte cytokine production involved in immune response (GO:0061081),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,KIT
positive regulation of syncytium formation by plasma membrane fusion (GO:0060143),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,CAMK1
regulation of amyloid-beta clearance (GO:1900221),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,LRP1
regulation of cellular carbohydrate metabolic process (GO:0010675),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,PRKN
regulation of chromatin silencing (GO:0031935),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,HMGA1
regulation of ERBB signaling pathway (GO:1901184),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,ERBB2
regulation of establishment of cell polarity (GO:2000114),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,CDH5
regulation of hormone secretion (GO:0046883),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,ANXA1
regulation of intrinsic apoptotic signaling pathway in response to DNA damage (GO:1902229),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,CXCL12
regulation of leukocyte activation (GO:0002694),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,PLA2G2A
regulation of monocyte differentiation (GO:0045655),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,IRF7
regulation of phosphate metabolic process (GO:0019220),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,BARD1
regulation of Rac protein signal transduction (GO:0035020),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,SH3BP1
response to organophosphorus (GO:0046683),1/16,0.30243259362846453,0.3704853627195568,0,0,2.933933933933934,3.5086823711820667,STAT1
protein modification by small protein conjugation (GO:0032446),11/409,0.303574951949425,0.3717511448953074,0,0,1.2199650325359517,1.4543529375471418,BARD1;PRKN;EGR2;TRIM63;EPAS1;KCTD13;CBLC;DTX1;ELOB;KLHL3;BRCA1
calcium ion transmembrane transport (GO:0070588),3/87,0.30567786306505973,0.3741918668555041,0,0,1.5732870071105365,1.8646966805652603,PKD2;GRIN2C;GRIN2D
neuron migration (GO:0001764),2/50,0.3060374987409368,0.374363171467736,0,0,1.8347441685477803,2.1724245020989477,NRP1;MEF2C
positive regulation of ion transport (GO:0043270),2/50,0.3060374987409368,0.374363171467736,0,0,1.8347441685477803,2.1724245020989477,NKX2-5;MYLK
protein transport (GO:0015031),10/369,0.3076626831541196,0.37621615507328293,0,0,1.2292126917042872,1.4489360346310207,NGFR;CENPF;RAB3A;LRP1;TXNIP;PPARG;CD36;APOB;RAMP1;STX11
negative regulation of cell growth (GO:0030308),4/126,0.3081791466465136,0.37671252932974114,0,0,1.444779004497974,1.7006118310414957,CDKN2C;CDKN2A;WT1;INHBA
inositol lipid-mediated signaling (GO:0048017),2/51,0.31426724071210965,0.38346679425237007,0,0,1.797208273828719,2.080289370604364,IRS2;EZR
mitotic nuclear membrane organization (GO:0101024),2/51,0.31426724071210965,0.38346679425237007,0,0,1.797208273828719,2.080289370604364,CCNB2;RCC1
mitotic nuclear membrane reassembly (GO:0007084),2/51,0.31426724071210965,0.38346679425237007,0,0,1.797208273828719,2.080289370604364,CCNB2;RCC1
regulation of axonogenesis (GO:0050770),2/51,0.31426724071210965,0.38346679425237007,0,0,1.797208273828719,2.080289370604364,NGFR;PAK3
regulation of interleukin-12 production (GO:0032655),2/51,0.31426724071210965,0.38346679425237007,0,0,1.797208273828719,2.080289370604364,MDK;CCL19
post-Golgi vesicle-mediated transport (GO:0006892),3/89,0.3178790437365256,0.38372085264479017,0,0,1.5365410922866463,1.7610056746746778,RABIF;AP1M2;SH3D19
cell surface receptor signaling pathway involved in heart development (GO:0061311),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,BMP2
DNA biosynthetic process (GO:0071897),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,TERT
DNA replication checkpoint signaling (GO:0000076),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,CDT1
epithelial cell morphogenesis (GO:0003382),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,MET
maturation of 5.8S rRNA (GO:0000460),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,EXOSC4
mesenchyme morphogenesis (GO:0072132),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,BMP2
midbody abscission (GO:0061952),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,CEP55
negative regulation of amyloid-beta formation (GO:1902430),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,BIN1
negative regulation of fatty acid metabolic process (GO:0045922),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,BRCA1
negative regulation of insulin secretion (GO:0046676),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,PRKN
negative regulation of peptidyl-threonine phosphorylation (GO:0010801),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,SPRY2
positive regulation of blood coagulation (GO:0030194),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,F12
positive regulation of collagen metabolic process (GO:0010714),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,VIM
positive regulation of cytokine production involved in inflammatory response (GO:1900017),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,IL6
positive regulation of dendrite extension (GO:1903861),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,RIMS2
positive regulation of DNA replication (GO:0045740),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,CDT1
positive regulation of regulated secretory pathway (GO:1903307),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,RAB3A
protein autoprocessing (GO:0016540),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,F12
protein heterooligomerization (GO:0051291),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,PKD2
pyrimidine-containing compound catabolic process (GO:0072529),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,DPYSL2
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion (GO:0010881),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,DMD
regulation of cholesterol biosynthetic process (GO:0045540),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,FGF1
regulation of neuroblast proliferation (GO:1902692),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,SIX3
regulation of NLRP3 inflammasome complex assembly (GO:1900225),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,CD36
regulation of osteoblast proliferation (GO:0033688),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,BMP2
regulation of receptor recycling (GO:0001919),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,TRAT1
response to purine-containing compound (GO:0014074),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,STAT1
RNA interference (GO:0016246),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,TERT
ruffle organization (GO:0031529),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,CCL21
stabilization of membrane potential (GO:0030322),1/17,0.3179658708535468,0.38372085264479017,0,0,2.7504222972972974,3.1514647453683433,KCNK15
amide biosynthetic process (GO:0043604),2/52,0.32247516764296813,0.38861222465602385,0,0,1.76117381489842,1.9931717362026953,DMD;PCSK5
negative regulation of protein metabolic process (GO:0051248),2/52,0.32247516764296813,0.38861222465602385,0,0,1.76117381489842,1.9931717362026953,CRYAB;MAD2L1
negative regulation of protein-containing complex assembly (GO:0031333),2/52,0.32247516764296813,0.38861222465602385,0,0,1.76117381489842,1.9931717362026953,OPRD1;CRYAB
plasma membrane bounded cell projection morphogenesis (GO:0120039),2/52,0.32247516764296813,0.38861222465602385,0,0,1.76117381489842,1.9931717362026953,CNTNAP2;SGK1
protein complex oligomerization (GO:0051259),3/90,0.3239829916615225,0.39015336946376983,0,0,1.5188016851302855,1.7117870964869148,BLM;PKD2;ECT2
sodium ion transport (GO:0006814),3/90,0.3239829916615225,0.39015336946376983,0,0,1.5188016851302855,1.7117870964869148,SCN4A;PKD2;SGK1
regulation of primary metabolic process (GO:0080090),4/130,0.328320042241022,0.3952365609174861,0,0,1.398625058489004,1.5577416072267847,IRS2;PPARG;FGFR4;PPARA
cellular macromolecule catabolic process (GO:0044265),2/53,0.330658180756628,0.39601984179504335,0,0,1.7265524720046033,1.9107240378180597,PRKN;SIAH2
epidermal cell differentiation (GO:0009913),2/53,0.330658180756628,0.39601984179504335,0,0,1.7265524720046033,1.9107240378180597,ANXA1;TXNIP
cellular response to dsRNA (GO:0071359),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,CAV1
embryonic axis specification (GO:0000578),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,TDGF1
embryonic heart tube development (GO:0035050),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,NKX2-5
endothelial cell proliferation (GO:0001935),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,TEK
fluid transport (GO:0042044),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,AQP1
hyaluronan catabolic process (GO:0030214),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,FGF2
intracellular estrogen receptor signaling pathway (GO:0030520),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,ESR1
leukocyte tethering or rolling (GO:0050901),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,SELE
microtubule depolymerization (GO:0007019),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,STMN1
negative regulation of leukocyte cell-cell adhesion (GO:1903038),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,PPARA
negative regulation of lipid catabolic process (GO:0050995),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,ALK
negative regulation of peptide hormone secretion (GO:0090278),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,PRKN
negative regulation of signal transduction by p53 class mediator (GO:1901797),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,PRKN
positive regulation of cell cycle phase transition (GO:1901989),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,EZH2
positive regulation of excitatory postsynaptic potential (GO:2000463),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,RIMS2
positive regulation of interleukin-4 production (GO:0032753),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,GATA3
positive regulation of lymphocyte chemotaxis (GO:0140131),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,CCL21
positive regulation of myoblast differentiation (GO:0045663),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,MEF2C
positive regulation of nitric-oxide synthase activity (GO:0051000),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,TERT
"positive regulation of synaptic transmission, glutamatergic (GO:0051968)",1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,CCL2
regulation of cellular protein catabolic process (GO:1903362),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,EZR
regulation of dendrite extension (GO:1903859),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,RIMS2
regulation of early endosome to late endosome transport (GO:2000641),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,EZR
regulation of platelet aggregation (GO:0090330),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,PRKCA
regulation of single stranded viral RNA replication via double stranded DNA intermediate (GO:0045091),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,HMGA2
regulation of spindle organization (GO:0090224),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,GPSM2
regulation of telomere maintenance via telomere lengthening (GO:1904356),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,PARP1
regulation of transcription by RNA polymerase I (GO:0006356),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,ERBB2
regulation of transforming growth factor beta production (GO:0071634),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,PTGS2
release of cytochrome c from mitochondria (GO:0001836),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,BAK1
response to interferon-alpha (GO:0035455),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,GATA3
rRNA catabolic process (GO:0016075),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,EXOSC4
"synaptic transmission, glutamatergic (GO:0035249)",1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,GRIA2
water transport (GO:0006833),1/18,0.3331540159701846,0.39601984179504335,0,0,2.588500264970853,2.845151064124307,AQP1
retinoid metabolic process (GO:0001523),3/92,0.33618977460462557,0.3994891045511032,0,0,1.4845187859067568,1.6182434559342511,LRP1;SDC1;APOB
inorganic anion transport (GO:0015698),2/54,0.3388133292992604,0.4023260718647664,0,0,1.6932627192220873,1.8326283570739963,CLIC5;RACGAP1
nuclear membrane reassembly (GO:0031468),2/54,0.3388133292992604,0.4023260718647664,0,0,1.6932627192220873,1.8326283570739963,CCNB2;RCC1
regulation of heart contraction (GO:0008016),3/93,0.3422895818908901,0.4063123981484338,0,0,1.4679487179487178,1.5737851334600046,FXYD6;NKX2-5;AGT
pyruvate metabolic process (GO:0006090),2/55,0.34693780552225845,0.4082616010064378,0,0,1.6612291835257038,1.7585934105085723,ENO2;ALDOA
regulation of gene silencing by RNA (GO:0060966),2/55,0.34693780552225845,0.4082616010064378,0,0,1.6612291835257038,1.7585934105085723,H4-16;POLR2H
regulation of posttranscriptional gene silencing (GO:0060147),2/55,0.34693780552225845,0.4082616010064378,0,0,1.6612291835257038,1.7585934105085723,H4-16;POLR2H
triglyceride metabolic process (GO:0006641),2/55,0.34693780552225845,0.4082616010064378,0,0,1.6612291835257038,1.7585934105085723,CAV1;APOB
cellular response to copper ion (GO:0071280),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,AQP1
detection of mechanical stimulus (GO:0050982),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,PKD2
DNA alkylation (GO:0006305),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,FOS
DNA methylation or demethylation (GO:0044728),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,FOS
establishment or maintenance of apical/basal cell polarity (GO:0035088),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,DLG2
ethanol metabolic process (GO:0006067),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,ALDH2
fatty acid transmembrane transport (GO:1902001),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,CD36
glycerolipid catabolic process (GO:0046503),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,PLA2G4A
leukocyte adhesion to vascular endothelial cell (GO:0061756),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,SELE
leukotriene biosynthetic process (GO:0019370),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,PLA2G4A
maintenance of protein localization in organelle (GO:0072595),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,BCL3
mitochondrion localization (GO:0051646),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,NECTIN2
negative regulation of amyloid precursor protein catabolic process (GO:1902992),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,BIN1
negative regulation of nervous system development (GO:0051961),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,IL6
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902176),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,PRKN
neural crest cell differentiation (GO:0014033),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,MEF2C
NLS-bearing protein import into nucleus (GO:0006607),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,KPNA2
positive regulation of cellular protein catabolic process (GO:1903364),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,EZR
positive regulation of establishment of protein localization (GO:1904951),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,CCT3
positive regulation of leukocyte activation (GO:0002696),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,NECTIN2
positive regulation of macrophage migration (GO:1905523),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,MDK
positive regulation of oxidoreductase activity (GO:0051353),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,AGT
pyroptosis (GO:0070269),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,GZMB
regulation of autophagy of mitochondrion (GO:1903146),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,PRKN
regulation of glucose transmembrane transport (GO:0010827),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,C3
regulation of histone H3-K4 methylation (GO:0051569),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,BRCA1
regulation of insulin-like growth factor receptor signaling pathway (GO:0043567),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,BMP2
regulation of stem cell population maintenance (GO:2000036),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,HMGA2
response to cholesterol (GO:0070723),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,TGFBR2
telomere capping (GO:0016233),1/19,0.34800468043535854,0.4082616010064378,0,0,2.4445695695695697,2.580339373933961,H4-16
negative regulation of cellular protein metabolic process (GO:0032269),3/94,0.34838503879101956,0.40856717556772015,0,0,1.451742827308438,1.530785836429968,DNAJC1;GZMB;CALR
defense response to bacterium (GO:0042742),5/176,0.35446796051277235,0.41542291525826086,0,0,1.2881446039340776,1.3359828377443523,IL6;ANXA3;PLA2G2A;CTSG;AQP1
mRNA metabolic process (GO:0016071),3/95,0.354474717597131,0.41542291525826086,0,0,1.4358892386385993,1.4891869401689029,ZFP36;SNRPE;PPARGC1A
mitochondrial transport (GO:0006839),2/56,0.3550289399244564,0.41578646984967266,0,0,1.6303820750773346,1.6883518943501703,PMAIP1;BAK1
protein-containing complex disassembly (GO:0032984),2/56,0.3550289399244564,0.41578646984967266,0,0,1.6303820750773346,1.6883518943501703,CAV1;PPP1CA
organic substance transport (GO:0071702),4/136,0.35865054779092154,0.419704171580985,0,0,1.3346389060674775,1.368547768508104,CENPF;TAP1;TXNIP;RAMP1
protein localization to plasma membrane (GO:0072659),4/136,0.35865054779092154,0.419704171580985,0,0,1.3346389060674775,1.368547768508104,RAB3A;EZR;NECTIN3;RAMP1
innate immune response (GO:0045087),8/302,0.358743618490437,0.419704171580985,0,0,1.1993337380718878,1.2294937436789197,C3;CXCL10;CR1;F12;MX1;SAA1;IRF7;PPARG
glycerophospholipid biosynthetic process (GO:0046474),5/177,0.35888003364561105,0.4197196824516961,0,0,1.2805893234672305,1.3123058258159286,PLA2G2A;PLA2G4A;PLD1;BMX;FGF2
adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains (GO:0002460),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,IL18
"base-excision repair, AP site formation (GO:0006285)",1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,H4-16
cardiac epithelial to mesenchymal transition (GO:0060317),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,BMP2
cellular response to interferon-beta (GO:0035458),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,STAT1
cellular response to nitrogen compound (GO:1901699),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,BLM
endoplasmic reticulum calcium ion homeostasis (GO:0032469),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,BAK1
energy reserve metabolic process (GO:0006112),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,LEPR
eye morphogenesis (GO:0048592),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,FBN2
glucose transmembrane transport (GO:1904659),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,SLC2A4
mesoderm formation (GO:0001707),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,HMGA2
microtubule nucleation (GO:0007020),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,TUBG1
mitotic cytokinetic process (GO:1902410),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,CEP55
myeloid cell development (GO:0061515),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,KIT
natural killer cell mediated immunity (GO:0002228),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,GZMB
negative regulation of axon extension involved in axon guidance (GO:0048843),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,SEMA3F
negative regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045736),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,CDKN2A
nucleobase-containing compound biosynthetic process (GO:0034654),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,TERT
oligodendrocyte differentiation (GO:0048709),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,SOX10
positive regulation of embryonic development (GO:0040019),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,CFL1
positive regulation of epithelial cell differentiation (GO:0030858),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,FGF2
positive regulation of natural killer cell mediated cytotoxicity (GO:0045954),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,NECTIN2
production of small RNA involved in gene silencing by RNA (GO:0070918),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,TERT
regulation of granulocyte chemotaxis (GO:0071622),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,MDK
regulation of hippo signaling (GO:0035330),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,CIT
regulation of protein localization to cell periphery (GO:1904375),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,MMP14
skeletal muscle contraction (GO:0003009),1/20,0.3625253465492457,0.4202334629387174,0,0,2.3157894736842106,2.349740998270119,TNNI2
arachidonic acid metabolic process (GO:0019369),2/57,0.36308419632935246,0.42045223958220634,0,0,1.6006566796634516,1.6216581369285896,PLA2G4A;PTGS2
positive regulation of interferon-gamma production (GO:0032729),2/57,0.36308419632935246,0.42045223958220634,0,0,1.6006566796634516,1.6216581369285896,IL18;FADD
protein K48-linked ubiquitination (GO:0070936),2/57,0.36308419632935246,0.42045223958220634,0,0,1.6006566796634516,1.6216581369285896,PRKN;KLHL3
protein maturation (GO:0051604),3/97,0.36663120185143505,0.4244154673606286,0,0,1.4051939924906132,1.409970016089109,MMP14;F12;PCSK5
regulation of pathway-restricted SMAD protein phosphorylation (GO:0060393),2/58,0.37110116746642396,0.42929829556197313,0,0,1.5719929055143502,1.5582860154893865,BMP2;INHBA
regulation of tumor necrosis factor-mediated signaling pathway (GO:0010803),2/58,0.37110116746642396,0.42929829556197313,0,0,1.5719929055143502,1.5582860154893865,PRKN;FADD
antigen processing and presentation of exogenous peptide antigen via MHC class II (GO:0019886),3/98,0.372695323058564,0.4309961523527608,0,0,1.3903310311979042,1.3722484155391024,RACGAP1;KIF22;AP1M2
protein dephosphorylation (GO:0006470),4/139,0.37381764812947194,0.43214740326500695,0,0,1.3047787016040984,1.2838855050892193,PTPRB;DUSP1;TNS2;PPP1CA
calcium-mediated signaling using intracellular calcium source (GO:0035584),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,KDR
cyclic purine nucleotide metabolic process (GO:0052652),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,ADCY5
extrinsic apoptotic signaling pathway in absence of ligand (GO:0097192),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,BAK1
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,BCL3
NAD biosynthetic process (GO:0009435),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,PTGS2
negative regulation of microtubule depolymerization (GO:0007026),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,CIB1
neurotrophin signaling pathway (GO:0038179),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,NGFR
nuclear-transcribed mRNA poly(A) tail shortening (GO:0000289),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,ZFP36
"nucleotide-excision repair, DNA incision, 3'-to lesion (GO:0006295)",1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,PARP1
"nucleotide-excision repair, preincision complex stabilization (GO:0006293)",1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,PARP1
positive regulation of immune system process (GO:0002684),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,ANXA1
positive regulation of transcription regulatory region DNA binding (GO:2000679),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,GATA3
protein localization to chromatin (GO:0071168),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,ESR1
regulation of anoikis (GO:2000209),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,CAV1
regulation of cardiac muscle contraction by calcium ion signaling (GO:0010882),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,DMD
regulation of fibroblast migration (GO:0010762),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,FGF2
regulation of lipid catabolic process (GO:0050994),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,ALK
regulation of lipoprotein lipase activity (GO:0051004),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,PCSK5
sensory perception of pain (GO:0019233),1/21,0.3767233311723716,0.43271759778747637,0,0,2.1998873873873874,2.1476273697252033,CCL2
protein localization to cell periphery (GO:1990778),4/140,0.37886801432740486,0.4350344315457533,0,0,1.2951180472188875,1.256999332093408,RAB3A;CAV1;EZR;RAMP1
antigen processing and presentation of peptide antigen via MHC class II (GO:0002495),3/100,0.3847888671570985,0.4416842233989194,0,0,1.3615244670429631,1.3003382275186661,RACGAP1;KIF22;AP1M2
protein ubiquitination (GO:0016567),13/525,0.38668257608130774,0.4437084913417835,0,0,1.1192446108217593,1.0634515421930497,BARD1;PRKN;TRIM63;EPAS1;SIAH2;PELI2;CBLC;DTX1;UBE2L6;KLHL3;BRCA1;KCTD13;ELOB
protein localization to organelle (GO:0033365),4/142,0.38895593303512027,0.4446174112049712,0,0,1.2762167668999966,1.205117741067429,COL1A1;SIX1;CALR;ZNF423
ubiquitin-dependent protein catabolic process (GO:0006511),9/354,0.3898290006717813,0.4446174112049712,0,0,1.1493817311527723,1.082771721827932,CDC20;PRKN;SIAH2;KCTD13;CBLC;UBE2L6;KLHL3;MAD2L1;AURKA
cellular response to nerve growth factor stimulus (GO:1990090),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,CIB1
error-free translesion synthesis (GO:0070987),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,RFC4
glutamate metabolic process (GO:0006536),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,GAD1
homologous chromosome segregation (GO:0045143),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,FANCD2
membrane protein intracellular domain proteolysis (GO:0031293),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,NGFR
natural killer cell mediated cytotoxicity (GO:0042267),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,GZMB
negative regulation of cyclin-dependent protein kinase activity (GO:1904030),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,CDKN2A
neuronal action potential (GO:0019228),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,SCN4A
"nucleotide-excision repair, DNA duplex unwinding (GO:0000717)",1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,PARP1
osteoclast differentiation (GO:0030316),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,TNFSF11
positive regulation of amyloid precursor protein catabolic process (GO:1902993),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,EFNA3
positive regulation of axon extension (GO:0045773),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,NRP1
positive regulation of calcium ion transmembrane transporter activity (GO:1901021),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,PKD2
positive regulation of dendritic spine development (GO:0060999),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,CAMK1
positive regulation of signal transduction by p53 class mediator (GO:1901798),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,PMAIP1
positive regulation of translational initiation (GO:0045948),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,HABP4
protein localization to cell junction (GO:1902414),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,NPHS1
regulation of adenylate cyclase activity (GO:0045761),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,AKAP5
regulation of centrosome cycle (GO:0046605),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,AURKA
regulation of macrophage chemotaxis (GO:0010758),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,MDK
regulation of vacuole organization (GO:0044088),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,ENO2
regulation of voltage-gated calcium channel activity (GO:1901385),1/22,0.39060578906915605,0.4446174112049712,0,0,2.095023595023595,1.9694404217914498,DMD
monocarboxylic acid metabolic process (GO:0032787),4/143,0.3939919277961806,0.44817239316735097,0,0,1.2669700973914746,1.1800874426996595,PER2;PPARG;CD36;PPARA
nitrogen compound transport (GO:0071705),4/143,0.3939919277961806,0.44817239316735097,0,0,1.2669700973914746,1.1800874426996595,CENPF;TXNIP;RAMP1;AQP1
positive regulation of interleukin-8 production (GO:0032757),2/61,0.3949001361348045,0.4490556102593973,0,0,1.4918315032329648,1.3860940158933641,IL6;FADD
stress-activated MAPK cascade (GO:0051403),2/62,0.40274231669348043,0.45610744210082566,0,0,1.4668924003009782,1.3340775188550404,ZFP36;ARHGEF6
antigen processing and presentation of exogenous peptide antigen (GO:0002478),3/103,0.4028240741775777,0.45610744210082566,0,0,1.320475113122172,1.2006490649106025,RACGAP1;KIF22;AP1M2
acylglycerol biosynthetic process (GO:0046463),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,PLA2G4A
DNA methylation (GO:0006306),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,FOS
ERK1 and ERK2 cascade (GO:0070371),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,KDR
hexose transmembrane transport (GO:0008645),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,SLC2A4
hyaluronan metabolic process (GO:0030212),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,FGF2
membrane protein ectodomain proteolysis (GO:0006509),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,PRTN3
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand (GO:2001240),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,TERT
negative regulation of intracellular protein transport (GO:0090317),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,BARD1
negative regulation of signal transduction in absence of ligand (GO:1901099),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,TERT
"nucleotide-excision repair, DNA damage recognition (GO:0000715)",1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,PARP1
positive regulation of natural killer cell mediated immunity (GO:0002717),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,NECTIN2
positive regulation of protein autophosphorylation (GO:0031954),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,PDGFA
positive regulation of receptor internalization (GO:0002092),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,SELE
positive regulation of transcription by RNA polymerase I (GO:0045943),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,ERBB2
regulation of cysteine-type endopeptidase activity (GO:2000116),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,NGFR
regulation of interleukin-4 production (GO:0032673),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,GATA3
regulation of mononuclear cell migration (GO:0071675),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,MDK
regulation of peptidase activity (GO:0052547),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,CAV1
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum (GO:0010880),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,DMD
response to copper ion (GO:0046688),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,AQP1
response to nutrient levels (GO:0031667),1/23,0.4041797168851213,0.45610744210082566,0,0,1.9996928746928746,1.8115130888375652,FAM107A
organonitrogen compound catabolic process (GO:1901565),2/63,0.4105359566580555,0.46312695805715093,0,0,1.4427709728749585,1.2844871109967382,CAPN3;PLA2G4A
activation of GTPase activity (GO:0090630),3/105,0.4147639607873167,0.46774175326379064,0,0,1.294450359329252,1.1391754593219852,ARHGEF15;CCL21;ECT2
DNA packaging (GO:0006323),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,CHAF1A
immune response-activating cell surface receptor signaling pathway (GO:0002429),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,CR1
lymphocyte activation involved in immune response (GO:0002285),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,MDK
negative regulation of lipid metabolic process (GO:0045833),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,ALK
negative regulation of protein depolymerization (GO:1901880),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,CIB1
"nucleotide-excision repair, DNA gap filling (GO:0006297)",1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,RFC4
peptidyl-glutamic acid modification (GO:0018200),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,PARP1
phospholipid catabolic process (GO:0009395),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,PLA2G4A
positive regulation of viral life cycle (GO:1903902),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,KPNA2
protein insertion into mitochondrial membrane (GO:0051204),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,PMAIP1
regulation of monooxygenase activity (GO:0032768),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,CAV1
regulation of vascular endothelial growth factor receptor signaling pathway (GO:0030947),1/24,0.41745195646431593,0.4689110967799567,0,0,1.9126517822169997,1.6708654672219938,VTN
antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844),2/64,0.41827933267620815,0.46922184521412685,0,0,1.4194276560110681,1.2371813913610101,CCL13;CXCL10
lipid homeostasis (GO:0055088),2/64,0.41827933267620815,0.46922184521412685,0,0,1.4194276560110681,1.2371813913610101,IRS2;PPARG
pre-replicative complex assembly (GO:0036388),2/64,0.41827933267620815,0.46922184521412685,0,0,1.4194276560110681,1.2371813913610101,CDT1;MCM4
regulation of cilium assembly (GO:1902017),2/64,0.41827933267620815,0.46922184521412685,0,0,1.4194276560110681,1.2371813913610101,YAP1;MAPK15
protein processing (GO:0016485),3/106,0.42070554933228227,0.4717882567043165,0,0,1.2818169837016211,1.109825469774558,MMP14;F12;PCSK5
protein autoubiquitination (GO:0051865),2/65,0.42597082183565016,0.47753571079470253,0,0,1.3968253968253967,1.1920290428473597,PRKN;BRCA1
acylglycerol homeostasis (GO:0055090),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,IL18
cAMP-mediated signaling (GO:0019933),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,RIMS2
cellular response to hexose stimulus (GO:0071331),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,PAX2
negative regulation of actin filament polymerization (GO:0030837),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,VIL1
negative regulation of cell junction assembly (GO:1901889),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,FAM107A
negative regulation of cellular carbohydrate metabolic process (GO:0010677),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,PPARA
negative regulation of response to endoplasmic reticulum stress (GO:1903573),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,PRKN
negative regulation of signaling (GO:0023057),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,TRAT1
receptor catabolic process (GO:0032801),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,GPRASP1
regulation of cAMP-mediated signaling (GO:0043949),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,PRKAR2B
regulation of cardiac muscle cell action potential (GO:0098901),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,CAV1
regulation of cholesterol transport (GO:0032374),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,LRP1
regulation of epidermal cell differentiation (GO:0045604),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,ZFP36
regulation of microtubule depolymerization (GO:0031114),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,CIB1
regulation of rhodopsin mediated signaling pathway (GO:0022400),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,NMT2
regulation of spindle assembly (GO:0090169),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,GPSM2
response to dsRNA (GO:0043331),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,PMAIP1
"RNA splicing, via transesterification reactions (GO:0000375)",1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,LSM1
ventricular cardiac muscle tissue development (GO:0003229),1/25,0.43042919810686536,0.47953668098993046,0,0,1.8328641141141142,1.5450539215743864,PROX1
negative regulation of G2/M transition of mitotic cell cycle (GO:0010972),2/66,0.43360889779933764,0.4827635163999159,0,0,1.3749294582392777,1.1489079783659282,CHEK1;AURKA
regulation of protein localization (GO:0032880),2/66,0.43360889779933764,0.4827635163999159,0,0,1.3749294582392777,1.1489079783659282,PARP1;CAMK1
transcription elongation from RNA polymerase II promoter (GO:0006368),2/67,0.44119212762556526,0.4898300650155245,0,0,1.3537072408404236,1.1077045689462202,ELOB;POLR2H
cellular response to drug (GO:0035690),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,MEF2C
clathrin-dependent endocytosis (GO:0072583),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,ITSN1
global genome nucleotide-excision repair (GO:0070911),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,PARP1
histone methylation (GO:0016571),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,EZH2
membrane depolarization during action potential (GO:0086010),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,SCN4A
mononuclear cell differentiation (GO:1903131),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,PPARG
negative regulation of cell development (GO:0010721),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,IL6
negative regulation of macroautophagy (GO:0016242),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,FEZ1
negative regulation of telomere maintenance via telomere lengthening (GO:1904357),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,PARP1
positive regulation of glucose import (GO:0046326),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,IRS2
positive regulation of histone methylation (GO:0031062),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,BRCA1
positive regulation of interleukin-2 production (GO:0032743),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,ANXA1
positive regulation of ion transmembrane transporter activity (GO:0032414),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,DMD
positive regulation of microtubule polymerization or depolymerization (GO:0031112),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,MET
positive regulation of viral transcription (GO:0050434),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,POLR2H
proteoglycan metabolic process (GO:0006029),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,BMPR1B
regulation of biomineral tissue development (GO:0070167),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,S1PR1
regulation of glycogen biosynthetic process (GO:0005979),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,IRS2
regulation of mitotic metaphase/anaphase transition (GO:0030071),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,DUSP1
regulation of myelination (GO:0031641),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,EGR2
regulation of synapse organization (GO:0050807),1/26,0.44311798428487736,0.4898300650155245,0,0,1.7594594594594595,1.432057860629081,MEF2C
regulation of interleukin-6 production (GO:0032675),3/110,0.44425921865722495,0.49077323085375124,0,0,1.233644859813084,1.000914131457046,IL6;MAPKAPK2;SIRPA
regulation of protein kinase activity (GO:0045859),3/110,0.44425921865722495,0.49077323085375124,0,0,1.233644859813084,1.000914131457046,CCL21;CCL19;ECT2
interferon-gamma-mediated signaling pathway (GO:0060333),2/68,0.44871916814793883,0.49537898446652917,0,0,1.3331281209385046,1.0683129482186473,STAT1;IRF7
regulation of translational initiation (GO:0006446),2/68,0.44871916814793883,0.49537898446652917,0,0,1.3331281209385046,1.0683129482186473,HABP4;ATF3
microtubule polymerization or depolymerization (GO:0031109),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,STMN1
mitotic chromosome condensation (GO:0007076),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,H4-16
modulation of excitatory postsynaptic potential (GO:0098815),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,RIMS2
negative regulation of catalytic activity (GO:0043086),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,TIMP1
negative regulation of cation channel activity (GO:2001258),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,PKD2
negative regulation of insulin receptor signaling pathway (GO:0046627),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,TNS2
nucleobase-containing small molecule interconversion (GO:0015949),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,NME3
peptidyl-lysine methylation (GO:0018022),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,ANTKMT
positive regulation of nuclear division (GO:0051785),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,AURKA
positive regulation of toll-like receptor signaling pathway (GO:0034123),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,CAV1
presynaptic endocytosis (GO:0140238),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,SNCG
protein peptidyl-prolyl isomerization (GO:0000413),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,FKBP4
regulation of cardiac muscle cell contraction (GO:0086004),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,CAV1
regulation of cell junction assembly (GO:1901888),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,MEF2C
regulation of epidermal growth factor-activated receptor activity (GO:0007176),1/27,0.45552471259808147,0.500460419256693,0,0,1.6917013167013166,1.3301937282071303,CBLC
"DNA-templated transcription, elongation (GO:0006354)",2/69,0.4561887628787504,0.5010284575864586,0,0,1.3131633031232102,1.030634381920511,ELOB;POLR2H
defense response to Gram-positive bacterium (GO:0050830),2/70,0.46359973871320415,0.5086760816273662,0,0,1.2937856858318948,0.9945766975400535,IL6;PLA2G2A
"DNA-templated transcription, termination (GO:0006353)",2/70,0.46359973871320415,0.5086760816273662,0,0,1.2937856858318948,0.9945766975400535,SNRPE;POLR2H
establishment of protein localization to membrane (GO:0090150),2/70,0.46359973871320415,0.5086760816273662,0,0,1.2937856858318948,0.9945766975400535,NACAD;NECTIN3
amide transport (GO:0042886),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,TAP1
cytosolic calcium ion transport (GO:0060401),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,ADRA1A
glycerophospholipid catabolic process (GO:0046475),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,PLA2G4A
glycogen metabolic process (GO:0005977),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,PER2
keratan sulfate biosynthetic process (GO:0018146),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,ACAN
macromolecule catabolic process (GO:0009057),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,CAPN3
negative regulation of axonogenesis (GO:0050771),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,NGFR
negative regulation of calcium ion transmembrane transporter activity (GO:1901020),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,PKD2
negative regulation of cellular response to insulin stimulus (GO:1900077),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,TNS2
positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway (GO:0051482),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,F2RL2
positive regulation of defense response to virus by host (GO:0002230),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,STAT1
positive regulation of microtubule polymerization (GO:0031116),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,MET
positive regulation of monooxygenase activity (GO:0032770),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,TERT
positive regulation of protein import into nucleus (GO:0042307),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,ECT2
protein localization to cell surface (GO:0034394),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,FGF7
receptor clustering (GO:0043113),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,DLG2
regulation of B cell activation (GO:0050864),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,IL6
regulation of calcium-mediated signaling (GO:0050848),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,TRAT1
"regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043516)",1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,PMAIP1
regulation of insulin secretion involved in cellular response to glucose stimulus (GO:0061178),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,ADCY5
regulation of muscle contraction (GO:0006937),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,CAV1
regulation of phosphatase activity (GO:0010921),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,BMP2
regulation of postsynapse organization (GO:0099175),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,CFL1
sulfur compound transport (GO:0072348),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,RACGAP1
T cell activation involved in immune response (GO:0002286),1/28,0.467655639053765,0.5090291976669534,0,0,1.6289622956289622,1.2380489214110837,MDK
cellular response to starvation (GO:0009267),4/158,0.46838023462127787,0.5096551211970993,0,0,1.1426804488028979,0.8666943772019071,PMAIP1;PRKD1;PPARA;FOXO1
homologous chromosome pairing at meiosis (GO:0007129),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,FANCD2
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress (GO:0070059),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,BAK1
MyD88-dependent toll-like receptor signaling pathway (GO:0002755),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,CD36
negative regulation of mRNA catabolic process (GO:1902373),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,E2F1
negative regulation of myeloid leukocyte differentiation (GO:0002762),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,INHBA
"nucleotide-excision repair, preincision complex assembly (GO:0006294)",1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,PARP1
protein ADP-ribosylation (GO:0006471),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,PARP1
protein K11-linked ubiquitination (GO:0070979),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,PRKN
regulation of calcium ion transmembrane transporter activity (GO:1901019),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,DMD
regulation of double-strand break repair via nonhomologous end joining (GO:2001032),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,HMGA2
regulation of fatty acid biosynthetic process (GO:0042304),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,BRCA1
regulation of gluconeogenesis (GO:0006111),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,PPARGC1A
regulation of response to biotic stimulus (GO:0002831),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,CD36
regulation of T cell mediated cytotoxicity (GO:0001914),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,FADD
telomere maintenance via telomerase (GO:0007004),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,TERT
transition metal ion homeostasis (GO:0055076),1/29,0.47951688118768576,0.5191211979312684,0,0,1.5707046332046333,1.154430490380118,PRKN
endoplasmic reticulum organization (GO:0007029),2/73,0.4854704091380485,0.5252327474103077,0,0,1.2389279242043685,0.8952950869520314,CAV2;MAPK15
transcription-coupled nucleotide-excision repair (GO:0006283),2/73,0.4854704091380485,0.5252327474103077,0,0,1.2389279242043685,0.8952950869520314,RFC4;POLR2H
cardiac muscle cell action potential (GO:0086001),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,DMD
extrinsic apoptotic signaling pathway via death domain receptors (GO:0008625),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,FADD
heterotypic cell-cell adhesion (GO:0034113),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,PARVA
ion homeostasis (GO:0050801),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,KLHL3
long-chain fatty acid biosynthetic process (GO:0042759),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,PTGS2
microtubule polymerization (GO:0046785),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,TUBG1
morphogenesis of an epithelium (GO:0002009),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,SOX10
ncRNA catabolic process (GO:0034661),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,EXOSC4
negative regulation of Notch signaling pathway (GO:0045746),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,MMP14
peptidyl-lysine trimethylation (GO:0018023),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,ANTKMT
positive regulation of DNA recombination (GO:0045911),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,PARP1
positive regulation of phosphate metabolic process (GO:0045937),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,NRP1
positive regulation of protein import (GO:1904591),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,ECT2
positive regulation of small GTPase mediated signal transduction (GO:0051057),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,IRS2
primary neural tube formation (GO:0014020),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,PAX2
regulation of macrophage activation (GO:0043030),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,IL6
regulation of natural killer cell mediated cytotoxicity (GO:0042269),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,NECTIN2
regulation of type I interferon-mediated signaling pathway (GO:0060338),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,FADD
RNA-dependent DNA biosynthetic process (GO:0006278),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,TERT
snRNA 3'-end processing (GO:0034472),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,EXOSC4
termination of RNA polymerase I transcription (GO:0006363),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,POLR2H
zinc ion homeostasis (GO:0055069),1/30,0.4911144211810633,0.5276538295665397,0,0,1.5164647406026717,1.0783249291066916,PRKN
positive regulation of immune response (GO:0050778),2/75,0.49973973573890235,0.5365825517952676,0,0,1.2048610037416123,0.8357733355130279,FADD;SKAP1
regulation of transcription from RNA polymerase II promoter in response to hypoxia (GO:0061418),2/75,0.49973973573890235,0.5365825517952676,0,0,1.2048610037416123,0.8357733355130279,EPAS1;ELOB
aminoglycan catabolic process (GO:0006026),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,SDC1
negative regulation of axon extension (GO:0030517),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,SEMA3F
negative regulation of interleukin-6 production (GO:0032715),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,SIRPA
negative regulation of osteoblast differentiation (GO:0045668),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,PPARG
negative regulation of response to biotic stimulus (GO:0002832),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,SIGIRR
negative regulation of response to DNA damage stimulus (GO:2001021),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,CXCL12
phosphatidylethanolamine metabolic process (GO:0046337),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,PLA2G2A
positive regulation of proteolysis involved in cellular protein catabolic process (GO:1903052),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,PRKN
positive regulation of RNA splicing (GO:0033120),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,HABP4
positive regulation of ubiquitin-protein transferase activity (GO:0051443),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,CDC20
protein acetylation (GO:0006473),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,FOXO1
proteoglycan biosynthetic process (GO:0030166),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,BMPR1B
triglyceride homeostasis (GO:0070328),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,IL18
tube closure (GO:0060606),1/31,0.5024541087705208,0.537127855297972,0,0,1.4658408408408408,1.0088663791805634,PAX2
phospholipid metabolic process (GO:0006644),2/76,0.5067786590625278,0.5414111818448573,0,0,1.18851808919529,0.8078130927983117,PLA2G2A;PLA2G4A
regulation of RNA splicing (GO:0043484),2/76,0.5067786590625278,0.5414111818448573,0,0,1.18851808919529,0.8078130927983117,HABP4;QKI
7-methylguanosine mRNA capping (GO:0006370),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,POLR2H
7-methylguanosine RNA capping (GO:0009452),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,POLR2H
B cell proliferation (GO:0042100),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,MEF2C
gene silencing by miRNA (GO:0035195),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,ZFP36
negative regulation of chemotaxis (GO:0050922),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,SEMA3F
negative regulation of developmental growth (GO:0048640),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,FGFR3
negative regulation of double-strand break repair (GO:2000780),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,HMGA2
peptidyl-proline modification (GO:0018208),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,FKBP4
positive regulation of interleukin-10 production (GO:0032733),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,IL6
positive regulation of lamellipodium organization (GO:1902745),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,VIL1
regulation of dendritic spine morphogenesis (GO:0061001),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,CFL1
RNA biosynthetic process (GO:0032774),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,TERT
transcription initiation from RNA polymerase I promoter (GO:0006361),1/32,0.513541664371444,0.5462931925019037,0,0,1.4184829991281604,0.9453112771784983,POLR2H
phosphatidylcholine metabolic process (GO:0046470),2/77,0.513752840953228,0.5462931925019037,0,0,1.1726109857035365,0.780974140898587,PLA2G2A;PLA2G4A
regulation of organelle assembly (GO:1902115),2/77,0.513752840953228,0.5462931925019037,0,0,1.1726109857035365,0.780974140898587,EZR;MAPK15
protein modification process (GO:0036211),2/78,0.5206616727095973,0.5534669309402082,0,0,1.157122490198408,0.7552015806987864,PARP1;UBE2L6
apoptotic mitochondrial changes (GO:0008637),1/33,0.5243826815523948,0.5565544001029464,0,0,1.3740850225225225,0.8870179865761124,BAK1
keratan sulfate metabolic process (GO:0042339),1/33,0.5243826815523948,0.5565544001029464,0,0,1.3740850225225225,0.8870179865761124,ACAN
positive regulation of cytokine production involved in immune response (GO:0002720),1/33,0.5243826815523948,0.5565544001029464,0,0,1.3740850225225225,0.8870179865761124,KIT
RNA stabilization (GO:0043489),1/33,0.5243826815523948,0.5565544001029464,0,0,1.3740850225225225,0.8870179865761124,E2F1
very long-chain fatty acid metabolic process (GO:0000038),1/33,0.5243826815523948,0.5565544001029464,0,0,1.3740850225225225,0.8870179865761124,SLC27A6
negative regulation of NF-kappaB transcription factor activity (GO:0032088),2/79,0.5275046045355849,0.5595193564448407,0,0,1.1420362932778283,0.7304437690154189,CDKN2A;KLF4
positive regulation of ubiquitin-dependent protein catabolic process (GO:2000060),2/79,0.5275046045355849,0.5595193564448407,0,0,1.1420362932778283,0.7304437690154189,PRKN;ELOB
protein targeting (GO:0006605),3/125,0.5287480625442925,0.5606637825609673,0,0,1.0811327052889252,0.6889444786324941,HOMER3;NACAD;AP1M2
synapse organization (GO:0050808),3/126,0.534127789297672,0.565164539283177,0,0,1.0722878269506677,0.6724533166595085,CTNND2;SNCG;PAK3
glycerophospholipid metabolic process (GO:0006650),2/80,0.5342811431804612,0.565164539283177,0,0,1.1273369219193148,0.7066520898565954,PLA2G2A;PLA2G4A
central nervous system neuron differentiation (GO:0021953),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,PROX1
female gamete generation (GO:0007292),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,MDK
histone lysine methylation (GO:0034968),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,EZH2
neural tube closure (GO:0001843),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,PAX2
positive regulation of protein dephosphorylation (GO:0035307),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,CDH5
protein localization to chromosome (GO:0034502),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,ESR1
regulation of amyloid-beta formation (GO:1902003),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,BIN1
regulation of keratinocyte differentiation (GO:0045616),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,ZFP36
termination of RNA polymerase II transcription (GO:0006369),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,SNRPE
transcription by RNA polymerase I (GO:0006360),1/34,0.5349826302017398,0.565164539283177,0,0,1.3323778323778324,0.8334303134550379,POLR2H
negative regulation of T cell proliferation (GO:0042130),1/35,0.5453468590760396,0.5748660982774956,0,0,1.2931240063593006,0.784064078957,CR1
positive regulation of lipid biosynthetic process (GO:0046889),1/35,0.5453468590760396,0.5748660982774956,0,0,1.2931240063593006,0.784064078957,PPARA
positive regulation of reproductive process (GO:2000243),1/35,0.5453468590760396,0.5748660982774956,0,0,1.2931240063593006,0.784064078957,INHBA
regulation of autophagosome assembly (GO:2000785),1/35,0.5453468590760396,0.5748660982774956,0,0,1.2931240063593006,0.784064078957,FEZ1
regulation of mitotic spindle organization (GO:0060236),1/35,0.5453468590760396,0.5748660982774956,0,0,1.2931240063593006,0.784064078957,GPSM2
regulation of protein polymerization (GO:0032271),1/35,0.5453468590760396,0.5748660982774956,0,0,1.2931240063593006,0.784064078957,PAK3
response to exogenous dsRNA (GO:0043330),1/35,0.5453468590760396,0.5748660982774956,0,0,1.2931240063593006,0.784064078957,CAV1
cilium assembly (GO:0060271),7/314,0.5510859485195837,0.5805566963074934,0,0,1.0020079425282227,0.5970609572316258,PLK4;PRKAR2B;RFX2;PARVA;NEK2;TUBG1;SSX2IP
protein polyubiquitination (GO:0000209),7/314,0.5510859485195837,0.5805566963074934,0,0,1.0020079425282227,0.5970609572316258,BARD1;PRKN;SIAH2;PELI2;UBE2L6;KLHL3;BRCA1
long-chain fatty acid metabolic process (GO:0001676),2/83,0.5542082718822915,0.5814121252252499,0,0,1.0854164924894798,0.6406287921288635,PLA2G4A;PTGS2
peptide metabolic process (GO:0006518),2/83,0.5542082718822915,0.5814121252252499,0,0,1.0854164924894798,0.6406287921288635,DMD;PCSK5
positive regulation of canonical Wnt signaling pathway (GO:0090263),3/130,0.5552941988597291,0.5814121252252499,0,0,1.0383012078241352,0.6107881795943392,COL1A1;CAV1;RUVBL1
axonal transport (GO:0098930),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,DST
calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules (GO:0016339),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,CDH5
cellular response to heat (GO:0034605),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,FGF1
establishment of protein localization to plasma membrane (GO:0061951),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,NECTIN3
mitochondrion disassembly (GO:0061726),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,PRKN
negative regulation of cellular protein localization (GO:1903828),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,CDT1
negative regulation of DNA metabolic process (GO:0051053),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,BLM
positive regulation of innate immune response (GO:0045089),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,FADD
positive regulation of interferon-beta production (GO:0032728),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,IRF7
positive regulation of mitotic nuclear division (GO:0045840),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,AURKA
positive regulation of T cell mediated immunity (GO:0002711),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,FADD
regulation of androgen receptor signaling pathway (GO:0060765),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,H4-16
regulation of defense response to virus by host (GO:0050691),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,STAT1
regulation of mRNA processing (GO:0050684),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,QKI
regulation of osteoclast differentiation (GO:0045670),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,TNFSF11
regulation of protein import into nucleus (GO:0042306),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,ECT2
regulation of receptor internalization (GO:0002090),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,SELE
regulation of sodium ion transport (GO:0002028),1/36,0.5554805985133255,0.5814121252252499,0,0,1.2561132561132562,0.7384961111462957,NKX2-5
spindle assembly (GO:0051225),2/84,0.5607153623326586,0.5867110699507831,0,0,1.072124649011727,0.6202690076095779,RCC1;NEK2
anterograde axonal transport (GO:0008089),1/37,0.565388963002432,0.5910569281939535,0,0,1.2211586586586587,0.6963551676977084,DLG2
regulation of glucose import (GO:0046324),1/37,0.565388963002432,0.5910569281939535,0,0,1.2211586586586587,0.6963551676977084,IRS2
regulation of protein autophosphorylation (GO:0031952),1/37,0.565388963002432,0.5910569281939535,0,0,1.2211586586586587,0.6963551676977084,PDGFA
RNA processing (GO:0006396),4/179,0.56617965280406,0.591702010658153,0,0,1.0044703595724005,0.5713867798814928,WT1;LSM1;PPARGC1A;LSM4
B cell activation (GO:0042113),2/85,0.5671543676226083,0.5923573658773672,0,0,1.0591530909189806,0.6006708822847219,MEF2C;KIT
"retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890)",2/85,0.5671543676226083,0.5923573658773672,0,0,1.0591530909189806,0.6006708822847219,RACGAP1;KIF22
positive regulation of proteasomal protein catabolic process (GO:1901800),2/86,0.5735250897167194,0.5988276672042219,0,0,1.04649037944749,0.5818000885379752,PRKN;ELOB
mRNA destabilization (GO:0061157),1/38,0.5750769539571536,0.6000802997813777,0,0,1.1880934989043097,0.6573144084357728,ZFP36
positive regulation of potassium ion transport (GO:0043268),1/38,0.5750769539571536,0.6000802997813777,0,0,1.1880934989043097,0.6573144084357728,GNG2
cilium organization (GO:0044782),5/228,0.5753621017698187,0.6001940749407843,0,0,0.9851202609050143,0.5445308336681449,PLK4;RFX2;PARVA;PKD2;SSX2IP
sodium ion transmembrane transport (GO:0035725),2/87,0.579827373237779,0.6046669791904378,0,0,1.0341256141282698,0.5636241598844232,SCN4A;PKD2
negative regulation of protein secretion (GO:0050709),1/39,0.5845494618591173,0.6081027368790818,0,0,1.1567686107159791,0.6210851220432462,PRKN
negative regulation of secretion by cell (GO:1903531),1/39,0.5845494618591173,0.6081027368790818,0,0,1.1567686107159791,0.6210851220432462,ANXA1
protein acylation (GO:0043543),1/39,0.5845494618591173,0.6081027368790818,0,0,1.1567686107159791,0.6210851220432462,FOXO1
protein monoubiquitination (GO:0006513),1/39,0.5845494618591173,0.6081027368790818,0,0,1.1567686107159791,0.6210851220432462,PRKN
regulation of dendrite development (GO:0050773),1/39,0.5845494618591173,0.6081027368790818,0,0,1.1567686107159791,0.6210851220432462,ALK
regulation of peptidyl-threonine phosphorylation (GO:0010799),1/39,0.5845494618591173,0.6081027368790818,0,0,1.1567686107159791,0.6210851220432462,SPRY2
regulation of protein targeting to mitochondrion (GO:1903214),1/39,0.5845494618591173,0.6081027368790818,0,0,1.1567686107159791,0.6210851220432462,PRKN
regulation of viral entry into host cell (GO:0046596),1/39,0.5845494618591173,0.6081027368790818,0,0,1.1567686107159791,0.6210851220432462,NECTIN2
endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888),4/185,0.5922607525612448,0.6159367240551487,0,0,0.970872326831285,0.5085509642625623,SPTA1;PROC;PROS1;SPTB
autophagy of mitochondrion (GO:0000422),1/40,0.593811268947025,0.6162328881155484,0,0,1.127050127050127,0.5874114699283974,PRKN
bone development (GO:0060348),1/40,0.593811268947025,0.6162328881155484,0,0,1.127050127050127,0.5874114699283974,FGFR3
carboxylic acid metabolic process (GO:0019752),1/40,0.593811268947025,0.6162328881155484,0,0,1.127050127050127,0.5874114699283974,PLA2G4A
intraciliary transport involved in cilium assembly (GO:0035735),1/40,0.593811268947025,0.6162328881155484,0,0,1.127050127050127,0.5874114699283974,SSX2IP
negative regulation of cell-substrate adhesion (GO:0010812),1/40,0.593811268947025,0.6162328881155484,0,0,1.127050127050127,0.5874114699283974,CDKN2A
nucleocytoplasmic transport (GO:0006913),1/40,0.593811268947025,0.6162328881155484,0,0,1.127050127050127,0.5874114699283974,SNRPE
positive regulation of double-strand break repair (GO:2000781),1/40,0.593811268947025,0.6162328881155484,0,0,1.127050127050127,0.5874114699283974,PARP1
negative regulation of protein kinase activity (GO:0006469),2/90,0.5983226360223547,0.620536683981797,0,0,0.998717422532321,0.5129663813635347,PTPRB;CAV1
negative regulation of translation (GO:0017148),2/90,0.5983226360223547,0.620536683981797,0,0,0.998717422532321,0.5129663813635347,GZMB;CALR
cellular protein localization (GO:0034613),7/329,0.6004819361450155,0.622586686456408,0,0,0.9545860631328171,0.48686057969789315,NGFR;CNTNAP2;FGF7;ITSN1;CAPN3;DMD;STX11
potassium ion transmembrane transport (GO:0071805),3/139,0.6007529059476459,0.6226781944858811,0,0,0.9691409369177535,0.4938466660412258,KCNK15;KCNQ5;PKD2
acylglycerol metabolic process (GO:0006639),1/41,0.6028670517114371,0.6237313030457127,0,0,1.0988175675675675,0.5560660630365292,CAV1
JNK cascade (GO:0007254),1/41,0.6028670517114371,0.6237313030457127,0,0,1.0988175675675675,0.5560660630365292,ARHGEF6
positive regulation of cation transmembrane transport (GO:1904064),1/41,0.6028670517114371,0.6237313030457127,0,0,1.0988175675675675,0.5560660630365292,GNG2
protein methylation (GO:0006479),1/41,0.6028670517114371,0.6237313030457127,0,0,1.0988175675675675,0.5560660630365292,EZH2
regulation of protein dephosphorylation (GO:0035304),1/41,0.6028670517114371,0.6237313030457127,0,0,1.0988175675675675,0.5560660630365292,CDH5
regulation of response to DNA damage stimulus (GO:2001020),1/41,0.6028670517114371,0.6237313030457127,0,0,1.0988175675675675,0.5560660630365292,HMGA2
organelle assembly (GO:0070925),9/425,0.6067367065702199,0.6275443690413687,0,0,0.9496901464361327,0.4745225051219099,PLK4;CENPF;RFX2;RCC1;CAPN3;NEK2;PARVA;LSM4;SSX2IP
Wnt signaling pathway (GO:0016055),2/92,0.6103095174758383,0.6310481903997746,0,0,0.9764233759719088,0.48214716614490605,TCF7L2;RAC3
cellular respiration (GO:0045333),1/42,0.6117213828914553,0.631932850225547,0,0,1.0719622061085476,0.5268462236570121,PPARGC1A
histone H3 acetylation (GO:0043966),1/42,0.6117213828914553,0.631932850225547,0,0,1.0719622061085476,0.5268462236570121,BRCA2
positive regulation of protein tyrosine kinase activity (GO:0061098),1/42,0.6117213828914553,0.631932850225547,0,0,1.0719622061085476,0.5268462236570121,AGT
cellular response to glucose starvation (GO:0042149),1/43,0.6203787340224783,0.6402939810867978,0,0,1.0463856713856714,0.4995708111275468,PMAIP1
positive regulation of axonogenesis (GO:0050772),1/43,0.6203787340224783,0.6402939810867978,0,0,1.0463856713856714,0.4995708111275468,NGFR
regulation of cell-substrate adhesion (GO:0010810),1/43,0.6203787340224783,0.6402939810867978,0,0,1.0463856713856714,0.4995708111275468,FBLN2
interleukin-1-mediated signaling pathway (GO:0070498),2/94,0.6220221221507382,0.6417957590946762,0,0,0.9550986357836883,0.45346136804439363,EGR1;PELI2
antibacterial humoral response (GO:0019731),1/44,0.6288434776595022,0.6476574710980911,0,0,1.0219987429289754,0.4740775169964907,CTSG
cation transmembrane transport (GO:0098655),1/44,0.6288434776595022,0.6476574710980911,0,0,1.0219987429289754,0.4740775169964907,PKD2
metal ion homeostasis (GO:0055065),1/44,0.6288434776595022,0.6476574710980911,0,0,1.0219987429289754,0.4740775169964907,CAV1
positive regulation of mRNA catabolic process (GO:0061014),1/44,0.6288434776595022,0.6476574710980911,0,0,1.0219987429289754,0.4740775169964907,ZFP36
positive regulation of potassium ion transmembrane transport (GO:1901381),1/44,0.6288434776595022,0.6476574710980911,0,0,1.0219987429289754,0.4740775169964907,GNG2
protein K63-linked ubiquitination (GO:0070534),1/44,0.6288434776595022,0.6476574710980911,0,0,1.0219987429289754,0.4740775169964907,PRKN
chromosome condensation (GO:0030261),1/45,0.6371198893974103,0.6553892493408917,0,0,0.9987203112203112,0.45022055128879274,H4-16
negative regulation of T cell activation (GO:0050868),1/45,0.6371198893974103,0.6553892493408917,0,0,0.9987203112203112,0.45022055128879274,CR1
positive regulation of response to biotic stimulus (GO:0002833),1/45,0.6371198893974103,0.6553892493408917,0,0,0.9987203112203112,0.45022055128879274,PRKCA
regulation of insulin receptor signaling pathway (GO:0046626),1/45,0.6371198893974103,0.6553892493408917,0,0,0.9987203112203112,0.45022055128879274,TNS2
establishment of protein localization to extracellular region (GO:0035592),1/46,0.6452121502591643,0.6629131769922316,0,0,0.9764764764764765,0.4278686553140678,RAB3A
negative regulation of tumor necrosis factor production (GO:0032720),1/46,0.6452121502591643,0.6629131769922316,0,0,0.9764764764764765,0.4278686553140678,SIRPA
regulation of cellular protein localization (GO:1903827),1/46,0.6452121502591643,0.6629131769922316,0,0,0.9764764764764765,0.4278686553140678,PARP1
spliceosomal complex assembly (GO:0000245),1/46,0.6452121502591643,0.6629131769922316,0,0,0.9764764764764765,0.4278686553140678,SNRPE
organic anion transport (GO:0015711),2/99,0.6501105053407688,0.6677446058472996,0,0,0.905634032254311,0.3899777171865873,CA12;AQP1
histone deacetylation (GO:0016575),1/47,0.653124348544114,0.6699484561270648,0,0,0.9551997649823737,0.40690339035017986,PER2
negative regulation of cold-induced thermogenesis (GO:0120163),1/47,0.653124348544114,0.6699484561270648,0,0,0.9551997649823737,0.40690339035017986,ZNF423
polyol metabolic process (GO:0019751),1/47,0.653124348544114,0.6699484561270648,0,0,0.9551997649823737,0.40690339035017986,ITPKA
regulation of synapse assembly (GO:0051963),1/47,0.653124348544114,0.6699484561270648,0,0,0.9551997649823737,0.40690339035017986,MEF2C
regulation of macromolecule metabolic process (GO:0060255),4/200,0.6532390609478392,0.6699484561270648,0,0,0.8958767180341525,0.38147516483776084,SIRPA;PROX1;ASCL1;HNRNPAB
cognition (GO:0050890),1/48,0.6608604820941782,0.6769499618205468,0,0,0.9348284454667434,0.38721765772919703,FAM107A
negative regulation of tumor necrosis factor superfamily cytokine production (GO:1903556),1/48,0.6608604820941782,0.6769499618205468,0,0,0.9348284454667434,0.38721765772919703,SIRPA
purine ribonucleotide biosynthetic process (GO:0009152),1/48,0.6608604820941782,0.6769499618205468,0,0,0.9348284454667434,0.38721765772919703,ADCY5
regulation of interleukin-10 production (GO:0032653),1/48,0.6608604820941782,0.6769499618205468,0,0,0.9348284454667434,0.38721765772919703,IL6
dephosphorylation (GO:0016311),3/153,0.6651514765456613,0.681140694731855,0,0,0.8780542986425339,0.35801828118227125,PTPRB;DUSP1;PPP1CA
regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032434),2/102,0.6661537823597375,0.6819621779158864,0,0,0.8783295711060948,0.35680797674199366,PRKN;ELOB
aminoglycan biosynthetic process (GO:0006023),1/49,0.6684244600076338,0.6838758810285248,0,0,0.9153059309309309,0.36871441631461443,SDC1
secondary alcohol metabolic process (GO:1902652),1/49,0.6684244600076338,0.6838758810285248,0,0,0.9153059309309309,0.36871441631461443,APOB
proteasomal protein catabolic process (GO:0010498),4/205,0.6721570925001955,0.6874884067348939,0,0,0.8733655983122934,0.34695600989005704,PRKN;SIAH2;KCTD13;PMAIP1
organic hydroxy compound biosynthetic process (GO:1901617),1/50,0.6758201050546626,0.6908203113456179,0,0,0.8965802537231109,0.3513055660651524,PER2
regulation of cellular component movement (GO:0051270),1/50,0.6758201050546626,0.6908203113456179,0,0,0.8965802537231109,0.3513055660651524,ERBB2
mRNA transport (GO:0051028),2/104,0.6765165576609239,0.6913248661194689,0,0,0.8610188996591864,0.33648477063768306,ZFP36;DDX39A
regulation of protein modification process (GO:0031399),1/51,0.6830511550145831,0.6975841583127657,0,0,0.8786036036036036,0.33491097562862443,CDH5
sensory perception (GO:0007600),1/51,0.6830511550145831,0.6975841583127657,0,0,0.8786036036036036,0.33491097562862443,CCL2
positive regulation of developmental growth (GO:0048639),1/52,0.6901212649834398,0.704593550348581,0,0,0.8613319201554496,0.31945763054911464,RIMS2
positive regulation of NIK/NF-kappaB signaling (GO:1901224),1/53,0.6970340091800276,0.7114381261711692,0,0,0.8447245322245323,0.3048788868857733,CCL19
glycosaminoglycan metabolic process (GO:0030203),1/54,0.7037928824962,0.7176918442690154,0,0,0.8287438381778004,0.29111381527145186,SDC1
regulation of proteasomal protein catabolic process (GO:0061136),1/54,0.7037928824962,0.7176918442690154,0,0,0.8287438381778004,0.29111381527145186,PRKN
unsaturated fatty acid metabolic process (GO:0033559),1/54,0.7037928824962,0.7176918442690154,0,0,0.8287438381778004,0.29111381527145186,PLA2G4A
protein sumoylation (GO:0016925),1/55,0.7104013023037576,0.7242140706704175,0,0,0.813355021688355,0.27810662247080864,EGR2
regulation of macroautophagy (GO:0016241),2/112,0.7153688342913784,0.7290601038471943,0,0,0.7980710034886107,0.26731948279314655,KDR;DCN
negative regulation of metabolic process (GO:0009892),1/56,0.7168626104602335,0.7303640587289911,0,0,0.7985257985257985,0.26580614013502957,ZNF423
proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161),6/321,0.7221573518839018,0.7355386297729639,0,0,0.834797700401345,0.27173685683007603,CDC20;PRKN;SIAH2;KCTD13;MAD2L1;AURKA
monocarboxylic acid transport (GO:0015718),1/57,0.7231800745078244,0.7361402908968535,0,0,0.7842261904761905,0.2541653730063829,CD36
negative regulation of cell cycle G2/M phase transition (GO:1902750),1/57,0.7231800745078244,0.7361402908968535,0,0,0.7842261904761905,0.2541653730063829,AURKA
cellular response to lectin (GO:1990858),2/115,0.7288967266740247,0.7415164311955451,0,0,0.7767634191653848,0.24563063065796878,MUC1;PAK3
stimulatory C-type lectin receptor signaling pathway (GO:0002223),2/115,0.7288967266740247,0.7415164311955451,0,0,0.7767634191653848,0.24563063065796878,MUC1;PAK3
membrane lipid biosynthetic process (GO:0046467),1/58,0.7293568898171885,0.7417631395096922,0,0,0.770428323059902,0.24314109697919817,PRKD1
fatty acid oxidation (GO:0019395),1/59,0.7353961807886813,0.7476820358376569,0,0,0.7571062441752097,0.23269350266757663,PPARGC1A
nuclear-transcribed mRNA catabolic process (GO:0000956),3/171,0.7363776687977766,0.7484566344356762,0,0,0.7832498383968972,0.2396839708803568,ZFP36;EXOSC4;LSM1
innate immune response activating cell surface receptor signaling pathway (GO:0002220),2/119,0.7460831891310332,0.7580952619435185,0,0,0.7500530570507997,0.2197041699356108,MUC1;PAK3
cation transport (GO:0006812),3/174,0.7470058051855624,0.758423997451172,0,0,0.7693895371913948,0.22441732715116966,SCN4A;SGK1;AQP1
B cell differentiation (GO:0030183),1/61,0.7470743425597371,0.758423997451172,0,0,0.7317942942942943,0.2133843207397855,KIT
O-glycan processing (GO:0016266),1/61,0.7470743425597371,0.758423997451172,0,0,0.7317942942942943,0.2133843207397855,MUC1
macroautophagy (GO:0016236),2/120,0.750231290192864,0.7614020955858489,0,0,0.7436584152733673,0.2137078949256082,PRKN;KLHL3
I-kappaB kinase/NF-kappaB signaling (GO:0007249),1/62,0.7527191221048719,0.7634722524206558,0,0,0.7197607443509083,0.2044574917494203,BCL3
negative regulation of kinase activity (GO:0033673),1/62,0.7527191221048719,0.7634722524206558,0,0,0.7197607443509083,0.2044574917494203,IRS2
monocarboxylic acid biosynthetic process (GO:0072330),1/63,0.7582381976297697,0.7688413500512511,0,0,0.708115373437954,0.19597638053669494,PER2
intracellular protein transport (GO:0006886),6/336,0.761298910394568,0.7717152547961592,0,0,0.7962311037481881,0.21715548142679558,NGFR;EGR2;HOMER3;CALR;STX11;AP1M2
non-canonical Wnt signaling pathway (GO:0035567),2/124,0.7662455423357859,0.7764986049004932,0,0,0.719128150094364,0.1914697463513119,TCF7L2;GNG2
regulation of RNA metabolic process (GO:0051252),1/65,0.7689103473026596,0.7789674386466896,0,0,0.6859163851351351,0.18024572484213916,MITF
Golgi organization (GO:0007030),2/130,0.7885927713319529,0.7984710422588799,0,0,0.6852073927765236,0.16274033533367285,PRKD1;SYNE1
positive regulation of protein transport (GO:0051222),1/69,0.7888650232645682,0.7984710422588799,0,0,0.6454358770535241,0.15307160225746863,EZR
RNA 3'-end processing (GO:0031123),1/69,0.7888650232645682,0.7984710422588799,0,0,0.6454358770535241,0.15307160225746863,DDX39A
snRNA transcription by RNA polymerase II (GO:0042795),1/70,0.7935790049512392,0.8027655829248511,0,0,0.6360490925708318,0.1470559360363245,POLR2H
sterol metabolic process (GO:0016125),1/70,0.7935790049512392,0.8027655829248511,0,0,0.6360490925708318,0.1470559360363245,APOB
fatty acid biosynthetic process (GO:0006633),1/71,0.7981879684562023,0.8067095481906102,0,0,0.6269305019305019,0.14131713157037576,PTGS2
regulation of glycolytic process (GO:0006110),1/71,0.7981879684562023,0.8067095481906102,0,0,0.6269305019305019,0.14131713157037576,PPARA
snRNA transcription (GO:0009301),1/71,0.7981879684562023,0.8067095481906102,0,0,0.6269305019305019,0.14131713157037576,POLR2H
RNA metabolic process (GO:0016070),2/133,0.799045741780963,0.8073370554371544,0,0,0.6694122309720332,0.15017398927409234,LSM1;POLR2H
mRNA processing (GO:0006397),5/300,0.8004750058009446,0.8085414403585118,0,0,0.7419106317411402,0.16511218903485161,DDX39A;SNRPE;POLR2H;PPARGC1A;LSM4
positive regulation of neurogenesis (GO:0050769),1/72,0.8026942481991949,0.8105428141815871,0,0,0.6180687729983505,0.13584001987819333,NGFR
ribonucleoprotein complex assembly (GO:0022618),2/136,0.8090386853298984,0.8167072984609876,0,0,0.65432431521849,0.1386569131805411,SNRPE;LSM4
cellular response to amino acid starvation (GO:0034198),1/74,0.8114078364155886,0.8186139450871303,0,0,0.6010736764161422,0.12561506391433044,PRKD1
sphingolipid biosynthetic process (GO:0030148),1/74,0.8114078364155886,0.8186139450871303,0,0,0.6010736764161422,0.12561506391433044,PRKD1
"RNA splicing, via transesterification reactions with bulged adenosine as nucleophile (GO:0000377)",4/251,0.8126463913840559,0.8196208647046056,0,0,0.7090253105290699,0.14709382866279844,DDX39A;SNRPE;POLR2H;LSM4
response to amino acid starvation (GO:1990928),1/75,0.8156195594571529,0.8223761711923009,0,0,0.5929206233260287,0.1208415269798351,PRKD1
chloride transport (GO:0006821),1/76,0.819737430120138,0.8255511707592879,0,0,0.584984984984985,0.11627816579291349,CLIC5
positive regulation of interleukin-6 production (GO:0032755),1/76,0.819737430120138,0.8255511707592879,0,0,0.584984984984985,0.11627816579291349,IL6
protein import into nucleus (GO:0006606),1/76,0.819737430120138,0.8255511707592879,0,0,0.584984984984985,0.11627816579291349,KPNA2
water-soluble vitamin metabolic process (GO:0006767),1/76,0.819737430120138,0.8255511707592879,0,0,0.584984984984985,0.11627816579291349,FLAD1
cholesterol metabolic process (GO:0008203),1/77,0.8237635350746383,0.8291158084862278,0,0,0.5772581792318634,0.11191406048310497,APOB
import into nucleus (GO:0051170),1/77,0.8237635350746383,0.8291158084862278,0,0,0.5772581792318634,0.11191406048310497,SNRPE
mRNA 3'-end processing (GO:0031124),1/79,0.8315485646487791,0.8367043130566989,0,0,0.5623989373989374,0.10374324391942642,DDX39A
glycoprotein biosynthetic process (GO:0009101),1/83,0.8461042385385116,0.8510989506904508,0,0,0.5348549769281477,0.08938106655744105,BMPR1B
ERAD pathway (GO:0036503),1/87,0.8594047402396479,0.86396795124977,0,0,0.5098732453383616,0.07725359360030169,PRKN
protein targeting to membrane (GO:0006612),1/87,0.8594047402396479,0.86396795124977,0,0,0.5098732453383616,0.07725359360030169,NACAD
inorganic cation transmembrane transport (GO:0098662),4/274,0.8619421015500363,0.8660078661799893,0,0,0.647854203409759,0.09624987085297759,KCNK15;KCNQ5;SCN4A;PKD2
"mRNA splicing, via spliceosome (GO:0000398)",4/274,0.8619421015500363,0.8660078661799893,0,0,0.647854203409759,0.09624987085297759,DDX39A;SNRPE;POLR2H;LSM4
cellular amino acid catabolic process (GO:0009063),1/90,0.8686217431265885,0.8722047438348302,0,0,0.4926105881162061,0.06938298301816365,GAD1
"regulation of mRNA splicing, via spliceosome (GO:0048024)",1/90,0.8686217431265885,0.8722047438348302,0,0,0.4926105881162061,0.06938298301816365,QKI
peptide biosynthetic process (GO:0043043),2/162,0.8786297916735925,0.8819942061925193,0,0,0.5472629796839729,0.07081125439570962,DMD;PCSK5
mRNA-containing ribonucleoprotein complex export from nucleus (GO:0071427),1/99,0.8928097643273222,0.895700817435241,0,0,0.44716400073542933,0.050700237239243516,DDX39A
sensory perception of chemical stimulus (GO:0007606),1/99,0.8928097643273222,0.895700817435241,0,0,0.44716400073542933,0.050700237239243516,CD36
protein O-linked glycosylation (GO:0006493),1/102,0.8998409412182496,0.9024890899563847,0,0,0.43381500312193383,0.04578364818909262,MUC1
gene expression (GO:0010467),5/356,0.9004239720205344,0.902808148468956,0,0,0.6217301217301218,0.06521299054995253,DDX39A;BCL3;E2F1;DTX1;POLR2H
peptidyl-lysine modification (GO:0018205),1/106,0.908505147345091,0.9103750491479183,0,0,0.4172029172029172,0.04003259135612461,EGR2
RNA export from nucleus (GO:0006405),1/106,0.908505147345091,0.9103750491479183,0,0,0.4172029172029172,0.04003259135612461,DDX39A
mRNA export from nucleus (GO:0006406),1/107,0.9105517116690345,0.9121576229770927,0,0,0.4132457929627741,0.03872302620337245,DDX39A
lipid transport (GO:0006869),1/109,0.9145088228192859,0.9158525031349181,0,0,0.4055513847180514,0.036243382457272315,CD36
sphingolipid metabolic process (GO:0006665),1/116,0.927032716400072,0.9281220615427278,0,0,0.3807285546415981,0.028846440059197318,PRKD1
rRNA metabolic process (GO:0016072),1/162,0.9742686986678083,0.9751270851864584,0,0,0.27130546695764085,0.007072429455096757,EXOSC4
rRNA processing (GO:0006364),1/173,0.9799523357154596,0.9805277628063084,0,0,0.2538104965430547,0.005140004063461449,EXOSC4
ribosome biogenesis (GO:0042254),1/192,0.9869774264585299,0.9872671175141385,0,0,0.22833828592990896,0.0029930835228255616,EXOSC4
ncRNA processing (GO:0034470),1/201,0.9893858262485313,0.9893858262485313,0,0,0.21796171171171172,0.002325848914170885,EXOSC4